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Abstract 
 
Epithelial ovarian cancer frequently metastasizes to the omentum, a process that 
requires pro-angiogenic activation of local microvascular endothelial cells (ECs) 
by tumour-secreted factors.  We have previously shown that ovarian cancer cells 
secrete factors, other than vascular endothelial growth factor (VEGF), with 
possible roles in metastatic angiogenesis including the lysosomal proteases 
cathepsin L (CathL) and cathepsin D (CathD), and insulin-like growth factor 
binding protein 7 (IGFBP7). However, the mechanisms by which these factors 
may contribute to omental endothelial angiogenic changes are unknown.  
Therefore the aims of this thesis were a) to examine disease relevant human 
omental microvascular endothelial cell (HOMEC) proliferation, migration and 
angiogenesis tube-formation induced by CathL, CathD and IGFBP7; b) to 
investigate whether CathL and CathD act via a proteolytic or non-proteolytic 
mechanism; c) to identify activated downstream intracellular signalling cascades 
in HOMECs and their activation in proliferation and migration; and finally d) to 
identify activated cell surface receptors by these factors.  
CathL, CathD and IGFBP7 significantly induced proliferation and migration in 
HOMECs, with CathL and CathD acting in a non-proteolytic manner. Proteome-
profiler and ELISA data identified increased phosphorylation of the ERK1/2 and 
AKT (protein kinase B) pathways in HOMECs in response to these factors. CathL 
induced HOMEC proliferation and migration via the ERK1/2 pathway, whereas, 
although CathD-induced proliferation was mediated by activation of ERK1/2, its 
migratory effect was dependent on both ERK1/2 and AKT pathways. 
Interestingly, CathL induced secretion of galectin-1 (Gal1) from HOMECs which 
in turn significantly induced HOMEC proliferation via ERK1/2. However, none of 
the ERK1/2 or AKT pathways was observed to be active in Gal1-induced HOMEC 
migration. Interestingly, Gal1-induced proliferation and migration were 
significantly inhibited by L-glucose, suggesting a role for a receptor with 
extracellular sugar moieties. IGFBP7-induced migration was shown to be 
mediated via activation of the ERK1/2 pathway only. CathL, Gal1 and IGFBP7 
significantly induced angiogenesis tube-formation in HOMECs which was not 
observed in CathD-treated cells. Receptor tyrosine kinase array revealed 
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activation of Tie-1 and VEGF receptor type 2 (VEGFR2) in CathL and IGFBP7-
treated HOMECs respectively. 
In conclusion, all CathL, CathD, Gal1 and IGFBP7 have the potential to act as 
proangiogenic factors in the metastasis of ovarian cancer to the omentum. These 
in vitro data suggest all four factors activate intracellular pathways which are 
involved in well-known angiogenesis models. 
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M6PR Mannose-6-phosphate receptor 
MAPK Mitogen-activated protein kinase 
MCP1 Monocyte chemotactic protein 1 
MEK mitogen-activated protein kinase kinase 
MHC Major histocompatibility complex 
MIP Macrophage Inflammatory Proteins 
MLC Myosin light-chain 
MLCK Myosin light-chain kinase 
MMP Matrix metalloproteinases 
mTOR Mechanistic target of rapamycin 
mTORC2 Mechanistic target of rapamycin protein complex 2 
Na2HPO4 Sodium phosphate dibasic 
ND Not determined 
NFκB   
Nuclear factor kappa-light-chain-enhancer of activated B 
cell 
NRP1 Neuropilin 1 
PAS periodic acid-Schiff 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
pCathD Pro-cathepsin D 
pCathL Pro-cathepsin L 
PDGF Platelet-derived growth factor 
PDK1 Phosphoinositide-dependent kinase-1 
PECAM1, CD31 Platelet endothelial cell adhesion molecule1 
pepA Pepstatin A 
PFS Progression-free survival 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKCα Protein kinase C alpha 
PLCγ Phospholipase C, gamma 
ppCathL Preprocathepsin L 
PSF Prostacyclin-stimulating factor 
PtdIns Phosphatidylinositol 
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qRT-PCR 
Real-time reverse transcription polymerase chain 
reaction 
RCC Renal cell carcinoma 
rER Rough endoplasmic reticulum 
RSK Ribosomal s6 kinase 
RT2 mice RIP1-Tag2 mice 
RTK Receptor tyrosine kinase 
S473 Serine 743 
S536 Serine 536 
SD Standard deviation 
SGK3 Serum- and glucocorticoid- inducible protein kinase 3 
SLC Secondary lymphoid tissue chemokine 
SMC Smooth muscle cells 
SOS Son of Sevenless 
STAT Signal transducer and activator of transcription 
T185 Tyrosine 185 
T202 Tyrosine 202 
TAMRA 6-carboxytetramethylrhodamine 
tBid Truncated BH3-interacting domain 
TCF Ternary complex factor 
TGF- β1 Transforming growth factor- beta 1 
TGN Trans Golgi network 
TIMP2 Tissue inhibitor of metalloproteinases 
TKIs Tyrosine kinase inhibitors 
TNF-α Tumour necrosis factor-alpha 
TRAIL TNF-related apoptosis-inducing ligand 
VCAM1 Vascular cell adhesion protein 1 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VLA-4 Very late antigen-4 
vWF Von Willebrand factor 
WB Western blot 
WST-1 Water soluble tetrazolium salt 1 
β2M  Beta 2 microglobulin 
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Chapter 1 Introduction 
 
1.1 The vasculature 
 
The vascular network consists of three major types of vessels – arteries, veins 
and capillaries, which are specifically designed to accommodate varying levels of 
blood flow and pressure. The walls of larger vessels i.e. arteries and veins have 
three layers: an outer layer (tunica externa) composed of connective tissue, a 
middle layer (tunica media) composed of smooth muscle and elastic fibres and 
an innermost layer (tunica intima) composed of endothelial cells (ECs), which rest 
on a thin sheet of extracellular matrix called the basement membrane (BM) and 
an internal elastic lamina (absent in veins). The walls of capillaries, the smallest 
of the blood vessels connecting the arteries and veins, consists of only a single 
layer of ECs surrounded by a BM (Figure: 1.1).  
 
1.1.1 Microvasculature 
 
Microvasculature refers to the narrowest of blood vessels that distribute blood 
within tissues. The microcirculation is comprised of arterioles, metarterioles, 
capillaries and post capillary venules as shown in Figure: 1.2. Capillaries are the 
smallest blood vessels (8-10 μm diameter) consisting only of tunica intima which, 
depending on the location, differently regulates permeability. Specialised 
capillaries in the body include continuous (fenestrated and unfenestrated), and 
sinusoidal capillaries (Figure: 1.2). Unfenestrated capillaries are found in organs 
such as the brain where they form an essential component of the blood brain 
barrier. Continuous, fenestrated capillaries found in exocrine and endocrine 
glands, gastric and intestinal mucosa, choriocapillaris, and renal glomeruli have 
fenestrations in ECs that allow greater permeability to water and small solutes 
but similar permeability to albumin and larger macromolecules compared with 
unfenestrated capillaries. Discontinuous, sinusoidal capillaries are characterised 
by fenestrae without diaphragms and poorly organised basement membrane that 
allow passage of large molecules. These ‘leaky capillaries’ are found in liver, 
spleen and bone marrow (Aird, 2007a, Aird, 2007b). 
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Figure 1.1: Structural layers of the three main blood vessels: arteries, veins 
and capillaries. The walls of arteries and veins consist of an outer layer of 
connective tissue, a middle layer of smooth muscle and an innermost layer of 
endothelial cells, while the capillary wall is a one-layer endothelium. Taken from 
(Mescher, 2010). 
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Figure 1.2: Types of specialised capillaries and their role in regulation of 
permeability. Continuous nonfenestrated endothelium is permeable to water and 
small solutes (molecular radius <3 nm), whereas larger solutes (illustrated as 
black dots) pass through ECs either via transendothelial channels or transcytosis 
(mediated mainly by caveolae, typical for capillaries in the heart and skeletal 
muscle but rare in blood–brain barrier). Continuous fenestrated endothelium is 
more permeable to water and small solutes with similar permeability to albumin 
and larger macromolecules compared with its nonfenestrated counterpart (the 
diaphragms of the fenestrae act as molecular filters). Discontinuous endothelium 
is highly permeable to water and both small and larger solutes (fenestrae without 
diaphragms, incomplete basement membrane). Taken from (Aird, 2007a). 
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1.1.2 Endothelium 
 
An endothelium lines the interior surface of the entire vascular and lymphatic 
system and is composed of a monolayer of ECs. It is now well-known that 
vascular ECs are highly metabolically active and play critical roles in physiology 
and most pathological conditions. Some common functions of ECs are regulation 
of vascular growth, modulation of leukocyte interactions with the vessel wall at 
sites of inflammation, maintenance of selective permeability, regulation of 
vascular tone, production of signalling molecules upon activation and 
maintenance of thromboresistance (Yang et al., 2008). These functions are 
organ/tissue specific, giving rise to the concept of heterogeneity. For example, 
brain capillary ECs create a tight blood-brain barrier in order to selectively 
regulate entry of macromolecules, antibodies, non-specific drugs and other toxic 
products. On the other hand, glomerular ECs form a semi-permeable barrier, 
enabling filtration of components to be excreted. In disease states the 
microvascular ECs play critical roles. For instance, in inflammatory conditions, 
activated ECs in post-capillary venules express specific adhesion molecules that 
aid rolling/tethering of leukocytes to facilitate their entry to the inflamed tissue via 
transcellular/paracellular migration pathways. Also, during tumour growth, pro-
angiogenic and pro-inflammatory factors activate ECs to rapidly proliferate and 
form new blood vessels from the existing ones, in a process called neo-
angiogenesis. This process alters the normal EC physiology which is a quiescent 
and proliferatively inactive state with a long life span (0.1% replications per day) 
(Cines et al., 1998). 
 
1.1.2.1 Microvascular EC function 
 
Regulation of vascular tone and growth  
 
Vascular ECs play an important role in regulating vascular tone. Endothelium-
derived nitric oxide and prostacyclin are released in response to physical stimuli, 
hormones, and platelet-derived substances. These stimuli have several effects 
on the vascular tone such as vasorelaxation, hyperpolarisation of smooth muscle 
cells and inhibition of platelet function (Rajendran et al., 2013). In addition, ECs 
can release several contraction-inducing factors (e.g., endothelin, thromboxane 
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A2, angiotensin (Ang) II, superoxide, and unidentified endothelium-derived 
contraction-inducing factors), at least under certain conditions. ECs are also a 
source of growth inhibitors and promoters, such as heparin and heparin 
sulphates, platelet-derived growth factor, and thrombospondin (Rajendran et al., 
2013). Several vasoactive substances are also produced by the endothelium, 
such as nitric oxide, endothelin, and angiopoetin-2 (Ang2) that may also play a 
role in the regulation of vascular growth. Thus, the endothelial layer can regulate 
vascular tone and growth. Dysfunction of these endothelium-dependent 
regulatory mechanisms may contribute to cardiovascular diseases, such as 
hypertension and atherosclerosis (Barton et al., 2012). 
 
Thrombosis, thrombolysis and coagulant mechanism 
 
The endothelium serves an integral role in the haemostatic system. Depending 
on specific tissue needs and local stresses, ECs are capable of evoking either 
antithrombotic or prothrombotic events. Under normal physiological conditions, 
ECs prevent thrombosis by means of different anticoagulant and antiplatelet 
mechanisms (Stern et al., 1991). These cells are involved in all main haemostatic 
pathways triggered upon vascular injury and limit clot formation to the areas 
where haemostasis is needed to restore vascular integrity.  One important way in 
which ECs control the clotting system is by regulating the expression of binding 
sites for anticoagulant and procoagulant factors on the cell surface. In a quiescent 
state, ECs maintain blood fluidity by promoting the activity of numerous 
anticoagulant pathways, including the protein C/protein S pathway (Rajendran et 
al., 2013). Once activated (discussed below) by cytokines, the balance of EC 
properties can be tipped in favour for clot formation through a coordinated and 
regulated induction of procoagulant and suppression of anticoagulant 
mechanisms. For example, tumour necrosis factor-α (TNF-α) suppresses the 
formation of thrombomodulin, an endothelial anticoagulant cofactor, and induces 
the expression of tissue factor (procoagulant cofactor) (Yau et al., 2015). This 
coordinated mechanism can allow fibrin formation to proceed in an inflamed focus 
whilst maintaining blood fluidity in the surrounding area of normal vasculature. 
However, a dysfunctional endothelium can induce a disturbance in the complex 
balance of pro- and anti-coagulation mechanism, resulting in atherogenesis and 
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predisposition to arterial thrombosis (Rajendran et al., 2013). Thus, ECs play a 
significant role in the haemostatic and coagulation system. 
 
Platelet and leukocyte interaction 
 
The concept of “rolling” of blood cells along the endothelium surface was first 
described more than 160 years ago, when leukocytes were shown to adhere to 
blood vessel walls- a key interaction during a pro-inflammatory response (de 
Gaetano et al., 2003). Platelet adhesion to and leukocyte rolling on the 
endothelium represent the initial stage of a multistep process leading to 
extravasation of white blood cells to sites of inflammation or infection, to platelet-
leukocyte interaction and aggregation on a thrombogenic surface, and finally to 
vascular occlusion (Rajendran et al., 2013). During inflammation, leukocytes are 
recruited from the vasculature to a site of tissue injury through a sequence of 
adhesion and activation events. On arrival, leukocytes transiently adhere to the 
EC surface, which is mediated by the rapid and reversible interactions of selectins 
such as E- and P-selectin (present on ECs) with their corresponding carbohydrate 
ligands such as α, β-integrins and L-selectins (found on leukocytes) (Gout et al., 
2008). The flow of blood in the vessels pushes along the loosely tethered 
leukocytes, causing them to roll along the endothelium. The rolling movement 
stimulates the leukocytes by eliciting the release of chemokines. This induces the 
expression of other adhesion molecules such as integrins and immunoglobulins, 
whose interactions consequently lead to the reinforcement and stabilisation of the 
initial adhesive bonds (Brooks et al., 2010). For instance, an increased 
expression of intercellular adhesion molecule 1 (ICAM1) and vascular cell 
adhesion molecule 1 (VCAM1) on the EC surface which interact with lymphocyte 
function-associated antigen 1 (LFA1) and very late antigen 4 (VLA-4) 
respectively, which are expressed on leukocytes. This firm adhesion is followed 
by transendothelial migration via a number of cell adhesion molecules, allowing 
entry of leukocytes to the site of inflammation or infection (Muller, 2011). 
 
Angiogenesis 
 
The endothelium is also involved in blood vessel formation. The production and 
development of new functional blood vessels from existing ones is known as 
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angiogenesis (discussed below). The development of a functional vascular 
network requires a remarkable degree of coordination between different cell 
types undergoing complex changes and is exquisitely dependent upon signals 
exchanged between these cell types. Growth factors such as vascular endothelial 
growth factor (VEGF), Ang, platelet-derived growth factors (PDGF) and basic 
fibroblast growth factor (bFGF) are some key proangiogenic factors (Apte et al., 
2004). Angiogenesis is a key phenomenon in embryogenesis and also plays 
important role in disease progression, such as tumour metastasis. 
 
1.1.2.2 Vascular EC heterogeneity  
 
It is now widely accepted that ECs vary functionally, proteomically and 
morphologically. This heterogeneity (specialised to a particular site arises from 
the variations in the biochemical and biomechanical properties of their local 
microenvironment. Therefore, it is important to use disease-site specific ECs 
when investigating their role in pathogenesis. This section briefly describes the 
level of heterogeneity that exists in ECs from different vascular beds and their 
physiological and pathological relevance.  
 
Markers  
 
Although anatomically ECs represent the inner layer of the vessels, their 
characteristic ultrastructural features such as Weibel-Palade bodies or fenestrae, 
vary. ECs arise from the same precursor as haemapoetic cells, a blast-like 
bipotential cell, the haemangioblast, and hence share frequent molecular 
markers. However, other cell lineages may transdifferentiate into ECs, and ECs 
into other lineages. The expression of EC markers is determined by the local 
microenvironment and the location of activated vascular beds. Furthermore, this 
heterogeneity is also observed between different organs, vessels of differing 
sizes (macro- and micro-vascular) and between ECs of various vascular beds 
within the same organ, as well as within the same vessel (Muller et al., 2002). 
 
Despite this enormous variance, there are few protein/mRNA markers that are 
both specifically and uniformly expressed on all human vascular endothelium, 
such as platelet endothelial cell adhesion molecule 1 (PECAM1, CD31), vascular 
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endothelial cadherin (VE-cadherin), thrombomodulin (CD141) and vascular 
endothelial growth factor receptor 2 (VEGFR2). Other markers (e.g. VCAM1, 
ICAM1, Tie-2 and eNOS) are differentially expressed and their expression solely 
depends on pathogenesis, tumour angiogenesis, site and type of organs and 
also, varying sizes of vessels.  
 
Morphology  
 
ECs display differing morphologies depending on the tissue –specific vascular 
beds, shear stress and direction of blood flow and requirements of the underlying 
tissues. A typical EC is characterised by a flat morphology; however, they are 
plump or cuboidal in high endothelial venules. Their thickness also varies from 
less than 0.1µm in capillaries and veins to 1µm in the aorta. In the arteries (not 
at the branch points) the cells and their nuclei are aligned in straight segments in 
the direction of the blood flow, representing a reversible endothelial structural 
remodelling in response to haemodynamic shear stress, reviewed in (Aird, 
2007a). 
 
Tight junctions and adhesive proteins  
 
There are highly specialised cellular structures such as intracellular junctions in 
the endothelium that regulate transfer of molecules from luminal to abluminal 
space and vice-versa, and also maintain different functions of vascular 
homeostasis. These dynamic structures can be divided into tight junctions, 
adherens junctions and gap junctions (Aird, 2007a).  
 
Tight junctions: A unique structure mainly composed of junctional adhesion 
molecule A (JAM-A), occludin and claudins forming a transport barrier between 
ECs to regulate paracellular permeability and to maintain cell polarity between 
luminal and abluminal side of the endothelium, reviewed in (Bazzoni and Dejana, 
2004, van Buul et al., 2004).  
 
Adherens junctions: These are key structures in ECs for the maintenance of cell-
specific properties, such as permeability to solutes or circulating inflammatory 
cells (leukocytes), contact inhibition of cell growth, and apoptosis. The molecular 
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organisation of adherens junctions are complex and include both adhesive and 
signalling molecules. The predominant transmembrane protein is VE-cadherin 
that is found in all ECs in all types of vascular beds. VE-cadherin has been shown 
to interact with endothelial-specific signalling proteins by binding to VEGFR2 and 
aid modulation of signalling cascade through phosphatidylinositol 3-kinase  
(PI3K), reviewed in (Bazzoni and Dejana, 2004). 
 
Gap junctions: These structures consist of tightly packed clusters of channels at 
the plasma membrane of one cell that interacts with a matched set of channels 
in an opposing cell, effectively connecting the cytoplasms of the two cells. The 
sets of proteins that make up gap junctions are called connexins, which allow 
transfer of ions, simple sugars, amino acids, nucleotides, short polypeptides, and 
second messengers between cells. Phosphorylation of specific connexins such 
as Cx43, has been shown to affect endothelial biology through both gap-junction 
dependent and independent means, reviewed in (Marquez-Rosado et al., 2012). 
 
The endothelial junctions are organised in a diverse manner along the vascular 
tree depending on tissue-specific requirements. The brain, for instance, is a very 
immune privileged organ that requires a strict control of permeability between 
blood and the nervous system. Hence, the junctions are well developed and are 
rich in tight junctions. In large arteries, where maintenance of permeability during 
high pressure and pulsatile blood flow is required, the tight junctions are well 
developed. In contrast, post-capillary venules, which are involved in trafficking of 
leukocytes and plasma proteins to the site of inflammation (discussed above), 
display poorly organised tight junctions. This morphology may account for the 
high sensitivity of post-capillary venules to permeability-increasing agents such 
as histamine and bradykinin, which are pathologically relevant in causing septic 
shock.  
 
1.1.2.3 Activation of ECs 
 
Although vascular ECs vary functionally, proteomically and morphologically, 
activation of these cells is essential for eliciting a response within the local 
microenvironment. ECs remain proliferatively quiescent in normal physiology. 
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However, in some conditions these cells are activated, which may contribute to a 
number of pathogenic states, including tumour development and metastasis. 
Activation of ECs is necessary to initiate the process of angiogenesis. As 
described above EC activation can take place during the inflammatory response 
and tumour angiogenesis. It is well established that tumours interact with 
neighbouring vasculature, tissues and cells by secreting molecules that 
encourage tumour growth and metastasis. When a tumour reaches 2-3 mm3, it 
requires an increased supply of oxygen and essential nutrients. This induces an 
angiogenic switch in order to initiate new blood vessels and progress into the 
angiogenic stage, allowing the tumour to grow and effectively establish 
secondary foci and further metastases. Secretion of pro-angiogenic factors, such 
as VEGF, bFGF, PDGF and interleukin 8 (IL8) by cancer cells activates cognate 
receptors on ECs transducing multiple signals downstream. For instance, VEGF 
increases vascular permeability that leads to extravasation of plasma proteins 
(fibrinogen and other clotting factors), which in turn activate tissue factor 
(procoagulant expressed by many cells, including tumour cells) generating 
thrombin and contributing to the stromal matrix creation found in tumours, healing 
wounds and inflammation, reviewed in (Dvorak, 2005). Local degradation of the 
vascular basement membrane, necessary to capillary formation, is achieved by 
VEGF-induced activity of endothelial proteases, reviewed in (Brown et al., 1997, 
Ferrara, 2002). The breakdown of extracellular matrix is followed with EC 
migration and proliferation, and homing of newly sprouting vessels. 
 
Angiogenesis plays a key role in tumour metastasis. It has been shown that 
patients with highly angiogenic tumours, such as bladder cancer, are associated 
with poor prognosis (Papadopoulos et al., 2004). Although angiogenesis is a 
common phenomenon in both physiology (embryology) and pathology, the 
development of new blood vessels vary depending on the type of organ and 
disease. Therefore, it is important to recognise the different types of angiogenesis 
in the body.  
 
1.2 Different types of angiogenesis 
 
In tumours the angiogenic switch is initiated by the tumour resulting in EC 
activation (mediated by interactions of secreted potent angiogenic factors on 
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ECs) leading to new vessel formation. For many years, tumour angiogenesis 
(sprouting angiogenesis) was considered to be the main mechanism of tumour 
vascularisation (Figure 1.3). Briefly, the process of sprouting angiogenesis 
consists of enzymatic degradation of capillary basement membrane containing 
extracellular matrix (ECM), EC proliferation and directed migrations, tube 
formation, vessel fusion, vessel pruning, and pericyte stabilisation. Specifically, 
in poorly perfused tissues, hypoxia is induced which results in an increased 
demand for new blood vessel formation to meet the metabolic requirements of 
local cells (Hanahan and Weinberg, 2000). Tumour secreted factors such as 
VEGF activate endothelial tip cells that guide the developing capillary sprout 
through the ECM towards an angiogenic stimulus (Gerhardt, 2008). Long, thin 
cellular processes on tip cells called filopodia secrete large amounts of proteolytic 
enzymes, which digest a pathway through the ECM for the developing sprout 
(Small et al., 2002). The filopodia of tip cells are heavily endowed with VEGFR2, 
allowing them to “sense” differences in VEGF-A concentrations and causing them 
to align with the VEGF-A gradient (van Hinsbergh and Koolwijk, 2008). 
Meanwhile, endothelial stalk cells proliferate as they follow behind a tip cell 
causing elongation of the capillary sprout (Blanco and Gerhardt, 2013). Vacuoles 
develop and coalesce, forming a lumen within a series of stalk cells. These stalk 
cells become the trunk of the newly formed capillary (Adair and Montani, 2010). 
When the tip cells of two or more capillary sprouts converge at the source of 
VEGF-A secretion, the tip cells fuse together creating a continuous lumen through 
which oxygenated blood can flow. When the local tissues receive adequate 
amounts of oxygen, VEGF-A levels return to near normal (Adair and Montani, 
2010). Pericytes surrounding the ECs induce maturation and stabilisation of the 
capillary. These process are also accompanied by deposition of ECM along with 
shear stress and other mechanical signals (Chien, 2007). 
 
Although sprouting angiogenesis is well-known in tumour progression, recently, 
additional mechanisms have been recognised that strengthen the number of 
possible ways that a tumour can achieve survival (Figure 1.3). These include 
intussusceptive angiogenesis, angioblast recruitment, cooption, mosaic vessels 
and vasculogenic mimicry, reviewed in (Auguste et al., 2005), which are 
described below in greater detail.  
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Figure 1.3: Mechanisms of tumour vascularisation. The different mechanisms 
of tumour vascularisation are depicted. These include: (A) sprouting 
angiogenesis; (B) intussusception; (C) recruitment of circulating endothelial 
precursors (CEP); (D) cooption; (E) mosaic vessels; (F) vascular mimicry- 
periodic acid-Schiff (PAS) and laminin network development. Taken from 
(Auguste et al., 2005) 
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Intussusceptive angiogenesis occurs when interstitial tissue folding in from the 
vessel wall induces the partition of the vessel lumen. The intussusception 
incorporates the process of EC membrane “kissing”, during which intra-EC 
junctions are created, allowing two membranes to be thinned and finally two 
separated vessels to be formed (Burri et al., 2004). This mechanism was firstly 
described as occurring primarily during lung development, and has now been 
found in most organs, and also occurs in tissue repair and tumour angiogenesis. 
 
Angioblasts, multipotent progenitor cells found in adults with characteristics close 
to both the hematopoietic and EC lineage, can be stimulated by VEGF-A to 
differentiate into ECs in vitro, reviewed in (Moore, 2002). It has been shown that 
VEGF responsive hematopoietic stem and progenitor cells are recruited to the 
tumour vasculature and may act as endothelial precursors and become 
incorporated into the endothelium (Lyden et al., 2001). 
 
Cooption was first described by Holash et al. in brain tumours, where cancer cells 
surrounding the host vasculature create coopted vessels (Holash et al., 1999). In 
these vessels ECs produce both Ang2 and its receptor Tie2, inhibiting 
angiostatin-1 and inducing EC apoptosis. Therefore, the number of vessels is 
reduced with time. In surviving vessels the diameter is enlarged and the 
progressing hypoxia upregulates VEGF-A secretion that causes robust 
angiogenesis at the tumour margin (Holash et al., 1999). 
 
The process of mosaic blood vessel creation was described by Chang et al. and 
depends on intravasation of cancer cells into the capillary vessel wall, where they 
temporarily stay (with preservation of the vascular function) (Holash et al., 1999, 
Chang et al., 2000). 
 
Vasculogenic mimicry has been primarily described in aggressive uveal 
melanoma (Maniotis et al., 1999). It has been shown that an absence of ECs 
within the tumour is compensated for by a system of “vascular channels” created 
by cancer cells laid on a thin basal lamina with circulating blood cells inside. 
Vasculogenic mimicry has also been observed in other cancer types, including 
ovarian cancer (Sood et al., 2001, Passalidou et al., 2002). Mechanisms of 
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tumour vascularisation together with factors regulating these mechanisms are 
shown in Figure 1.3. 
 
One tumour type where metastasis significantly impacts on survival of patients is 
epithelial ovarian cancer (EOC). The nature of its aggressiveness while 
metastasising to secondary organs and the lack of availability and efficiency of 
anti-tumour therapy has highlighted an importance for development of novel 
treatment targets. Hence, understanding this process in the metastasis of EOC, 
specifically angiogenesis, is the main focus of this study. Below are sections 
where the epidemiology and risk factors, along with the metastatic cascade of 
this disease is discussed. 
  
1.3 Epidemiology of epithelial ovarian cancer (EOC) 
 
EOC is the fifth most common cancer among women and the leading cause of 
gynaecological cancer death in the UK. Globally, incidence of this disease is 
highest in the developed countries of Europe and North America with decreasing 
trends in Africa and Asia. Each year more than 6,500 women are diagnosed with 
ovarian cancer in the UK and about 4,400 women die of the disease (Doufekas 
and Olaitan, 2014). Incidence in England and Wales has increased gradually 
since the early 1970s, especially in older women (Coleman et al., 1993), whereas 
the ascending trend in younger women reached its peak by the late 1990s. In 
most cases (80%-90%), ovarian cancer occurs after the age of 40 with a plateau 
at the age of 60. However, this type of carcinoma remains relatively rare in 
premenopausal women with only 10% of cases arising under the age of 45. 
Although the ideal therapy of primary cytoreductive surgery and combination 
chemotherapy with platinum has improved the prognosis of patients with 
malignant ovarian cancer, the 5-year survival rate remains ~45%. It is the most 
lethal of all gynaecological cancers due to non-specific initial symptoms, and as 
a result, around 75% women present with advanced stage of the disease at 
diagnosis.  
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1.3.1 Risk factors 
 
The exact aetiology of ovarian cancer remains uncertain and is the subject of 
current research. Some geographical and race variation exists (Ushijima, 2009, 
Ferlay et al., 2010). However, tumour types appear to share major common risk 
factors irrespective of geographical or racial factors (Purdie et al., 2003). Theories 
about causes focus on continual ovulation, excessive gonadotropin secretion, 
and oestrogen and progestogen imbalance (Riman et al., 2004b). But none are 
certain and no effective screening tools are currently available in clinical practice. 
However, the most current theories associated with EOC pathogenesis are as 
follows: 
 
Hereditary  
 
A significant family history, where two or more cases of ovarian or breast cancer 
have been diagnosed at an early stage in first-degree relatives, has been linked 
to the development of hereditary ovarian malignancy (Whittemore et al., 2004, 
Kauff et al., 2008). Approximately 5–15% of ovarian carcinomas occur in women 
known to carry mutations of the tumour suppressant genes BRCA1 and BRCA2 
(breast cancer genes) (Gayther and Pharoah, 2010). Women with a family history 
of either breast or ovarian cancer, and a known BRCA mutation, are estimated to 
have a lifetime risk of developing ovarian cancer of approximately 40–50%, 
compared with a 2% risk in the general UK population (Kauff et al., 2008, Watson 
et al., 2008). However, not all women with known BRCA mutations go on to 
develop malignant disease. Equally, BRCA mutations do not account for all 
ovarian cancers diagnosed in women with a known family history (McLaughlin et 
al., 2007). Further research into the role of gene mutations may benefit women 
at risk of hereditary ovarian cancer and facilitate informed choice for women 
considering prophylactic oophorectomy (surgical ovary removal) to prevent 
ovarian disease. Genetic mutations contributing to the development of ovarian 
tumours can also be acquired throughout life. Known as somatic mutations, these 
have been observed in epithelial ovarian tumours and include mutations in other 
tumour suppressor genes and cell-signalling genes, which lead to chromosomal 
instability (Hennessy et al., 2009). 
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Reproductive factors 
 
Reproductive history influences ovarian cancer risk and is related to factors that 
affect a woman’s exposure to oestrogen and progesterone, the hormones 
produced by the ovaries (Riman et al., 2004b, Sueblinvong and Carney, 2009). 
Early age at menarche and late age at menopause increase the risk of ovarian 
cancer only modestly, so that it can be assumed that the length of menstrual life 
plays no crucial role in the pathogenesis of this disease. However, factors that 
reduce ovulation such as increasing parity, oral contraceptives and breastfeeding 
are associated with lower ovarian cancer risk (Salehi et al., 2008, Hennessy et 
al., 2009). Pregnancy appears to have a protective effect, with an associated risk 
reduction with each birth (Kurian et al., 2005, Pasalich et al., 2013). Conversely, 
factors associated with increased ovarian activity, such as null parity (never 
having children) or infertility, appear to increase the risk (Tworoger et al., 2007) 
(Jensen et al., 2009). 
 
Oral contraceptives 
 
Women taking oral contraceptives for five or more years appear to have a 50% 
reduction in ovarian cancer risk compared with women who have never used this 
method of contraception (Riman et al., 2004a, Pasalich et al., 2013). The risk 
reduction is already apparent after a few months of use and persists for years 
after discontinuation. However, insufficient evidence exists to determine whether 
oral contraception influences risk in women who are carriers of BRCA1 or BRCA2 
mutations (Whittemore et al., 2004).  
 
Hormone replacement therapy (HRT) 
 
The evidence that HRT may increase risk of this disease remains inconsistent. 
Several recent studies revealed a small increase of the risk, especially for long-
term users of oestrogen replacement therapies (Daniilidis and Karagiannis, 
2007). However, short-term and past use of HRT for the relief of menopausal 
symptoms appears unlikely to increase ovarian cancer risk (Beral et al., 2007). 
Intermittent rather than continuously added progestins might further increase the 
risk (Cramer et al., 2001). However, other studies have recorded an increased 
38 
 
risk of approximately 50% in HRT users compared with non-HRT users, with risks 
increasing further in long-term use of five years or more (Riman et al., 2004b). 
 
1.4 Introduction to EOC metastasis  
 
The potential sites of origin of high grade serous carcinomas (high mitotic grade) 
are the ovarian surface epithelium, the fallopian tube epithelium and the 
mesothelium covering the surface of the peritoneal cavity. As this thesis 
investigates factors secreted by ovarian epithelial cancer cells and their effects 
on omental microvascular ECs, the metastasis cascades from the ovarian surface 
to the omentum will be discussed in the following sections. 
 
The metastasis process starts at the primary tumour- from detachment of tumour 
cells to their arrival and establishment in the secondary site, usually the omentum 
or other organs within the peritoneum. Thus, the omentum, its structure and the 
establishment of the secondary tumour foci and further tumour invasion process 
will be discussed in the following section. 
 
1.4.1 Omentum: Structure, physiology/pathology 
 
The omentum is a flap of adipose tissue that forms a sac within the peritoneum. 
It has two sections- greater omentum and lesser omentum. Anatomically the 
greater omentum hangs from the greater curvature of the stomach like an apron, 
covering the intestines. The lesser omentum extends from the liver to the lesser 
curvature of the stomach and the first part of the duodenum (Platell et al., 2000). 
It is the greater omentum, also commonly referred to as the omentum, which 
homes ovarian cancer cells and allows invasion and further metastasis. 
 
Metastases of primary epithelial tumours of the ovaries as well as the stomach 
and colon are known to spread to the omentum very extensively. Direct seeding 
of epithelial ovarian malignant cells onto the highly vascularised omentum 
characterises metastatic disease (advanced) and is associated with a poor 
survival prognosis. The ultrastructure of the omentum comprises two mesothelial 
layers surrounding the adipose tissue and loose connective tissue. The adipose 
region of the omentum contains so-called “milky spots”, which contain a dense 
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capillary network accompanied by an accumulation of immune cells 
(macrophages, B and T cells). These sites (in mice) are characterised by a 
discontinuous layer of mesothelium allowing direct contact of the vascular beds 
with the peritoneal cavity (Cui et al., 2002).   
 
The omental “milky spots” play a role in the clearance of bacteria and debris, and 
provide a niche for the origination and maturation of peritoneal macrophages 
(Mandache et al., 1985, Van Vugt et al., 1996). In response to external stimuli 
(such as inflammation, foreign material) the omental tissue in these areas can 
adhere to and enclose the pathological insult. This induces local activation of 
omental tissue, with increased local omental blood flow, production of multipotent 
stem cells and secretion of various inflammatory and growth factors, such as 
VEGF and bFGF (Zhang et al., 1997, Bikfalvi et al., 1990). Indeed, in an 
experimental wound model it has been shown that the expression of bFGF 
(macrophages, fibroblasts, and ECs) and transforming growth factor beta 1 (TGF-
β1) (macrophages) from the omentum promoted wound healing (gastric ulcers) 
by inducing bFGF mediated angiogenesis and TGF-β1 mediated collagen 
production (Matoba et al., 1996). Interestingly, although milky spots are filled with 
active immune cells, it is not known how tumour cells escape the potent immune 
response. It was thought that, tumour cells undergo differentiation at the milky 
spots, expressing a variation of antigens on their cell surface membranes (Dunn 
et al., 2002). Already differentiated and activated immune cells target only a 
specific variant or a group of variants of antigens on tumour cells, killing a small 
number of tumour cells. However, newly differentiated tumour cells retain the 
potency to proliferate, and therefore, these cells form micro-metastases within 
the milky spots and evade the immune response (Oosterling et al., 2006). This 
allows the tumour cells to metastasise further in the omentum.  
 
It is important to note that, these immune cells secrete both pro- and anti-
inflammatory factors, where the balance is “tipped” towards a pro-inflammatory 
reservoir. Interestingly, immune cell-secreted growth factors VEGF and bFGF 
have also been shown to be highly proangiogenic, which explains the highly 
vascularised milky spots, aiding active metastasis via angiogenesis. The 
metastatic cascade is discussed below in two phases- early phase and late phase 
metastasis. 
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1.4.2 Early phase metastasis 
 
The ovarian surface epithelium is a single layer of cells covering the ovary, 
derived from the coelomic epithelium. Approximately 90% of human ovarian 
cancers are thought to originate from the epithelium (Ahmed et al., 2007). Before 
ovarian cancer cells detach and initiate the metastasis cascade, they gain 
resistance to anoikis (a process of apoptosis when cells lose their cell-to-matrix 
interactions), followed by an epithelium-to-mesenchymal (EMT) transition 
(Lengyel, 2010). This weakens the attachment of epithelial cells to the basement 
membrane and loosens the intercellular adhesions between the cancer cells. 
During EMT, cancerous epithelial cells lose E-cadherin-mediated-cell-cell 
interactions, and upregulate other cadherins such as N-cadherin and P-cadherin, 
as part of a global “cadherin switch” (Lengyel, 2010). E-cadherin, a membrane 
glycoprotein located at cell adherens junctions, connects through α and β-catenin 
to the actin microfilaments within the cytoplasm, thereby anchoring epithelial cells 
to each other. In cancerous cells, E-cadherin is cleaved off by matrix 
metalloproteinase (MMP)-9, induced by cancer cells, contributing to the 
loosening of cell-cell adhesion and allowing the transformed cells to shed as 
single cells or spheroids into ascites (abnormal accumulation of fluid within the 
peritoneum). Also, active MMP1, a transmembrane protease, cleaves α3-integrin, 
contributing to the detachment of the spheroid from the primary tumour, reviewed 
in (van Zijl et al., 2011, Pranjol et al., 2015).  
 
With reduced levels of E-cadherins, the transformed cells appear as fibroblasts, 
acquiring an invasive phenotype with enhanced cellular proliferation (Lengyel, 
2010). It has been shown that EOC cells with low E-cadherin expression are more 
invasive and the absence of E-cadherin expression in ovarian cancer predicts 
poor patient survival (Lengyel, 2010). Detached cancer cells, with a decrease in 
expressed E-cadherin, increase upregulation of the fibronectin receptor, α5β1 
integrin, α6β1 integrin (binds laminin) and α2β1 integrin (binds type IV collagen), 
facilitating the adhesion of ovarian cancer cells to the secondary site. These cells 
spread to the secondary sites within the peritoneum, including the omentum, 
carried by the physiological movement of peritoneal fluid, reviewed in (Lengyel, 
2010). A schematic diagram of omental metastasis is shown in figure 1.4. 
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Figure 1.4: Mechanisms of ovarian cancer metastasis: Transcoelomic 
dissemination. (1) The cancer cells loose cell–cell contact and exfoliate into the 
peritoneal cavity. (2) They float in the peritoneal fluid and are carried all over the 
peritoneal cavity. (3) Attachment to the peritoneal organs such as the omentum. 
(4) Formation of the metastatic tumour. 
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Once at the secondary site (the omentum), disseminated cancer cells interact 
with the mesothelial cells covering the basement membrane. β1 integrins have 
been identified as important mediators of this adhesion to the mesothelium. This 
integrin has been shown to dimerise with different types of α integrin subunits, 
thus aiding this attachment (Lengyel, 2010). Another important adhesion receptor 
VCAM1 is present on mesothelial cells and binds to α4β1 integrin on ovarian 
cancer cells. Neutralising antibodies directed against VCAM1 and β1 integrin 
blocked this migration and metastasis in a xenograft model (Lengyel, 2010). 
Other lesser characterised adhesion factors that may influence this attachment 
between ovarian cancer cells and the mesothelium are the vitronectin receptor 
(αvβ3 integrin) and CD44 (surface receptor for hyaluronic acid). These factors 
are currently under investigation for their roles in ovarian cancer metastasis, 
reviewed in (Lengyel, 2010). 
 
Once attached to mesothelial cells, migrant cancer cells upregulate MMP2, 
promoting cleavage of the extracellular matrix proteins fibronectin and vitronectin 
into smaller fragments. The cancer cells adhere more strongly to these smaller 
fragments, using the fibronectin (α5β1) and vitronectin (αvβ3) receptors. 
Interestingly, MMP9 also plays a key role in the metastatic process by aiding 
angiogenesis and tumour growth as shown in mice lacking the MMP9 gene which 
had impaired angiogenesis and reduced tumour growth, reviewed in (Pranjol et 
al., 2015, Lengyel, 2010).  
 
1.4.3 Late phase metastasis 
 
Early metastasis is well-coordinated via adhesion and proteolysis, which provides 
a niche for EOCs to establish secondary foci in the omentum by invading the 
basement membrane- initiating late phase of the metastatic cascade. Although 
early metastasis is very well studied because of the availability of appropriate 
models, less is known about what happens after the ovarian cancer cells have 
implanted. In order for the secondary tumour to grow and survive, a 
microenvironment is created by cancer and surrounding cells such as fibroblasts, 
mesothelial cells, adipocytes and monocytes. A number of factors are secreted 
by these cells into the microenvironment which influence tumour cell implantation, 
proliferation and chemoresistance acquisition, are briefly discussed below. 
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Fibroblasts 
 
Ovarian cancer cells stimulate the secretion of urokinase-type plasminogen 
activator in fibroblasts, by releasing fibroblast growth factor 2 (FGF2), heparin-
binding EGF-like growth factor, hepatocyte growth factor (HGF), insulin-like 
growth factor 1 (IGF1), IL1α, pro-matrix metalloproteinases 2 (pro-MMP2) and 
tissue inhibitor of metalloproteinase 2 (TIMP2) (Noskova et al., 2009). proMMP-
2 is activated by a membrane bound metalloproteinase which then results in the 
degradation of ECM, allowing the invasion of ovarian cancer cells. Fibroblasts in 
the omentum are able to enhance ovarian cancer cell adhesion and invasion into 
the omentum by cell-cell contact through a complex cross talk between the 
expressions of the aforementioned secreted factors and activation of MMP2, 
reviewed in (Thibault et al., 2014). 
 
Mesothelial cells 
 
Mesothelial cells line the peritoneal cavity and its organs including the omentum. 
The major known role of these cells is to express ECM proteins and adhesion 
molecules such as hyaluronan which promotes ovarian cancer cell adhesion to 
the omentum via CD44 (Thibault et al., 2014). Mesothelial cells are also able to 
secrete pro-tumoural factor IL6, and pro-proliferative and proangiogenic factor 
bFGF. In addition, mesothelial cells constitutively produce lysophosphatidic acid 
(LPA) that enhances adhesion, migration and invasion of ovarian cancer cells, 
reviewed in (Thibault et al., 2014).  
 
Adipocytes 
 
Role of adipocytes in the ovarian tumoural microenvironment is poorly studied. 
The omentum is principally composed of adipocytes (as previously described) 
and is a major site of advanced ovarian cancer metastasis that results in 
transformation of this soft pad of tissue, primarily composed of adipocytes, to a 
solid tumour histologically devoid of adipocytes. If metastasis was a random 
event, all organs in contact with peritoneal fluid would have an equal distribution 
of metastases. However, both primary and recurrent high-grade serous ovarian 
carcinomas preferentially metastasise to adipose tissue (Nieman et al., 2011). 
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Thus, it is believed that the adipocytes play a major role in cancer cell migration 
and invasion, although the molecular mechanisms underlying this predilection are 
unknown. Interestingly, these cells are known to induce the homing of ovarian 
cancer cells by secreting cytokines such as IL6, 8, monocyte chemotactic protein 
1 (MCP1) and adiponectin (Thibault et al., 2014, Nieman et al., 2011). Omental 
adipocytes significantly promoted invasion of ovarian cancer cells when 
compared with subcutaneous adipocytes, suggesting that adipocytes promote 
the early steps of ovarian cancer metastasis to the omentum, although a 
mechanistic explanation for the prevalence of omental metastatic tumours in 
women with ovarian cancer remained elusive (Nieman et al., 2011). 
 
1.5 Tumour cells- secreted factors  
 
Ovarian tumour cells secrete a number of cytokines, growth factors, pro- and anti-
angiogenic factors.  These factors create a niche for cancer cells to establish 
secondary foci, grow and metastasise further from the omentum. As the focus of 
this thesis is tumour-angiogenesis, only the secreted proangiogenic factors that 
have been identified in EOC are described in the following table 1.1: 
 
Although these aforementioned cells and their secreted factors enhance ovarian 
cancer cell invasion into the omentum, their survival as secondary tumour foci is 
vastly dependent on angiogenesis. As EOC cells metastasise to the omentum 
where angiogenesis occurs, it is important to discuss the omentum and its 
suitability as a niche for secondary tumour foci.   
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Table 1.1: Proangiogenic factors secreted by ovarian cancer cells- an exhaustive 
list. 
 
Activators  Function  References 
Vascular endothelial 
growth factor (VEGF) 
Stimulates angiogenesis, 
permeability 
(Banerjee and 
Kaye, 2011) 
Angiopoietin-1 (Ang1) 
and Tie2 receptor 
Ang1: stabilises vessels by 
strengthening endothelial-smooth 
muscle interactions; Tie2R: 
inhibits permeability  
(Lin et al., 2011) 
Fibroblast growth factor 
(FGF) 
Stimulate angiogenesis and 
arteriogenesis  
(Tebben et al., 
2005) 
Transforming growth 
factor (TGF-β1) 
Stabilises vessels by stimulating 
ECM production  
(Toutirais et al., 
2003) 
Heparin-binding 
epidermal growth factor-
like growth factor 
Binds to epidermal growth factor 
receptor (EGFR) and promote 
angiogenesis 
(Tanaka et al., 
2005) 
IL6 Induces migration of ECs in the 
mesentery in EOC 
(Toutirais et al., 
2003, Nilsson et 
al., 2005) 
IL8 Stimulates VEGF expression and 
the autocrine activation of 
VEGFR2 in ECs 
(Lokshin et al., 
2006, Toutirais et 
al., 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
1.6 Angiogenesis – an overview in EOC  
 
The development of new blood vessels from the existing ones in response to 
tumour-cell secreted proangiogenic factors is known as tumour-angiogenesis. 
Without angiogenesis tumour expansion cannot proceed beyond 1–2 mm 
because tumour proliferation is severely limited by nutrient supply to, and waste 
removal from the tumour (Bamberger and Perrett, 2002). Therefore, it is a crucial 
factor in secondary solid tumour formation and metastases, including EOC.  
Vascularisation is also a prerequisite for tumour cells to spread by shedding into 
the circulation; the newly formed, immature, and leaky capillaries aid the process 
of metastasis because their basement membranes are fenestrated, allowing 
greater accessibility for stray tumour cells, reviewed in (Bamberger and Perrett, 
2002). 
 
In the growing secondary tumour, hypoxia induces hypoxia inducible factor 1 
(HIF-1) expression and the consequent release of proangiogenic factors such as 
VEGF, which activate ECs within these microvessels (Hu et al., 2001, Lee et al., 
2006). In the tumour microenvironment the balance between pro- and anti-
angiogenic factors favours the proangiogenic process. This hypoxic 
microenvironment containing VEGF also triggers ECs to secrete proteases such 
as matrix metalloproteinases initiating degradation of the ECM (basement 
membrane), followed by induction of EC migration along angiogenic factor 
gradient towards the tumour site. These ECs are differentiated into highly 
proliferative stalk cells which make up the main body of the new blood vessels- 
tube formation (Blanco and Gerhardt, 2013). This increased blood supply 
stimulates further tumour growth, invasion and metastasis (Bamberger and 
Perrett, 2002). 
 
VEGF plays a key role in vascular maturation and patterning. There is fine-tuning 
in the activity of proaniogenic and promaturation factors that results in vascular 
remodelling and maturation. For instance, VEGF and Ang2 cooperatively 
promote EC sprouting and pericyte detachment (Brudno et al., 2013). Pro-
maturation factors platelet-derived growth factor B (PDGF) and Ang1 inhibit the 
early stages of VEGF- and Ang2-mediated angiogenesis if present 
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simultaneously with VEGF and Ang2, but promote these behaviours if added 
subsequently to the pro-angiogenesis factors (Brudno et al., 2013). VEGF and 
Ang2 were also found to additively enhance microvessel density in a 
subcutaneous model of blood vessel formation, while simultaneously 
administered PDGF/Ang1 inhibit microvessel formation (Brudno et al., 2013). 
However, a temporally controlled scaffold that released PDGF and Ang1 at a 
delay relative to VEGF/Ang2, promoting both vessel maturation and vascular 
remodeling without inhibiting sprouting angiogenesis. This also ensures correct 
vascular patterning in physiological antiogenesis. However, in pathology, due to 
increased secretion of pro-angiogenic factors (e.g. VEGF) into the tumour 
microenvironment, local microvascular ECs become overactive and as a 
compensatory mechanisms, these cells express an increased amount of 
VEGFR2 (Nagy et al., 2009). This results in a disrupted vascular patterning where 
immature blood vessels are formed with increased pearmeability to solutes, 
proteins and migrating tumour cells, aiding metastasis to distant organ through 
circulation. 
 
In advanced EOC, angiogenesis plays a significant role in disease prognosis and 
patient survival. Although debulking surgery and chemotherapy offer some 
clinical benefits to patients, chemoresistance portrays a massive challenge. 
Therefore, targeting angiogenesis for therapeutic purposes holds a promising 
clinical outcome. The following sections explore anti-tumour and anti-angiogenic 
therapies in place and/or are undergoing clinical trials.  
 
1.6.1 Anti-tumour/angiogenic therapies 
 
General assessment of patients with EOC 
 
As discussed earlier, patients are often diagnosed with advanced stage disease. 
This is primarily due to having non-specific symptoms such as pain and 
abdominal swelling (that may refer to primary ovarian mass, epigastric omental 
plaques, ascites or a combination of these), gastroenterological manifestations 
(vomiting, dyspepsia and alternations of bowel) and less common urinary 
symptoms (pressure on the bladder).  
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A definitive diagnosis of EOC requires histopathological assessment, using a 
surgical specimen which is often obtained during staging laparotomy. The type of 
treatment for EOC depends on the cancer stage and histotype. Early stages of 
disease may involve surgery including abdominal hysterectomy and 
omentectomy. In patients with advanced EOC, primary debulking surgery 
(maximal surgical cytoreduction) has been shown to have a survival advantage 
(Griffiths, 1975). This is carried out to remove as much malignant tissue as 
possible. Depending on the remaining cancerous tissue, chemotherapies are 
given to patients intravenously. However, if the cancer reoccurs (recurrent 
ovarian cancer), a combination of chemotherapeutic drugs are often used such 
as carboplatin with gemcitabine or paclitaxel, although chemotherapy cannot 
usually cure the disease at this stage. This lack of treatment efficacy meant 
development of therapies targeting other steps of pathogenesis of EOC 
metastasis, such as antiangiogenic therapies. 
 
1.6.1.1 Antiangiogenic therapies 
 
Angiogenesis plays a major role in solid tumour progression, including in EOC. It 
is well established that the degree of angiogenesis, measured as microvessel 
density, in omental metastases of ovarian cancer and in primary ovarian tumours 
is an independent prognostic indicator of the overall survival of patients with 
advanced EOC (Hollingsworth et al., 1995, Abulafia et al., 1997). Due to limited 
treatment options for advanced stage EOC and the risk of recurrence and gaining 
chemoresistance, much enthusiasm has been shown for novel therapeutic 
strategies for ovarian cancer, particularly developing anti-angiogenesis agents. 
Since vascular endothelial growth factor (VEGF) has been extensively shown to 
be involved in the progression of other cancers, an anti-VEGF monoclonal 
antibody, bevacizumab, was approved for the treatment of advanced stage EOC. 
 
Bevacizumab (avastin) is an IgG1 anti-VEGF monoclonal antibody that targets 
VEGFA by binding to it and thereby inhibiting its ability to bind to VEGFR1 and 
VEGRF2. A phase III trial conducted by Perren et al. with 1528 patients reported 
that 7.5mg/kg bevacizumab taken intravenously with chemotherapy increased 
the progression free period by a mean of 1.5 months against the patients treated 
with chemotherapy alone (Perren et al., 2011). Another phase III study conducted 
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by Aghajanian et al. involved 484 ovarian cancer patients who had experienced 
a recurrence more than 6 months after a prior chemotherapy treatment 
(Aghajanian et al., 2012). The results concluded there was a 52% increase in the 
progression free period in those who were treated with bevacizumab and 
chemotherapy compared to those who were treated with chemotherapy alone. 
Tumour shrinkage was also greater in the group treated with bevacizumab (79% 
versus 57% respectively), and hence bevacizumab (despite showing relatively 
modest benefits) in combination with paclitaxel and carboplatin has been 
prescribed for first-line treatment in advanced ovarian cancer.  
 
Many other studies have indicated the therapeutic benefits of bevacizumab in 
ovarian angiogenesis but despite this, the clinical significance still remains 
unknown due to its toxicity. It has been reported in 16 clinical studies with over 
600 patients that 21% of those treated with bevacizumab alone were later 
diagnosed with grade 3 – 4 hypertension (Stone et al., 2010). Further to this, 
bevacizumab treatment in clinical trials has been found to be linked to a 
proteinuria diagnosis in patients when used alongside aflibercept (Stone et al., 
2010), which is a recombinant fusion protein consisting of VEGF-binding portions 
from the extracellular domains of human VEGF receptors 1 and 2 that are able 
to “trap” soluble VEGF (Rodriguez, 2013).  
 
Although bevacizumab combined with chemotherapy has been prescribed to be 
the first-line treatment for advanced EOC, it has been found to be associated with 
increased arterial thromboembolic events in various metastatic cancers against 
chemotherapy treatment alone (Scappaticci et al., 2007). The links between the 
side effects and ovarian cancer are not well characterised as arterial 
thromboembolic events are relatively rare in ovarian cancer. However, Tateo et 
al. found of 253 patients there was a 16.6% incidence of vascular thromboembolic 
events in ovarian cancer malignancies (Tateo et al., 2005). Stone et al. reported 
a total of 30 vascular thromboembolic events including 2 deaths resulting from 
bevacizumab treatment (Stone et al., 2010). Due to the mechanism of VEGF 
antagonism, bleeding can also be a common side effect due to the decreased 
ability of ECs to renew although life threatening haemorrhages are most 
commonly linked to tumours situated close to major blood vessels. 10 – 90% of 
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ovarian malignancies treated with bevacizumab have reported mild bleeding 
present as grade 1 or 2 mucosal bleeding (Stone et al., 2010). 
 
 
1.6.1.2 Tyrosine kinase inhibitors 
 
Besides antibody-dependent antiangiogenic therapies, several tyrosine kinase 
inhibitors such as sorafenib, cediranib, vatalanib, sunitinib and panzopanib, are 
being investigated that inhibit the VEGFRs directly rather than the binding of the 
VEGF ligand (Table 1.2).  These inhibitors have been developed to inhibit 
activation of tyrosine residues present on the intracellular domain of cell surface 
receptors which in turn leads to the activation of downstream cell signalling 
pathways such as RAS/Raf/MEK, PI3K/AKT/mTOR, JAK/STAT and p38, 
mediating cellular proliferation, survival, migration and altered cell permeability. 
Despite high specificity and efficacy, these inhibitors have been shown to be very 
toxic in completed clinical trials. For example, it was recently been shown that 
sorafenib, when added to standard therapy of advanced ovarian cancer, did not 
induce any benefit but rather increased severe toxicity (Hainsworth et al., 2015). 
The investigators suggested that sorafenib is not the angiogenesis inhibitor of 
choice in the treatment of patients with advanced ovarian cancer. 
 
The other drugs stated in table 1.2 are undergoing clinical trials. However, data 
from completed clinical trials show severe side effects associated with using 
these inhibitors such as leukopenia (reduction of leukocytes), lymphopenia (low 
levels of lymphocytes), hypertension, diarrhoea and prolonged irregular 
heartbeat  (that can lead to life threatening arrhythmia) (reviewed in (Morotti et 
al., 2013). These reports promise very little in treating the advanced disease, 
suggesting an urgent need for the identification of new targets in the development 
of anti-angiogenic therapies in the treatment of advanced EOC. 
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Table 1.2: A table displaying a brief summary of clinical trials for tyrosine kinase 
inhibitors (TKIs) for ovarian cancer, including route of administration, molecular 
target and observed response. 
Key: RCC - renal cell carcinoma; GIST – gastrointestinal stromal tumour; PFS – 
progression free survival. 
 
 
Drug Administration Target Response 
Sorafenib Oral 
 
 
 
VEGFR 2 and 3, 
and elements of the 
signal transduction 
pathway 
FDA approved for RCC. 20% 
ovarian cancer patients showed 6 
months PFS (Matei et al., 2008). 
Cediranib Oral VEGFRs (1-3) Significant tumour response / non-
progression for up to 16 weeks in 
ovarian cancer (Matulonis et al., 
2009). 
Vatalanib Oral VEGFRs (1-3) but 
most selective 
towards VEGFR2 
Significantly reduced tumour 
growth for ovarian cancer patients 
(Xu et al., 2000). 
Sunitinib Oral  VEGFRs (1-3) FDA approved for GIST and RCC 
(Wen et al., 2013). 
Panzopanib Oral VEGFRs (1-3) Significant CA-125 response 
(Friedlander et al., 2007). 
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It should be of concern that antiangiogenic therapy is currently only aimed at 
inhibiting VEGF/VEGFRs axis. Winiarski et al. showed that proangiogenic 
changes in human omental microvascular ECs (HOMECs) were not solely due to 
VEGF and identified other potential pro-angiogenic factors secreted by EOC cells 
(Winiarski et al., 2013). Therefore, this thesis hypothesises that non-VEGF 
proteins play significant roles in inducing or enhancing continuous development 
of tumour angiogenesis in the omental tissue, supporting metastasis of the 
cancer. 
 
 
1.7 Potential proangiogenic factors in ovarian cancer metastasis 
 
Recently, Winiarski et al. suggested that omental metastasis of EOC may 
primarily occur via non-VEGF dependent pathways and reported the presence of 
potential proangiogenic factors cathepsin L (CathL), cathepsin D (CathD) and 
insulin-like growth factor binding protein 7 (IGFBP7) in tumour (EOC) conditioned 
media and ascites of EOC patients (Winiarski et al., 2013). Previously, these 
proteins have been studied in other cancer models. All three proteins are usually 
highly expressed or over-secreted or only secreted in cancer models (discussed 
later). However, their involvement in inducing metastatic angiogenesis in 
secondary locations such as the omentum is not fully understood, and therefore 
it is important to review the biological and clinical significance knowledge of these 
tumour secreted factors in tumour progression, particularly in EOC.  
 
 
1.7.1 Cathepsin L 
 
CathL is a lysosomal ubiquitous cysteine proteinase that plays an important role 
in degrading endocytosed proteins as well as intracellular proteins (Kirschke et 
al., 1977, Kominami et al., 1991). CathL is translated as preprocathepsin L 
(ppCathL) and processed into procathepsin L (pCathL) in the rough endoplasmic 
reticulum with a molecular mass of 30kDa and a two-chain form with molecular 
masses 25kDa and 5kDa (Kominami et al., 1988, Nishimura et al., 1988). It is 
then transported to endosome/lysosomes via the mannose-6-phosphate/receptor 
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(M6P/M6PR) pathway (Dong and Sahagian, 1990). CathL contains covalently N-
linked oligosaccharides including a mannose moiety that is phosphorylated by 
phosphodiesterases in the cis Golgi (Lang et al., 1984). These M6P groups are 
recognised by an M6PR protein in the trans Golgi network (TGN), and facilitate 
the delivery of the protein to lysosomes (via endosomes) (Kornfeld, 1986). The 
cathepsins dissociate from the receptors at low lysosomal pH, and the phosphate 
group is removed from the M6P moiety by a lysosomal acid phosphatase (Samie 
and Xu, 2014). However, CathL has also been shown to be secreted out of the 
cell (discussed later). 
It has been reported that 1, 10-phenanthrolin and pepstatin partially inhibited the 
processing of the proenzyme form of CathL to the mature enzyme and it was 
speculated that metallo-proteinases or an aspartic protease such as CathD are 
involved in the proteolysis-mediated activation of CathL in the lysosome (Ishidoh 
et al., 1991, Ritonja et al., 1988). CathL can also be activated by autocatalysis of 
pCathL at pH 3 as shown in in vitro study of pCathL collected from conditioned 
media of murine fibroblast cultures (Mason et al., 1987). However, CathL is highly 
active at physiological pH 5.5 in lysosomes as shown in several studies (Mason 
et al., 1987, Mason and Massey, 1992).  
 
1.7.1.1 Main role and tight regulation 
 
The main role of CathL is to degrade proteins in the acidic pH of lysosomes 
(Mason et al., 1987, Mason and Massey, 1992). However, it is also known that 
CathL is secreted in different forms into the extracellular space in both 
physiological and pathological conditions, and retains its function as a protease. 
In physiology, CathL has been shown to degrade the Ii peptide of MHC II complex 
that in turn allows peptides derived from the proteolytic degradation of foreign or 
self-proteins to then bind to class II molecules and appear on the cell surface 
(Nakagawa et al., 1998). Studies showed that CathL is essential for MHC II 
mediated antigen presentation in cortical thymic epithelial cells but not in bone 
marrow-derived antigen-presenting cells in vivo (Hsieh et al., 2002). This was 
reflected in CathL deficient mice with a reduction in CD4+ T cells. CathL has also 
been shown to degrade and process foreign antigens which are then presented 
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on the MHC II molecule to elicit a CD4+ T-cell dependent immune response 
(Hsieh et al., 2002). Intracellular CathL is essential for epidermal homeostasis 
and regular hair follicle morphogenesis and cycling. It was found that CathL-
deficient mice develop periodic hair loss and epidermal hyperplasia, acanthosis, 
and hyperkeratosis (Roth et al., 2000).  
In another study, CathL null mice showed reduced bone mass compared to wild 
type mice suggesting a role for CathL in bone remodelling. CathL null mice 
showed significant decrease in bone volume in trabecular bone, but not cortical, 
bone compared to wild type. Bone loss was exacerbated in null mice (compared 
to wild type) following overiectomy suggesting that CathL is stimulated by external 
stimuli (e.g. oestrogen) and is likely to play a role in controlling bone turnover 
during normal development and in pathological states (Potts et al., 2004). 
 
1.7.1.2 CathL secretion 
 
CathL was first identified as a major secreted protein from a transformed murine 
fibroblast cell line (Mason et al., 1987). However, the mechanism of secretion of 
CathL remains a mystery. It has been shown that CathL has only one M6P 
residue, and hence its lower affinity for M6PR, as opposed to enzymes with two 
M6P residues such as CathD (von Figura and Hasilik, 1986, Dahms et al., 1989, 
Dong et al., 1989). This observation suggested that not all CathL binds to M6PR 
and therefore some is secreted out of the cell by default protein trafficking (Dong 
and Sahagian, 1990). M6PR saturation, downregulation or redistribution to the 
plasma membrane has also been suggested (Prence et al., 1990, Achkar et al., 
1990). Interestingly, hypoxia also induced CathL secretion from the murine 
fibrosarcoma cell line KHT-LP1 which may accelerate the metastatic process in 
these cells (Cuvier et al., 1997). Secreted CathL has also been shown to be 
protective against bacterial infection in airways of mice (Xu et al., 2013). 
 
1.7.1.3 CathL in cancer 
In the field of cancer, CathL is less well studied than other cathepsins such as 
cathepsins B (CathB) and S (CathS).  A role for CathL has been linked to tumour 
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invasion and metastasis, particularly by degrading several ECM components 
such as proteoglycan, aggrecan, elastin, laminin, fibronectin and collagens: I, II, 
IX, XI (Maciewicz and Wotton, 1991, Maciewicz et al., 1990, Nguyen et al., 1990, 
Nosaka et al., 1999, Mason et al., 1986, Ishidoh and Kominami, 1995). Over-
expression of CathL was linked to metastasis following ras transformation of 
NIH/3T3 cells in vitro (Chambers et al., 1992). Additionally, non-metastatic 
melanoma cells were converted to a metastatic state by over-expressing CathL 
in vitro (Frade et al., 1998). An extra-lysosomal role for CathL has been 
suggested in human and murine melanoma cells in the context of metastasis 
(Ishidoh and Kominami, 1998). Recently, it was shown that CathL is involved in 
B16F10 melanoma cell invasion (in vitro), particularly through cell migratory 
influences (Yang and Cox, 2007). There was approximately 70% reduction in 
CathL anti-sense clone invasion and migration compared to control after 24 
hours. However, testing for CathL-induced proliferation in these cells revealed 
that there was no difference between the rate of proliferation of antisense cell and 
control cell colonies (Yang and Cox, 2007). Effect of secreted CathL was also 
investigated where intracellular expression of an antibody to CathL has been 
shown to block CathL secretion, which resulted in a dramatic inhibition of 
melanoma metastasis (Rousselet et al., 2004). Although this study did not 
investigate migratory effects of exogenous CathL, Yang and Cox demonstrated 
a direct effect of secreted CathL on cell motility where CathL contributes its 
proteolytic action to the active invasion of melanoma cells (Yang and Cox, 2007). 
CathL-induced pancreatic cancer cell invasion was also observed in mice. CathL-
null mice had a significant reduction in tumour volume and invasion, suggesting 
a role for its extracellular proteolytic activity in wild-type mice. In contrast to the 
melanoma cell study discussed above, the latter work demonstrated significant 
proliferative effects of CathL on pancreatic cancer cells, with a 58% decrease in 
proliferation in CathL knockout cells, although the mechanism of action, i.e. 
proteolytic or non-proteolytic, was not investigated (Gocheva et al., 2006).  
An increased level of secreted CathL has been observed in the sera of malignant 
epithelial ovarian cancer patients (Nishida et al., 1995, Zhang et al., 2014b). 
These studies showed that there was significant increase in the expression of 
CathL mRNA levels in tumours which correlated with its protein level in serum. 
These authors also reported that increased level of secreted CathL was higher in 
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the sera of malignant EOC patient than those with benign or normal ovarian 
tissue. The levels of CathL mRNA expression and secreted protein in sera 
samples were higher than benign ovarian tumour and normal ovarian tissue. 
CathL was later shown to be involved in the invasion and metastasis of EOC, and 
hence was suggested to be a marker of advanced staged ovarian cancer (Zhang 
et al., 2014b). This was supported by data demonstrating that the endothelium of 
vessels within omentum hosting metastatic ovarian high-grade serous carcinoma 
expressed significantly increased CathL in vivo compared with omentum from 
control patients with benign ovarian cystadenoma (Winiarski et al., 2014). 
However, CathL-induced cell proliferation produced contradictory data. CathL 
had less influence on cell growth and proliferation of the A2780 ovarian cancer 
cell line (Zhang et al., 2014b), whereas downregulation of CathL-gene expression 
significantly inhibited the proliferative and invasive capability of SKOV3 ovarian 
cancer cells (Zhang et al., 2015).  
 
1.7.1.4 CathL in angiogenesis 
A role for CathL in angiogenesis is a relatively new observation and interestingly 
evidence from different models suggests that CathL may be both pro-and anti-
angiogenic. For instance, recently, CathL derived from skeletal muscle cells 
transfected with bFGF was shown to promote migration of human umbilical 
vascular ECs (HUVECs) in vitro (Chung et al., 2011). Cell migration, a key 
component of angiogenesis, was tested in the presence of a cell impermeable 
CathL-proteolytic inhibitor Z-Phe-Tyr-Cho and CathL for 12 hours.  The data 
revealed a significant reduction in HUVEC migration, suggesting that CathL 
influences cell migration via its proteolytic-dependent mechanism. Subsequently, 
CathL was found to activate c-Jun N-terminal kinase (JNK) in migratory HUVECs. 
However, the exact role of CathL in activating the JNK pathway has not been 
elucidated (Chung et al., 2011). Interestingly, CathL was found to be secreted by 
SKOV3 and A2780 EOC cells. Addition of exogenous CathL induced migration 
and in vitro angiogenesis of HOMECs (Winiarski et al., 2013). Together, these 
data suggest that CathL may trigger a proangiogenic phenotype in these ECs. 
In contrast, both secreted and intracellular CathL has been shown to release 
endostatin, a potent inhibitor of angiogenesis, by cleaving ECM collagen (Felbor 
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et al., 2000). Since the tumour microenvironment provides a slightly acidic milieu, 
CathL can efficiently cleave collagen even outside the cells. However, in other 
studies, CathL had no effect on angiogenesis. For example, Gocheva et al. 
demonstrated that CathL had no significant effects in altering microvascular 
density in pancreatic cancer in mice (Gocheva et al., 2006). When evaluating the 
role of CathL in angiogenic switching in homozygous cathepsin knockout RT2 
mice compared to control mice, no significant effect on the development of these 
precursor lesions was observed, suggesting that CathL does not contribute to 
angiogenic switching. However, other cathepsins such as CathB and CathS were 
found to be very important in inducing angiogenesis in the same study (Gocheva 
et al., 2006). 
Intriguingly, endothelial progenitor cells (EPCs) have been reported to produce 
CathL which in turn induces angiogenesis. Urbich et al. showed that EPCs are 
able to stimulate neovascularisation and blood flow in the ischaemic murine hind 
leg after injection in the affected leg (Urbich et al., 2005). These EPCs 
significantly enhanced expression of CathL which was revealed in mRNA array 
analysis. It was suggested that in the neovascularisation process CathL activity 
may be extra- or pericellular. Mature CathL was shown to remain proteolytically 
active extracellularly at neutral pH by the chaperone action of a p41 splice variant 
of the MHC class II-associated invariant chain (Fiebiger et al., 2002), which 
indeed is strongly expressed in EPCs (Urbich et al., 2005). Such activity may 
facilitate EPC invasion and neovascularisation. It was shown that CathL deficient 
mice suffered from impaired neovascularisation. Furthermore, mice treated with 
CathL-deficient bone marrow cells demonstrated a significant reduction in 
angiogenesis (Urbich et al., 2005). Another study also showed that CathL 
expressed in EPCs cells plays a critical role in intraocular angiogenesis (Shimada 
et al., 2010). However, although CathL has been suggested to induce 
angiogenesis in these studies, its mechanism of action has not been elucidated. 
 
1.7.2 Cathepsin D 
 
CathD is a soluble lysosomal aspartic endopeptidase primarily involved in 
degrading unfolded or non-functional proteins intracellularly. The protein is 
synthesised in rough endoplasmic reticulum as inactive preprocathepsin D (43 
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kDa), which is in turn cleaved and glycosylated to form 52 kDa procathepsin D 
(pCathD) containing two N-linked oligosaccharides modified with mannose 6-
phosphate (M6P) residues. pCathD is then targeted to intracellular vesicular 
structures such as lysosomes, endosomes and phagosomes both by M6P 
receptor (M6PR)-dependent and -independent pathways (reviewed in (Benes et 
al., 2008)). The latter pathway of targeting is not fully understood; however the 
sphingolipid activator precursor protein pro-saponin has been suggested to be 
involved (Gopalakrishnan et al., 2004). 
Once pCathD enters the late endosome, the low pH induces its dissociation from 
M6PR and subsequently the phosphate group is removed. Proteolytic cleavage 
of propeptide (44aa) of pCathD generates active intermediate enzyme (Laurent-
Matha et al., 2006). The propeptide (also known as activation peptide) is essential 
for the correct folding, activation and delivery of the protein to lysosomes 
(Takeshima et al., 1995, Yasuda et al., 2005). This peptide, which is expressed 
in, and secreted from, cancer cells, has also been demonstrated to act as a 
growth factor for tumour cells (Vetvicka et al., 2000). The intermediate CathD is 
further processed by cysteine proteases and autocatalysis to generate mature 
CathD (48 kDa) containing a heavy chain (34 kDa) and a light chain (14 kDa) 
(Gieselmann et al., 1985). The optimum pH for CathD activity is 3.5 at which it is 
highly proteolytically active (Yoshinari and Taurog, 1985). However, proteolytic 
activity has also been reported at neutral pH in the cytosol of apoptotic cells and 
in neurofibrillary degeneration (Kenessey et al., 1997, Roberg et al., 1999). 
 
1.7.2.1 Physiological roles of CathD as both an intracellular and 
extracellular protein 
CathD has been shown to play a significant role during foetal development. The 
lysosomal system matures gradually which correlates with increased CathD 
levels in all tissues (Kageyama et al., 1998). A reduction of CathD expression or 
its catalytic activity results in neurodegenerative disorders. CathD knockout mice 
die shortly after birth and display significant neurodegeneration (Kageyama et al., 
1998). Congenital mutations in the CathD gene lead to a reduction in expression 
and subsequent production of enzymatically inactive protein that results in 
neurodegenerative disease in dogs and humans (Tyynela et al., 2000, Tyynela 
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et al., 2001, Steinfeld et al., 2006, Fritchie et al., 2009, Siintola et al., 2006, Awano 
et al., 2006). Recently, it has been shown that CathD deficiency is associated 
with Parkinson’s disease (Cullen et al., 2009). Interestingly, increased CathD 
expression and activity in cardiac cells induces heart failure in postpartum female 
mice (Hilfiker-Kleiner et al., 2007). Higher CathD levels have also been suggested 
to play an important role in the pathogenesis of autism by increasing apoptosis in 
the cerebellum of autistic subjects (Sheikh et al., 2010). 
Several physiological functions of CathD have been suggested based on its 
proteolytic activity to cleave structural and functional proteins and peptides. 
These include metabolic degradation of intracellular proteins, activation and 
degradation of polypeptide hormones and growth factors such as plasminogen, 
prolactin, endostatin, osteocalcin, thyroglobulin, insulin-like growth factor binding 
proteins (IGFBP) and secondary lymphoid tissue chemokine (SLC); activation of 
enzymatic precursors of CathL, CathB and transglutaminase 1; and processing 
of the enzyme activators and inhibitors prosaposin and cystatin C, reviewed in 
(Benes et al., 2008). 
Although CathD is a lysosomal enzyme and its enzyme activity is usually 
regulated within the acidic compartment of lysosomes, it has also been shown to 
be enzymatically active and biologically relevant extra-lysosomally at cytosolic 
pH, for instance in the control of apoptosis as discussed later. 
 
Unlike other aspartic endopeptidases, under normal physiological conditions, 
pCathD is sequestered to the lysosome and not secreted extracellularly. 
However, in some conditions, pCathD/CathD escape the normal targeting 
pathway and are secreted from cells. Most probably, over-expression of pCathD 
saturates the limited number of M6PR binding sites available and the protein 
accumulates in the cytosol, and is subsequently secreted via an as yet unknown 
mechanism (Mathieu et al., 1991). Indeed pCathD has been found in human, 
bovine and rat milk and serum and the presence of both pCathD and CathD (34 
kDa) was observed in human eccrine sweat and urine (Vetvicka et al., 1993, 
Larsen and Petersen, 1995, Benes et al., 2002, Zuhlsdorf et al., 1983). CathD in 
human eccrine sweat was found to be proteolytically active at sweat pH 5.5 
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(Baechle et al., 2006). Interestingly, there is increasing evidence that extracellular 
CathD may act via both proteolytic dependent and independent mechanisms. 
 
1.7.2.2 Expression of CathD in ovarian cancer 
In many cancer microenvironments, pCathD is a major secreted protein. In the 
last 2 decades, studies have shown increased overexpression and 
hypersecretion of CathD in numerous cancer types including ovarian cancer, but 
also in breast cancer, endometrial cancer, lung cancer, malignant glioma, 
melanoma and prostate cancer (Table 1.3) (Winiarski et al., 2013, Rochefort, 
1992, Ferrandina et al., 1997, Foekens et al., 1999, Briozzo et al., 1991, Chen et 
al., 2011, Konno et al., 2001, Morikawa et al., 2000, Losch et al., 1996, Zhu et 
al., 2013, Fukuda et al., 2005, Rochefort et al., 2000, Pruitt et al., 2013, Vetvicka 
et al., 2004, Nazeer et al., 1992). Early studies investigating ovarian carcinoma 
suggested that the expression level of CathD was associated with increased cell 
differentiation and with histological type (Baekelandt et al., 1999, Ferrandina et 
al., 1998). 
Additionally, immunohistochemistry studies have indicated that enhanced CathD 
expression is an indicator of malignancy in serous ovarian cancer (Henzen-
Logmans et al., 1994, Losch et al., 2004, Chai et al., 2012), for instance Losch et 
al. observed that over 70% of invasive ovarian cancers express CathD (Losch et 
al., 2004). Intriguingly, however, it has also been shown that in ovarian tumours 
that do express CathD, a high expression level was associated with a favourable 
survival prognosis (Chai et al., 2012). More recently, in an investigation into 
omental metastasis of ovarian cancer in our laboratory observed a significantly 
higher expression of CathD in the omental lesion of serous ovarian carcinoma 
compared with omentum from patients with benign ovarian cystadenoma and that 
high omental mesothelial expression of CathD was associated with poor disease-
specific survival (DSS) (Winiarski et al., 2014). This stronger expression of CathD 
in mesothelial cells was observed close to the metastatic tumour, suggesting a 
paracrine effect for factors secreted from the tumour cells contributing to the 
increased CathD expression. 
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Table 1.3. Involvement of CathD in the stages of tumour progression in different 
cancer types. Taken from (Pranjol et al., 2015) 
 
Cancer Type Metastasis Invasion Angiogenesis References 
Breast ↑ ↑ ↑ 
(Rochefort, 1992, 
Ferrandina et al., 1997, 
Foekens et al., 1999, 
Briozzo et al., 1991) 
Ovarian ND ND ↑ (Winiarski et al., 2013) 
Prostate ↑ ↑ ↓ 
(Chen et al., 2011, 
Konno et al., 2001, 
Morikawa et al., 2000) 
Endometrial ND ↑ ND (Nazeer et al., 1992) 
Melanocytic ↑ ↑ ND (Zhu et al., 2013) 
Glioma ↑ ↑ ND (Fukuda et al., 2005) 
Lung ND ↑ ND (Vetvicka et al., 2004) 
↑, increase in effects; ↓, reduction in effects; ND, not determined. 
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A number of studies have also examined CathD expression in breast cancer. 
CathD overexpression is correlated with increased risk of clinical metastasis and 
short survival in breast cancer (Rochefort, 1992, Ferrandina et al., 1997, Foekens 
et al., 1999) and increased serum pCathD levels were detected in the plasma of 
patients with metastatic breast carcinoma (Brouillet et al., 1997). Additionally, 
total CathD concentration in breast cancer tissue was much higher than in other 
tissues including normal mammary cells (Vetvicka et al., 1994). 
 
1.7.2.3 Role of CathD in tumour progression 
It is now recognised that CathD has a potential role in multiple tumour progression 
steps, both in its intracellular and extracellular form. 
As indicated above, a role for intracellular cytosolic CathD has been identified in 
apoptosis. Here the lysosomal enzyme is translocated to the cytosol due to 
lysosomal membrane permeabilisation (Roberg et al., 1999, Ollinger, 2000, 
Kagedal et al., 2001). Subsequently, CathD actively cleaves the BH3-interacting 
domain (Bid) to form truncated Bid (tBid) which in turn triggers the insertion of 
Bax into the mitochondrial membrane (Heinrich et al., 2004, Blomgran et al., 
2007), and leads to the release of cytochrome c from mitochondria into the 
cytosol (Johansson et al., 2003). Inhibition of enzymatically-active cytosolic 
CathD, using the inhibitor pepstatin A (pepA), partially delayed apoptosis induced 
by IFN-γ or oxidative stress when pepA was co-microinjected with CathD in 
human foreskin fibroblasts, HeLa cells and neutrophils (Kagedal et al., 2001, 
Heinrich et al., 2004, Blomgran et al., 2007). The role of CathD in inducing 
apoptosis has also been shown to be associated with caspases; the pan caspase 
inhibitor Z-VAD-FMK added in combination with pepA, induced a significant 
reduction in cell death compared to individual inhibitor treatments. This 
suggested a strong association between caspases and proteolytically active 
cytosolic CathD (Zuzarte-Luis et al., 2007b, Zuzarte-Luis et al., 2007a). 
Additionally, CathD has been shown to cleave tau  
protein in vitro at pH 7 (Kenessey et al., 1997). These studies suggest that, 
intracellularly, CathD is proteolytically active at cytosolic pH. However, this has 
been contested by other studies indicating that the effect of a mutant CathD, 
deprived of its catalytic activity, was indistinguishable from that of the normal 
enzyme (Beaujouin et al., 2006, Tardy et al., 2003). 
63 
 
Although, a role for intracellular CathD in apoptosis suggests that the protein may 
be anti-tumourigenic; this is in contrast to the functions observed for extracellular 
CathD. 
For instance CathD is secreted by EOC cancer cell lines (SKOV3 and A2780) 
(Winiarski et al., 2013), is present in the ascites of patients suffering from ovarian 
cancer (unpublished data), and exogenous CathD induced migration of human 
omental microvascular ECs; a key step in angiogenesis during omental 
metastasis (Winiarski et al., 2013). In a separate study pCathD and CathD have 
been reported to induce proliferation and migration of breast cancer cells, 
fibroblasts and ECs in both a proteolytic dependent and independent manner 
(Ohri et al., 2008) (Figure 1.5). While secreted pCathD is generally considered to 
be proteolytically inactive, it has been proposed that the acidic pH in the tumour 
microenvironment promotes the conversion of pCathD into mature, biologically 
active CathD. This was supported by data indicating that pCathD, collected from 
tumour-conditioned media, became auto-activated if the pH was lowered and was 
subsequently able to degrade ECM proteins and release growth factors such as 
bFGF (Briozzo et al., 1991, Briozzo et al., 1988, Westley and May, 1996), steps 
important for cancer cells to invade surrounding tissue (Crowe and Shuler, 1999). 
There is evidence that CathD may induce mitogenic responses via both 
proteolytic-dependent and—independent mechanisms. Both the wild type and 
mutant form of CathD were shown to induce fibroblast proliferation via a 
mechanism whereby they acted as a protein ligand (Laurent-Matha et al., 2005). 
In this study, the authors demonstrated an interaction between M6PR and 
pCathD. Co-incubation with excess M6P partially prevented fibroblast 
proliferation. Although an unknown receptor molecule was suggested to be 
involved, the identity of this potential receptor has not yet been resolved. 
CathD actions on tumour growth were further reported in studies showing that 
3Y1-Ad12 rat tumour cells transfected with human CathD cDNA grew more 
rapidly in vitro and presented an increased experimental metastatic potential in 
vivo (Garcia et al., 1990, Liaudet et al., 1994, Liaudet et al., 1995). Additionally, 
both wild-type and mutated (Asn 231, proteolytically inactive) CathD stimulated 
proliferation of 3Y1-Ad12 cells embedded in Matrigel or collagen 1 matrices, 
colony formation in soft agar and tumour growth in athymic nude mice (Glondu et 
al., 2001, Berchem et al., 2002). Again, an unknown receptor, other than M6PR, 
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Figure 1.5. Potential roles of tumour cell-secreted pCathD/CathD on 
extracellular matrix (ECM), tumour, fibroblast and ECs in the tumour 
microenvironment. pCathD is synthesised and processed in the rough 
endoplasmic reticulum (rER) and Golgi bodies (G), and subsequently transported 
to early endosome (EE), late endosome (LE) and finally lysosome (LY). 
Overexpressed pCathD/CathD is secreted into the extracellular space by tumour 
cells. Mature CathD cleaves ECM and releases basic fibroblast growth factor 
(bFGF) that may induce angiogenesis. Both pCathD and CathD induce tumour 
cell proliferation, and hence invasion via an autocrine mechanism. CathD induces 
proliferation of fibroblasts and migration of ECs. Mannose-6-phosphate receptor 
(M6PR) may be involved in inducing the proliferative effects. C and N denote 
cytoplasm and nucleus, respectively. Taken from (Pranjol et al., 2015) 
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was suggested to be involved in CathD mediated cell growth as no inhibition of 
cell outgrowth was observed when excess M6P was added, suggesting that M6P 
did not compete with CathD interacting with M6PR. In the same study the 
propeptide (27-44aa) of pCathD was found not to be mitogenic, contradicting 
studies which found otherwise (Vetvicka et al., 2000, Vetvicka et al., 1994, Fusek 
and Vetvicka, 1994, Vetvicka et al., 1998, Vetvicka et al., 1999, Vetvicka et al., 
1997). 
The role of CathD has also been extensively studied in human primary breast 
cancer. Upregulation of CathD expression was observed in oestrogen receptor 
(ER) positive breast cancer cell lines treated with oestrogen (Rochefort et al., 
1987). In vitro experiments with the MCF7 cell line supported these data and 
revealed that pCathD/CathD were overexpressed and hyper-secreted from these 
cells into the media. Further studies have reported that as a mitogen pCathD acts 
as a protein ligand rather than enzymatically and that purified pCathD from MCF7 
breast cancer cells stimulated MCF7 cell growth on plastic via an autocrine 
mechanism (Vignon et al., 1986). Intriguingly, CathD has also been shown to 
selectively degrade macrophage inflammatory protein (MIP)-1α (CCL3), MIP-1β 
(CCL4), and SLC (CCL21) that, in turn, may affect the generation of the anti-
tumoural immune response, the migration of human breast cancer cells, or both 
processes (Wolf et al., 2003). 
In recent years studies have emerged that suggest that CathD can induce 
angiogenesis in vivo and in vitro. In vivo, overexpression of CathD in xenografts 
in an athymic mice model correlated with increased vascular density. The number 
of microvessels was significantly increased by 1.5-fold and 1.9-fold in the CathD 
and CathD-Asn 231(proteolytically inactive) groups respectively, suggesting that 
CathD induces angiogenic effects via an unknown mechanism other than its 
proteolytic activity (Berchem et al., 2002). 
CathD has also been shown to induce blood vessel formation in the chick 
chorioallantoic membrane (CAM) model (Hu et al., 2008) and a role for CathD in 
angiogenesis was further illustrated by the observation that migration of HUVECs 
and in vitro angiogenic tube formation were increased when cells were treated 
with active pure CathD. CathD was proteolytically active in these experiments as 
complete inhibition of angiogenesis, tube formation and migration was achieved 
by addition of pepA (Hu et al., 2008). Proteolytically active CathD has also been 
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suggested to induce angiogenesis in breast cancer by cleaving and releasing 
ECM-bound pro-angiogenic bFGF (Briozzo et al., 1991). These aforementioned 
studies suggest that CathD can induce proangiogenic responses via both its 
proteolytic-dependent mechanism and an unknown mechanism that is not 
dependent on its proteolytic activity.  
In contrast it has also been suggested that CathD activity may be anti-angiogenic 
For instance, pCathD secreted by prostate cancer cells was shown to have a 
possible role in generating angiostatin via proteolysis—a specific inhibitor of 
angiogenesis in vitro as well as in vivo (Morikawa et al., 2000), suggesting an 
opposing effect of CathD in angiogenesis. Due to the variability of its mechanisms 
of action and the opposing effect in angiogenesis, it was important to investigate 
a specific role for CathD in inducing a proangiogenic response in HOMECs in 
ovarian cancer metastasis, which was examined in this thesis. 
1.7.3 IGFBP7 
 
Insulin-like growth factor-binding protein 7 (IGFBP7), also known as insulin-like 
growth factor-binding protein-related protein-1 (IGFBP-rp1), tumour adhesion 
factor, prostacyclin-stimulating factor (PSF), and angiomodulin (AGM), is a 
secreted protein which is thought to be a vital component of mammalian cell 
growth, differentiation and proliferation (Chen et al., 2013), particularly in ECs 
(Akaogi et al., 1996a). IGFBP7 is different from the other IGFBPs in that it has 
100-times less affinity for binding to IGF-1 and is the only family member that 
binds insulin with strong affinity, limiting insulin binding to the insulin receptor 
(Yamanaka et al., 1997). This difference may suggest that IGFBP7 has unique 
functions that are primarily IGF1-independent (Hwa et al., 1999). 
 
IGFBP7 is synthesised from the mac25 protein, the propeptide of which has been 
found to have around a 45% amino acid sequence similarity to human IGFBPs 
1-6 (Oh et al., 1996). The mRNA for IGFBP7 has been found in a wide range of 
healthy tissues including the small intestine, prostate, lungs, skeletal muscle, 
colon and ovaries (Hwa et al., 1998): this protein is particularly abundant in blood 
vessels in the mature follicular wall (Wandji et al., 2000), uterus (Kutsukake et al., 
2007) and the corpus luteum (Abu-Safieh et al., 2011). 
 
67 
 
The available data on the role of IGFBP7 in tumour development is conflicting. A 
negative role for IGFBP7 was first documented when it was identified as a 
differentially expressed gene in normal leptomeninges compared with 
meningiomas and in primary prostate epithelial cell lines compared with prostate 
cancer cell lines (Akiel et al., 2014). A number of studies have reported IGFBP7 
downregulation in breast, colorectal and lung cancer (Swisshelm et al., 1995, 
Hwa et al., 1998, Chen et al., 2007). Moreover, overexpression of IGFBP7 in the 
breast-cancer cell line MDA-MB-468 abrogated their growth and migration via 
inhibition of phosphorylation of MAPK extracellular signal-regulated kinase 
(ERK)-1/2. Treatment of the breast-cancer cell line MDA-MB-231 with 
recombinant IGFBP7 protein induced G1 cell-cycle arrest and senescence, as 
indicated by cell-cycle analysis and β-galactosidase staining, respectively. The 
IGFBP7-induced cell-cycle arrest and senescence was mediated by induction of 
the p53–p21 axis and the activation of stress-activated p38 MAPK (Akiel et al., 
2014). Tail-vein injection of recombinant IGFBP7 for 3–4 days in NOD/SCID mice 
harbouring xenografted breast-cancer tumours resulted in decreased 
angiogenesis, as shown by a reduction in cluster of differentiation (CD) 31 and 
VEGF expression. Recombinant IGFBP7 was able to induce apoptosis as seen 
by caspase-3 and poly adenosine diphosphate ribose polymerase cleavages 
(Benatar et al., 2012). Taken together, these results suggest that IGFBP7 could 
act as a negative regulator of mitogenesis by suppressing ERK-1/2 and activating 
p38 MAPK and p53-p21 pathways to curb uncontrolled proliferation, induce 
senescence, and suppress angiogenesis in breast cancer. 
 
Interestingly, a recent study investigating effects of IGFBP7 on angiogenesis 
demonstrated that VEGF-induced stimulation of tube formation in HUVECs was 
reduced by treatment with IGFBP7 (Tamura et al., 2009). In the same study it 
was also found that cell proliferation induced by VEGFA was also inhibited in the 
presence of IGFBP7. However, IGFBP7 in the absence of VEGFA has not been 
found to reduce the proliferation or tube formation of vascular ECs (Tamura et 
al., 2009). This indicates a lack of evidence that IGFBP7 directly affects tumour 
blood vessels; only in the case of VEGFA-induced angiogenesis (Tamura et al., 
2009). 
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Although the above data suggest that IGFBP7 negatively influences cancer 
growth by reducing cancer cell proliferation, other data point towards a positive 
role in tumour development by influencing angiogenesis.  Glioblastoma-secreted 
IGFBP7 has been found to induce capillary formation in human brain ECs, and 
hence was suggested to be a proangiogenic factor (Pen et al., 2008). In a recent 
study, Winiarski et al. identified secreted-IGFBP7 in EOC tumour conditioned 
media (Winiarski et al., 2013). IGFBP7 induced omental microvascular EC 
proliferation, migration and angiogenic tube formation, again suggesting a 
proangiogenic role for this protein in the metastasis of ovarian cancer to the 
omentum (Winiarski et al., 2013).  
 
Thus, the role of IGFBP7 in carcinogenesis and angiogenesis remains 
contradictory across different cancer models. However, since IGFBP7 showed 
proangiogenic activity in HOMECs and thus may be involved in EOC metastasis, 
this will be further examined, specifically investigating the activated signalling 
pathways in these ECs. 
 
 
1.8 Rationale for this study and aims 
 
EOC is characterised with the highest mortality and the highest post-menopausal 
morbidity of all gynaecological cancers. Symptoms are vague at the primary 
stage, and hence early diagnosis is difficult. Therefore, many patients are 
diagnosed with advance stage of disease that requires a radical surgical 
intervention such as omentectomy. 
 
Although chemotherapy is applied as second line treatment, the progression-free 
survival rate has not improved drastically (Fung-Kee-Fung et al., 2007). 
Unfortunately, due to drug and chemotherapy resistance it is extremely common 
for a small proportion of the tumour cells in later stages of progression to survive 
and further proliferate once the chemotherapy schedule is completed. For this 
reason, it is essential that more permanently effective and targeted treatments 
are discovered and made available. Since angiogenesis plays a key role in late 
stage metastasis, numerous anti-angiogenic therapies have been developed 
targeting the VEGF/VEGFR axis. For example, anti-VEGF monoclonal antibody 
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bevacizumab, alone or in combination with chemotherapy, demonstrated 
increased progression-free period. Specifically, progression-free survival at 42 
months was 22.4 months without bevacizumab versus 24.1 months with 
bevacizumab (P=0.04 by log-rank test) (Perren et al., 2011). However, this drug 
has been observed to be highly toxic, with numerous side-effects as discussed 
above.  
As the tumour microenvironment at the secondary site contains a mixture of 
growth factors and cytokines released by immune cells, mesothelial cells, ECs, 
adipocytes, fibroblasts and ovarian cancer cells, targeting only one factor (VEGF) 
may not be successful in preventing tumour-angiogenesis. Thus, it was essential 
to investigate tumour-secreted proangiogenic factors, other than VEGF, that may 
enhance the proangiogenic response in the metastatic cascade of EOC. Indeed 
Winiarski et al. reported that despite blocking the VEGF/VEGFR axis, HOMECs 
treated with EOC-conditioned media induced significant angiogenic tubule 
formation, suggesting the presence of potential factors with pro-angiogenic roles 
(Winiarski et al., 2013). Further studies investigating EOC-secreted factors 
revealed a number of factors including CathL, CathD and IGFBP7 in the tumour 
conditioned media, which were shown to be proangiogenic in HOMECs in EOC 
metastasis. However, their activatory mechanisms in HOMECs have not yet been 
elucidated.  
 
Interestingly, CathL was shown to induce expression and secretion of Gal1 in 
HOMECs. Gal1 is a glycoprotein which has been shown to be proangiogenic in 
several tumour models (discussed later). Thus, Gal1 was investigated in the 
induction of HOMEC proliferation, migration and angiogenesis, in addition to 
CathL-induced proangiogenic response in HOMECs. 
 
Therefore, the overall aim of this thesis was to examine possible cross-talk 
between ovarian cancer cells and omental microvascular ECs in metastasis of 
ovarian cancer to the omentum, specifically to investigate whether non-VEGF 
factors secreted from EOC can induce angiogenic changes in the local 
microvasculature and the signalling pathways activated. Alternative factors 
examined will be CathL, CathD, Gal1 and IGFBP7. In order to investigate 
interactions between these cells, the following aims were executed:  
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 Investigation into the proangiogenic changes induced in HOMECs by 
CathL (Chapter 3) 
 Investigation into the proangiogenic changes induced in HOMECs by 
Gal1, a glycoprotein secreted by HOMECs in response to CathL (Chapter 
4) 
 Investigation into the proangiogenic role of CathD in ovarian cancer 
metastasis to the omentum (Chapter 5) 
 Investigation into potential proangiogenic roles of IGFBP7 in HOMECs 
(chapter 6) 
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Chapter 2 Materials and methods 
 
2.1 Materials 
Abcam, Cambridge, UK: Insulin-like growth factor binding protein-7 (IGFBP-7) 
protein, goat anti-rabbit IgG-FITC conjugated. 
Alphalabs, Hampshire, UK: 300µl tips (autoclavable). 
BD Biosciences, Oxford, UK: Syringes, cell strainers (nylon, 40μm and 100μm 
pore size), cell scrapers. 
Biotechne (R&D system, Tocris), Abingdon, UK:  
Enzyme-linked immunosorbent assay (ELISAs): Phospho-ERK1 
(T202/Y204)/ERK2 (T185/Y187) Cell-Based ELISA, Phospho-Akt (T308) Pan 
Specific Cell-Based ELISA, Human Galectin-1 Quantikine ELISA Kit, Phospho-
RelA/NFκB (nuclear factor κB) p65 (S536) Cell-Based ELISA. 
Migration assay kit: Cultrex Cell Migration Assay, 96 well. 
Proteome Profiler Antibody Arrays: phosphor-kinase array, phosphor-receptor 
tyrosine kinase array. 
CELLutions Biosystems, Ontario, Canada: Human cerebral microvascular 
endothelial cell/D3. 
eBioscience, Hatfield, UK: Calcein acetoxymethyl (AM) viability dye (ultrapure 
grade). 
Enzo LifeSciences, Exeter, UK: Cathepsin D & E substrate- fluorogenic, 
Cathepsin L fluorogenic substrate (Z-VVR-AMC), Collagen type 1 (rat tail). 
Fisher Scientific, Loughborough, UK: Formaldehyde 16% (Methanol-free), 
Molecular Probes™ CellLight™ Golgi-GFP- BacMam 2.0, Cyquant NF cell 
proliferation kit, Corning™ Costar™ Flat Bottom Cell Culture Plates 6 well plate, 
Corning™ Matrigel™ Membrane Matrix GFR 10ml, GlycoBlue, Gibco™ 
Collagenase- Type I (powder), Gibco™ Collagenase- Type II (powder), CD31 
dynabeads, RNaseZap® RNase decontamination solution, Sodium Chloride, 
Nuclease-Free water, BCA assay. 
Greiner Bio-One Ltd, Gloucestershire, UK: Cell culture plastic-ware. 
Lonza, Wokingham, UK: PBS (without/with Ca2+, Mg2+). 
Merck Chemicals, Nottingham, UK: Aprotinin, Thrombin (bovine), Cathepsin L 
(human liver), Pepstatin A, CathL inhibitor Z-Phe-Tyr-CHO (FY-CHO), swinnex 
filter holders, millex® 0.22 µm filter units, nylon net filters 30 µm, Fibrinogen, 
Dithiothreitol (DTT). 
PeproTech: Human VEGF165, recombinant human galectin 1. 
Primerdesign Ltd, Chandler’s Ford, UK: Precision DNase kit, PrecisionPLUS 
master.  
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Promocell, Heidelberg, Germany: EC growth medium MV2 and supplementation 
(Foetus calf serum (FCS), EC growth factor kit). 
Quanta Biosciences, USA: qScript cDNA Supermix kit. 
Roche Diagnostics Ltd, West Sussex, UK: WST-1 reagent. 
Santa Cruz Biotechnology (Heidelberg, Germany): Mouse monoclonal anti-
human endoglin (CD105) antibody (SN6/N1-3A1). 
Sarstedt, Leicester, UK: cell culture plastic-ware. 
Stratech Scientifc Ltd (Selleckchem) Newmarket, UK: Kinase inhibitors- U0126, 
PD98059, LY294002, MK2206; NFκB inhibitor: Sulfasalazine. 
Sigma Aldrich, Gillingham, UK: Haemocytometer, Hank’s balanced salt solution 
(HBSS), Trypsin, Cathepsin D from human liver, Bovine Serum Albumin (BSA), 
L-glucose, D-glucose, Gentamicin (50mg/ml), Dimethyl sulfoxide (DMSO), 
Gelatin type B (bovine skin), HEPES, TRI Reagent, SU5416, Sodium phosphate 
dibasic (Na2HPO4), Citric Acid, 96 well plates black flat bottom (non-sterile), 
diethyl pyrocarbonate (DEPC), Tween® 20, Golgi apparatus transportation 
blocker: Brefeldin A, Calcium chloride (CalCl2) solution (1M), Potassium chloride 
(KCl), Cytodex 1 bead, Cytodex 3 bead, goat anti-mouse IgG-FITC conjugated, 
rabbit anti-human von Willebrand Factor (vWF) IgG fraction of antiserum. 
Thermo Fischer Scientific, Northumberland, UK: TaqMan® gene expression 
assays (primers)-LGALS1, GAPDH, B2M (β2-microglobulin), CellLight® Golgi-
GFP, BacMam 2.0.  
 
2.2 Buffers and solutions 
2.2.1 Cell culture solutions 
 
Complete growth media for HOMECs/HCMECs 
Endothelial cell basal medium MV2 
FCS (heat inactivated)  5% (v/v) 
Gentamicin     50 µg/ml 
 
Endothelial cell growth MV2 kit 
VEGF165     0.5ng/ml 
Human EGF     5ng/ml 
Human bFGF    10ng/ml 
IGF1      20ng/ml 
Ascorbic acid    1µg/ml 
Hydrocortisone    0.2µg/ml 
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Experimental and starvation media for HOMECs/HCMECs (unless otherwise 
stated) 
Endothelial cell basal medium MV2 
FBS (heat inactivated)   2% (v/v) 
Gentamicin      50µg/ml  
 
Freezing solution for HOMECs 
Growth Media    20% (v/v) 
FBS      70% (v/v) 
DMSO     10% (v/v) 
For primary cultures of HOMECs tissue culture plastic ware was coated with 
gelatin: 
Gelatin type B (bovine skin)  2% w/v  
Dissolved in ddH2O and then autoclaved and sterile filtered (while still warm) 
 
For culturing HCMECs tissue culture plastic ware was coated with collagen: 
Collagen solution, type I from rat tail  4mg/ml  
Diluted stock 1:30 in PBS  
 
HOMEC isolation solutions 
Omental samples were collected in medium consisting of: 
HBSS     50ml 
Amphotericin B   250µg/ml 
HEPES solution   10 µM 
Gentamicin     50µg/ml 
 
Digest solution 1 (stored at -20C) 
The following reagents were dissolved in deionised water by stirring using a 
magnetic stirrer. The final volume was 100ml. 
0.7g NaCl 
0.373g KCL 
0.09g D-glucose 
0.595g HEPES 
1.5g BSA 
150mg (0.15g) collagenase type 1 
100µl of 1M CaCl2 
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Digest solution 2 (stored at -20C) 
The following reagents were dissolved in deionised water by stirring using a 
magnetic stirrer. The final volume was 100ml. 
0.7g NaCl 
0.373g KCL 
0.09g D-glucose 
0.595g HEPES 
1.5g BSA 
150mg (0.15g) collagenase type 2 
100µl of 1M CaCl2 
 
BSA solution for HOMEC isolation (sterile filtered) 
BSA/PBS    10% and 0.1% w/v 
 
 
2.3 Cell culture 
2.3.1 HOMEC isolation 
Non-malignant omental tissue samples were collected from non-diabetic female 
patients undergoing routine abdominal invasive procedures at the Royal Devon 
and Exeter NHS Foundation Trust (Exeter, United Kingdom) with ethical approval 
and informed written consent. However, information on tumour or cancer 
diagnosis of any origin and their ethnicities were not provided by the clinical 
research facility. HOMECs were isolated and cultured as previously described 
(Winiarski et al., 2011). Briefly, omental tissue was chopped into approximately 
1g segments and digested using digest solution 2. Next, digested tissue was 
chopped into 6mm2 and further digested using digest solution 1. Digested tissue 
was passed through a sterile gauze to remove undigested tissue and the filtrate 
was then centrifuged to separate layers of cells, oil and digest solution. After 
discarding oil and digest solution, the cell pellet was resuspended in ice-cold 10% 
(w/v) BSA and washed in ice-cold PBS. Next, the cell pellet was resuspended in 
serum free basal EC growth media MV2 and filtered through a 30 µm nylon 
swinnex filter. Immunoselection was carried out using anti-CD31 dynabeads to 
isolate pure HOMECs from the mixture and CD31-bead-bound HOMECs were 
then cultured and subcultured in complete EC growth media.  
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2.3.2 HOMEC characterisation 
Prior to their use, the HOMECs were characterised by immunocytochemistry 
techniques to confirm their EC origin (data not shown) as previously described 
(Winiarski et al., 2011). Briefly, HOMEC monolayer was stained either for cell 
surface proteins CD31 (mouse monoclonal anti-human) and CD105 (mouse 
monoclonal anti-human) or for intracellular protein von Willebrand factor (vWF) 
(rabbit anti-human antibody). A FITC-conjugated secondary antibody (anti-
mouse IgG or anti-rabbit IgG) was utilised against corresponding primary 
antibody staining. Counterstaining of nuclei was performed with DAPI. Cells were 
washed in PBS (x2) and distilled water and mounted using fluorescence mounting 
medium with coverslips. To avoid false positives produced by non-specific 
binding of secondary antibodies, control cells were treated in a similar manner 
with PBS substituting for primary antibody. The cells were then assessed for 
fluorescence using an inverted fluorescence microscope (Nikon). 
 
2.3.3 Cell culturing  
For all experiments human microvascular omental (HOMECs) and brain 
(HCMECs) endothelial cells were maintained at 37˚C in a humidified incubator 
with 5% CO2. 
HOMECs/HCMECs were passaged by trypsinisation when they reached >90% 
confluency in the tissue culture flasks. The medium was removed and the cells 
were washed twice with PBS followed by addition of 2 ml trypsin solution 
(0.2mg/ml). The cells were placed in the incubator at 37˚C for 2-3 minutes. 
Detachment was monitored by microscope until cells could be seen floating in the 
trypsin solution. Trypsin was then neutralized by the addition of 8 ml of growth 
medium (containing 5% (v/v) FCS) and cell suspension was transferred to a tube 
and centrifuged at 200 g for 5 minutes. The supernatant was removed and the 
cells were resuspended in complete growth medium. Required amount of cells 
was plated into tissue culture flask (75cm2 [T75]) and the total volume of medium 
was filled up to 12ml for T75. The endothelial cells were split at a ratio of 1:2 or 
1:3 and fed every 2-3 days. The HOMECs were only used between passage 3 
and 7, while the HCMECs were between passages 27 and 35. 
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It is important to note that, the oxygen concentration in the body is much lower 
than in the atmospheric air. For instance, oxygen can range from 0.5 to 7% in 
brain, 4-12% in the liver, heart and kidneys (Ivanovic, 2009). In tumour 
microenvironment, oxygen concentration can be reduced, known as hypoxia. 
Therefore, growing ECs in 20% oxygen (atmospheric) may influence the 
phenotype of the cells in cell culture and, therefore, may not replicate the in vivo 
situation. This can be overcome by using a hypoxic incubator where the oxygen 
concentration can be lowered to 0.5-1%, making it more physiological. Hence, 
this was a limitation of this study. 
 
2.3.4 Freezing cells  
Cells were trypsinised, centrifuged and resuspended (~2x106 cells) in 1ml 
freezing medium. The cell suspension was transferred into sterile labelled vials, 
which were then placed in a cryocontainer containing isopropanol and stored at -
80˚C overnight for slow cooling. Frozen vials were ultimately transferred into 
liquid nitrogen for long term storage. 
 
2.3.5 Thawing cells  
The frozen cells in cryovials were rapidly thawed by placing in a 37˚C water bath. 
Thereafter, the cells were slowly diluted in 12mls of pre-warmed growth medium 
and plated in T75 flasks (gelatin-coated for HOMECs and collagen-coated for 
HCMECs). The medium was replaced after cell attachment (usually 24 hours) in 
order to remove the DMSO used during freezing. 
 
2.4 Cell viability and proliferation assays 
The assessment of cell proliferation and growth (whether as a result of a 
proliferative response to certain molecules [increased DNA synthesis], or a 
reduction in cell death) was performed in cell populations using two independent 
commercially available assays: WST-1 and CyQUANT. WST1 assay is based on 
cleavage of the tetrazolium salts added to the cell culture media. The tetrazolium 
salts are cleaved to formazan by the cellular enzymes of metabolically active 
77 
 
cells. The resulting formazan is dissolved to form a colour, which is 
spectrophotometrically measured. Quantification of the formazan dye 
corresponds to the number of metabolically active cells.  
CyQUANT assay is a highly sensitive fluorescence-based method for quantifying 
cells and assessing cell proliferation and cytotoxicity. The main component of the 
Kit is CyQUANT® GR, a proprietary dye that exhibits strong fluorescence 
enhancement when bound to nucleic acids. The amount of fluorescence 
detection is a measure of a sample's DNA content i.e. directly quantifying the 
entire cell population within a broad linear detection range. This method offers 
improved accuracy over metabolically based cell proliferation or cytotoxicity 
assays that can be influenced by cell changes that are unrelated to cell number. 
 
2.4.1 WST1 assay 
2.4.1.1 Cell seeding and treatments 
HOMECs (between passage 3 and 7) were plated onto 2% (w/v) gelatin coated 
96-well plates (flat bottom microplates, 10,000cells/well) over-night in 100μl/well 
MV2 medium supplemented with 2% (v/v) FCS only. Cultures were maintained 
at 37˚C in a humidified incubator with 5% CO2. The medium was then aspirated, 
the plates were washed once with PBS, and fresh medium was applied to the 
wells (100μl/well). Depending on the experimental procedure, MV2 (containing 
2% (v/v) FCS) medium was supplemented with various growth factors and/or 
compounds, i.e. ± DMSO (vehicle control), inhibitors (Table 2.1) and/or growth 
factors (positive control 20ng/ml of VEGF, 20-80ng/ml of CathL, 5-125ng/ml of 
Gal1, 20-80ng/ml of CathD and 10-50 ng/ml of IGFBP7). HOMECs were treated 
with freshly applied media for 24, 48 and 72 hours as described. 
 
 
 
Table 2.1: List of commercially available compounds and their experimental 
concentrations in µM (unless otherwise stated). 
Targets Compounds Concentrations (µM) 
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CathL enzymatic 
activity FY-CHO 0.1, 1, 10, 50, 100 
CathD enzymatic 
activity pepA 0.1, 1, 2.5, 5, 10 
ERK1/2  U0126 1, 10, 25 
PD98059 1, 10, 25 
PI3K LY294002 1, 25, 50 
AKT MK2206 1, 3, 5 
NFκB  Sulfasalazine 50, 100, 200 
Golgi bodies Brefeldin A 0.025, 0.1, 0.5, 1, 5, 10, 20 
Gal1 L-glu 25 mM, 50 mM 
VEGFR2 SU5416 10 µM 
 
Cell toxicity induced by compounds was also tested using WST1 assay (Table 
2.1). Cell seeding was carried out in an identical manner. However, cell viability 
was tested over 24 hours after treated with the compounds. 
 
2.4.1.2 WST1 assay procedure 
After incubation, pre-warmed (room temperature) WST-1 reagent was added to 
each sample/blank well (10μl/well) on the cell culture plates. As a blank, serum 
free MV2 medium was used (100μ/well). WST-1 was incubated with HOMECs for 
2 hours at 37˚C in a humidified incubator with 5% CO2, followed by measurement 
of the absorbance against the background blank on a microplate reader 
PHERAstar Plus, (BMG Labtech Ltd, Bucks, UK) (set at 450nm). 
 
2.4.2 CyQUANT assay  
2.4.2.1 Cell seeding and treatments 
As described in 2.4.1.1 of the WST1 assay. 
2.4.2.2 CyQUANT assay procedure 
This procedure was performed according the manufacturers instruction. Briefly, 
after 72 hour treatment, media was removed from each well, followed by addition 
of the dye binding solution (1X HBSS buffer) containing CyQUANT NF dye 
reagent. The plates were incubated for 2 hours in a humidified incubator at 37˚C 
with 5% CO2.  The plates were then read at Ex/Em: 485/530 using a FLUOstar 
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BMG plate-reader (BMG Labtech Ltd, Bucks, UK) and cell proliferation was 
assessed based on the fluorescence intensity against the background containing 
HBSS buffer.  
 
2.5 Cell migration using Cultrex migration assay 
The Cultrex migration assay kit is based on the principle of a filter assay (Boyden 
chamber). It involves a two-compartment system where cells may be induced to 
migrate from an upper compartment (insert), through a porous membrane, into a 
lower compartment (plate well). Both chemokinesis and chemotaxis can be 
assessed using this assay kit. In these studies, a 96-well plate format was used 
with cell inserts containing an 8 µm pore-size membrane. 
2.5.1 Protocol for Cultrex migration assay 
HOMECs were seeded into the cell culture inserts (5x104 cells/insert) in a total 
volume of 50μl MV2 (supplemented with 0.5% (v/v) FCS ± growth 
factors/inhibitors) medium. Into the lower compartments MV2 (0.5% (v/v) FCS) 
medium (150μl/well) was added supplemented with or without various 
compounds. The final concentrations of the growth factors and inhibitors are 
shown in tables 2.2 and 2.3.   
In order to carry out inhibition of migration studies, HOMECs were pre-treated 
with inhibitors of ERK1/2 or PI3K/AKT inhibitors for 30 minutes to 1 hour. These 
cells were seeded into the inserts (as described above) and their corresponding 
treatments were added with or without growth factors, for instance, VEGF ± an 
inhibitor. The control wells contained MV2 media supplemented with 0.5% (v/v) 
FCS ± corresponding inhibitor in both compartments. Each condition was carried 
out in triplicate. All conditions were then incubated for 6 hours at 37˚C in a 
humidified incubator with 5% CO2, to allow HOMECs migration.  
After 6 hours incubation, the media was aspirated out from both compartments 
and both upper and lower chambers were washed with pre-warmed PBS. Cell 
dissociation solution was supplemented with 2 µM calcein AM dye and added to 
the bottom chamber of the well (100µl/well), and incubated for 1 hour. This 
allowed dissociation and labelling of migrated cells on the underside of the 
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inserts. The solution was the transferred to a black opaque 96-well plate and read 
using a FLUOstar BMG plate reader at Ex/Em: 485/520.   
Table 2.2: Experimental concentrations of growth factors used in migration assay. 
 
VEGF CathL Gal1 CathD IGFBP7 
20ng/ml 50ng/ml 50ng/ml 50ng/ml 50ng/ml 
 
 
Table 2.3: Experimental concentrations of inhibitory compounds used in 
migration assay. 
 
MAPK/ERK1/2 inhibitors PI3K 
inhibitor 
AKT 
inhibitor 
Gal1 
inhibitor 
U0126 PD98059 LY294002 MK2206 L-glucose 
10 µM 25 µM 25 µM 5 µM 25 mM 
 
 
2.6 pH studies 
The proteolytic activity of CathL and CathD was tested at an array of pHs. This 
required preparing pH buffer solutions as shown in table 2.4. The pH of cultured 
media was also measured over time. The pHs of both the cultured media and 
buffers were measured down to 2 decimal places in 100µl of media/buffer using 
blood-gas analyser ABL800 FLEX (Radiometer, Akandevej, Denmark). The pH 
buffer was kept the same for both CathL and CathD experiments.  
The stock solutions of both acid and base were prepared as follows:  
21.01g citric acid monohydrate to 1 L distilled water  
28.40g sodium phosphate dibasic (Na2HPO4) in 1 L distilled water  
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Table 2.4: Preparation of buffer solutions at an array of pHs (derived from buffer 
reference centre, Sigma-Aldrich). Final volume of each pH buffer was 50ml 
containing freshly prepared 1 mM DTT (CathL proteolysis assay) or 0.005% (v/v) 
Tween 20 (CathD proteolysis assay). 
                                 
pH 
Citric 
acid (ml)  
Na2HPO4 
(ml) 
3.0 39.725 + 10.275 
3.6 33.900 + 16.100 
4.0 30.725 + 19.275 
4.6 26.625 + 23.375 
5.0 24.250 + 25.750 
5.6 21.000 + 29.000 
6.0 18.425 + 31.575 
6.6 13.625 + 36.375 
7.0 8.825 + 41.175 
7.6 3.175 + 46.825 
 
2.6.1 CathL proteolytic activity 
CathL fluorogenic substrate Z-Val-Val-Arg-AMC (ZVA) 10mg was reconstituted 
in 150.6µl DMSO to produce a 100 mM stock solution. This was further diluted to 
a final concentration of 5 µM in individual pH buffer. Substrate and substrate-pH 
buffer solution were protected from light. 
CathL inhibitor Z-Phe-Tyr-CHO (FY-CHO) 2mg was reconstituted in 45µl of 
DMSO to produce a stock solution of 100 mM. The stock solution was diluted 
further to final concentration of 10 µM in individual pH buffer solution with or 
without ZVA.   
CathL 336µg/ml (20 mM malonate, pH 5.5, 1 mM EDTA, and 400 mM NaCl) was 
diluted to produce 300ng/ml in individual pH buffer before dispensing in to the 
test wells. The experiment was carried out in 96 well black opaque plates. The 
conditions were as follows (Tables 2.5 and 2.6): 
Table 2.5: Experimental conditions for testing CathL proteolytic activity. 
 
 Control wells Test wells 
ZVA + + 
CathL - + 
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Table 2.6: Experimental conditions for examining inhibition of CathL proteolytic 
activity: 
 Control wells Test wells 
ZVA + + 
FY-CHO + + 
CathL - + 
 
Procedure: 
To test the proteolytic activity of CathL, 100µl of substrate (ZVA) pH buffer 
solution was dispensed in to both control and test wells. Each condition was run 
in quadruplets per plate. Finally, 20µl of corresponding pH buffer was added to 
each control well and 20µl of enzyme solution (300ng/ml) was added to all test 
wells to obtain a final concentration of 50ng/ml of CathL. Plates were shaken for 
2 minutes at room temperature and read immediately using a SpectraMAX plate 
reader (Molecular Devices, Berkshire, UK) at Ex/Em: 365/440. 
In order to test for inhibition of CathL-mediated substrate breakdown, 100µl of 
solution containing ZVA and FY-CHO was dispensed in both control and test 
wells. Finally, 20µl of 300ng/ml CathL or 20µl corresponding pH buffer was added 
to test or control wells respectively, followed by shaking and reading plate as 
described above.  
 
2.6.2 CathD proteolytic activity 
CathD fluorogenic substrate 1mg was reconstituted in 570µl DMSO to produce a 
10 mM stock concentration which was further diluted into 100 nM (final 
concentration) in individual pH buffer. Substrate and substrate-pH buffer solution 
were protected from light. 
Inhibitor of CathD proteolytic activity pepA (5mg) was reconstituted in 363.5µl 
DMSO, producing a stock solution of 20 mM (stored at -20 ˚C). This was further 
diluted to produce a final concentration of 1 µM in individual buffer containing 
CathD substrate.  This concentration (1 µM) was recommended by the supplier 
(Calbiochem, Millipore) to be the effective concentration.  
CathD was diluted from its stock solution (50µg/ml) to a working concentration 
300ng/ml, which was added (20µl/well) to the wells containing 100µl buffer 
(substrate + pepA) producing a final concentration 50ng/ml in final volume 
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120µl/well. The experiment was carried out in 96 well black opaque plates. The 
conditions were as follows (tables 2.7 and 2.8): 
Table 2.7: Experimental conditions for testing CathD proteolytic activity. 
 Control 
wells 
Test wells 
Substrate + + 
CathD - + 
 
Table 2.8: Experimental conditions for examining inhibition of CathD proteolytic 
activity: 
 Control 
wells 
Test wells 
Substrate + + 
PepA + + 
CathD - + 
 
To test the proteolytic activity of CathD, 100µl of pH buffer solution containing 
fluorogenic substrate (100 nM) was dispensed into both control and test wells. 
Each condition was run in quadruplets per plate. Finally, 20µl of corresponding 
pH buffer or enzyme solution (300ng/ml) was added to control or test wells to 
obtain a final concentration of 50ng/ml of CathD. Plates were shaken for 2 
minutes at room temperature and read immediately using a SpectraMAX plate 
reader at Ex/Em: 320/393. 
Inhibition of CathD-proteolytic activity was examined in the presence of an 
inhibitor pepA. pH buffer solutions containing CathD-fluorogenic substrate (100 
nM) and pepA (1 µM) were dispensed in a 96 well plate, followed by addition of 
20µl of the corresponding pH buffer or CathD (50ng/ml) in the control or test wells 
respectively. The plate was shaken and read as described above. 
 
 
 
 
2.7 Molecular biology 
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2.7.1 Protein quantification- bicinchoninic acid (BCA) assay  
Protein quantification was performed using a colorimetric BCA protein assay kit 
according to the manufacturer’s instruction. Briefly, in a 96-well flat-bottom 
microtiter plate, 10μl of standard or each lysate sample was added to 200μl of 
working reagent (50 parts of reagent A to 1 part of reagent B). The plate was 
incubated at 37 ˚C for 30 minutes and absorbance was measured at 562 nm. 
Protein concentration calculated using a standard curve of bovine serum albumin 
(BSA) (Figure 2.1). Final concentration was calculated from the linear regression 
equation. 
 
 
Figure 2.1: Standard curve derived from BCA protein assay. 
 
2.7.2 Proteome Profiler Human Phospho-Kinase Array kit  
HOMECs were seeded in 10cm2 dishes and cultured until confluent. Cells were 
treated with or without CathL, CathD and IGFBP7 supplemented in EC basal 
media containing 2% (v/v) FCS for 4 minutes, washed once with ice cold PBS 
and scraped in lysis buffer (provided in kit). Cell lysates were incubated on a 
rocker at 4˚C for 30 minutes and centrifuged (14,000g) for 5 minutes at 4˚C. 
Supernatants were collected into fresh microcentrifuge tubes and total protein 
concentration was determined with the BCA assay. Lysates were stored at -80˚C 
or experimented immediately according to the manufacturer’s instructions. 200µg 
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cell lysate was added to each membrane. Dot blots were detected via enhanced 
chemiluminescence using Kodak films (Figure 2.2) Pixel density of the dot blots 
was analysed using ImageJ software. 
 
Figure 2.2: Representation of developed membrane of phosphokinase 
array data. a) control (untreated), b) CathL, c) CathD and d) IGFBP7. 
 
2.7.3 Proteome Profiler Human Phospho-Receptor Tyrosine Kinase Array 
Kit 
HOMECs were treated for 10 minutes with or without VEGF, CathL, CathD and 
IGFBP7, followed by producing cell lysates and total protein quantification (as 
described in section 2.7.2). The rest of the experiment was performed according 
to the manufacturer’s instructions. The blots were detected via enhanced 
chemiluminescence using the Azure c600 imaging system. The pixel density of 
the blots was analysed by AzureSpot.  
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2.7.4 ELISAs 
2.7.4.1 Cell-based ELISAs 
Cells were seeded at a density of 10,000 cells per well in a clear bottom black 96 
well microplate (provided in the kit). Cells were grown, starved overnight in 2% 
(v/v) FCS MV2 and treated with various compounds and proteins, followed by 
fixation with 4% (v/v) methanol free paraformaldehyde (v/v). Fixed cells were 
permeabilised and levels of phosphorylated and total protein level was 
determined according to the manufacturer’s instructions.  
To confirm the inhibitory effect of the inhibitors, HOMECs were pre-incubated with 
the inhibitors for 20-30 mins (ERK1/2 inhibitors), 1-2 hours (PI3K/AKT inhibitors) 
and 24 hours (NFκB inhibitor) (Toscano et al., 2011), and then co-treated with or 
without proangiogenic factors (VEGF, CathL, CathD and IGFBP7) in the absence 
or presence of the inhibitors for 4 and/or 10 minutes or 4 hours. 
The following cell-based ELISAs were performed (Table 2.9): 
 
Table 2.9: Commercially available ELISA kits and their protein targets.  
 
ELISA kit Treatment time Target Source 
Phospho-total 
ERK1/2 (KCB1018) 
4 and 10 mins ERK1(T202/Y204)/2 
(T185/Y187) 
Biotechne 
Phospho-total AKT 
(KCB887) 
4 and 10 mins AKT( S473) Biotechne 
Phospho-total 
/NFκB  p65 
(KCB7226) 
4 hours RelA/NFκB  p65 
(S536) 
Biotechne 
 
 
2.7.4.2 Human Gal1 Quantikine ELISAs (quantitative sandwich ELISA) 
HOMECs were grown, starved overnight and treated with or without CathL for 4 
mins, 30 mins, 8 hours and 24 hours. Supernatants were collected, centrifuged 
at 200 g for 10 mins, and transferred into new microfuge tubes which were either 
stored at -20˚C for future experiments or immediately used to detect levels of 
Gal1. The assay was carried out according to the manufacturer’s instructions. 
2.7.4.2.1 Inhibition of Gal1 secretion 
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HOMECs were pre-treated with the NFκB inhibitor sulfasalazine (100nM) for 24 
hours, followed by co-incubation with or without CathL. The cell culture 
supernatant was collected after 8 hours treatment. Levels of Gal1 was quantified 
as described in section 2.7.4.2 and according to the manufacturer’s instructions. 
 
2.7.5 Reverse transcription and qRT-PCR  
2.7.5.1 Prevention of contamination and RNA degradation 
For all appropriate steps of the RNA isolation protocol, molecular biology grade 
chemicals were used and deionised water was pre-treated with 0.1% (v/v) DEPC 
overnight at room temperature and subsequently autoclaved to deactivate the 
DEPC. All equipment was thoroughly cleaned with RNaseZap and filtered, 
nuclease free pipette tips were used to minimise RNA degradation and 
contamination of the samples with foreign nuclear material.  
 
2.7.5.2 RNA extraction  
Cells were grown in a 6 well plate, starved overnight in 2% (v/v) FCS MV2 
medium and then treated with CathL (also in 2% (v/v) FCS MV2 medium) for 8 or 
24 hours in the presence or absence of sulfasalazine. Total RNA from cell 
cultures was isolated with TRI Reagent as per manufacturer’s protocol. TRI 
Reagent is a solution of phenol and guanidine isothiocyanate that disrupts cell 
membrane and dissolves cell components while preserving the integrity of RNA 
and other nucleic acids. Medium supplemented with or without treatment was 
removed and TRI Reagent (500µl/well) was added directly onto the surface of 
culture vessels for cultured cells. Cells were then scraped with a 1ml pipette tip, 
transferred to a 1.5ml microcentrifuge tube, and treated directly for RNA 
extraction or stored at -80˚C until needed. 
For mRNA extraction, the samples were incubated for 5 minutes at room 
temperature. 200μl of chloroform per mL TRI Reagent lysate was added, after 
which the sample was vortexed vigorously and incubated for 10 minutes at room 
temperature. This incubation allows the formation of an organic phase (containing 
proteins), an interphase (containing DNA), and an aqueous phase (containing 
RNA). The tubes were centrifuged at 13000 g, 4°C for 15 minutes to firmly 
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separate the layers. The aqueous phase was removed to a new 1.5 mL tube and 
combined with 500µl isopropanol (per 1ml TRI Reagent) and 1µl Glycoblue co-
precipitant. The addition of 2-propanol changes the solute balance of the solution 
which causes the RNA to precipitate out of solution. The samples were inverted 
to mix and incubated at room temperature for 10 minutes to allow full precipitation 
and spun again at 12000 g, 4°C for 12 minutes to pellet the RNA. The 
supernatants were discarded and the pellets were washed with 500µl of 75% (v/v) 
ethanol (per 1 ml TRI Reagent), inverted to mix and spun at 10000 g, 4°C, for 10 
minutes. After the supernatant was removed, the pellets were air dried and 
dissolved in 10μl nuclease free water.  
 
2.7.5.3 DNase treatment 
Contaminating genomic DNA was removed using a Precision DNase kit 
(according to the manufacturer’s instructions). For each sample, 1.2µl 10x 
reaction buffer (per 10µl sample) and 1µl DNase enzyme were added to the RNA 
samples. Samples were then incubated at 30°C for 10 minutes followed by 55°C 
for 5 minutes to deactivate the DNase.  
The concentration and purity of the RNA was quantified using a Nanodrop 8000 
spectrophotometer (Thermo Scientific, USA). The ratio of the absorbance at 
260nm to the absorbance at 280nm (A260/A280) was used as a measure of RNA 
concentration (ng/µl) of the sample. A ratio of 2 was considered ideal with a range 
from 1.9 to 2 considered acceptable. These RNA samples were immediately used 
for c-DNA synthesis, followed by RT-PCR or stored at -80˚C until needed. 
 
2.7.5.4 cDNA synthesis  
Total RNA was reverse transcribed into cDNA using the qScript cDNA Supermix 
kit. As per manufacturer instructions, up to 1μg of RNA was diluted up to a volume 
of 20 μl containing the following reagents (cDNA synthesis master mix) (Table 
2.10). 
Table 2.10: List of reagents and their volumes per reaction in cDNA synthesis 
master mix. 
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Reagent Volume per Reaction 
qScript 5X Reaction Mix 4.0μl 
qScript Reverse 
Transcriptase 
1.0μl 
RNA sample 10pg – 1μg total RNA 
Nuclease free water Up to 20.0μl 
Total Volume 20.0μl 
 
The samples and mixtures were pulse vortexed. Reverse transcription was then 
performed under the following conditions: 22°C for 5 minutes, 42°C for 30 
minutes, 85°C for 5 minutes with a 4˚C hold. cDNA was produced which can be 
stored at -80˚C or used immediately. 
 
2.7.5.5 RT-PCR 
In order to perform RT-PCR, firstly, 20X TaqMan gene expression (genes of 
interest and reference genes- GAPDH and β2M), and PrecisionPLUS master mix 
were defrosted on ice. A RT-PCR master mix (8µl) was made for each well of a 
96 well plate with the following constituents (Table 2.11):  
Table 2.11: List of reagents and their volume per reaction in RT-PCR master mix. 
 
Reagent Volume per Reaction 
20X TaqMan Primer 0.5 μl 
PrecisionPLUS Master mix 5 μl 
Nuclease free water 2.5 μl 
Total Volume 8.0 μl 
 
2µl of cDNA sample was dispensed into each well containing 8µl of master mix, 
to make a total volume of 10µl. An optical adhesive seal was applied on the plate 
to prevent spillage of the sample. This plate was then spun for 1 min in a plate 
centrifuge to pellet down the mixture. DNA polymerase was activated for 5 
minutes at 95°C followed by amplification cycling as shown in Table 2.12. 
Fluorescence was measured at the end of each 60°C step. 
Table 2.12: Stages of cDNA amplification cycles.  
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Program Cycles Step 
Preincubation 1 95°C for 120 secs 
2 step amplification 40 95°C for 10 secs 
60°C for 30 secs  
Cooling 1 37°C for 30 secs 
 
Specificity of the amplification was confirmed by examining a melt curve of the 
reaction. Following amplification, a melting curve analysis was performed by 
slowly increasing the temperature from 60°C to 95°C while measuring 
fluorescence (data not shown). TaqMan probes rely on the 5′– 3′ nuclease activity 
of Taq DNA polymerase to cleave a dual-labelled probe during hybridisation to 
the complementary target sequence. These fluorogenic hybridisation probes 
include a re-porter dye i.e. FAM (6-carboxyfluorescein) covalently linked to the 5′ 
end whose emission spectra is quenched by a second dye i.e. TAMRA (6-
carboxytetramethylrhodamine), covalently linked to the 3′ end. During a PCR 
cycle, the probe specifically hybridises to the corresponding template, cleaves via 
the 5′ to 3′exonuclease activity of Taq DNA polymerase and subsequently 
increases the FAM fluorescent emission. The increase in fluorescence is 
proportional to the amount of specific PCR product as the exonuclease activity of 
Taq polymerase acts only if the fluorogenic probe is annealed to the target. 
Quantitative differences in mRNA expression between treated and untreated 
HOMECs were determined using the Cp (crossing point at which the amplification 
curve crosses the vertical threshold line) value for each target and normalised to 
the geometric mean of the Cp of at least two commercial housekeeping genes 
(GAPDH and β2M) (both Primer Design, UK). Fold change in expression was 
calculated using the standard 2-ΔΔCp method.  
 
 
 
 
2.8 Angiogenesis 
2.8.1 Optimising 3D angiogenesis 
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To investigate the angiogenic potential of EOC secreted factors, an in vitro 3D 
angiogenesis model was utilised. The experimental design of this assay is based 
on the fibrin matrix gel which was previously published by Nakatsu et al. (Nakatsu 
et al., 2007). Briefly, cytodex 3 (collagen pre-coated) or cytodex 1 (coated with 
gelatin) beads were coated with approximately 400 HOMECs or HCMECs (per 
bead). Cell-coated beads were counted and resuspended in fibrinogen 
(1.82mg/ml)/aprotinin (0, 0.07 or 0.14 U/ml) solution at a concentration of 
approximately 500 beads/ml. Thrombin solution (0.60 U/ml) was added to each 
well, followed by addition and careful mixing of the fibrinogen/beads suspension 
to each well of a 24 well plate. Thrombin converts fibrinogen to fibrin forming a 
tight matrix. Once the gel was formed, media supplemented with the following 
treatments were added on top of the 3D matrix (Table 2.13) and media/treatments 
was replaced every other day up to day 5. Photographs were taken using a Nikon 
phase-contrast microscope (Nikon UK Limited, Surrey, UK) at 10X magnification.  
The protocol was carried out in an identical manner as described above with the 
exceptions of the following optimisation steps. Due to a lack of responsiveness 
to the treatments (stage 1; Table 2.13), increasing concentrations of FCS were 
used to examine HOMEC sprouting (stage 2; Table 2.14). Various concentrations 
of aprotinin (protease inhibitor), along with a different bead (gelatin-coated 
cytodex 1) were utilised to test for HOMEC sprouting in the fibrin gel (Table 2.15) 
in media containing 5% (v/v) FCS with or without supplemented EC growth 
factors (stage 3). 
 
Table 2.13: Conditions for 3D beads angiogenesis assay using HCMECs and 
HOMECs 
HCMECs and HOMECs ng/ml in 2% v/v FCS basal medium 
Optimisation stage 1 Control 
Positive 
control VEGF CathL CathD IGFBP7 
 
2% v/v 
FCS 
5% v/v 
FCS 20 50 50 50 
 
Table 2.14: Increasing FCS concentrations to test for HOMEC angiogenesis in 
3D assay. 
HOMECs Higher concentrations of FCS 
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Optimisation stage 2 Control FCS + Basal or complete EC growth media 
 2% v/v FCS 5% v/v FCS 10% v/v FCS 20% v/v FCS 
 
Table 2.15: Various concentrations used in HOMEC angiogenesis assay. 
 
  (Aprotinin concentrations U/ml) 
Optimisation stage 3 
5% v/v FCS 
basal media 0 0.07 0.14 
5% v/v FCS EC 
growth media 0 0.07 0.14 
 
 
2.8.2 2D angiogenesis 
2.8.2.1 Fibrin matrix angiogenesis model  
An in vitro 2D angiogenesis assay was carried out to test for angiogenic tube 
formation in HOMECs by modifying the protocol from Winiarski et al. (Winiarski 
et al., 2013) To carry out the 2D model, the same fibrin gel was used as above. 
HOMECs were seeded at 35,000 or 50,000 cells per well in a 48 well plate on top 
of the gel. After overnight incubation, cells were treated with media supplemented 
with 2% (v/v) FCS (control media), VEGF (20ng/ml; positive control), CathL 
(50ng/ml), CathD (50ng/ml) and IGFBP7 (50ng/ml). Photographs were taken at 
72 hours after treatment using a Nikon phase contrast microscope camera. 
 
2.8.2.2 Growth factor reduced (GFR) Matrigel model 
A commercially available GFR Matrigel was used to examine angiogenic tube 
formation in HOMECs treated with media supplemented with 2% (v/v) FCS 
(control media), VEGF (20ng/ml; positive control), CathL (50ng/ml), CathD 
(50ng/ml) and IGFBP7 (50ng/ml). HOMECs were seeded in 2% (v/v) FCS 
medium at a density of 50,000 cell per well of a 96 well plate on top of the gel. 
After a 2 hour incubation, cell culture media was replaced with media 
supplemented with or without 2% (v/v) FCS (control media), VEGF (20ng/ml; 
positive control), CathL (50ng/ml), CathD (50ng/ml) and IGFBP7 (50ng/ml) for a 
further 8 hour incubation at 37°C, 5% CO2.  
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Tubular structure formation was analysed at 8 hours after treatment using a Nikon 
phase contrast microscopy (x4 resolution) and photography (96-well format: 1 
photograph taken of the whole well). Quantification of the tube-like structures and 
nascent tubule-structures was examined using ImageJ grid by two persons. Each 
point that coincided with a tube-structure or a nascent tubule-structure was 
recorded. The results were presented as an angiogenic index (AI). 
 
2.9 Staining of the Golgi body 
HOMECs were grown in a 6 well plate until 70% confluency. According to the 
manufacturer’s instructions, CellLight® Golgi-GFP, BacMam 2.0 was added to 
the cultured media and cells were incubated overnight (~16 hours). Next, GFP-
transfected cells were treated with BFA (0.025 µM) for 8 hours. Photographs were 
taken using a Nikon fluoresence microscope (Nikon UK Limited, Surrey, UK) and 
analysed using ImageJ software. 
 
2.10 Statistical analysis 
Statistical analyses were carried out using GraphPad PRISM software 5.04 and 
Microsoft Office Excel. The Mann Whitney U test was used to test the significance 
of variables between the two groups. This non-parametric statistical test was 
chosen over parametric tests due to smaller sample size in these experiments. 
Also, as the data are presented as percentage of control (100%), there is no 
normal distribution to perform parametric t-tests. P<0.05 was considered 
statistically significant. The graphical representation of the data was done with 
mean ± standard deviation (SD). 
 
 
 
 
Chapter 3 Investigation into the proangiogenic changes in HOMECs by 
Cathepsin L (CathL) 
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3.1 Introduction 
It is well established that tumour-secreted proteins in the tumour 
microenvironment interact with the host tissue. One of the most significant 
outcomes of this interaction is enhanced neo-vascularisation of tumours. CathL 
was previously shown to be secreted by ovarian cancer cell lines SKOV3 and 
A2780 and to induce proliferation and migration in human omental microvascular 
endothelial cells (HOMECs), although the mechanisms of action are unknown 
(Winiarski et al., 2013). Furthermore, CathL has been suggested to be involved 
in the invasion and metastasis of EOC (Zhang et al., 2014b). Indeed, it was 
recently shown that the endothelium of vessels within omentum hosting 
metastatic ovarian high-grade serous carcinoma expressed significantly 
increased CathL in vivo compared with omentum from control patients with 
benign ovarian cystadenoma (Winiarski et al., 2014).  
CathL is a lysosomal protease which is active at an optimum pH of 4.5-5.5. 
However, CathL has been also shown, in some cases, to be active at neutral pH 
(Fiebiger et al., 2002). The presence of this protease in the tumour cell secretome 
and its ability to induce migration and tube-formation in HOMECs (Winiarski et 
al., 2013) raised important questions (i) does CathL, being a protease, act via its 
proteolytic activity or a non-proteolytic manner? (ii) what are the signalling 
pathways activated in inducing cell proliferation and migration?  
The literature suggests that CathL can be active as a protease at neutral pH in 
normal physiological processes and therefore, to answer the former question, 
CathL-induced HOMEC proliferation was assessed in the presence or absence 
of an inhibitor of CathL-proteolytic activity. Additionally, in order to address the 
question of whether CathL is proteolytically active in cell culture media (neutral 
pH), CathL activity was tested at an array of pHs using a CathL-specific substrate, 
in the presence or absence of an inhibitor of CathL-proteolytic activity. 
The upstream signalling pathways activated during CathL activation of migration 
and proliferation were examined using several techniques. Initially, a proteome-
profiler and cell-based ELISA kits were used to screen and detect activated or 
phosphorylated levels of intracellular kinases. Kinase-specific inhibitors were 
then used to investigate whether candidate signalling proteins play a role in 
CathL-induced proangiogenic effects in HOMECs. Furthermore, tube-structure 
95 
 
formation was assessed when HOMECs were treated with CathL. Finally, 
receptor targets of CathL was also elucidated in a brief investigation. 
 
3.1.1 Aims 
The aims of this chapter are: 
 To investigate whether CathL induces HOMEC proliferation in a proteolytic 
or non-proteolytic manner 
 To study potential cell signalling pathways involved in inducing HOMEC 
proliferation and migration 
 To examine angiogenic tube-formation of HOMECs by CathL 
 To identify potential receptor targets of CathL in HOMECs 
 
3.2 Methods 
HOMEC isolation: HOMECs were isolated according to previously published 
work (Winiarski et al., 2011) as described in the Method chapter section 2.3.1. 
Cell proliferation: HOMEC proliferation was tested using both the WST-1 assay 
and CyQuant cell proliferation kit as described in the Method chapter sections 
2.4.1 and 2.4.2. 
CathL-proteolytic activity:  The WST-1 assay was used to study CathL-induced 
HOMEC proliferation in the presence or absence of FY-CHO, a specific inhibitor 
of CathL-proteolytic activity (Method section 2.4.1). An array of pHs were used to 
investigate proteolytic activity of CathL in the presence of a CathL-specific 
fluorogenic substrate and in the presence or absence of FY-CHO, as described 
in the Method chapter sections 2.6 and 2.6.1.  The pH of cultured media was also 
measured. These pHs were measured down to 2 decimal places in 100µl 
media/buffer using ABL800 FLEX blood gas analyser. 
Activation of intracellular kinases: A commercially available proteome-profiler 
and cell-based ELISAs were used to detect and assess levels of phosphorylated 
intracellular kinases as described in the Method chapter sections 2.7.2 and 
2.7.4.1. 
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Cell migration: A commercially available cultrex Boyden chamber kit was used 
to investigate the underlying mechanisms of CathL-induced HOMEC migration, 
as described in the Method chapter section 2.5.1. 
3D in vitro angiogenesis: A 3D angiogenesis model was used to assess 
HOMEC sprouting as described in the Method chapter section 2.8.1. 
2D tube-formation: Angiogenic tube-formation was investigated in HOMECs 
treated with CathL using both a fibrin matrix assay and commercially available 
GFR-Matrigel, as described in the Method chapter section 2.8.2. 
Identification of potential cell surface receptors: A commercially available 
human receptor-tyrosine kinase array was used as a screening tool to identify 
potential receptor as described in the Method chapter section 2.7.3. 
 
3.3 Results 
3.3.1 CathL induces HOMEC proliferation 
 
Initially the proliferative effect of CathL in HOMECs was confirmed. A 
commercially available WST-1 colorimetric assay was used to assess CathL-
induced cell proliferation. HOMECs were treated with increasing concentrations 
of CathL (20, 50 and 80 ng/ml) for 72 hours. CathL significantly increased 
HOMEC proliferation at 50 and 80ng/ml (167.8± 32.5%, n=50, and 156±40.5%, 
n=9 vs control (100%) respectively; Figure 3.1), with 50ng/ml being the most 
effective dose in producing this proangiogenic effect. At 20ng/ml (107.8±38.9%, 
n=13, vs control (100%); Figure 3.1), CathL did not induce significant HOMEC 
proliferation compared to control. CathL was not toxic at all concentrations tested. 
On the basis of this data future experiments were carried out using 50ng/ml of 
CathL. VEGF was used as a positive control in this assay (Appendix 1, Figure 
A1.1) 
The initial proliferation data was complemented using a CyQUANT kit, which 
utilises a proprietary green fluorescent dye that exhibits strong fluorescence 
enhancement when bound to cellular nucleic acids. HOMECs were treated with 
CathL at 50ng/ml for 72 hours. The data showed an increase in fluorescence 
intensity which correlates with an escalation of the amount of DNA, and hence 
demonstrates proliferation of cells (109.1±5.0%, n=20 vs control (100%); Figure 
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3.2a). VEGF was used as positive control (Appendix 1, Figure A1.2). The data 
obtained using the CyQUANT kit confirmed the WST-1 proliferation data, and 
therefore only WST-1 was carried out to investigate cell proliferation/toxicity in 
the subsequent experiments. 
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Figure 3.1: Increased proliferation of HOMECs in media supplemented with 
CathL (WST-1 assay). Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without various concentrations of 
CathL and incubated for 72 hours. A commercially available WST-1 kit was used 
to assess cellular proliferation based on absorbance using PHERAstar BMG 
plate-reader at 450nm. a) Results are mean ±SD and shown as percentage of 
the control, n.s., *p<0.05, ***p<0.001 vs control (100%), n=9-50. b) Raw data 
from representative experiment. n.s. denotes not significant. 
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Figure 3.2: Increased proliferation of HOMECs in media supplemented with 
CathL (CyQUANT). Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without 50ng/ml of CathL and 
incubated for 72 hours. A commercially available CyQUANT reagent was used to 
assess cell proliferation based on fluorescence intensity using FLUOstar BMG 
plate-reader at Ex/Em: 485/530nm. a) Results are mean ±SD and shown as 
percentage of the control, **p<0.01 vs control (100%), n=20. b) Raw data from 
representative experiment. 
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3.3.2 CathL induces HOMEC proliferation in a non-proteolytic manner 
In normal physiology CathL is active as a lysosomal protease and therefore 
functions at the pH found in these conditions i.e. pH 4.5-5.5. Since CathL is 
secreted by EOC cells and has now been shown to induce proliferative changes 
at neutral pH (from Figures 3.1 and 3.2), it was important to investigate whether 
CathL is acting in a proteolytic or a non-proteolytic mechanism in HOMECs. 
Initially, cell proliferation was tested with CathL in the presence or absence of FY-
CHO (a specific inhibitor of CathL proteolytic activity) at increasing concentrations 
over 24, 48 and 72 hours (Figure 3.3a, b), c, d) and e), f) respectively). The data 
demonstrated that at concentrations up to 10 µM FY-CHO did not inhibit CathL-
induced HOMEC proliferation. 50 µM and 100 µM did appear to inhibit CathL-
induced proliferation (Figure 3.3 a), c), e); Table 3.1); however, the data shown 
in figure 3.3 b), d), f) and table 3.1 indicated that FY-CHO was toxic in HOMECs 
at concentrations higher than 10 µM i.e. at 50 µM and 100 µM at all time points 
and, hence these concentrations were excluded from further experiments. This 
set of experiments suggested that CathL is acting in a non-proteolytic manner. 
The above data demonstrated that FY-CHO did not inhibit CathL-induced 
HOMEC proliferation. However, this only means that CathL is not acting in a 
proteolytic manner if FY-CHO actually inhibits any CathL activity at the pH 
observed in the tissue culture media (pH 7). Thus, this was investigated further. 
Initially, the pH of the cell culture media was tested over 24, 48 and 72 hours to 
confirm that the pH of the media remains unchanged over time. It was found that 
the pH of the basal media was initially 7.34 and did not reach a lower pH than 
7.11 in all conditions tested over time (Table 3.2). It was essential to test for 
CathL’s proteolytic activity at its optimum pH and the ability of the inhibitor to 
actually inhibit enzyme action. Thus, enzyme activity was tested at a range of 
pHs using an ionic buffer in the presence of a CathL specific fluorogenic substrate 
Z-VVR-AMC (5 µM) and in the presence or absence of FY-CHO (10 µM, non—
toxic concentration which did not reduce cell proliferation (Table 3.1)). The 
experiment demonstrated that CathL was active, but with a decreasing trend, 
from optimum pH 5 to pH 7.6 (Figure 3.4a). This agrees with the current literature 
which suggests that CathL can be active as a protease at neutral pH. However, 
the addition of FY-CHO completely abolished CathL-proteolytic activity 
throughout all pHs (Figure 3.4b), including pH 7. Figure 3.4c) represents a 
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summary of the proteolytic activity of CathL at pH 5 and pH 7 in the absence or 
presence of FY-CHO. These combined data suggest that in cell culture media 
CathL may be proteolytically active but induces HOMEC proliferation by an 
unknown non-proteolytic mechanism. Since proliferation still occurred in the 
presence of an inhibitor of CathL-proteolytic activity, it was assumed that CathL 
was acting as an external ligand, and hence potential downstream signalling 
pathways were investigated. 
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Figure 3.3: Z-Phe-Tyr-CHO (FY-CHO), an inhibitor of CathL proteolytic 
activity, does not inhibit CathL-induced HOMEC proliferation. Cells were 
seeded in 2% gelatin pre-coated 96 well plates at a density of 10,000cells/well in 
starvation media containing 2% FCS. After overnight incubation, cells were 
treated with or without CathL (50ng/ml) in the presence or absence of various 
concentrations of FY-CHO (as shown above- CathL+ FY-CHO a), c), e) or FY-
CHO alone b), d), f)) and incubated for a), b) 24, c), d) 48 and e), f) 72 hours. 
WST-1 assay was used to assess cellular proliferation based on absorbance 
using PHERAstar BMG plate-reader at 450nm. Control wells contained 0.1% 
DMSO (carrier only). Results are mean ±SD and shown as percentage of the 
control, n.s., **p<0.01, ***p<0.001 vs control (100%); n.s., ###p<0.001 vs CathL 
(expressed as % of control), n=8-16. n.s. denotes not significant. 
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Table 3.1: Summary of effects of FY-CHO on CathL-induced proliferation in 
HOMECs (shown in figure 3.3). HOMECs were treated with or without CathL 
(50ng/ml) and in the presence or absence of increasing concentrations of FY-
CHO for 24, 48 and 72 hours. Results are mean ±SD and shown as percentage 
of control (100%). n.s., ###p<0.001 vs CathL (expressed as % of control), n=8-
16. n.s. denotes not significant. Toxic concentrations are highlighted in bold. 
 
 
   CathL+FY-CHO (% of control) 
 
Control 
(%) 
CathL (% of 
control) 
(50ng/ml) 
0.1 µM 
(n.s.) 
1 µM 
 (n.s.) 
10 µM 
(n.s.) 
50 µM 
(###) 
100 µM 
(###) 
24h 100 128.0±23.4 125.7±20.2 131.1±25.7 117.5±21.1 26.4±6.8 12.0±2.0 
48h 100 132.0±17.1 140.5±36.1 139.6±36 128.4±27 32.9±8.5 13.0±2.2 
72h 100 175.5±31.3 182.3±34.4 182.1±37.8 172.6±21.9 42.0±15.2 22.1±9.4 
 
 
Table 3.2: pH of cell culture media and supernatant overtime. Cells were 
seeded in 6 well plates and treated with or without CathL (50ng/ml) for 24, 48 and 
72 hours. Media were collected and their pH was measured by using a blood-gas 
analyser (ABL800 flex). The pH of basal MV2 (starvation media) was analysed at 
0 hour. n.d. denotes not determined. 
 
  pH 
  0h 24h 48h 72h 
Basal MV2 7.34 n.d. n.d. n.d. 
Control n.d. 7.19 7.13 7.12 
CathL n.d. 7.19 7.13 7.11 
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Figure 3.4: CathL proteolytic activity is inhibited at an array of pHs by FY-
CHO, an inhibitor of CathL proteolytic activity. A specific fluorogenic substrate 
Z-Val-Val-Arg-AMC (Z-VVR-AMC, ZVA, 5 µM) was incubated with or without 
CathL (50ng/ml) and in the a) absence or b) presence of FY-CHO (CathL 
inhibitor, 10 µM). c) A summary of data at pH 5 and 7 with or without CathL and 
in the presence of the substrate ± FY-CHO. Fluorescence signals were measured 
immediately using SpectraMax plate reader at Ex/Em: 365/440.  Control wells 
contained pH buffer and substrate and/or inhibitor. The data are represented as 
percentage of control. *p<0.05, ***p<0.001 vs control (substrate ± FY-CHO) 
(100%); ###p<0.001 vs CathL + substrate (expressed as % of control), n=3, a) 
and b) Representative data are from 1 of 3 independent experiments.  n.s. 
denotes not significant. 
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3.3.3 Activation of intracellular signalling kinases in CathL-treated HOMECs 
The induction of cell proliferation is reported to involve activation of several 
intracellular signalling pathways including MAPK/ERK1/2 and PI3/AKT kinases. 
Therefore, it was essential to investigate signalling cascades activated in CathL-
treated HOMECs. Initially, a commercially available proteome profiler was used 
to simultaneously screen and detect activation and phosphorylation of 43 
kinases.  It was revealed that after 4 minutes treatment CathL increases 
phosphorylation of p38-α, ERK1/2 and AKT (S473) by ~2.5-, 3- and 3-fold 
respectively, compared to control (Figure 3.5). The spots for ERK1/2 and AKT 
are shown in figure 2.2 (Chapter 2, Method section 2.7.2). ERK1/2 and AKT were 
selected for further investigations on HOMECs as these two kinases have been 
shown to be significantly involved in cell proliferation, survival and cell migration 
in tumour biology.  
The proteome profiler data was confirmed using commercially available cell-
based ELISAs. CathL significantly induced ERK1/2 phosphorylation in HOMECs 
(>2-fold compared to control), similar to positive control VEGF (>2-fold compared 
to control), after 4 minutes treatment (Figure 3.6a). However, after 10 minutes 
treatment, levels of phosphorylated ERK1/2 reduced to the basal level (Figure 
3.6b). Similar experiments were performed with AKT where AKT phosphorylation 
was induced (~1.6-fold compared to control) at 4 minutes after treatment (Figure 
3.6c) and was reduced to basal level after 10 minutes (Figure 3.6d). VEGF was 
used as positive control in all cell-based ELISAs.  
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Figure 3.5: CathL induces phosphorylation of p38α, ERK1/2 and AKT(S473) 
in HOMECs. Phosphorylation statuses of intracellular kinases were assessed in 
cell lysates from cells treated with or without CathL for 4 minutes. The results of 
1 minute exposure are expressed as mean dots density (arbitrary units). The 
relative expression of specific phosphorylated proteins was determined following 
quantification of scanned images. A combination of 2 cell batches were used in 
this experiment. n= 2 (n=1). 
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Figure 3.6: CathL induces phosphorylation of ERK1/2 and AKT in HOMECs. 
Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without 50ng/ml of CathL or 20ng/ml of 
VEGF and incubated for 4 or 10 minutes. ERK1/2 (a, b) and AKT (c, d) 
phosphorylation was examined after 4 minutes (a, c) and 10 minutes (b, d) 
treatments. Commercially available cell-based ELISAs were used for the 
determination of ERK1/2 and AKT(S473) phosphorylation level.  The ELISA 
experiments were carried out on two cell batches. The data is represented by fold 
change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT (compared to 
control). Results are mean ±SD, n.s., **p<0.01 vs control; n=4-6. n.s. denotes not 
significant. 
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3.3.4 CathL-induced HOMEC proliferation is mediated via the ERK1/2 
pathway  
Since CathL induces activation of the proliferative kinase ERK1/2, it was 
hypothesised that ERK1/2 might be involved in the downstream signalling 
cascade in the induction of HOMEC proliferation and experiments were carried 
out to test this. Firstly, two well-known inhibitors of MEK/ERK1/2 were selected- 
U0126 and PD98059. Initially toxicity assays were carried out in order to identify 
their non-toxic concentrations in HOMECs. WST-1 assay was used to test this 
cytotoxicity 24 hour following inhibitor treatment. It was found that U0126 was not 
toxic to HOMECs at concentrations of 1 µM (97±6.0%, n=16 vs control (100%)) 
and 10 µM (96.2±7.1%, n=16 vs control (100%)), although slightly toxic at 25 µM 
(80.8±10.8%, n=21 vs control (100%)). However, cell viability reduced to less 
than 20% at 100 µM (7.6±1.3%, n=16 vs control (100); Figure 3.7a), 
demonstrating that U0126 is toxic at this concentration. On the other hand, 
PD98059 was not toxic at concentrations of 1 µM (96.4±10.1%, n=10 vs control 
(100%)), slightly toxic at 10 µM (84.1±12.5%, n=10 vs control (100%)) and 25 µM 
(63.8±13.3%, n=10 vs control (100%)), and very toxic at 50 µM (54.3±9.3%, n=10 
vs control (100%)) (Figure 3.7b). Very toxic concentrations were excluded from 
further experiments. Non-toxic/slightly toxic concentrations of U0126 (1, 10 and 
25 µM) and PD98059 (1, 10 and 25 µM) were used to investigate cell proliferation 
treated with CathL for 72 hours. 
CathL-induced HOMEC proliferation was reduced significantly in the presence of 
all inhibitor concentrations compared to CathL treatment alone at 72 hour after 
treatment. For instance, at 1, 10 and 25 µM of U0126 cell proliferation decreased 
to 84.6±6.2 % (Figure 3.8 a), 88.2±11.4% (Figure 3.8b) and 77.4±4.8% (Figure 
3.8c) respectively, compared to CathL (134.8±14.7%) (all expressed as 
percentage of control).  In the case of PD98059, inhibition of proliferation was as 
follows: 113.6± 3.9% (Figure 3.8d), 73.1± 10.3% (Figure 3.8e) and 64.4± 4.9% 
(Figure 3.8f) at concentrations 1, 10 and 25 µM respectively, compared to CathL 
alone (127.0±7.9%) (all expressed as percentages of control).  
Although the inhibitors significantly reduced CathL-induced HOMEC proliferation 
at all concentrations, in consultation with the current literature and data from 
inhibition of VEGF-induced (positive control, Appendix 1, Figure A1.3) HOMEC 
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proliferation, a concentration for each drug was selected to carry out further 
investigations i.e. 10 µM for U0126 and 25 µM for PD98059.  
At these concentrations of ERK1/2 inhibitors, CathL-induced HOMEC 
proliferation was significantly reduced compared to CathL treatment alone. To 
confirm the validity of the experimental use of the inhibitors it was important to 
confirm their effect on cellular levels of phosphorylated ERK1/2. Cell-based 
ELISAs showed that the levels of phosphorylated ERK/2 abolished or reduced in 
HOMECs to 0.8-fold and 0.25-fold in the presence of U0126 (Figure 3.9a) and 
PD98059 (Figure 3.9b) respectively when compared with CathL-alone (1.5-fold). 
These data, along with inhibition of cell proliferation data suggest that CathL 
induces HOMEC proliferation via activation of ERK1/2.  
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Figure 3.7: Cytotoxicity (cell viability) induced by ERK1/2 inhibitors. Cells 
were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without increasing concentrations of a) 
U0126 and b) PD98059 as indicated above and incubated for 24 hours. WST-1 
was used to assess cellular viability. Results are mean ±SD and shown as 
percentage of the control, n.s., **p<0.01, ***p<0.001 vs control (100%), n=10-21. 
n.s. denotes not significant. 
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Figure 3.8: Inhibition of ERK1/2 reduces CathL-induced HOMEC 
proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without CathL (50ng/ml) and in 
the absence or presence of various concentrations of a-c) U0126 and d-f) 
PD98059 as indicated above and incubated for 72 hours. WST-1 assay was used 
to assess cellular proliferation. Results are mean ±SD and shown as percentage 
of the control, **p<0.01, ***p<0.001 vs control (100%), ##p<0.01, ###p<0.001 vs 
CathL (normalised to control 100%), n=7-13.  
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Figure 3.9: CathL-induced ERK1/2 phosphorylation is inhibited in intact 
HOMECs treated with ERK1/2 inhibitors a) U0126 (10 µM) and b) PD98059 
(25 µM). Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were pre-incubated with the inhibitors for 20-30 minutes, and 
then co-treated with or without 50ng/ml of CathL or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of ERK1/2 phosphorylation level.  The 
data is represented by fold change in phosho-ERK1/2 relative to total ERK1/2 
(compared to control). Results are mean ±SD, n.s., *p<0.05, **p<0.01 vs control 
(1-fold), #p<0.05 vs VEGF/CathL (normalised to control), n=4. The dotted lines 
represent basal level (control) of phosphorylation status in untreated HOMECs. 
n.s. denotes not significant. 
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3.3.5 CathL-induced HOMEC proliferation is mediated via PI3K but not AKT 
activation 
The PI3K/AKT pathway is also known to promote cell survival and induce 
proliferation by inhibiting cell cycle arrest (Lawlor and Alessi, 2001). Since CathL 
induces AKT phosphorylation, it was logical to assess the role of AKT in HOMEC 
proliferation. In order to address this, two well-known inhibitors of the PI3K/AKT 
pathway were utilised- PI3K inhibitor LY294002 and AKT inhibitor MK2206. PI3K 
is upstream of AKT and hence it was necessary to see whether there is a generic 
role of PI3K in the induction of cell proliferation, and then focus further 
downstream involving AKT. Initially, a cytotoxic assay was performed to identify 
their non-toxic concentrations. PI3K inhibitor LY294002 was slightly cytotoxic 
over 24 hour treatment at concentrations 25 µM (89.0±4.6%, n=8), 50 µM (87.0 
±3.2%, n= 8) and reduced cell viability by approximately 20% at 100 µM 
(78.6±2.4%, n=8, vs control (100%); Figure 3.10a). With MK2206 the data 
showed that cells were viable after 24 hours at concentrations 1 µM 
(100±10.87%, n= 4) and that 5 µM did induce low levels of cytotoxicity 
(75.7±7.7%, n= 4) (Figure 3.10b). However, 25 µM of MK2206 significantly 
reduced cell viability to 44.1±1.3% (n= 4) compared to control (100%) (Figure 
3.10b), indicating that it is toxic to HOMECs.  
Next, proliferation was tested in HOMECs treated with CathL in the absence or 
presence of LY294002 or MK2206. Based on the data above LY294002 was used 
at 1, 25 and 50 µM  and MK2206 at 1, 3 and 5 µM. Interestingly, LY294002, an 
inhibitor of PI3K, reduced cell proliferation in a dose-dependent manner. For 
instance, cell proliferation in the presence of CathL plus at 1 µM, 25 µM and 50 
µM of LY294002 were 142.9±6.0% (n= 10; Figure 3.11a), 102.0±5.9% (n= 10; 
Figure 3.11b) and 74.7±3.7% (n=10; Figure 3.11c), respectively, compared to 
50ng/ml CathL alone, 137.3±5.7% (n= 10) (all data expressed as percentage of 
control). However, cell proliferation was not significantly altered in the presence 
of MK2206, a selective inhibitor of AKT. For example, cell proliferation in the 
presence of CathL plus at 1 µM, 3 µM and 5 µM of MK2206 were 128.1±6.4% 
(n= 9; Figure 3.11d), 127.8±9.7% (n= 8; Figure 3.11e) and 126.7±10.9% (n=10; 
Figure 3.11f) respectively, compared with CathL-induced proliferation, 
125.1±6.7% (n= 9) (all data normalised to control (100%)). Data from control wells 
for LY294002 demonstrated a significant reduction in cell proliferation over 72 
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hour period (Figure 3.11 a, b, c). Interestingly, MK2206 did not show any 
reduction, rather a significant increase in proliferation was observed across all 
three concentrations (Figure 3.11 d, e, f). These data may suggest that CathL 
induces HOMEC proliferation by activating the PI3K pathway, but via an AKT-
independent mechanism since the AKT-specific inhibitor did not reduce cell 
growth. A similar observation was made in VEGF-treated HOMECs (Appendix 1, 
Figure A1.4). 
On the basis of the toxicity data, cell proliferation data with LY294002 and 
MK2206, and current literature (Yang et al., 2015), the concentrations that were 
chosen to perform further experiments were: 25 µM for LY294002 and 5 µM for 
MK2206.  
The ELISA data with LY294002 (25 µM) and MK2206 (5 µM) confirmed that both 
drugs do inhibit phosphorylation of AKT in intact HOMECs. In the presence of 
LY294002, CathL-induced levels of phosphorylated AKT reduced from 1.9-fold to 
0.5-fold (Figure 3.12a). In the case of MK2206, levels of phosphorylated AKT 
decreased from 1.5-fold to 0.5-fold (Figure 3.12b). This suggests that both drugs 
inhibit the PI3K/AKT pathway in HOMECs. However, a lack of inhibition of cell 
proliferation suggests that PI3K, but not AKT(S473) is involved in the induction of 
CathL-mediated HOMEC proliferation.  
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Figure 3.10: Cytotoxicity (cell viability) induced by PI3K/AKT inhibitors. Cells 
were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without increasing concentrations of a) 
LY294002 and b) MK2206 as indicated above and incubated for 24 hours. WST-
1 assay was used to assess cellular viability. Results are mean ±SD and shown 
as percentage of the control, n.s., *p<0.05, ***p<0.001, vs control (100%), n=4-
8. n.s. denotes not significant vs control. 
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Figure 3.11: PI3K inhibitor, but not AKT inhibitor, reduces CathL-induced 
HOMEC proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without CathL (50ng/ml) and in 
the absence or presence of various concentrations of a-c) LY294002 (PI3K 
inhibitor) and d-f) MK2206 (AKT inhibitor) as indicated above and incubated for 
72 hours. WST-1 assay was used to assess cellular proliferation. Results are 
mean ±SD and shown as percentage of the control, ***p<0.001 vs control (100%), 
n.s., ###p<0.001 vs CathL, n=10-15 (normalised to control 100%). n.s. denotes 
not significant. 
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Figure 3.12: CathL-induced AKT phosphorylation is inhibited in HOMECs 
treated with PI3K and AKT inhibitors a) LY294002 (25 µM) and b) MK2206 (5 
µM), respectively. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were pre-incubated with the inhibitors for 2.5 hours, 
and then co-treated with or without 50ng/ml of CathL or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of level of AKT phosphorylation.  The 
ELISA experiments were carried out on two cell batches. The data is represented 
by fold change in phospho-AKT relative to total AKT (compared to control). 
Results are mean ±SD, *p<0.05 vs control (1-fold), #p<0.05 vs VEGF/CathL 
(normalised to control), n=4. The dotted lines represent basal level (control) of 
phosphorylation status in untreated HOMECs. 
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3.3.6 CathL induces migration via ERK1/2, not AKT 
In the process of angiogenesis, EC migration is a key step. Cells proliferate and 
migrate towards the secondary tumour foci and sprout out forming new blood 
vessels. Since EC migration is vital in angiogenesis, a role for CathL was 
investigated in HOMECs using a transwell migration Boyden chamber kit 
(Chapter 2, Section 2.5). Initially, cell migration was tested for 48 hours as was 
previously tested using the Oris migration kit (Winiarski et al., 2013). However, 
no significant differences were observed between untreated and CathL-treated 
HOMECs. Therefore, the incubation time was reduced to 6 hours, and it was 
revealed that CathL (197.4±49.6%, n= 10; Figure 3.13a) significantly induced 
HOMEC migration compared to control (100%). VEGF was used as positive 
control in these experiments. This led to further investigation into the activation 
of potential downstream signalling cascades.  
As previous data showed activation of ERK1/2 and AKT by CathL in HOMECs, 
cell migration was tested in the presence or absence of the corresponding kinase 
inhibitors at their chosen concentrations. Initially it was hypothesised that AKT 
may be involved in the induction of migration in CathL treated cells as AKT has 
been shown to be activated during cell migration in other models (Zhou et al., 
2016, Enomoto et al., 2005, Xue and Hemmings, 2013, Kakinuma et al., 2008, 
Chin and Toker, 2010, Kawasaki et al., 2003, Goetze et al., 2002, Morales-Ruiz 
et al., 2000). Therefore, the role of AKT in cell migration was examined in cells 
pre-treated with or without PI3K and AKT inhibitors for 1 hour and then co-treated 
with CathL in the absence or presence of the corresponding inhibitor for 6 hours. 
Neither PI3K inhibitor LY294002 (25 µM) nor AKT inhibitor MK2206 (5 µM) 
significantly reduced migration of CathL-treated HOMECs. For instance, 
migration of CathL-treated cells in the presence of LY294002 was 188.8±46.5% 
(n= 6; Figure 3.14a) with no significant difference compared with CathL-induced 
migration (199.2±62.2% (n=12) (both expressed as percentage of control 
(100%)). In the presence of MK2206, cell migration was 175.3±27.0% (n=6; 
Figure 3.14b), which was not significantly different to CathL-induced migration 
(199.2±62.2%, n= 12) (both normalised to control 100%). HOMECs treated with 
only LY294002 and/or MK2206 demonstrated a significant reduction in migration 
(Figure 3.14 a, b).  
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Interestingly, a similar observation was made in VEGF-treated HOMECs in the 
presence of both PI3K/AKT inhibitors, with a non-significant reduction in HOMEC 
migration compared with corresponding VEGF treatment. VEGF was used as a 
positive control (Appendix 1, Figure A1.5). 
HOMEC migration was then tested using ERK1/2 inhibitors. Cells were pre-
treated with U0126 (10 µM) or PD98059 (25 µM) and then were co-treated with 
CathL in the presence or absence of the inhibitors. After 6 hours incubation, both 
inhibitors of ERK1/2 abolished HOMEC migration compared to CathL-treated 
cells. For instance, in the presence of U0126 and PD98059, CathL-induced 
HOMEC migration was reduced to 75.6±19.1% (n= 7; Figure 3.15a) and 
91.5±14.1% (n= 7; Figure 3.15b) respectively, whereas CathL-alone significantly 
induced migration (146.6±17.3%, n= 9) (all expressed as percentage of control 
100%).  U0126 treatment alone significantly reduced HOMEC migration (Figure 
3.15a), however, although there was a slight reduction in migration by PD98059 
alone, it was not significantly different compared to control (Figure 3.15b). These 
data combined with the ELISA data showing inhibition of ERK1/2 phosphorylation 
by U0126 and PD98059 (Figure 3.9), suggest that CathL induces HOMEC 
migration through activation of ERK1/2, but not AKT(S473). A similar observation 
was made in VEGF-treated HOMECs (Appendix 1, Figure A1.6). 
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Figure 3.13: CathL induces HOMEC migration. HOMECs were seeded on the 
upper transwell insert and treated with or without CathL (50ng/ml) or VEGF 
(20ng/ml) supplementation of starvation media containing 0.5% FCS. The lower 
well contained correspondent treatment i.e. 0.5% FCS media, CathL (50ng/ml) 
or VEGF (20ng/ml). After 6 hours, migrated cells were stained with calcein AM 
and fluorescence was quantified using a FLUOstar plate reader at Ex/Em: 
485/520. a) Results are mean ±SD and shown as percentage of the control, 
***p<0.001 vs control (100%), n=10-15, b) Raw data from representative 
experiment. 
 
 
Figure 3.14: CathL does not induce HOMEC migration via the AKT pathway. 
HOMECs were seeded in the upper transwell chamber and treated with or without 
CathL (50ng/ml) in the absence or presence of PI3K and AKT inhibitors a) 
LY294002 (25 µM) and b) MK2206 (5 µM) respectively in media containing 0.5% 
FCS. The lower well contained correspondent treatments. After 6 hours, migrated 
cells were stained with calcein AM and fluorescence was quantified using a 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control, *p<0.05, ***p<0.001 vs control (100%), n=6-12. n.s. 
denotes not significant vs CathL. 
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Figure 3.15: CathL induces HOMEC migration via the ERK1/2 pathway. 
HOMECs were seeded in the upper transwell chamber and treated with or without 
CathL (50ng/ml) in the absence or presence of ERK1/2 inhibitors a) U0126 (10 
µM) and b) PD98059 (25 µM) respectively in media containing 0.5% FCS. The 
lower well contained correspondent treatments. After 6 hours, migrated cells 
were stained with calcein AM and fluorescence was quantified using a FLUOstar 
plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as percentage 
of the control, n.s., **p< 0.01, ***p<0.001 vs control (100%), ###p<0.001 vs 
CathL, n=7-9. n.s. denotes not significant. 
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3.3.7 Optimisation of in vitro 3D and 2D angiogenesis 
The data previously described indicate that CathL induces cell proliferation and 
migration, both critical steps in angiogenesis. To examine the ability of CathL to 
induce angiogenesis in HOMECs, a 3D in vitro model of angiogenesis was 
established according to a protocol described by Nakatsu et al. (Nakatsu et al., 
2007). This technique studies 3D sprouting of ECs grown on the surface of 
cytodex beads embedded in a fibrin gel.  As described in Chapter 2, Section 
2.8.1, HCMECs were primarily used to establish the model due to easy 
availability. Different conditions were examined: media supplemented with 2% 
FCS as basal control (Figure 3.16a), media supplemented with 5% FCS and 
manufacturer-provided growth factors as positive control (complete growth 
media) (Figure 3.16b), and 2% FCS media supplemented with 20ng/ml of VEGF 
(a known angiogenic stimulator) (Figure 3.16c) or 50ng/ml of CathL (Figure 
3.16d). Cell sprouting was observed in the positive control and in CathL- and 
VEGF-treated wells, but not in control wells (media with 2% FCS).  
However, when the same conditions were applied using HOMECs, the outcome 
was unsuccessful. No sprouting was observed in any condition, including the 
positive control after 5 days (Figure 3.17a-d). As ECs show heterogeneity, this 
may have been due to the requirement for different assay conditions for HOMECs 
versus HCMECs. Thus, initially alteration of the concentration of serum for 
HOMECs in the fibrin gel was examined.  This may influence access of sufficient 
FCS to HOMECS for optimal growth. Therefore, higher concentrations of FCS 
(5%, 10% and 20%) were supplemented with basal media or complete growth 
media to assess cell survival and sprouting (Figure 3.18 a), b) represent only 20% 
FCS±GFs data). Visually, it was observed that cells survived across all FCS 
concentrations in media and therefore, the lowest FCS concentration (5%) was 
selected to carry out further investigation. Although cells survived across all FCS 
concentrations, they did not sprout or branch out. This led to a series of 
experiments to optimise the concentration of the constituents of the fibrin gel. 
Thrombin-mediated conversion of fibrinogen to fibrin forms a tight network of 
fibrin monomers which may act as barrier and physically prevent cell proliferation 
and migration and therefore branching out in HOMECs. In order to address this, 
a lower thrombin concentration was investigated to reduce the tightened fibrin 
linkages and to allow flexibility for the cell movement. However, at lower 
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concentrations of thrombin the gel failed to form fully and so was not used in 
further experiments (data not shown).  
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Figure 3.16: Formation of angiogenic sprouts in human cerebral 
microvascular endothelial cells (HCMECs) in 3D fibrin gel. Cells were seeded 
on cytodex 3 microcarriers and embedded in fibrin gel in media supplemented 
with 2% FCS a) Control, b) 5% FCS with added EC growth factors (positive 
control), c) 20ng/ml of VEGF (positive control) or d) 50ng/ml of CathL. 
Media/treatments were replaced every other day up to day 5. Photographs were 
taken on day 6 post-seeding using a Nikon phase-contrast microscope at 10X 
magnification. Arrows pointing to cell sprouting. Scale bar =100 μm.  
 
 
 
 
 
 
 
a) b) 
c) d) 
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Figure 3.17: Investigation of angiogenic sprout formation in human omental 
microvascular endothelial cells (HOMECs) in 3D fibrin gel. Cells were seeded 
on cytodex 3 microcarriers and embedded in fibrin gel in media supplemented 
with 2% FCS a) Control, b) 5% FCS with added EC growth factors (positive 
control), c) 20ng/ml of VEGF (positive control) or d) 50ng/ml of CathL. 
Media/treatments were replaced every other day up to day 5. Photographs were 
taken on day 6 post-seeding using a Nikon phase-contrast microscope at 10X 
magnification. Arrows pointing to live cells on beads. Scale bar =100 μm. 
 
 
 
 
 
 
 
a) b) 
c) d) 
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Figure 3.18: Investigation of effects of higher serum concentrations on 
angiogenic sprout formation in HOMECs in 3D fibrin gel. Cells were seeded 
on cytodex 3 microcarriers and embedded in fibrin gel in media supplemented 
with 20% FCS a) without or b) with added EC growth factors (GFs). 
Media/treatments were replaced every other day up to day 5. Photographs were 
taken on day 6 post-seeding using a Nikon phase-contrast microscope at 10X 
magnifications. Arrow pointing to live cells on beads. Scale bar =100 μm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Aprotinin (0.14 U/ml) is another constituent of this fibrin gel. It is a protease 
inhibitor which is included to slow down rapid fibrinolysis of the gel (Sacchi et al., 
2014). It was hypothesised that aprotinin may inhibit proteases secreted by 
HOMECs that actively cleave and breakdown fibrin mesh in order for cells to 
sprout out. Thus, reducing aprotinin concentration may allow more efficient 
HOMEC sprouting.  Three different concentrations of aprotinin were tested- 0, 
0.07 and 0.14 U/ml. 0.14U/ml is normally used in the original protocol (Nakatsu 
et al., 2007). At 0 U/ml of aprotinin, HOMECs supplemented with complete growth 
media formed a monolayer within the fibrin gel (Figure 3.19b) that was not 
observed in media without growth factors (Figure 3.19a), suggesting that 
HOMECs secrete proteases in response to growth factors which then cleave and 
break down fibrin linkages, allowing EC movement (Figure 3.19). Intriguingly, 
visually, the fibrin gel remained intact in the absence of aprotinin, indicating 
durability of fibrin matrix. However, there were no features of sprouting or 
branching of these ECs at low (0.07 U/ml; Figure 3.19c, d) or recommended (0.14 
U/ml; Figure 3.19e, f) concentrations of aprotinin.  
The final variable to be studied for optimisation was bead type. Previously, 
cytodex 3 beads were used to embed cells in the gel. Cytodex 3 beads are pre-
coated with collagen. As HOMECs grow on 2% gelatin coated plastic, it was 
thought that the material might affect cell growth and migration in the gel. 
Therefore, cytodex 1 beads were used instead of cytodex 3 beads (Figure 3.20). 
Cytodex 1 beads are pre-coated with gelatin which was thought to be a better 
option for HOMECs. When tested in fibrin gel containing different concentrations 
of aprotinin and media supplemented with 5% FCS and with (Figure 3.20b, d, f) 
or without (Figure 3.20a, c, e) growth factors, there was no difference observed 
in cell growth between the two beads. At this stage, it was decided that this model 
may not be suitable to study HOMECs angiogenesis and that angiogenesis of 
HOMECs should be tested using a 2D fibrin gel model. 
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Figure 3.19: Investigation of effects of different aprotinin concentrations on 
angiogenic sprout formation in HOMECs in 3D fibrin gel. Cells were seeded 
on cytodex 3 microcarriers and embedded in fibrin gel containing 0 (a, b), 0.07 
(c, d) and 0.14 (e, f) U/ml aprotinin as indicated. Next, cells were treated with 
media supplemented with 5% FCS with (b, d, f) or without (a, c, e) added EC 
growth factors (GFs) as shown. Media/treatments were replaced every other day 
up to day 5. Photographs were taken on day 6 post-seeding using a Nikon phase-
contrast microscope at 10X magnifications. Arrow pointing to the monolayer of 
HOMECs. Scale bar =100 μm. 
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Figure 3.20: Investigation of effects of seeding HOMECs on cytodex 1 
microcarriers on angiogenic sprout formation in HOMECs in 3D fibrin gel. 
Cells were seeded on cytodex 1 microcarriers and embedded in fibrin matrix gel 
containing 0 (a, b), 0.07 (c, d) and 0.14 (e, f) U/ml aprotinin as indicated. Next, 
cells were treated with media supplemented with 5% FCS with (b, d, f) or without 
(a, c, e) added EC growth factors (GFs) as shown. Media/treatments were 
replaced every other day up to day 5. Photographs were taken on day 6 post-
seeding using a Nikon phase-contrast microscope at 10X magnifications. Scale 
bar =100 μm. 
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To carry out the 2D model, the same fibrin gel was used as above, but cells were 
seeded at 35,000 per well on top of the gel. After overnight incubation, cells were 
treated with media supplemented with 2% FCS (control media), VEGF (20ng/ml; 
positive control) or CathL (50ng/ml). At 72 hours after treatment, a complete 
monolayer formed in the control (Figure 3.21a) and VEGF-treated wells (Figure 
3.21b). However, in CathL-treated wells cells did not form a monolayer, rather 
they loosely organised themselves in a tubule-forming manner (Figure 3.21c). 
This may have been caused due to seeding cells at a low density. Therefore, this 
experiment was repeated under the same conditions except with a higher cell 
density- 50,000 cells per well (Figure 3.22). It was thought that at higher cell 
density cells will form a confluent monolayer more quickly and after treatment, 
cells would organise themselves to form tubes. However, after monitoring at 24, 
48 and 72 hours incubation no such organisation was observed (Figure 3.22). 
This may indicate that perhaps fibrin matrix gel is not the ideal model for testing 
angiogenesis in HOMECs. Therefore, commercially available growth factor-
reduced (GFR) Matrigel was chosen to carry out further investigation on 
HOMECs angiogenesis.  
GFR-Matrigel contains a solubilized basement membrane preparation extracted 
from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour rich in 
extracellular matrix protein, supplemented with low concentrations of growth 
factors. Although this model is usually used to study inhibition of angiogenesis, 
at this stage it was the best commercially available model that could be used to 
test for angiogenesis in HOMECs. 
Initially, cells were seeded on the Matrigel and incubated overnight. Interestingly, 
tube-like structures were formed in this period, halting any further treatment of 
these cells (Figure 3.23). This indicated the importance of reducing the time 
between cell seeding and treatment in order to reduce the window of cells forming 
tubes. Therefore, cells were seeded and treated 2 hours later with or without 
CathL and positive control VEGF for another 8 hours.  A shorter incubation was 
chosen so that cells do not further proliferate and migrate to form a monolayer 
after forming tube-like structure. A significant increase in tube formation was 
observed in CathL treated cells (200±11.1, n=3 (Figure 3.24 c, d) compared to 
control (145±15) (Figure 3.24 a, d). VEGF also significantly increased tube 
formation in HOMECs (210.3±22.4, n=3; Figure 3.24 b, d).  These data, along 
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with proliferation and migration data, strongly suggest that CathL plays a 
proangiogenic role in HOMECs in the metastasis of ovarian cancer.  
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Figure 3.21: Investigation of tubule structure formation in CathL-treated 
HOMECs in 2D fibrin gel. HOMECs were plated onto fibrin matrices and treated 
with medium containing a) 2% FCS (control), b) supplemented with VEGF 
(positive control, 20ng/ml) and/or c) CathL (50ng/ml) for 72 hours. Controls 
contained HOMECs grown in medium containing 2% FCS alone. Photographs 
were taken at 72 hours after treatment using a Nikon phase contrast microscope 
camera. Scale bar =40 μm. 
 
 
 
 
 
 
 
 
 
a) b) 
c) 
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Figure 3.22: CathL did not induce tubule structure formation in HOMECs in 
2D fibrin gel. HOMECs were plated onto fibrin matrices and treated with medium 
containing a) 2% FCS (control), b) supplemented with VEGF (positive control, 
20ng/ml) and/or c) CathL (50ng/ml) for 72 hours. Controls contained HOMECs 
grown in medium containing 2% FCS alone. Photographs were taken at 72 hours 
after treatment using a Nikon phase contrast microscope camera. Scale bar =40 
μm. 
 
 
 
 
 
 
 
 
 
a) b) 
c) 
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Figure 3.23: Spontaneous tubule structure formation in HOMECs in 2D 
Matrigel after 24 hours. HOMECs were plated onto GFR-Matrigel in medium 
containing 2% FCS. Photographs were taken at 24 hours after cell seeding using 
a Nikon phase contrast microscope. Scale bar =75 μm. 
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Figure 3.24: CathL-induced tubule structure formation in HOMECs in a 2D 
Matrigel- stage 2. HOMECs were plated onto GFR-Matrigel in medium 
containing 2% FCS and treated with media supplemented without a) control or 
with b) VEGF (20ng/ml) and/or c) CathL (50ng/ml) for 8 hours. Controls contained 
HOMECs grown in medium containing 2% FCS alone. Photographs were taken 
at 8 hours after treatment using a Nikon phase contrast microscope camera and 
d) tubule-structure formation (including nascent tubule structures) was quantified 
as described in method section. The results are presented as an angiogenesis 
index. *p<0.05, **p<0.01 vs control levels, n=4. Scale bars =40 µm. 
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3.3.8 CathL activates Tie-1 receptor tyrosine kinase 
The previous data suggest that CathL plays a role in inducing pro-angiogenic 
changes via ERK1/2, and activating important intracellular kinases. Since the 
data also indicate that CathL induces these changes in a manner that is not 
dependant on its proteolytic activity, it is possible that the protein acts via an 
extracellular receptor. The possibility that CathL may act via a known tyrosine 
kinase receptor was investigated using a commercially available kit which 
simultaneously screens and detects activation of 49 different receptor tyrosine 
kinases. Cells were treated for 10 minutes with starvation media (2% FCS MV2), 
media supplemented with CathL (50ng/ml) or VEGF (20ng/ml) (positive control). 
The experiment was carried out according to the manufacturer’s instructions and 
the membranes containing 49 antibodies were scanned using the Azure system. 
The data was analysed by Azure software which sets a threshold margin for 
detecting bands and subtracts any background that may interfere with the actual 
data. The results revealed that VEGF strongly activated VEGFR2 as expected 
and slightly activated VEGFR3. Intriguingly, CathL activated Tie-1 receptor 
kinase which is an orphan receptor and may be involved in angiopoetin/Tie-2 
pathways (Ang) (a potent proangiogenic factor (Figure 3.25). Representation of 
VEGF-induced activation of VEGFR2,3 RTKs are shown in Appendix 1, Figure 
1.8. 
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Figure 3.25: CathL induces phosphorylation and activation of the RTK Tie-
1. Phosphorylation statuses of RTKs were assessed in cell lysates treated with 
or without CathL or VEGF for 10 minutes. The results of 1 minute exposure are 
expressed as mean dot density. The relative expression of specific 
phosphorylated proteins was determined following quantification of scanned 
images of membrane using Azure software. n=1. 
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3.4 Discussion 
 
In this chapter, CathL was shown to induce HOMEC proliferation by a non-
proteolytic mechanism. In addition, CathL was also observed, for the first time, to 
induce phosphorylation and activation of ERK1/2, AKT and p38α in HOMECs. 
Subsequent data suggested that CathL-induced HOMEC proliferation and 
migration were mediated via activation of the ERK1/2 and PI3K pathways, 
independent of AKT. Interestingly, CathL was also shown to induce tube 
formation in HOMECs. In a preliminary investigation, CathL was found to activate 
receptor tyrosine kinase Tie-1 in HOMECs. 
Cells respond to their environment through actions of intracellular pathways. An 
agent such as a peptide hormone or growth factor typically binds to the 
extracellular domain of its transmembrane receptor(s), triggering activation of 
multiple signalling networks which are interconnected and non-linear. In these 
studies, only the ERK1/2 and AKT pathways have been investigated for their 
roles in angiogenesis as they have been reported to be involved in several EC 
models as discussed below. 
 
Role of ERK1/2 and AKT in cellular proliferation and migration 
The Raf-mitogen-activated protein kinase kinase- extracellular signal–regulated 
kinase (Raf-MEK-ERK) pathway represents one of the best characterised MAPK 
pathways in humans. The stimulation of receptor tyrosine kinases (RTK) by 
growth factors or cytokines provokes the activation of MAPKs in a multistep 
process which sequentially activates MEK1 and MEK2 (Mebratu and Tesfaigzi, 
2009). The MEKs ultimately phosphorylate p44 MAPK and p42 MAPK, also 
known as ERK1 and ERK2 respectively, thereby increasing their enzymatic 
activity.  Activated ERK1/2 translocates to the nucleus and transactivates 
transcription factors, including the ternary complex factor (TCF) - Elk1, serum 
response factor accessory protein Sap-1a, Ets1, c-Myc, Tal etc, changing gene 
expression such as the immediate early gene c-fos (Mebratu and Tesfaigzi, 
2009). Thus, the ERK1/2 pathway can link G0/G1 mitogenic signals to the 
immediate early response to promote growth, differentiation or mitosis. A 
summary of the ERK1/2 pathway in cell proliferation is given in figure 3.26.  
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Figure 3.26: Mechanism of ERK activation and cell proliferation. Activation of 
receptor tyrosine kinases (RTKs) or G protein-coupled receptors (GPCRs) by 
growth factors or mitogens leads to the recruitment of an adaptor protein Grb2 
(growth factor receptor bound protein) and the guanine nucleotide exchange 
factor Son of Sevenless (SOS). SOS activates Ras to recruit and activate Raf at 
the plasma membrane by phosphorylation at multiple sites. MEK1/2 is then 
phosphorylated at two serine residues and subsequently phosphorylates ERK1/2 
on both threonine and tyrosine. Activated ERK1/2 phosphorylates ribosomal s6 
kinase (RSK) and both RSK and ERK translocate to the nucleus where it 
activates multiple transcription factors, ultimately resulting in effector protein 
synthesis and causing changes in cell proliferation and survival. ERK 
phosphorylation of MEK and possibly Raf can inactivate the pathway at those 
steps creating a negative feedback loop. (Adapted from (Mebratu and Tesfaigzi, 
2009)). 
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A role for activation of ERK1/2 in cell migration is now emerging. It is now known 
that on receiving extracellular stimuli, active Raf and inactive ERK bind to paxillin, 
thus mediating ERK activation at focal complexes in HUVECs (Abedi and 
Zachary, 1997, Ishibe et al., 2003). The paxillin-focal adhesion kinase (FAK) 
interaction is also involved in ERK activation (Subauste et al., 2004) where ERK 
phosphorylates paxillin, which in turn enhances paxillin-FAK association (Liu et 
al., 2002). However, it was also reported that ERK-mediated phosphorylation of 
FAK at Ser910 blocks the interaction of FAK with paxillin (Hunger-Glaser et al., 
2003). These observations suggest a sophisticated regulation of the FAK-paxillin 
complex, in which ERK might initially promote complex-assembly by 
phosphorylation of paxillin and then promote disassembly by subsequent 
phosphorylation of FAK, leading to focal adhesion disassembly, and hence cell 
motility. Because dynamic integrin activation is required for cell migration 
(Huttenlocher et al., 1997, Palecek et al., 1997), ERK might regulate integrin 
activation and induce cell migration. Alternatively, coordinated activation of all 
these pathways by ERK may be crucial for promoting migration. 
There are several other mechanisms that have been suggested by which ERK1/2 
may regulate cell migration (Figure 3.27). One possible pathway involves myosin-
based contraction via activation of myosin light chain kinase (MLCK) (Huang et 
al., 2004). In a more recent study, involvement of MLCK was strongly suggested 
to be a critical component of ERK1/2-mediated cell migration in COS-7 cells (a 
fibroblast-like cell line derived from monkey kidney tissue), MCF7 human breast 
cancer cells and HT1080 fibrosarcoma cells whereby ERK1/2 regulates 
phosphorylation of myosin light chain (MLC), leading to actin-myosin association 
and cell contraction, and therefore cell motility (Huang et al., 2004). Interestingly, 
Enomoto et al. reported that ERK1/2 is not involved in EGF-induced migration in 
COS-7 cells (Enomoto et al., 2005). Activated ERK1/2 has also been shown to 
phosphorylate m-calpain both in vitro and in vivo (Glading et al., 2004). Calpains 
are a family of Ca2+-activated proteases that are involved in cell migration 
(Dourdin et al., 2001, Huttenlocher et al., 1997). Activated m-calpain interacts 
with FAK and together the complex then associates with the cytoskeleton 
whereby calpain degrades cytoskeletal proteins and causes adhesion 
disassembly in mouse embryo fibroblasts (Cuevas et al., 2003). 
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Figure 3.27: Signalling pathways for cell migration mediated by ERK. Growth 
factors, such as PDGF, EGF and FGF, activate ERK through the Ras-Raf-
MEK1/2- ERK signalling module. Activated ERK regulates membrane protrusions 
and focal adhesion turnover via phosphorylating MLCK and promotes focal 
adhesion disassembly via phosphorylating and activating calpain. 
Phosphorylation of FAK and paxillin by ERK may regulate focal adhesion 
dynamics, probably by influencing the paxillin-FAK interaction. Orange lines 
represent speculative pathways (Adapted from (Huang et al., 2004)). 
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The AKT kinase is a downstream component of PI3K signalling, which is 
activated upon autophosphorylation of RTK induced by ligands such as insulin or 
other growth factors, stimulation of G-protein-coupled receptors, or activation of 
integrin signalling (Wymann et al., 2003). AKT is translocated to the plasma 
membrane from the cytoplasm upon activation of PtdIns(3,4,5)P3, a second 
messenger which is generated by active PI3K. Once recruited to the plasma 
membrane, AKT is activated by a multistep process that requires phosphorylation 
of Thr308 and Ser473. Phosphorylation of Ser473 is the key step because it 
stabilises the active conformation state (Yang et al., 2002). Once activated at the 
plasma membrane, phosphorylated AKT can translocate to the cytosol or the 
nucleus (Andjelkovic et al., 1999) and can directly phosphorylate many 
substrates within several subcellular compartments, including mediators of 
immediate changes in cell shape, movement and intermediary metabolism, cell 
viability, division or differentiation (Manning and Cantley, 2007). 
In cellular proliferation, AKT is known to regulate cell cycle progression through 
multiple mechanisms such as by upregulating the expression of cyclin D1 and by 
regulating the CDK (cyclin –dependent kinase) inhibitor p21 Waf1/Cip1 (Lawlor 
and Alessi, 2001). Unlike other cyclins that are periodically induced throughout 
cell cycle progression, cyclin D is regulated by the extracellular mitogenic 
environment (Lawlor and Alessi, 2001). When the PI3K/AKT pathway was 
inhibited by LY294002, a marked reduction in cyclin D1 level in HUVECs was 
observed, suggesting that the PI3K/AKT pathway is involved in the induction of 
cell proliferation (Chen et al., 2008). Inhibition of AKT was also shown to inhibit 
cell cycle arrest by phosphorylating p21 which is known to block the cell cycle by 
reversibly inhibiting several cyclin-CDK complexes in NIH3T3 cells (Zhou et al., 
2001). It has been reported that activation of AKT decreases cellular levels of 
p27, possibly via phosphorylating the forkhead transcription factor which is 
required for transcription of p27Kip1, an enzyme inhibitor that typically causes cell 
cycle arrest in the G1 phase (Lawlor and Alessi, 2001). 
The PI3K/AKT pathway has been shown to be extensively linked to mammalian 
cell migration. Hawkins et al. reported that PI3K activation enhances actin 
remodelling and generates membrane protrusions through activating Rac1 in 
porcine aortic ECs, induced by platelet derived growth factor (PDGF) (Hawkins 
et al., 1995). The PI3K/AKT signals also induce activation of P70S6K (ribosomal 
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protein S6 kinase β-1) which causes remodelling of actin, leading to cell migration 
and invasion in chicken embryo fibroblasts (Qian et al., 2004). Girdin/AKT 
phosphorylation enhancer (APE) is an AKT substrate that upon activation 
promotes actin organisation and cell motility in COS-7 cells (Enomoto et al., 
2005). In human saphenous vein ECs, human aortic ECs and bovine aortic ECs, 
nitric oxide has also been shown to induce cell migration and angiogenesis via 
activating PI3K (Kawasaki et al., 2003). Leptin is another factor that also induced 
human umbilical vein EC migration via activation of AKT (Goetze et al., 2002).  
Bovine lung microvascular EC and bovine aortic EC migration was also induced 
by VEGF via activation of the AKT pathway (Morales-Ruiz et al., 2000). 
 
CathL has been linked to tumour invasion and metastasis by its ability to degrade 
ECM components. As discussed in chapter 1 (section 1.7.1.3), there is 
considerable evidence that CathL may play a role in the pathogenesis of EOC. 
The involvement of CathL in the invasion and metastasis of EOC raises the 
possibility that it may be a marker of advanced stage ovarian cancer. This is 
supported by data showing a significant increase in CathL expression in the 
endothelium of vessels within omentum hosting metastatic ovarian high-grade 
serous carcinoma in vivo compared with omentum from control patients with 
benign ovarian cystadenoma. Recently SKOV3 and A2780 EOC cells were 
shown to secrete CathL and exogenous addition of CathL to HOMECs used as 
an in vitro model of omental angiogenesis, induced migration and in vitro tube 
structure formation (Winiarski et al., 2013).  
 
CathL in cellular proliferation 
The mechanism of CathL-induced cell proliferation, a key step in angiogenesis, 
had not been explored and therefore, the generic hypothesis of this study was: 
CathL induces proangiogenic changes in HOMECs in a non-proteolytic 
mechanism. In order to address the hypothesis, initially, cell proliferation was 
tested in HOMECs treated with CathL at increasing concentrations using the 
WST-1 assay, which estimates cell number based on metabolic activity. 
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Previous published data reported that EOC cell-secreted concentration of CathL 
into tumour conditioned media was in the ng/ml range. In this current study, three 
increasing concentrations of CathL (20, 50 and 80ng/ml) were selected to 
examine proliferation in HOMECs based on the previous findings. CathL at 
50ng/ml and 80ng/ml induced significant cell proliferation compared to control, 
although at the former concentration this rise in cell proliferation was most 
significant. Therefore, 50ng/ml of CathL was selected to carry out further 
investigations.  
Although WST-1 is an established technique, measuring cell proliferation via 
metabolic activity may give false positive results as factors other than treatment 
such as temperature, media conditions, and compounds within the treatment may 
interfere with the enzymes that generate the metabolically active readout. 
Therefore, to eliminate the possibility of a false positive, HOMEC proliferation was 
tested using a second technique the CyQUANT cell proliferation assay which 
consists of a cell-permeant fluorescently-labelled DNA binding dye that stains 
nucleic acids within cells and emits a fluorescent measurement. The data from 
both techniques complemented each other and suggested that CathL 
significantly induces HOMEC proliferation compared to control.  
 
In normal physiological processes, CathL acts as a lysosomal protease, in which 
it breaks down unfolded or wrongly folded proteins. Lysosomes have an acidic 
environment, with a pH ranging from 3-5.5. CathL has an optimum pH of 5.5-6 at 
which it is proteolytically active (Mason et al., 1987, Mason and Massey, 1992). 
However, CathL has also been shown to be proteolytic at neutral pH. Since 
exogenous CathL induces HOMEC proliferation in culture media, it was important 
to investigate whether CathL is acting via a proteolytic or non-proteolytic 
mechanism at the prevailing pH. The first set of experiments were designed to 
examine whether inhibiting proteolytic activity of CathL altered HOMEC 
proliferation. In the presence of FY-CHO (a potent and selective inhibitor of 
CathL-proteolytic activity), there was no inhibition of CathL-induced HOMEC 
proliferation. FY-CHO has been used to prevent secreted CathL-induced bone 
resorption in unfractionated rat bone cells in the pit formation assay and reduced 
bone-weight loss in mice in a dose-dependent manner (Woo et al., 1996). 
Furthermore, it has been extensively used to inhibit CathL mediated in vitro 
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migration and invasion of breast and prostate cancer cells (Sudhan and Siemann, 
2013). Here, this inhibitor was primarily chosen over cystatin C, a commonly used 
CathL inhibitor, because cystatin C elicits non-selective inhibition on all cysteine 
proteases. The range of concentrations of FY-CHO was selected based around 
a concentration of 10 μM which strongly inhibited CathL-proteolytic activity 
against CLN7 membrane glycoprotein in COS-7 cells (Steenhuis et al., 2012). 
These data initially suggested that CathL induces HOMEC proliferation in a non-
proteolytic mechanism. 
These data indicate that a CathL inhibitor had no effect in CathL-induced 
proliferation. Thus, the next set of experiments were designed to examine 
whether CathL was actually proteolytically active at pH 7.2 (i.e. in culture media) 
and if so whether FY-CHO would actually inhibit in these conditions. In vitro 
CathL-proteolytic activity at an array of pHs was examined using ZVA, a CathL-
specific fluorogenic substrate. Interestingly, CathL was found to be proteolytically 
active throughout the pH range starting from its optimum pH (4.5) up to pH 7.6, 
including the pH of cell culture media which was demonstrated to be between 
7.11 and 7.34 throughout a typical proliferation experiment. These data coincide 
with previous findings (Dehrmann et al., 1995), where CathL was also 
proteolytically active at pH 7 up to pH 8. Thus, CathL is catalytically active at 
culture media pH. Finally it was important to demonstrate that the inhibitor was 
active in culture media pH conditions. When FY-CHO was included at the same 
concentration as in the proliferation experiment (10 µM), CathL proteolytic activity 
was completely blocked across all pHs. It can be concluded that if CathL was 
active as a protease in cell culture media, it would have been inhibited by FY-
CHO, as was shown in previous studies and in this pH experiment. However, the 
fact that CathL-induced proliferation was not altered in the presence of the 
inhibitor suggests that CathL induces HOMEC proliferation via a novel 
proteolytic-independent mechanism. 
 
CathL-induced activation of intracellular signalling pathways and their role in 
cellular proliferation 
As CathL appeared to induce HOMEC proliferation in a non-proteolytic manner, 
it was logical to assess the intracellular signalling pathways activated by CathL. 
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A human phosphokinase array indicated that kinases ERK1/2, AKT(S473) and 
p38α which are mainly involved in cell survival, proliferation and migration were 
activated in CathL treated cells compared to untreated cells after 4 minutes 
treatment. This time point (4 minutes) for CathL was selected because previous 
reports suggest that MAPK/ERK1/2 and AKT phosphorylation are maximum at 4-
5 minutes (Konopatskaya et al., 2005). Out of these three kinases, ERK1/2 and 
AKT were selected to be investigated in further experiments primarily because 
both kinases have been shown to be involved in cell proliferation and cell 
migration, two critical steps of angiogenesis. 
Subsequently, cell-based ELISAs were carried out to further confirm the above 
finding of the proteome profiler. These commercially available ELISA kits use live 
cells in a 96 well plate which are then fixed and permeabilised. This 
permeabilsation allows primary and secondary antibodies to enter the cell and 
bind to corresponding targets. The main benefit of this kit is that there is no need 
for cell lysis and quantification of protein, and hence it is very efficient and also 
cost-effective. ELISAs were chosen over western blots (WBs) as WBs only 
visualise the presence of a particular protein target and quantifying is less 
sensitive, whereas using these ELISA kits, 96 samples can be analysed and 
quantified at the same time.  
The ELISA was performed at 2 time points, 4 and 10 minutes after CathL 
treatment. Multiple time points are important to test for phosphorylative statuses 
of kinases as they vary over time and the activation of intracellular kinases can 
be transient. Interestingly, CathL induced phosphorylation of both ERK1/2 and 
AKT 4 minutes after treatment. However, 10 minutes later, the level of 
phosphorylation reduced back down to their basal level (control). VEGF was used 
as a positive control in this experiment as it is a well-known activator of ERK1/2 
and AKT. As shown for CathL, VEGF also induced ERK1/2 and AKT 
phosphorylation at 4 minutes after treatment. VEGF-induced AKT 
phosphorylation was reduced 10 minutes later, although the level of 
phosphorylated ERK1/2 increased further. This may demonstrate a transient 
activation and subsequent deactivation of these kinases.  
These data demonstrate for the first time that CathL is able to induce ERK1/2 and 
AKT phosphorylation in ECs. Previously, CathL was shown to induce HUVEC 
migration via the JNK pathway in a proteolytic manner (Chung et al., 2011). 
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However, this pathway was not activated by CathL treatment in HOMECs as 
indicated by proteome profiler (data not shown).  
Activation of ERK1/2 has been extensively shown to be involved in cell 
proliferation (Rubinfeld and Seger, 2005). Therefore, it was hypothesised that 
ERK1/2 may be involved in the induction of proliferation in CathL-treated 
HOMECs. Two well-known inhibitors (U0126 and PD98059) of MEK/ERK1/2 
were used to examine this. Both inhibitors at different concentrations 
demonstrated significant inhibition of proliferation in HOMECs compared to 
CathL-treatment alone, suggesting that ERK1/2 may be involved in CathL-
induced HOMEC proliferation. The validity of the use of the inhibitors was 
established by ELISA data indicating that both inhibitors at their selected 
concentrations inhibited ERK1/2 phosphorylation.  
It is important to note that the concentrations for U0126 and PD98059 were 
chosen for the above experiments primarily based on their toxicity assay results 
and also their inhibitory effects on VEGF-induced (positive control, Appendix 1, 
Figure A1.3) HOMEC proliferation and the current literature. Reported 
investigations into the cross-reactivity of U0126 and PD9859 showed that the 
selected concentrations of the ERK1/2 inhibitors in this study do not activate the 
AMPK pathway, unlike higher concentrations (Dokladda et al., 2005).  
The role of activated ERK1/2 in cell proliferation has been reported in other EC 
types. For instance, Jin et al. demonstrated VEGF-induced proliferation of RF/6A 
cells (rhesus macaque choroid-retinal EC line) mediated by ERK1/2 pathway (Jin 
et al., 2013). It was reported that hypoxia enhances FGF2- and VEGF-stimulated 
human placental artery EC proliferation via the MEK/ERK1/2 pathway (Wang et 
al., 2009). TRAIL, a member of the tumour necrosis factor family of cytokines, 
was shown to induce HUVEC proliferation via activation of the ERK1/2 pathway 
but not JNK or p38α pathways (Secchiero et al., 2003). Extracellular VEGF was 
shown to induce proliferation in HUVECs via activation of the MAPK/ERK1/2 
pathway (Kanno et al., 2000). This was further demonstrated by a reduction in 
DNA synthesis upon PD98059 treatment. Activation of ERK1/2 pathway was 
observed in FGF2 induced cellular proliferation of murine brain ECs (Klint et al., 
1999).  Together, these data suggest an important role of ERK1/2 in the induction 
of cellular proliferation in different EC models. In this study, CathL induced 
HOMEC proliferation via activation of the ERK1/2 pathway, and this, to my 
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knowledge, is the first study to report such an observation in mammalian cells to 
date. 
Based on the previously described role for PI3K/AKT in EC proliferation and the 
fact that CathL induced increased levels of phosphorylated AKT, the involvement 
of this pathway in HOMEC proliferation stimulated by CathL was also 
investigated. Initially two well-known inhibitors of this pathway were chosen- PI3K 
inhibitor LY294002 and selective AKT inhibitor MK2206. As PI3K is upstream of 
AKT, activation and involvement of this kinase was tested. LY294002 decreased 
HOMEC proliferation in a dose-dependent manner and ELISA data confirmed 
that LY294002 inhibited phosphorylation of AKT in HOMECs. This suggested 
that, like the ERK1/2 pathway, PI3K/AKT pathway is also involved in CathL-
induced HOMEC proliferation.  
In order to further understand the above findings, a selective inhibitor of AKT was 
used. Intriguingly, MK2206 did not inhibit cell proliferation induced by CathL, 
although phosphorylated levels of AKT were maintained at basal level by the 
inhibitor (Figure 3.12). This may suggest that activated AKT is not responsible for 
inducing HOMEC proliferation since MK2206 has been shown to be a potent 
selective inhibitor of AKT, and that PI3K may act via an AKT-independent 
pathway to induce proliferation. This observation is supported by reports in the 
literature. An analysis of 547 human breast cancers showed no correlation 
between AKT phosphorylation and activating PI3K mutations (Stemke-Hale et al., 
2008). This was later confirmed in another study that showed that activating 
mutation of PI3K can markedly reduce AKT phosphorylation (Vasudevan et al., 
2009). Additionally, overexpression of PDK1 (phosphoinositide-dependent 
kinase-1) in human breast cancer cell lines increased anchorage independent 
growth and tumour formation, which was not prevented by AKT inhibition 
(Gagliardi et al., 2012). Similarly, no correlation was found between the 
phosphorylation of AKT and the mutation status of PI3K in colon cancer cell lines 
(Morrow et al., 2005). It was suggested that a prolonged inhibition of PI3K may 
fail to block AKT phosphorylation i.e. there are other kinases responsible for AKT 
activation under chronic PI3K inhibition (Dufour et al., 2013). These reports 
indicate that to elicit an activated PI3K-mediated cellular response in cancer AKT 
activation is not essential and that kinases other than AKT may be involved. 
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Figure 3.28: AKT-independent PI3K signalling cascades in cancer. Several 
AKT-independent mechanisms used by PI3K to promote cancer growth have 
been described. They include activation of RAC, Burton’s tyrosine kinase (BTK) 
in B cell malignancies, PDK1/SGK3 and mTORC2/NF-κB; mTORC2/c-Myc. Light 
grey ovals imply components of the signalling pathway that are not activated or 
bypassed. Taken from (Faes and Dormond, 2015) 
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Several kinases downstream of PI3K, other than AKT, have been identified 
(Figure 3.28). For instance, PDK1 was found to activate MAPK or PKCα (protein 
kinase C-alpha) pathways (Sato et al., 2004, Zeng et al., 2002). More recent 
evidence suggests that SGK3 (serum- and glucocorticoid- inducible protein 
kinase 3) may be involved as a key downstream mediator of PI3K/PDK1 
signalling in breast cancer cells (Faes and Dormond, 2015). Activation of 
mTORC2 has also been identified as another AKT-independent kinase which 
mediates proliferation of glioblastoma cells (Tanaka et al., 2011). RAC proteins, 
a subfamily of the Rho family of small GTPases, are also activated by PI3K 
(Welch et al., 2003). In breast cancer, RAC proteins were shown to activate the 
MAPK/ERK1/2 pathway which is responsible for mediating cellular proliferation 
(Ebi et al., 2013). These data strongly indicate that PI3K is able to mediate cellular 
proliferation via mechanisms independent of AKT. It should be noted that a study 
investigating cross-reactivity of LY294002 has shown that this inhibitor is able to 
strongly inhibit ERK1/2 phosphorylation in a dose-dependent manner (1 µM to 30 
µM) in Jurkat T cells (Guo et al., 2014). So it is possible that the concentration 
used in my studies (25 µM) is simply inhibiting ERK1/2 and PI3K is not involved 
in mediating CathL-induced HOMEC proliferation. This could be examined further 
by using another PI3K inhibitor or knocking down PI3K in HOMECs using siRNA 
in future studies. 
None of these studies discussed above have used EC models. However, my 
studies do contradict available reports on ECs in the literature where cell 
proliferation has been shown to be promoted via activation of the PI3K/AKT 
pathway. For instance, VEGF-A-induced phosphorylation of PI3K/AKT was 
suppressed by SMEK1, a tumour suppressor protein, in HUVECs and SKOV3, 
halting cell proliferation (Kim et al., 2015). Jin et al. demonstrated VEGF-induced 
proliferation of RF/6A (monkey retinal EC) cells mediated by PI3K/AKT pathway 
(Jin et al., 2013). CD151, a member of the transmembrane 4 superfamily, was 
shown to significantly induce proliferation of HUVECs by nitric oxide (NO) 
production via activation of the PI3K/AKT pathway (Zheng and Liu, 2006). 
Secchiero et al. also reported activation of the AKT pathway in TRAIL-induced 
HUVEC proliferation (Secchiero et al., 2003) which was reduced significantly in 
the presence of LY294002.  
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In conclusion, the data presented here agree with the reports described above 
whereby LY294002 was able to inhibit CathL-induced HOMEC proliferation. 
However, in contrast to the current literature, CathL did not induce HOMEC 
proliferation via AKT activation as the selective AKT inhibitor MK2206 did not 
inhibit this cellular function. It is possible that PI3K elicits its pro-proliferative 
response in HOMECs via an AKT-independent mechanism as discussed above. 
Another possibility is that, LY294002 simply inhibits ERK1/2 which was observed 
to be activated in the proliferative pathway in HOMECs as reported elsewhere 
(Guo et al., 2014). 
 
CathL-induced HOMEC migration 
In angiogenesis, EC migration is another key step. This motile process is 
directionally regulated by stimuli, usually proangiogenic factors such as VEGF. 
Previously it was shown that CathL is able to induce HOMEC migration at 48 hour 
after treatment. This was shown using an Oris migration assay kit which assesses 
migration of cells in to a cell-free zone. However, ideally, cell migration should be 
assessed after a shorter incubation time. An incubation of 48 hours with CathL or 
VEGF, which have been shown to be proliferative, may induce cell proliferation 
and not just migration. Therefore, in my study, HOMEC migration was not 
assessed using an Oris migration kit, instead a cultrex transwell Boyden chamber 
assay kit was used. Also, the incubation period of CathL treatment was brought 
down to 6 hours which is much shorter than the time required for cells to proceed 
through a cell cycle (Cary et al., 1996), eliminating any possibility of cell 
proliferation giving false positive data. 
The cultrex cell migration assay kit utilises a simplified Boyden chamber design 
with an 8 micron polyethylene terephthalate membrane. There are pores in the 
membrane which allow access of migrating cells to the bottom chamber. With 
only 6 hour incubation, it allows the active migratory mechanism of cells to be 
assessed in response to growth factors (Chen, 2005). However, initially, a 48 
hour incubation was carried out with VEGF and/or CathL treatment to be 
consistent with the Oris migration kit data. Interestingly, it was revealed that there 
were no differences in migration compared to control (data not shown). This might 
have been because after 48 hours incubation, migratory effects of cells have 
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plateaued at their maximum level due to induction of cell-cell interaction and a 
reduction in cell motility and so there was no significant difference between 
different conditions (Sander et al., 1998, Royal et al., 2000, Ren et al., 2000, Chen 
et al., 2002). Thus, the incubation period was reduced to 6 hours. At this time 
point, CathL induced significant migration of HOMECs compared to control.  
 
Role of activated signalling pathways in CathL-induced HOMEC migration 
As CathL induces migration in HOMECs, the signalling pathway leading to 
migration was investigated. Initially, it was hypothesised that the PI3K/AKT 
pathway was involved in this process since the PI3K/AKT has been shown to be 
extensively linked to mammalian cell migration. The effects of both the PI3K 
inhibitor LY294002 and the AKT inhibitor MK2206 were examined. Neither of 
these inhibitors significantly inhibited CathL-induced HOMEC migration, 
suggesting that the PI3K/AKT pathway is not involved. This is in contrast to other 
EC studies previously described in the literature. However, PI3K/AKT 
independent migration has been observed in primary human fibroblasts 
stimulated by FGF1 (Marcinkowska and Wiedlocha, 2003). A similar observation 
was also revealed in VEGF-induced (positive control, Appendix 1, Figure A1.5) 
HOMEC migration. VEGF is a well-known proangiogenic factor that activates 
numerous cell signalling cascades. It is possible that VEGF-induced HOMEC 
migration is not mediated via AKT activation, however, there may be other 
kinases, such as activated p38-mediated actin polymerisation and ERK1/2 
pathway, involved which overcome the inhibitory effects on AKT activation 
(Rousseau et al., 2000, Chiu et al., 2013).  
As AKT phosphorylation was shown not to be involved in the CathL-induced 
migration of HOMECs, the role of ERK1/2 was investigated. Interestingly, in the 
presence of ERK1/2 inhibitors, cell migration was completely abolished, 
suggesting that ERK1/2 plays a significant role in CathL-mediated HOMEC 
migration. This agrees with the literature where numerous studies have reported 
the importance of ERK1/2 in cell migration. For instance, human colorectal cancer 
cell-derived vesicles induced migration in human microvascular ECs and 
HUVECs via activation of the ERK1/2 pathway (Yoon et al., 2014). It has also 
been reported that activation of the ERK1/2 pathway plays an important role in 
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VEGF-induced migration of human aortic ECs, HUVECs and bovine brain ECs 
(Bellou et al., 2009, Chiu et al., 2013). Ahmad et al. reported that activation of 
ERK1/2 was involved in proliferation of primary human lung microvascular ECs 
induced by activation of the adenosine A2A receptor (Ahmad et al., 2013). 
Additionally, activated ERK1/2 plays an important role in mediating human 
endometrial stromal cell migration induced by platelet derived growth factor BB. 
In murine brain ECs, activated ERK1/2 within focal adhesions was found to be 
associated with FGF2-induced chemotaxis (Shono et al., 2001). Zhao et al. 
recently suggested activation of ERK1/2 in conditioned medium-induced 
migration of human keratinocyte cell line (HaCaT) (Zhao et al., 2016a). Activation 
of ERK1/2 has also been shown to play an important role in inducing migration of 
pancreatic carcinoma cells (Cho and Klemke, 2000) and MAPK/ERK1/2 have 
also been reported to promote EGF-induced migration in human diploid dermal 
fibroblasts (Xie et al., 1998). Together, these studies strongly suggest that 
ERK1/2 activation plays an important role in migration in a variety of cell types, 
however, the exact molecular mechanism remains unknown. At this stage, it is 
difficult to discern a mechanism that ERK utilises to induce CathL-mediated 
HOMEC migration, however, MLCK activation and actin-myosin association 
seems to be a reasonable candidate as it has been confirmed in several cell 
models, including ECs, as discussed previously (Shono et al., 2001). 
 
CathL-induced angiogenesis in HOMECs 
Since CathL is pro-proliferative and pro-migratory in HOMECs, both critical steps 
in angiogenesis, it was logical to assess angiogenic-tube structure formation in 
these cells. Previously Winiarski et al. showed CathL-induced tube formation in 
HOMECs using a 2D fibrin matrix model (Winiarski et al., 2013). However, a 3D 
angiogenesis assay offers a model which is much closer to the actual 
environment in vivo than can be achieved using 2D cultures. Therefore, an in vitro 
3D model of angiogenesis was initially adopted. Firstly, to verify the technique, 
HCMEC cells were used. HCMEC proliferated and formed new vessel sprouts in 
the gel in response to complete growth media (positive control), VEGF and CathL. 
The assay was thus replicated using HOMECs, under the same conditions. 
However, HOMECs did not respond to any of the above conditions, i.e. there was 
no visible cell sprouting.  
154 
 
It was thought that the amount of FCS in culture media may play a role in the 
spouting of HOMECs. Due to the tight fibrin gel, cells might not have received 
sufficient quantity of FCS. As EC growth significantly depends on serum 
concentration (Bala et al., 2011), different concentrations of FCS were 
supplemented in media with or without EC growth factors. However, there was 
still no spouting of HOMECs. Also, there was no difference observed between 
5% serum and 10 or 20% serum, and hence 5% serum was used for further 
optimisation. 
The next set of experiments investigated the effect of using different 
concentrations of aprotinin, a potent inhibitor of several serine proteases such as 
trypsin, chymotrypsin, kallikrein, thrombin, activated protein C and plasmin 
(Mahdy and Webster, 2004). In the 3D fibrin gel, aprotinin is added to prevent 
fibrinolysis by proteases in serum such as plasmin. However, since ECs 
physiologically secrete proteases (matrix metalloproteinases and serine 
proteases) to break down ECM components during sprouting (Lafleur et al., 
2002), it was speculated that aprotinin might be blocking degradation of fibrin 
matrix by proteases secreted by HOMECs, and hence preventing sprouting. This 
may not have been observed in HCMEC if they secreted a different profile of 
proteases. In order to address this, different concentrations of aprotinin were 
used in the gel. Interestingly, in the absence of aprotinin, HOMECs degraded the 
fibrin matrix, and instead of forming branches, cells formed a monolayer within 
the gel. This was not observed in the presence of aprotinin at two different 
concentrations. This may indicate that HOMEC-secreted proteases are inhibited 
by aprotinin, and that in order to form branches, the fibrin gel matrix may need 
significant modifications. For instance, it was thought that the tightened fibrin 
polymer strands may act as a physical barrier for HOMECs to be mobile within 
the gel which could be tested by reducing the viscosity of the gel. However, when 
the rigidity of the gel was reduced by lowering the concentration of thrombin, the 
gel did not form at all (data not shown), indicating that the thrombin concentration 
that has been recommended in this protocol is the optimal for this system.  
As a future direction, ECM component fibronectin could be incorporated into the 
fibrin matrices. Fibronectin is an integral part of the ECM and has been shown to 
play a critical role in angiogenesis by promoting interactions between cell surface 
integrins and cell-binding domains such as the heparin-binding domain (Kim et 
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al., 2000). In fibrin gel, fibronectin has been shown to serve as a spacer between 
fibrin strands, increasing turbidity of the gel (Okada et al., 1985). In another study, 
fibronectin was shown to promote elongation of sprouting microvessels in 3D 
collagen gel from rat aorta probably by recruiting migratory ECs, instead of 
increasing proliferation as no change in DNA was observed (Nicosia et al., 1993). 
In addition, since ECs secrete proteases to breakdown surrounding ECM, 
fibronectin may be degraded in 3D culture gel, and fragmented fibronectin has 
been shown to aid migration of capillary ECs in chemotactic chambers by 
propelling cells toward areas where the matrix was actively degraded (Ungari et 
al., 1985). Thus, fibronectin may be a potential candidate, which can be included 
in the fibrin gel to test for HOMEC sprouting in the 3D environment in future 
studies. 
The assay optimisation process was taken a step further by assessing the effects 
of the beads that are used to embed cells in the fibrin gel. As recommended in 
the original protocol, collagen pre-coated cytodex 3 beads were used initially. 
Since HOMECs grow on 2% gelatin coated surface in culture, it was thought that 
the absence of gelatin on the beads might have affected growth of these cells. 
Therefore, gelatin pre-coated cytodex 1 beads were used to embed cells. No 
difference was observed in the survival or growth between cells embedded on 
either of the beads.  
At this stage of the investigation to produce timely results, it was decided to move 
on to a 2D fibrin gel assay to assess angiogenic tube-formation in HOMECs. Two-
dimensional assays have been popular in assessing angiogenesis. Tubule 
formation assays are usually performed on matrices consisting of fibrin, collagen 
or Matrigel (the basement membrane extract of the EHS sarcoma), which 
stimulate the attachment, migration and differentiation of ECs into tubules in a 
manner that mirrors the in vivo situation (Lawley and Kubota, 1989).  
However, as described in result section 3.3.7, developmental studies indicated 
that Matrigel was the most appropriate matrix for these studies. Matrigel is a 
solubilised basement membrane preparation extracted from EHS, a tumour rich 
in ECM proteins and contains large amounts of collagen IV, laminin, heparan 
sulphate proteoglycans, and entactin/nidogen. It also contains growth factors 
such as TGF-β, EGF, IGF, FGF, tissue plasminogen activator, and other growth 
factors already present in the tumour. Lawley and Kubota (1989) demonstrated 
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that the rate of differentiation of ECs was increased by plating onto Matrigel, with 
tubules beginning to form in 1 h and completed in 8–12 h (Lawley and Kubota, 
1989). This method is extensively used in EC-tubule formation assays, 
particularly to test for compounds that have anti-angiogenic potential.  
Recently, a second form of Matrigel has been developed known as GFR-Matrigel. 
In this form, the levels of growth factors and cytokines have been markedly 
reduced. Although extensive tubules can be formed in this GFR-Matrigel, it allows 
for more selective determination of the efficacy of proangiogenic factors. Thus, 
GFR-Matrigel was used to study tubule-formation/angiogenesis in HOMECs. 
Initially, cells were seeded on the Matrigel and incubated for 24 hours in 
starvation media (supplemented with 2% FCS, no growth factors). Interestingly, 
HOMECs formed tubules throughout under all conditions after 24 hours, and 
hence further experiments were not carried out at this time point. In order to 
overcome this issue, the time between cell seeding and treatment was reduced 
to two hours to restrict the period in which the cells could spontaneously form 
tubes. Also, cells were treated only for 6 hours prior to assessment of tubule-
formation. It was observed that CathL-induced tubule-structure formation was 
significantly higher than control (untreated) wells. VEGF was the positive control 
in this experiment and also induced significant tubule structure formation in 
HOMECs. Thus, this result, along with the proliferation and migration data, 
strongly suggests that CathL is a pro-angiogenic growth factor acting on 
HOMECs and plays a role in metastasis of ovarian cancer to the omentum.  
It is important to note that, despite having data that supports the angiogenic 
properties of CathL in HOMECs, ideally a more robust method should be 
developed to examine in vitro 3D angiogenesis tubule formation. Although 
Matirgel assay is a very efficient method to visualise in vitro angiogenesis, it has 
significant drawbacks. For instance, it has been shown that the morphology of 
tubules formed in Matrigel displayed little or no resemblance to capillaries formed 
in vivo (Donovan et al., 2001). Also, tubule length in Matrigel was found to be 
homogenous and significantly shorter than capillaries formed in vivo. This does 
not replicate the in vivo situation as in tumour angiogenesis, ECs form neovessels 
of various lengths and morphologies (Donovan et al., 2001). Matrigel also 
displays EC aggregates, which has been suggested to be regulated by growth 
factors already contained within the Matrigel (Donovan et al., 2001). It is important 
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to note that, Matrigel assay, due to the presence of numerous growth factors, are 
able to induce differentiation of non-endothelial cell types such as mesenchymal 
cells, kidney epithelial cells, blastocytes and colon cancer cells (Donovan et al., 
2001), making it less specific. Also, there are some bias in this method of 
analysing tubule structure formation. For instance, the angiogenic index may vary 
based on the orientation of the well at which the photograph has been taken. 
Thus, this method may not be ideal to quantify angiogenesis.  
HOMECs are a relatively new cell model that has been extensively used by our 
group, and so it is crucial to establish a novel way to demonstrate angiogenesis- 
cell sprouting and tubule-structure formation. This should, in the future, allow in-
depth research investigating critical and novel cell signalling pathways that aid 
the metastatic cascade in ovarian cancer. 
 
CathL induced activation of RTK Tie-1 
Since CathL activates intracellular kinases that promote cell survival and growth, 
it was hypothesised that a receptor tyrosine kinase (RTK) may be involved in 
mediating such cellular effects. A preliminary investigation was carried out to 
identify possible RTKs in HOMECs that might be activated by CathL. A 
commercially available array was used to simultaneously screen activation of 49 
RTKs in HOMECs. Intriguingly, it was found that CathL activated Tie-1 (tyrosine 
kinase with immunoglobulin-like and EGF-like domains 1) in HOMECs. The array 
was verified by VEGF (positive control) which strongly induced activation of 
VEGFR2.  
Tie-1 is an orphan receptor (an apparent receptor that has similar structure to 
other identified receptor but whose endogenous ligand has not yet been 
identified) expressed on activated ECs in vasculogenesis in the early stages of 
development and in microvessels undergoing angiogenic sprouting (Partanen et 
al., 1996), and a role has been hypothesised in pathology including tumour 
angiogenesis and atherosclerosis (Savant et al., 2015). The molecular function 
of Tie-1 is not completely understood, as it does not directly bind the angiopoietic 
growth factors, which are the ligands for Tie-2. However, Tie-1 tyrosine 
phosphorylation is induced by Ang (1 or 4), most likely in a complex with Tie-2 
(Marron et al., 2000, Saharinen et al., 2005, Yuan et al., 2007). Ang activates Tie-
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2 in a unique manner, which involves the translocation of Tie-2 to EC-cell 
contacts, with Tie-1 also present in these complexes (Saharinen et al., 2005). 
Phosphorylation of a chimeric form of Tie-1 has been shown to activate the 
PI3K/AKT pathway but only in conjunction with Tie-2 activation (Savant et al., 
2015). Although CathL induced activation of Tie-1, there was no increased 
activation of Tie-2 compared to untreated cells. It has been shown that 
upregulation of Tie-1 in sprouting (tip-like) cells induced downregulation of Tie-2 
surface presentation during angiogenic sprouting in HUVECs. This suggests that 
in spouting ECs, Tie-1, and not Tie-2, plays a significant role (Savant et al., 2015), 
which might be the case in CathL-treated HOMECs. However, this expression of 
Tie-1 has been suggested to be transient as it cannot function independently of 
Tie-2. Tie-1 has also been reported to sustain Ang1-Tie2 signalling, potentially 
by forming a heteromeric Tie-1-Tie-2 complex, preventing Tie-2 from being 
rapidly internalised/endocytosed and perpetuating Tie-2 signalling (Savant et al., 
2015).  
Although CathL induced phosphorylation of ERK1/2, AKT and p38α and activated 
Tie-1 RTK in HOMECs, it would not be reasonable to speculate at this stage of 
any association between the two. Tie-1, a receptor for which no growth factor 
ligands have yet been identified, has been shown to be a potential target for anti-
tumour therapy. Lewis lung carcinoma grown in Tie-1-deficient mice had 
decreased vessel density, vascular perfusion, and tumour-associated EC survival 
and this was associated with decreased tumour cell survival (D'Amico et al., 
2014). Since CathL is a potential proangiogenic factor in omental angiogenesis 
and has been shown briefly to activate Tie-1, further research should be carried 
out to investigate the presence of Tie-1 receptor using immunocytochemistry and 
immunoprecipitation at different time points after CathL treatment, and a role for 
Tie-1 receptor using function and inhibition studies, and possibly, activation of 
other novel receptors in HOMECs, which may be targeted in anti-tumour 
therapies.  
 
A summary of the data from this chapter are described in figure 3.29. 
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3.5 Conclusion 
Taken together, the presented data suggest that ovarian tumour-secreted CathL 
is a pro-angiogenic factor that induces proliferation, migration and in vitro 
angiogenesis in HOMECs via a non-proteolytic mechanism. These novel findings 
fit in well with the clinicopathological observations of advanced stage ovarian 
carcinoma where metastatic ovarian cancer causes extensive vascularisation of 
omental lesions, increasing the ability of the secondary tumour to survive and 
spread to other organs. As transcoelomic metastasis requires tumour 
angiogenesis, CathL, secreted from ovarian cancer cells, in cooperation with 
other cells present in the omentum may facilitate cellular angiogenesis in 
HOMECs. This may highlight CathL and its downstream pathways as novel anti-
tumourigenic/anti-angiogenic therapeutic targets in the treatment of ovarian 
cancer.  
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Figure 3.29: A summary of CathL-induced activation of ERK1/2 and AKT, 
and their potential role in mediating cellular functions in HOMECs. CathL 
possibly activates Tie-1 receptor tyrosine kinase on the cell surface membrane 
of HOMECs which leads to an increase in phosphorylation of ERK1/2 and AKT. 
The ERK1/2 activation induces cellular proliferation and migration in HOMECs in 
response to CathL, since the MEK/ERK1/2 inhibitors U0126 and PD98059 
significantly reduce these cellular functions by inhibiting activation of ERK1/2. 
Both PI3K inhibitor LY294002 and AKT inhibitor MK2206 inhibit phosphorylation 
of AKT at Ser473 (S473) in CathL-treated HOMECs. However, only LY294002 
inhibits CathL-induced HOMEC proliferation, suggesting activation of a pro-
proliferative signalling cascade downstream of PI3K that is independent of AKT 
activation. 
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Chapter 4 Investigating proangiogenic effects of galectin 1 (Gal1) on 
HOMECs 
 
4.1 Introduction 
Gal1 is the first of 14 members of the gene family of carbohydrate-binding 
proteins, known as galectins (Barondes et al., 1994a). It has a wide range of roles 
in physiological and pathological interactions that are both intracellular and 
extracellular and can be defined by their affinity for β-galactosidase sugars. Such 
processes may include cell-cell and cell-matrix interactions, as well as the 
regulation of the immune system (Camby et al., 2006). Defects in Gal1 are 
thought to be linked to cancer progression, particularly through cancer cell 
invasion, metastasis formation and angiogenesis (Rek et al., 2009, Hsu et al., 
2013) and studies have been carried out to assess the typical up-regulation of 
this protein in cancers including thyroid carcinoma, prostate, breast and EOC 
(Chiariotti et al., 1995, van den Brule et al., 2001, Jung et al., 2007, Zhang et al., 
2014a). 
 
4.1.1 Synthesis and structure of Gal1 
Gal1 is a member of the lectin family (carbohydrate binding proteins) that is a 
product of the LGALS1 gene. It consists of a chain of approximately 135 amino 
acids. Gal1 also has two β-galactosidase-binding sites, and therefore, an affinity 
for β-galactosidase sugars (Cho and Cummings, 1995). Gal-1 occurs as a 
monomer as well as a non-covalent homodimer consisting of subunits of one 
carbohydrate recognition domain (CRD) (Gal-1, ∼29 kDa) (Barondes et al., 
1994b). Human Gal-1 exists as a dimer in solution (Lopez-Lucendo et al., 2004). 
The integrity of this dimer is maintained principally by interactions between the 
monomers at the interface and through the well-conserved hydrophobic core, a 
factor which explains the observed stability of the dimer in molecular terms 
(Lopez-Lucendo et al., 2004). Nevertheless, homodimeric Gal1 can 
spontaneously dissociate into monomers which are still able to bind to 
carbohydrates, but with a lower level of affinity (Cho and Cummings, 1995, 
Leppanen et al., 2005).  
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4.1.2 Secretion of Gal1 
It is thought that after synthesis, Gal1 is externalised and attached to cell-surface 
glycoconjugates, staying here for several hours before it is released into the 
media, simultaneously losing its activity at a rapid rate (Cho and Cummings, 
1995). When lectin is newly synthesised, this displaces the surface-bound Gal1 
and results in its movement to the media. In Chinese hamster ovary cells 
specifically, Gal1 is quantitatively secreted at a rate of approximately 4% per hour 
(Cho and Cummings, 1995). 
Most secretory proteins contain an N-terminal or internal signal peptide that direct 
their sorting to the ER. From the ER, proteins are transported to the extracellular 
space or the plasma membrane through the classical ER-Golgi pathway. The ER-
Golgi pathway is an efficient molecular machine of protein export of eukaryotic 
cells. Nascent proteins containing signalling peptide are directed to the Golgi 
where further post-translational modification occurs, leading to the production of 
mature proteins which are transported to their destination. However, there are 
cytoplasmic or nuclear secretory proteins which lack these signalling peptides, 
and hence are exported in an unconventional secretory pathway, independent of 
the ER-Golgi machine. Such proteins include fibroblast growth factor-2 (FGF2), 
β-galactoside-specific lectins Gal1 and galectin-3, certain members of the 
interleukin family and the nuclear proteins high mobility group box 1 (HMGB1) 
(Seelenmeyer et al., 2005, Seelenmeyer et al., 2008, Lee et al., 2010). 
Secretion of Gal1 has been being investigated over the last two decades in 
several cell models. During differentiation induced with erythropoietin and 
deprivation of granulocyte-macrophage colony-stimulating factor, the leukaemic 
cells empty their cytoplasmic content of endogenous galectin 1 into the external 
medium (Lutomski et al., 1997). Galectin 1 is also secreted quantitatively from C2 
mouse myoblasts when induced to form multinucleate fused myotubes (Cooper 
and Barondes, 1990). Gal1 is also secreted from Chinese hamster ovary cells, 
although in an unstable denatured form, suggesting an involvement of a folding 
intermediate in the secretion of Gal1 directly through the plasma membrane (Cho 
and Cummings, 1995).  
Although Gal1 has been shown to be exported from cells, the exact mechanisms 
have not yet been investigated thoroughly. Several reports suggested an ER-
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Golgi-independent pathway, similar to that of FGF2 secretion. FGF2 is a growth 
factor that lacks an N-terminal signalling peptide which prevents this protein from 
entering the ER-Golgi pathway (Nickel, 2005). According to Schafer et al., FGF2 
translocation through cell membrane is dependent on elevated temperature 
(37˚C), without requiring ATP as an energy source (Schafer et al., 2004). A two-
step process has been suggested that involves FGF2 binding to integral 
membrane components followed by membrane translocation (Nickel, 2005). The 
latter process is shown to require cytosolic factors. This secretion was previously 
shown to be dependent on NA/K-ATPase. FGF2 secretion was also suggested 
to be mediated by ATP-binding cassette (ABC) transporters (Nickel, 2005), 
however, no experimental evidence for this model has been established on 
investigating Gal1 externalisation.   
 
4.1.3 Role of Gal1 in the human body 
Gal1 has both extracellular and intracellular functions (Barondes et al., 1994a). 
In a carbohydrate independent manner, it interacts intracellularly with cytoplasmic 
proteins, while its extracellular role involves interactions with glycoproteins of the 
extracellular matrix or those on the cell surface (Camby et al., 2006). 
Gal1 plays a role in a variety of processes in the human body, including 
embryonic development, inflammation, apoptosis, the regulation of cell growth 
and cell adhesion (Camby et al., 2006). In vitro research carried out on vascular 
ECs from inflamed tissue has shown an increase in the expression of Gal1 (Gil 
et al., 2006). At sites of inflammation, it has been shown that Gal1 hinders the T-
cell migration through the extracellular matrix, while it also prevents the 
leukocytes from entering these inflamed tissues from the bloodstream (Gil et al., 
2006). This has suggested that galectins have a role in the regulation of immune 
cell migration. 
In addition, a recent study has demonstrated selective regulation of dendritic cell 
migration when Gal1 accumulates in the extracellular matrix and is over-
expressed by lymphatic ECs (Norling et al., 2008). In the presence of Gal1, 
immunogenic dendritic cells exhibit reduced migration through the extracellular 
matrix. Using a mouse model with lymphoedema, mice with up-regulated Gal1 
had a higher number of dendritic cells in draining lymph nodes, indicating that 
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Gal1 may have contributed to inhibiting dendritic cell emigration (Thiemann et al., 
2015). 
Furthermore, Gal1 is thought to have a pivotal role in cell growth regulation. It has 
been suggested that crucial interactions with an α5β1 integrin is necessary for 
galectin-induced growth inhibition to occur (Fischer et al., 2005). These anti-
proliferative effects result from the inhibition of the Ras-MEK-ERK pathway, which 
is due to the induction of p27 and p21 transcription (Fischer et al., 2005). The 
promoter of p27 contains two binding sites which have a crucial role in the 
responsiveness of Gal1. The accumulation of p27 and p21 as mediated by Gal1 
results in an inhibition of the activity of CDK2, leading to the cell cycle arrest in 
G1, and therefore, growth inhibition (Fischer et al., 2005). 
 
4.1.4 Gal1 in cancers and angiogenesis 
It has been shown that Gal1 is produced by cancer cells as a tumour promoting 
protein (Zhang et al., 2014a). Studies have reported that Gal1 is upregulated in 
the majority of cases of thyroid carcinoma (Chiariotti et al., 1995), while in studies 
using both melanoma and orthotopic breast cancer, it was found that tumour 
growth was greatly reduced when Gal1 was “knocked down” (Ito et al., 2011). In 
a variety of cancers including prostate, colon and thyroid cancers (van den Brule 
et al., 2001), Gal1 has been found to be highly expressed in cancer-associated 
stroma, but this over-expression correlates with pathological factors including 
advanced stages of the disease, tumour invasion and increased rates of disease 
reoccurrence (Chen et al., 2015). In addition, it has been found that Gal1 
regulates cancer cell proliferation and invasion when it accumulates in the peri-
tumoural stroma of both breast cancer and ovarian cancer (van den Brule et al., 
2003): particularly EOC (Chen et al., 2015). 
Gal1 is dysregulated in EOC and has been shown to promote tumour progression 
(Chen et al., 2015). A recent study has suggested that Gal1 is released from EOC 
cells and has been detected in the peripheral circulation in patients suffering from 
the disease. Over-expression of Gal1 has been found to increase tumour cell 
invasion in the OVCAR-3 cell line (Chen et al., 2015). Moreover, when the levels 
of Gal1 were compared in patients alongside the most widely used EOC antigen 
and biomarker CA125, it was found that around 70% of patients were correctly 
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identified as positive by both proteins (Chen et al., 2015). This provides evidence 
that Gal1 could potentially be used as a biomarker for EOC progression, as well 
as outcome. 
A study by Seelenmeyer et al. has suggested that CA125 is a counter receptor 
for Gal1 in HeLa cells, with Gal1 levels ten times higher on the surface of CA125-
expressing tumour-derived HeLa cells, when compared to Chinese Hamster 
Ovary cells that are non-tumour derived, with a lack of CA125 (Seelenmeyer et 
al., 2003). This provides evidence that Gal1 could be regulated by this ovarian 
cancer antigen, in terms of its dissemination to the cell surface. 
Following on from tumour progression, Gal1 has been shown to encourage cell 
proliferation and migration in vitro, using glioblastoma cell lines (Camby et al., 
2002). Gal1 is thought to play a role in tumour angiogenesis, acting as a pro-
angiogenic factor (Le Mercier et al., 2008). It has been shown that in the presence 
of elevated Gal1, ECs migrate to form tubules (Thijssen et al., 2006) – a key step 
in angiogenesis. Furthermore, in Gal1 knockout mice, tumour growth and tubule 
formation becomes severely implicated (Thijssen et al., 2006), indicating a role 
for the protein as a pro-angiogenic factor. 
Aside from its role as a pro-angiogenic factor, Gal1 has been shown to mediate 
apoptosis in T-cells, when Gal1 is expressed in HeLa cells (Kovacs-Solyom et 
al., 2010). A study indicated that Gal1-expressing HeLa cells resulted in 
apoptosis of T-cells, whereas HeLa cells not expressing the protein led to T-cells 
surviving (Kovacs-Solyom et al., 2010). This may suggest that Gal1 has a role in 
the self-defence of tumours, when expressed by tumour cells.  
Nevertheless, the exact mechanism for the stimulation of apoptosis has been 
disputed, with various explanations being put forward in studies involving 
recombinant Gal1 (Stowell et al., 2008), as well as tumour cell-derived Gal1 
(Kovacs-Solyom et al., 2010). Further studies are therefore required to confirm 
the exact mechanism of cell death. 
 
4.1.5 Rationale of the study 
Recent studies have indicated a proangiogenic role for Gal1. Gal1 can be 
secreted by both tumour cells and EC, aiding EC proliferation, migration and 
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angiogenic tube-formation. In previous unpublished data, LGALS1, Gal1 mRNA, 
underwent differential expression when HOMECs were treated with the EOC 
secreted factor CathL. This raised several questions: (i) does CathL induce 
secretion of Gal1 in HOMECs? and (ii) what role does Gal1 play in the angiogenic 
process?  
To address these questions, initially secretion of Gal1 from CathL-treated 
HOMECs was analysed, followed by examination of the level of expressed 
LGALS1 mRNA. An attempt was also made to dissect the pathway via which 
CathL may induce expression of Gal1 in these cells. Potential proangiogenic roles 
of Gal1 and the activated signalling cascades involved in these processes in 
HOMECs were also investigated. Furthermore, in vitro angiogenic tube-structure 
formation was assessed when HOMECs were treated with Gal1. Finally, Gal1 
receptor targets were also elucidated in a preliminary investigation. 
 
4.1.6 Aims 
The aims of this chapter are: 
 To investigate whether CathL induces secretion of Gal1 and expression 
of LGALS1 mRNA in HOMECs 
 To assess the secretory pathway of Gal1 in HOMECs 
 To test whether Gal1 induces HOMEC proliferation and migration 
 To study the potential signalling pathways involved in Gal1-induced 
HOMEC proliferation and migration 
 To examine angiogenic tube-formation in HOMECs by Gal1 
 To identify potential receptor targets of Gal1 in HOMECs 
 
4.2 Methods 
HOMEC isolation: HOMECs were isolated according to (Winiarski et al., 2011) 
as described in the Method chapter section 2.3.1. 
Gal1 quantification: A commercially available solid-phase sandwich ELISA kit 
was used to measure secreted Gal1 in cell culture supernatant as described in 
the Method chapter section 2.7.4.2. 
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Activation of NFκB p65: A commercially available cell-based ELISA was used 
to detect level of phosphorylated NFκB in CathL-treated HOMECs as described 
the Method chapter section 2.7.4.1. 
Inhibition of the ER/Golgi pathway: HOMECs were grown in a 6 well plate. 
After 70% confluency reached, cells were transfected with CellLight® Golgi-GFP, 
BacMam 2.0. GFP-transfected cells were treated with BFA (0.025 µM) for 8 
hours, and photographs were analysed as described in Method chapter, section 
2.9. 
Expression of LGALS1: CathL-treated cells were scraped with TRI reagent and 
RNA was isolated. After quantification, RNA was amplified in the presence of 
TaqMan® Gal1 or reference genes (glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β2-microglobulin (β2M) primers and gene expression was 
analysed using Roche LightCycler 96 as described in the Method chapter section 
2.7.5. 
Cell proliferation: HOMEC proliferation was tested using both the WST-1 assay 
and CyQuant cell proliferation kit as described in the Method chapter sections 
2.4.1 and 2.4.2. 
Activation of intracellular kinases: Commercially available cell-based ELISAs 
were used to detect and assess levels of phosphorylated intracellular kinases as 
described in the Method chapter section 2.7.4.1. 
Cell migration: A commercially available cultrex Boyden chamber kit was used 
to investigate the underlying mechanisms of Gal1-induced HOMEC migration, as 
described in the Method chapter section 2.5.1. 
3D in vitro angiogenesis: A 3D angiogenesis model was used to assess 
HOMEC sprouting as described in the Method chapter section 2.8.1. 
2D Tube-formation: Angiogenic tube-formation was investigated in HOMECs 
treated with Gal1 using both a fibrin matrix assay and commercially available 
GFR-Matrigel, as described in the Method chapter section 2.8.2 
 
Identification of potential cell surface receptors: A commercially available 
human receptor-tyrosine kinase array was used as a screening to identify 
potential receptor as described in the Method section 2.7.3. 
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4.3 Results 
4.3.1 CathL induces secretion of Gal1 from HOMECs 
Previously unpublished data from this laboratory suggested that CathL induces 
differential gene expression of Gal1 mRNA (LGALS1) in HOMECs. Therefore, it 
was hypothesised that CathL induces production and secretion of Gal1 in these 
cells. To test this, HOMECs were treated with or without CathL for 4 minutes, 30 
minutes, 8 hours and 24 hours and supernates were analysed for Gal1 as 
described in Method chapter section 2.7.4.1. The results revealed an increase in 
HOMEC-secreted levels of Gal1 over time at 30 minutes up to 8 hours and then 
reduced after 24 hours. For example, CathL significantly induced secretion of 
Gal1 at 30 minutes (2-fold) and 8 hours (5.2-fold) treatment compared to 
untreated (control) cells (Figure 4.1a). At 24 hours after CathL treatment, a 1.3-
fold increase was observed in secreted Gal1 levels compared to control which 
was not significant and may suggest that the secreted Gal1 was degraded as it 
has a reported serum half-life of 1.07 hours (Van Ry et al., 2015). 
These data suggested that CathL induces secretion of Gal1 from HOMECs. Gal1 
secretion at 30 minutes may indicate that there is a rapid release of readily-stored 
intracellular Gal1 or cleavage of cell surface Gal1. However, the fact that this 
secretion increases at 8 hours after CathL-treatment raised the possibility of a 
transcriptional regulation of Gal1 protein levels via altered expression of LGALS1 
mRNA in these cells. Thus, this was investigated further. Initially, HOMECs were 
treated with or without CathL for 6 hours and 24 hours and real-time PCR was 
performed to quantify expressed levels of LGALS1 mRNA in CathL-treated cells 
versus untreated cells. It was found that, at 6 hours after CathL-treatment, the 
level of LGALS1 mRNA expression increased by 1.5-fold (p<0.05) compared to 
control (Figure 4.1b). At 24 hours after treatment, no significant difference was 
observed between treated and untreated cells. This suggests that CathL may 
induce a transient increase in LGALS1 mRNA expression, and Gal1 protein 
production and secretion in HOMECs.  
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Figure 4.1: CathL induces transcription and secretion of Gal1 in HOMECs. 
a) Cells were seeded in 2% gelatin pre-coated 24-well plates at a density of 
35,000 cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without CathL (50ng/ml) and supernatants 
were collected after 4 minutes, 30 minutes, 8 hours and 24 hours treatment. A 
commercially available ELISA kit was used to assess the levels of secreted Gal1 
using a SpectraMax plate reader. Results are mean ±SD and represented as fold 
change in secreted Gal1 vs control. n=4-6. 
 
b) Cells were seeded in 2% gelatin-coated 6-well plates at a density of 250,000 
cells/well. At 80-90% confluence, cells were starved in media containing 2% FCS. 
After overnight incubation, cells were treated with or without CathL (50ng/ml) and 
lysed after 6 hours or 24 hours treatment. A real-time PCR was performed on 
extracted RNA using a Roche LightCycler 96 and the data were normalised to 
GAPDH and β2M. Results are mean ±SD and represented as fold change in 
LGALS1 gene expression (relative to control). *p<0.05, n= 4. n.s. denotes not 
significant vs control. 
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4.3.2 CathL induces increased LGALS1 mRNA expression via activation of 
NFκB 
Since CathL induces secretion of Gal1, the signalling pathway involved in 
mediating this secretory process was investigated. Initially, the secreted level of 
Gal1 was quantified in HOMECs treated with or without CathL and in the 
presence or absence of both ERK1/2 inhibitors (U0126 and PD98059) and 
PI3K/AKT inhibitors (LY294002/MK2206). This is due to the previously obtained 
increased activation of these kinases in CathL-treated HOMECs. Interestingly, 
none of the inhibitors had a consistent effect on Gal1 secretion (data not shown). 
However, previous published reports suggested that NFκB is involved in 
regulating expression of Gal1 in peripheral blood mononuclear cells (PBMCs) 
(Toscano et al., 2011) and in Kaposi’s sarcoma cells (Croci et al., 2012). Since 
there is no other literature available on this, it was hypothesised that CathL 
induces activation of NFκB which in turn leads to an increase in the expression 
of LGALS1 mRNA. To test this, activation of NFκB (p65) was examined in cells 
treated with or without CathL for 4 hours using a commercially available cell-
based ELISA. It was found that CathL significantly induced NFκB activation (1.3-
fold) compared to control (untreated cells; Figure 4.2). The treatment time was 
selected based on previously published study (Takada et al., 2003). 
As CathL induced activation of NFκB in HOMECs, the next step was to examine 
whether inhibiting NFκB-activation reduced LGALS1 expression and Gal1 
secretion. A well-known NFκB inhibitor, sulfasalazine, was selected to examine 
this. Initial toxicity assays (WST-1) were carried out in order to identify non-toxic 
concentrations of sulfasalazine in HOMECs. It was found that sulfasalazine was 
not toxic to cells at 50 µM (107.1±4.2%, n=8) or 100 µM (106.1±3.1%, n=8) 
compared to control (100%; Figure 4.3) over 24 hours. However, cell viability 
reduced to 91.6±3.1% (n=8) at 200 µM compared to control (100%). Therefore, 
100 µM of sulfasalazine was selected to carry out further experiments, which was 
20-fold lower than previously published data (Toscano et al., 2011). 
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Figure 4.2: CathL increases phosphorylation of NFκB p65 in HOMECs. Cells 
were seeded in 2% gelatin coated 10cm petri dishes and treated with or without 
CathL (50ng/ml) in starvation media containing 2% FCS. 4 hours after treatment, 
cells were lysed and concentration of protein was analysed using BCA assay kit. 
A commercially available NFκB ELISA kit was used to determine NFκB p65 
phosphorylation level. Data are represented as fold change in phosphorylated 
NFκB relative to the total NFκB (normalised to control). Results are mean ±SD, 
*p<0.05 vs control (1-fold), n=4. 
 
 
Figure 4.3: Cytotoxicity (cell viability) induced by the NFκB inhibitor 
sulfasalazine. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without various concentrations of 
sulfasalazine as indicated above and incubated for 24 hours. WST-1 was used to 
assess cellular viability. Results are mean ±SD and shown as percentage of the 
control, n.s., *p<0.05 vs control (100%), n=8. n.s. denotes not significant. 
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Next, secreted level of Gal1 was examined in CathL-treated HOMECs in the 
presence or absence of 100 µM sulfasalazine. Cells were pre-incubated in the 
presence or absence of sulfasalazine for 24 hours (as previously described 
(Toscano et al., 2011) and co-treated with or without CathL for 8 hours (based on 
Figure 4.1a). It was revealed that the secreted level of Gal1 was significantly 
reduced in the presence of both the inhibitor and CathL after 8 hours treatment 
compared to CathL-only treatment (0.9-fold vs 4.8-fold (CathL-treatment), both 
normalised to control; Figure 4.4a). Although, there was a slight increase in the 
level of secreted-Gal1 with the inhibitor only treatment, in cells co-treated with 
CathL and sulfasalazine, the level of secreted Gal1 was abolished to the basal 
level (Figure 4.4a).  
The above data suggested that CathL-induced Gal1 secretion may be mediated 
by NFκB activation. Since NFκB is a transcription factor and has been shown to 
be involved in inducing Gal1 protein expression (Toscano et al., 2011), it was 
important to investigate its role in LGALS1 gene expression in HOMECs. To test 
this, a qRT-PCR was performed with HOMECs treated with or without CathL and 
in the absence or presence of sulfasalazine (100 µM). It was found that 
sulfasalazine significantly inhibited LGALS1 mRNA expression in CathL-treated 
cells after 6 hours treatment (n=4; Figure 4.4b). Interestingly, there was an 
increase in the level of LGALS1 mRNA in cells treated with sulfasalazine only 
compared to control. These results are consistent with the previous data (Figure 
3.33a) where the inhibitor abolished levels of secreted Gal1 in CathL-treated 
HOMECs at 8 hours after treatment. 
To confirm the validity of the experimental use of the inhibitor, it was important to 
confirm its effect on cellular levels of activated NFκB. A cell-based ELISA showed 
that the level of activated NFκB was significantly reduced in HOMECs in the 
presence of sulfasalazine when compared with CathL alone (Figure 4.5). These 
data suggest that CathL induces Gal1 production via activation of NFκB, followed 
by its secretion.  
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Figure 4.4: CathL-induced secretion of Gal1 and transcription of LGALS1 
mRNA is mediated via NFκB activation. a) Cells were seeded in 2% gelatin 
pre-coated 24-well plates at a density of 35,000 cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were pre-incubated with or 
without sulfasalazine (100 µM) for 24 hours, and then co-treated with or without 
CathL (50ng/ml) and in the absence or presence of the inhibitor. The cell culture 
supernatant was collected after 8 hours treatment. A commercially available 
ELISA kit was used to assess the levels of secreted Gal1 using a SpectraMax 
plate reader. Results are mean ±SD and represented as fold change in secreted 
Gal1 vs control. *p<0.05 vs control; ##p< 0.01 vs CathL, n=4-6. 
 
b) Cells were seeded in 2% gelatin-coated 6-well plates at a density of 250,000 
cells/well. At 80-90% confluence, cells were starved in media containing 2% FCS 
and pre-treated with or without sulfasalazine (100 µM) for 24 hours. After 24 hours 
incubation, cells were co-treated with or without CathL (50ng/ml) and in the 
absence or presence of the inhibitor for 6 hours. A real-time PCR was performed 
on extracted RNA using a Roche LightCycler 96 and the data were normalised to 
GAPDH and β2M. Results are mean ±SD and represented as fold change in 
LGALS1 gene expression (relative to control). n.s., *p<0.05 vs control; #<0.05 vs 
CathL, n= 4. n.s. denotes not significant. 
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Figure 4.5: CathL-induced NFκB p65 phosphorylation is inhibited by the 
NFκB-inhibitor sulfasalazine. Cells were seeded in 2% gelatin coated 10cm 
petri dishes in complete growth media. At 80-90% confluence, cells were starved 
in media containing 2% FCS overnight. After overnight incubation, cells were 
incubated with sulfasalazine (100 µM) or media alone for 24 hours and then 
treated with or without CathL (50ng/ml) and in the absence or presence of 
sulfasalazine (100 µM). After 4 hours, cells were lysed and the concentration of 
protein was analysed using a BCA assay kit. A commercially available NFκB 
ELISA kit was used to determine levels of NFκB p65 phosphorylation. Data are 
represented as fold change in phosphorylated NFκB relative to the total NFκB 
(normalised to control). Results are mean ±SD, n.s., *p<0.05 vs control (dotted 
line); #p<0.05 vs CathL, n=4. n.s. denotes not significant. 
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4.3.3 CathL-induced Gal1 secretion may not be dependent on the ER/Golgi 
pathway 
Protein secretion from cells usually takes place via the ER/Golgi pathway through 
vesicular membrane fusion followed by exocytosis. However, an ER/Golgi-
independent pathway (non-classical route) has also been shown to be important 
in this process as has been shown for FGF1 and interleukin-1α in NIH3T3 
fibroblasts (Prudovsky et al., 2003). There are reports that suggest that Gal1 
secretion may be through the non-classical route and since the previous data in 
this study suggested that CathL induces secretion of Gal1 in HOMECs, it was 
hypothesised that Gal1 is secreted via an ER/Golgi-independent pathway. To test 
this, firstly, a well-known inhibitor of intracellular protein transport, brefeldin A 
(BFA), was selected. Initially toxicity assays were carried out to identify its non-
toxic concentrations in HOMECs which was assessed using WST1 after 24 hour 
inhibitor treatment. It was revealed that BFA was toxic to cells above 
concentrations of 0.1 µM and therefore, a lower concentration (0.025 µM) was 
selected to carry out further investigation (Figure 4.6). 
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Figure 4.6: Cytotoxicity (cell viability) induced by brefeldin A (BFA), a 
specific inhibitor of Golgi body-dependent protein secretion. Cells were 
seeded in 2% gelatin pre-coated 96 well plates at a density of 10,000cells/well in 
starvation media containing 2% FCS. After overnight incubation, cells were 
treated with or without various concentrations of BFA as indicated above and 
incubated for 24 hours. WST-1 was used to assess cellular viability. Results are 
mean ±SD and shown as percentage of the control, *p<0.05, ***p<0.001 vs 
control (100%), n=10. 
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Next, the level of Gal1 secretion was tested in CathL-treated cells in the presence 
of BFA (0.025 µM). There was a partial but a significant decrease in the secreted-
Gal1 level (3.9-fold, normalised to control) in the presence of BFA in CathL-
treated HOMECs compared to CathL treatment only (4.9-fold, normalised to 
control; Figure 4.7). BFA-alone treatment had no effect on Gal1-secretion as 
shown in figure 4.7. These data suggest that the secretory pathway of Gal1 may 
be partially dependent on the ER/Golgi pathway, although since inhibition is only 
partial it is possible that an ER/Golgi-independent pathway may also play a role.  
 
To confirm the validity of the experimental use of BFA it was important to 
demonstrate its effect on the Golgi body. To test this, Golgi-specific green 
fluorescent protein (GFP)-transfected HOMECs were treated with or without BFA 
(0.025 µM) for 8 hours. Fluorescence photography confirmed that the Golgi body 
was fragmented in the presence of BFA (Figure 4.8b) compared to control 
(untreated) cells (Figure 4.8a). The area of the distorted Golgi body was 
measured by quantifying the fluorescence intensity which was shown to be 
significantly higher in BFA-treated cells compared to control (Figure 4.8c). These 
data suggest that BFA distorts the Golgi in HOMECs supporting at least a partial 
a role for an ER/Golgi-independent secretory pathway for Gal1. 
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Figure 4.7: CathL-induced secretion of Gal1 may partially depend on the 
ER/Golgi pathway. Cells were seeded in 2% gelatin pre-coated 24-well plates 
at a density of 35,000 cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were pre-incubated with or without BFA (0.025 µM) for 
1 hour, and then co-treated with or without CathL (50ng/ml) in the absence or 
presence of the inhibitor. The cell culture supernatant was collected after 8 hours 
treatment. A commercially available ELISA kit was used to assess the levels of 
secreted Gal1 using a SpectraMax plate reader. Results are mean ±SD and 
represented as fold change in secreted Gal1 vs control. n.s., *p<0.05 vs control; 
#p<0.01 vs CathL, n=4. n.s. denotes not significant. 
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Figure 4.8: BFA causes fragmentation of the Golgi apparatus in HOMECs. 
Cells were seeded in 2% gelatin pre-coated 6 well plates in starvation media 
containing 2% FCS. At 70% confluence, cells were transfected with CellLight 
BacMam 2.0 Golgi-GFP construct and incubated overnight. After overnight 
incubation, transfected cells were treated in the a) absence or b) presence of BFA 
(0.025 µM) for 8 hours. Photographs were taken using a Nikon fluorescence 
microscope. c) Quantification of fluorescence intensity of Golgi area indicating 
Golgi fragmentation. a) and b) show representative images. Golgi fragmentation 
Relative fluorescence were obtained and analysed by ImageJ. *p<0.05 vs control, 
n= 3.  
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4.3.4 Gal1 induces HOMEC proliferation 
The observation that Gal1 was secreted into the culture media from HOMECs in 
response to CathL raised the possibility that CathL-induced proliferation is 
mediated by Gal1. To examine this further a WST-1 colorimetric assay was 
initially used to assess proliferation of HOMECs treated with increasing 
concentrations of Gal1 (1, 5, 25 and 125 ng/ml) for 24 (Figure 4.9a), 48 (Figure 
4.9c) and 72 (Figure 4.9e) hours. The range of concentrations was selected 
based around the secreted concentrations of Gal1 (between 20ng/ml and 80 
ng/ml) in the supernatant of CathL-treated cells over 4 minutes, 30 minutes and 
8 hours (Appendix 1, Figure A1.7). The data demonstrated that Gal1 significantly 
induced cell proliferation at all concentrations tested after 48 and 72 hours 
treatment compared to control (100%) (Figure 4.9c), e); Table 4.1). However, no 
significant difference in cell proliferation was observed at 24 hours after Gal1 
treatment which also confirmed that Gal1 was non-toxic to HOMECs across all 
the concentrations examined (Figure 4.9a); Table 4.1). On the basis of these 
results and the levels of secreted Gal1, future experiments were carried out using 
50ng/ml. 
The initial proliferation data was complemented using a CyQUANT kit. HOMECs 
were treated with or without Gal1 at 50ng/ml for 72 hours. The data shows an 
increase in fluorescence intensity confirming proliferation of cells (110.7±6.2%, 
n=20 vs control (100%); Figure 4.10a) when treated with Gal1. The data obtained 
using the CyQUANT kit confirmed the WST-1 proliferation data, and therefore 
only WST-1 was carried out to investigate cell proliferation/toxicity in the 
subsequent experiments. 
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Figure 4.9: Gal1 induces HOMEC proliferation (WST-1 assay). Cells were 
seeded in 2% gelatin pre-coated 96 well plates at a density of 10,000cells/well in 
starvation media containing 2% FCS. After overnight incubation, cells were 
treated with or without Gal1 at various concentrations and incubated for a) 24, c) 
48 and e), 72 hours. WST-1 assay was used to assess cellular proliferation based 
on absorbance using a PHERAstar BMG plate-reader at 450nm. Results are 
mean ±SD and shown as percentage of the control, *p<0.05 **p<0.01, ***p<0.001 
vs control (100%); n=11-20. b), c) and d) are raw data from representative 
experiments from a), b) and c) respectively. n.s. denotes not significant vs control. 
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Table 4.1: Summary of the pro-proliferative effect of Gal1 on HOMECs at 
various concentrations (shown in figure 4.9). HOMECs were treated with or 
without various concentrations of Gal1 for 24, 48 and 72 hours. Results are 
mean ±SD and shown as percentage of control (100%). *p<0.05 **p<0.01, 
***p<0.001 vs control (100%); n=11-20. 
 
 
  
HOMEC proliferation (as % of control) at each Gal1 
concentration 
 
Control 
(%) 1ng/ml 5ng/ml 25ng/ml 125ng/ml 
24h 100 104.1±23.5 118.2±21.2 114.4±13.9 103.7±24.3 
48h 100 113.4±18.7* 116.7±10.1*** 113.2±13.7** 115.2±17.1* 
72h 100 147.2±12.3*** 152.9±13.7*** 144.9±14.1*** 141.0±13.2*** 
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Figure 4.10: Increased proliferation of HOMECs in media supplemented with 
Gal1 (CyQUANT). Cells were seeded in 2% gelatin pre-coated 96 well plates at 
a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without 50ng/ml of Gal1 and 
incubated for 72 hours. A commercially available CyQUANT reagent was used to 
assess cell proliferation based on fluorescence intensity using a FLUOstar BMG 
plate-reader at Ex/Em: 485/530nm. a) Results are mean ±SD and shown as 
percentage of the control, ***p<0.001 vs control (100%), n=20. b) Raw data from 
representative experiment. 
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4.3.5 CathL-induced HOMEC proliferation is not dependent on Gal1 
Data described in figures 3.1. 3.2, 4.9 and 4.10 indicate that both CathL and Gal1 
induce HOMEC proliferation. To understand the relationship between the two, 
experiments were carried out to examine effects of CathL in the presence of an 
inhibitor of Gal1. Gal1 binds to cell surface sugar residues via its carbohydrate 
binding domain and since L-glu is a metabolically inert carbohydrate molecule, it 
was selected to test for its inhibitory effect on Gal1 binding to potential cell surface 
binding sites. Thus, HOMECs were treated with or without exogenous Gal1 
(50ng/ml) and in the presence or absence of 25 mM and 50 mM of L-glucose for 
72 hours. The data demonstrated that L-glu significantly reduced Gal1-induced 
HOMEC proliferation. For example, at 25mM and 50mM of L-glu, cell proliferation 
was 107.1±9.8% (n=11; Figure 4.11a) and 108.9±4.5% (n=10; Figure 4.11b) 
respectively, compared to Gal1-treatment (124.7±10.1%, n=9), all data 
normalised to control (100%). 
The above data confirmed that L-glu indeed inhibits Gal1-induced HOMEC 
proliferation. Thus, CathL-induced HOMEC proliferation was carried out in the 
presence of L-glu to investigate whether this effect is mediated by Gal1. To test 
this, cells were treated with CathL (50ng/ml) in the presence or absence of L-glu 
at 25mM and 50mM for 72 hours and cell proliferation was measured using 
WST1. It was found that L-glu produced no significant inhibition of CathL-induced 
HOMEC proliferation. For instance, at 25mM and 50mM of L-glu cell proliferation 
was 119.3±9.0% (n=11; Figure 4.11c) and 117.8±7.4% (n=10; Figure 4.11d) 
respectively, compared to CathL-treated HOMECs (120.5±8.7%, n=9), all 
expressed as percentages of control. A significant increase in cell proliferation 
was also observed in L-glu only treatments. Together, these data suggest that 
CathL-induced HOMEC proliferation is not dependent on Gal1. 
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Figure 4.11: CathL-induced HOMEC proliferation is independent of Gal1-
pro-proliferative effect. Cells were seeded in 2% gelatin pre-coated 96 well 
plates at a density of 10,000cells/well in starvation media containing 2% FCS. 
After overnight incubation, cells were treated with or without a), b) Gal1 or c), d) 
CathL (50ng/ml) in the presence or absence of L-glucose (L-glu) at a), c) 25mM 
or b), d) 50mM for 72 hours. WST-1 assay was used to assess cellular 
proliferation based on absorbance using a PHERAstar BMG plate-reader at 
450nm. Results are mean ±SD and shown as percentage of the control (100%), 
**p<0.01, ***p<0.001 vs control (100%); ##p<0.01, ###p<0.001 vs Gal1 
(expressed as % of control), n=9-11. n.s. denotes not significant vs CathL. 
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4.3.6 Gal1 induces phosphorylation of ERK1/2 and AKT kinases 
According to the above data, although CathL-induced HOMEC proliferation does 
not require Gal1, Gal1 alone has been shown to be pro-proliferative in HOMECs, 
indicating that there may be signalling pathways activated downstream of Gal1-
cell surface interaction. The induction of cellular proliferation has been reported 
to involve activation of several intracellular pathways including ERK1/2 and 
PI3/AKT kinases (discussed in Chapter 3, section 3.4). Since Gal1 induces 
HOMEC proliferation, the pro-proliferative signalling cascades activated in these 
cells by Gal1 were investigated. As ERK1/2 and AKT have been shown to be 
activated in CathL-treated HOMECs in Chapter 3, it was hypothesised that Gal1 
also induces phosphorylation of these kinases. To test this, a cell-based ELISA 
was performed using intact live cells treated with Gal1 or VEGF for 4 minutes and 
10 minutes. It was revealed that after 4 minutes treatment Gal1 increased 
phosphorylation of ERK1/2 (1.8-fold vs control; Figure 4.12a). However, after 10 
minutes treatment, levels of phosphorylated ERK1/2 reduced to below the basal 
level (control; Figure 4.12b). Similar experiments were performed with AKT where 
AKT phosphorylation was induced (1.7-fold vs control; Figure 4.12c) 4 minutes 
after treatment and was reduced to basal level after 10 minutes (Figure 4.12d). 
VEGF was used as positive control in all cell-based ELISAs. 
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Figure 4.12: Gal1 induces phosphorylation of ERK1/2 and AKT in HOMECs. 
Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without 50ng/ml of Gal1 or 20ng/ml of VEGF 
and incubated for 4 or 10 minutes. ERK1/2 (a, b) and AKT (c, d) phosphorylation 
was examined after 4 minutes (a, c) and 10 minutes (b, d) treatments. 
Commercially available cell-based ELISAs were used for the determination 
ERK1/2 and AKT(S473) phosphorylation level.  The ELISA experiments were 
carried out in quadruplets on two cell batches. The data is represented by fold 
change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT (compared to 
control). Results are mean ±SD, n.s., *p<0.05, **p<0.01 vs control (dotted lines); 
n=4-6. n.s. denotes not significant vs control. 
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4.3.7 Gal1-induced HOMEC proliferation is mediated via the ERK1/2 
pathway 
Since Gal1 induces activation of the pro-proliferative kinase ERK1/2, it was 
hypothesised that ERK1/2 might be involved in the induction of HOMEC 
proliferation. Following the toxicity assay using U0126 and PD98059 (Figure 3.7), 
the concentrations that were selected for further experiments were 1, 10 and 25 
µM for both inhibitors. Cell proliferation experiments were carried out to test for 
any inhibitory effect of these inhibitors on HOMEC proliferation and it was 
revealed that Gal1-induced HOMEC proliferation was reduced significantly in the 
presence of both inhibitors at all concentrations. For instance, at 1, 10 and 25 µM 
of U0126, cell proliferation significantly reduced to 68.9±9.5% (n=15; Figure 
4.13a), 63.1±6.9% (n= 15; Figure 4.13b) and 55.9±5.1% (n= 15; Figure 4.13c) 
respectively compared to Gal1 (133.6±13.1%, n= 14), all data normalised to 
control (100%). Similarly PD98059 demonstrated a significant reduction in Gal1-
induced HOMEC proliferation. Specifically proliferation was: 74.0±6.8% (n= 15; 
Figure 4.13d), 65.2±4.3% (n= 15; Figure 4.13e) and 47.5±3.4% (n= 15; Figure 
4.13f) at concentrations 1, 10 and 25 µM respectively, compared to Gal1 alone 
(133.6±13.1%, n= 14), all expressed as percentage of control (100%). The 
inhibitors at all concentrations also prevented HOMEC proliferation at 72 hours 
in the absence of Gal1 (Figure 4.13).  
As discussed in Chapter 3 (section 3.3.4), the concentrations that were selected 
for further investigations were: 10 µM for U0126 and 25 µM for PD98059. The 
above data demonstrates that Gal1-induced HOMEC proliferation was 
significantly reduced at the given concentrations. A cell-based ELISA was 
performed to confirm such inhibitory effects of these inhibitors at the cellular 
levels on Gal1-induced phosphorylation of ERK1/2. The data revealed that the 
levels of phosphorylated ERK1/2 significantly abolished or reduced in HOMECs 
to 0.4-fold and 0.4-fold in the presence of U0126 (Figure 4.14a) and PD98059 
(Figure 4.14b) respectively, compared to Gal1 treatment (1.5-fold). Together, 
these data suggest that Gal1 may induce proliferation of HOMECs via activation 
of the ERK1/2 pathway. 
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Figure 4.13: Inhibition of ERK1/2 reduces Gal1-induced HOMEC 
proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without Gal1 (50ng/ml) and in the 
absence or presence of various concentrations of a-c) U0126 and d-f) PD98059 
as indicated above and incubated for 72 hours. WST-1 assay was used to assess 
cellular proliferation. Results are mean ±SD and shown as percentage of the 
control, ***p<0.001 vs control (100%), ###p<0.001 vs Gal1 (normalised to control 
100%), n=14-15. 
 
 
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
75
100
125
150
***
###
***
***
Gal1 50ng/ml
U0126 10µM
 -           - +  +
 - +          - +
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
75
100
125
150
***
###
***
***
Gal1 50ng/ml
PD98059 10µM
 -           - +  +
 - +          - +
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
75
100
125
150
***
###
*** ***
Gal1 50ng/ml
U0126 1µM
 -           - +  +
 - +          - +
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
50
75
100
125
150
***
###
***
***
Gal1 50ng/ml
U0126 25µM
 -           - +  +
 - +          - +
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
75
100
125
150 ***
###
***
***
Gal1 50ng/ml
PD98059 1µM
 -           - +  +
 - +          - +
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l)
0
10
50
75
100
125
150 ***
###
***
***
Gal1 50ng/ml
PD98059 25µM
 -           - +  +
 - +          - +
a)
c) f)
e)b)
d)
190 
 
 
 
Figure 4.14: Gal1-induced ERK1/2 phosphorylation is inhibited in intact 
HOMECs treated with ERK1/2 inhibitors a) U0126 (10 µM) and b) PD98059 
(25 µM). Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were pre-incubated with the inhibitors for 20-30 minutes, and 
then co-treated with or without 50ng/ml of Gal1 or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of ERK1/2 phosphorylation level.  The 
data is represented by fold change in phosho-ERK1/2 relative to total ERK1/2 
(compared to control). Results are mean ±SD, *p<0.05, **p<0.01 vs control (1-
fold, dotted lines), #p<0.05 vs VEGF/Gal1 (normalised to control), n=4. 
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4.3.8 Gal1-induced HOMEC proliferation is mediated via PI3K and not AKT 
activation 
It has been reported in several studies that the PI3K/AKT pathway plays a crucial 
role in mediating survival signals in a wide range of cell models, and thus the 
involvement of these pathways in Gal1-induced HOMEC proliferation was 
examined. The role of AKT was assessed in Gal1-induced HOMEC proliferation 
in the absence or presence of PI3K inhibitor LY294002 (1, 25 and 50 µM) and 
AKT inhibitor MK2206 (1, 3 and 5 µM), as previously discussed. The data 
demonstrated that at 1 µM of LY294002 there was no significant reduction in 
Gal1-induced cell proliferation (131.6±4.9%, n= 10) compared to Gal1 only 
treatment (124.1±4.8%, n=10; Figure 4.15a). However, a significant reduction in 
Gal1-induced cell proliferation was observed when HOMECs were co-treated 
with higher concentrations of LY294002 such as 25 µM (94.3±3.6%, n=10; Figure 
4.15b) and 50 µM (67.3±5.9%, n=10; Figure 4.15c), compared to Gal1 treatment 
(124.1±4.8%), where all data normalised to control (100%). Intriguingly, no 
significant difference was observed between cells treated with Gal1 and co-
treated with three increasing concentrations of MK2206. For example, at 1, 3 and 
5 µM of MK2206 cell proliferation was 125.3±3.7% (n=9; Figure 4.15d), 
127.8±2.4% (n=7; Figure 4.15e) and 129.0±1.6% (n=7; Figure 4.15f) 
respectively, compared to Gal1 treatment 125.3±9.2% (n=11), all data normalised 
to control). The inhibitor only treatment demonstrated that LY294002 abolished 
HOMEC proliferation, however, MK2206 slightly increased this cellular function 
(Figure 4.15 d), e), f). 
The above data suggested that Gal1 induces HOMEC proliferation via an AKT-
independent PI3K pathway. However, this can only be validated if the inhibitors 
inhibited AKT phosphorylation in Gal1-treated cells. Cell based ELISAs were 
performed to test this. It was found that both LY294002 (25 µM) and MK2206 (5 
µM) inhibited AKT activation in Gal1-treated HOMECs to 1.0-fold (vs 1.6-fold 
Gal1; Figure 4.16a) and 0.8-fold (vs 1.6-fold Gal1; Figure 4.16b) respectively. 
This suggested that both drugs inhibited AKT activation. However, a lack of 
inhibition of cell proliferation suggests that activated PI3K, but not AKT, is 
involved in the induction of Gal1-induced HOMEC proliferation. 
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Figure 4.15: PI3K inhibitor, but not AKT inhibitor, reduces Gal1-induced 
HOMEC proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without Gal1 (50ng/ml) and in the 
absence or presence of various concentrations of a-c) LY294002 (PI3K inhibitor) 
and d-f) MK2206 (AKT inhibitor) as indicated above and incubated for 72 hours. 
WST-1 assay was used to assess cellular proliferation. Results are mean ±SD 
and shown as percentage of the control, ***p<0.001 vs control (100%); 
###p<0.001 vs Gal1, n=7-11 (normalised to control 100%). n.s. denotes not 
significant vs Gal1. 
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Figure 4.16: Gal1-induced AKT phosphorylation is inhibited in HOMECs 
treated with PI3K and AKT inhibitors a) LY294002 (25 µM) and b) MK2206 (5 
µM), respectively. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were pre-incubated with the inhibitors for 2.5 hours, 
and then co-treated with or without 50ng/ml of Gal1 or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of level of AKT phosphorylation.  The 
data is represented by fold change in phosho-AKT relative to total AKT 
(compared to control). Results are mean ±SD, n.s., *p<0.05, **p<0.01 vs control 
(1-fold), #p<0.05 vs VEGF/Gal1 (normalised to control), n=4. n.s. denotes not 
significant.  
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4.3.9 Gal1 induces migration in HOMECs 
In addition to proliferation, a second key element of angiogenesis is EC migration. 
Since Gal1 was shown to induce proliferation in HOMECs, its pro-migratory role 
was also examined in these cells. Initially, cell migration was tested using a 
transwell Boyden chamber after 6 hours treatment, and it was revealed that Gal1 
significantly increased HOMEC migration (161.0±35.5%, n=22; Figure 4.17a) 
compared to control (100%). VEGF, used as a positive control treatment in the 
cell migration experiment also induced significant HOMEC migration 
(144.9±27.3, n=19). This suggested that Gal1 may play a pro-migratory role in 
HOMECs. 
Since Gal1 has been shown to induce phosphorylation of the ERK1/2 and AKT 
pathways, their role in Gal1-induced HOMEC migration was examined. The AKT 
pathway has been reported to be involved in the induction of cell migration in 
several cell models as previously discussed, and therefore the hypothesis was 
that activated AKT is involved in the induction of HOMEC migration of Gal1. To 
test this, cells pre-treated with PI3K (LY294002, 25 µM) or AKT (MK2206, 5 µM) 
inhibitors were co-treated with Gal1 in the presence of the corresponding 
inhibitors for 6 hours. The data revealed no significant inhibition in Gal1-induced 
cell migration with inhibitors compared to Gal1 treatment alone. For instance, at 
25 µM of LY294002 cell migration was 189.2±48.0% (n=4; Figure 4.18a) 
compared to Gal1 treatment (158.5±20.2%, n=11), both normalised to control 
(100%).  In the case of MK2206, although cell migration reduced (124.3±43.3%, 
n=5), it was not significantly different compared to Gal1 treatment (158.5±20.2%, 
n=11). Interestingly, inhibitor only treatments significantly inhibited cellular 
migration (Figure 4.18 a, b). 
Cell migration was then tested using ERK1/2 inhibitors. HOMECs were pre-
treated with U0126 (10 µM) or PD98059 (25 µM) and then co-treated with Gal1 
in the presence or absence of the inhibitors for 6 hours. The data revealed that 
neither of the inhibitors significantly inhibited Gal1-induced HOMEC migration. 
For instance, Gal1-induced cell migration in the presence of U0126 was 
160.7±25.8% (n=6; Figure 4.19a), compared to Gal1-treatment alone 
(163.4±47.2, n=11), both data normalised to control (100%). In the case of 
PD98059, there was a reduction in Gal1-induced cell migration (127.4±34.2, n=7; 
Figure 4.19), although it was not significantly different compared to Gal1 
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treatment. These data combined with the ELISA data (Figures 4.14, 4.16) 
suggest that Gal1-induced HOMEC migration may not solely depend on the 
activation of the ERK1/2 and AKT pathways, and that other kinases may be 
involved. Intriguingly, ERK1/2 inhibitor U0126-only significantly reduced HOMEC 
migration (4.19a, b). 
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Figure 4.17: Gal1 induces HOMEC migration. HOMECs were seeded on the 
upper transwell insert and treated with or without Gal1 (50ng/ml) or VEGF 
(20ng/ml) supplementation of starvation media containing 0.5% FCS. The lower 
well contained correspondent treatment i.e. 0.5% FCS media, Gal1 (50ng/ml) or 
VEGF (20ng/ml). After 6 hours, migrated cells were stained with calcein AM and 
fluorescence was quantified by using a FLUOstar plate reader at Ex/Em: 485/520. 
a) Results are mean ±SD and shown as percentage of the control, ***p<0.001 vs 
control (100%), n=19-22, b) Raw data from representative experiment. 
 
 
Figure 4.18: Gal1 does not induce HOMEC migration via the AKT pathway. 
HOMECs were seeded in the upper transwell chamber and treated with or without 
Gal1 (50ng/ml) in the absence or presence of PI3K and AKT inhibitors a) 
LY294002 (25 µM) and b) MK2206 (5 µM) respectively in media containing 0.5% 
FCS. The lower well contained correspondent treatments. After 6 hours, migrated 
cells were stained with calcein AM and fluorescence was quantified by using a 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control, *p<0.05, ***p<0.001 vs control (100%), p= n.s. vs Gal1 
(normalised to control), n=4-11. n.s. denotes not significant. 
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Figure 4.19: Gal1 does not induce HOMEC migration via the ERK1/2 
pathway. HOMECs were seeded in the upper transwell chamber and treated with 
or without Gal1 (50ng/ml) in the absence or presence of ERK1/2 inhibitors a) 
U0126 (10 µM) and b) PD98059 (25 µM) respectively in media containing 0.5% 
FCS. The lower well contained correspondent treatments. After 6 hours, migrated 
cells were stained with calcein AM and fluorescence was quantified a using 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control, **p<0.01, ***p<0.001 vs control (100%); p= n.s. vs Gal1 
(normalised to control), n=4-12. n.s. denotes not significant. 
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4.3.10 Gal1-induced HOMEC migration is inhibited by L-glucose 
Since Gal1-induced cell proliferation was inhibited by L-glu co-treatment, it was 
hypothesised that Gal1 may bind to a cell surface receptor with an extracellular 
sugar domain. If this was true, L-glu should also block Gal1-induced HOMEC 
migration. Thus, cellular migration was tested when cells were co-treated with 
Gal1 and L-glu (25mM) for 6 hours. The data revealed that in the presence of L-
glu, Gal1-induced cell migration reduced significantly to 124.8±23.2% (n=6; 
Figure 4.20) compared to Gal1 treatment (189.3±59.0%, n=5), both data 
expressed as percentage of control (100%). These data, in combination with the 
proliferation data (Figure 4.11 a, b), suggest that Gal1 may induce proangiogenic 
changes in HOMECs via binding with a receptor(s) expressing a sugar moiety on 
its extracellular domain.  
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Figure 4.20: Gal1-induced HOMEC migration is inhibited by L-glucose. 
HOMECs were seeded on the upper transwell insert and treated with or without 
Gal1 (50ng/ml) and in the absence or presence of L-glu (25mM) in media 
containing 0.5% FCS. The lower well contained correspondent treatment i.e. 
0.5% FCS media, Gal1 (50ng/ml) or Gal1±L-glu. After 6 hours, migrated cells 
were stained with calcein AM and fluorescence was quantified by using a 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control, *p<0.05, **p<0.001, ***p<0.001 vs control (100%); 
#p<0.01 vs Gal1 (normalised to control), n= 5-6. 
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4.3.11 Investigation into Gal1 induced angiogenesis in HOMECs 
The data described in this chapter indicate that Gal1 has the potential to induce 
cell proliferation and migration in HOMECs, two key steps of tumour 
angiogenesis. Thus angiogenesis was tested in HOMECs treated with Gal1 using 
a 3D in vitro model as described in the previous chapter (CathL section). Initially, 
HCMECs were used to establish the model with different treatments: media 
supplemented with 2% FCS as basal control (Figure 4.21a), media supplemented 
with 5% FCS and growth factors as positive control (complete growth media; 
Figure 4.21b), and 2% FCS media supplemented with 20ng/ml VEGF (Figure 
4.21c) or 50ng/ml of Gal1 (Figure 4.21d). Cell sprouting was observed in the 
positive control, VEGF and Gal1 treated wells, but not in cells containing media 
with 2% FCS (control). 
Interestingly, when the same conditions were applied using HOMECs, no 
sprouting was observed in any of the wells (data not shown). Therefore, as 
discussed previously (Chapter 3, section 3.3.7), further optimisation led to the 
investigation of angiogenesis in 2D growth factor reduced Matrigel (GFR-
Matrigel). Initially, cells were seeded and after 2 hours treated for another 6 hours 
with the following conditions: media with 2% FCS, VEGF (ng/ml) or Gal1 
(50ng/ml). It was found that Gal1 induced significant tube-like structures 
(223.3±18.5, n=3; Figure 4.22) compared to control (145±15, n=3). Positive 
control VEGF also induced significant tube-structure formation in HOMECs 
(210.3±22.4, n=3). 
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Figure 4.21: Formation of angiogenic sprout in human cerebral 
microvascular ECs (HCMECs) in 3D fibrin gel. Cells were seeded on cytodex 
3 microcarriers and embedded in fibrin matrix gel in media supplemented with 
2% FCS a) Control, b) 5% FCS with added ECs growth factors (Positive control), 
c) 20ng/ml of VEGF or d) 50ng/ml of Gal1. Media/treatments were replaced every 
other day up to day 5. Photographs were taken on day 6 post-seeding using a 
Nikon phase-contrast microscope at 10X magnification. Arrow pointing at cell 
sprouting. Scale bar =100μM. 
 
 
 
 
 
 
 
 
 
 
 
a)
c) d)
b)
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Figure 4.22: Gal1-induced tubule structure formation in HOMECs in 2D 
Matrigel. HOMECs were plated onto growth factor reduced- (GFR) Matrigel in 
medium containing 2% FCS and treated with media supplemented with or without 
VEGF (20ng/ml) and/or Gal1 (50ng/ml) for 8 hours. Controls contained HOMECs 
grown in medium containing 2% FCS alone. Photographs were taken at 8 hours 
after treatment using a Nikon phase contrast microscope camera and tubule-
structure formation (including nascent tubule structures) was quantified as 
described in method section. The results are presented as an angiogenesis 
index. **p<0.01 vs control levels, n=4. 
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4.3.12 Investigating activation of receptor tyrosine kinases (RTKs) by Gal1 
Although Gal1 has been shown to interact with cell surface sugar residues, due 
to its proangiogenic role, it is possible that the glycoprotein acts via an 
extracellular receptor with intracellular tyrosine kinase activity. Thus, this was 
tested using RTK array kit. After 10 minutes treatment with or without Gal1 or 
VEGF, no increase in activity was observed in any of the RTKs (Figure 4.23). The 
experiment was validated by the positive control VEGF which induced a 12-fold 
increase in the activation of VEGFR2 and 1.5-fold of VEGFR3. 
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Figure 4.23: Investigation into activation of potential RTK by Gal1. 
Phosphorylation status of RTKs were assessed in cell lysates treated with or 
without Gal1 or VEGF for 10 minutes. The results of 1 minute exposure are 
expressed as mean dot density. The relative expression of specific 
phosphorylated proteins was determined following quantification of scanned 
images of membrane using Azure software. n=1.  
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4.4 Discussion 
In this chapter, Gal1 was shown to be secreted by HOMECs during CathL 
treatment. This secretion seems to be transcriptionally regulated and mediated 
via NFκB activation. Exogenous Gal1 then acted on HOMECs inducing cell 
proliferation and migration where the former was shown to be mediated via 
activation of the ERK1/2 and AKT-independent PI3K pathways. Gal1 was also 
observed to induce angiogenic tube formation in HOMECs. Interestingly, Gal1 
was not found to increase activation of any RTKs, although data suggests that 
Gal1 may be acting on HOMECs by interacting with a cell-surface receptor with 
a glucose moiety.  
 
CathL induced production and secretion of Gal1 in HOMECs 
Gal1 has been shown in the recent years to play a proangiogenic role in several 
EC models (Thijssen et al., 2006, D'Haene et al., 2013). Previous unpublished 
data from this laboratory found that CathL (EOC secreted factor) induced 
differential expression of LGALS1 mRNA in HOMECs. Since Gal1 is shown to be 
secreted, its presence in the supernatant of CathL-treated HOMECs was 
examined. Interestingly, a significant increase was observed in the levels of 
secreted Gal1 in CathL-treated HOMECs after 30 minutes and 8 hours, however 
it reduced to basal (control) level after 24 hours CathL treatment. Initially, the 
increased secretion of Gal1 after 30 minutes indicated that Gal1 may have been 
readily stored in the cytoplasm, possibly associated with unknown intracellular 
proteins closer to the intracellular side of the cell membrane (Camby et al., 2006). 
In this study, exogenous CathL triggered a response in HOMECs, and Gal1 was 
externalised or secreted, and this is the first report to describe this link between 
these two proteins.  
Interestingly, at 8 hours treatment of CathL, the secreted level of Gal1 was even 
greater, possibly indicating an additional transcriptional regulation of LGALS1 by 
CathL treatment. Therefore, level of LGALS1 was assessed in HOMECs treated 
with CathL for 6 hours. The difference in time-points between assaying protein 
quantity and mRNA expression is to allow a timeframe for protein translation and 
subsequent secretion from its mRNA (Ben-Ari et al., 2010). The results showed 
that CathL increases expression of LGALS1, which correlates with the secreted 
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Gal1 data. Although CathL has never been reported to induce expression of 
LGALS1 or secretion of Gal1, transcriptional regulation of Gal1 has been reported 
in ECs. Specifically, minimally oxidised LDL was shown to induce expression of 
Gal1 in human aortic ECs (HAECs) (Perillo et al., 1995). Interestingly, level of 
expression of Gal1 mRNA was found to increase at 4 hour onwards in LDL 
treated HAECs (Baum et al., 1995).   
Thijssen et al. reported a strong expression of Gal1 in an immunofluorescent 
study of angiogenically-active EC of human colon carcinoma and breast 
carcinoma, especially in EC that stained positive for the proliferation marker Ki67 
(Thijssen et al., 2006). Interestingly, when HUVECs were activated by a mixture 
of growth factors, it also resulted in a significant increase in both Gal1 mRNA and 
protein expression (Thijssen et al., 2006). High LGALS1 mRNA expression and 
increased secreted levels of Gal1 were also observed in syngeneic tumour 
models of B16F10 melanoma cells and TC-1 lung carcinoma cells in Gal1wt  mice, 
which in turn increased vessel formation and escalated tumour progression in 
vivo (Thijssen et al., 2010).  These reports suggest that Gal1 secretion can be 
induced from both ECs and tumour cells. In the current study, CathL has been 
shown, for the first time, to increase both LGALS1 expression and Gal1 secretion 
in HOMECs. There is a possibility that CathL increases LGALS1 expression in 
HOMECs at a shorter incubation period and that Gal1 level may upsurge at a 
shorter duration of treatment, which can be tested in future studies. Taken 
together, these data suggest that CathL increases Gal1 secretion from HOMECs 
by both a rapid intracellular mobilisation and longer-term transcriptionally-
regulated manner. 
At 24 hours after treatment, both expression of LGALS1 and secretion of Gal1 
reduced to basal level, which contrasted with previous findings where minimally 
oxidised LDL consistently induced increased expression of LGALS1 mRNA in 
HAECs from 4 hours and persisted up to 24 hours (Baum et al., 1995). However, 
in this study the authors only investigated expression of Gal1 on the cell surface 
membrane and intracellularly, but not the secreted level. As it has been shown 
that Gal1 can be taken up by cells (Thijssen et al., 2010), it may be that after a 
certain period, secreted Gal1 was taken up by HOMECs from the culture media. 
For instance, it has been shown that Gal1 was retaken up by HUVECs and 
human vascular ECs (EC-RF24) (Thijssen et al., 2006, Thijssen et al., 2010). 
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However, it is also possible that Gal1 degraded after a certain number of hours 
as it has a half-life of 1 hour 7 minutes in culture media (Van Ry et al., 2015). 
 
Since CathL was shown to induce LGALS1 expression and subsequent Gal1 
secretion, the intracellular pathways that may be activated by CathL upstream of 
mRNA transcription were investigated. As CathL was shown to activate ERK1/2 
and AKT, it was hypothesised that either or both of these kinases may induce 
LGALS1 transcription. In order to address this hypothesis, both inhibitors of 
ERK1/2 and AKT were tested. However, due to a lack of consistency in the 
obtained data on the secreted Gal1 level, no conclusions could be drawn. It would 
be important to examine this further in future work as signalling pathways 
upstream of LGALS1 transcription has not been elucidated in any other systems. 
 
It has been reported that in Kaposi’s sarcoma cells and T cells hypoxia induces 
LGALS1 mRNA expression and Gal1 secretion via activation of NFκB. Since the 
data in this study suggested that CathL induces LGALS1 expression and 
subsequent Gal1 secretion from HOMECs, it was hypothesised that activation of 
NFκB may play a role in this. Thus CathL-induced activation of NFκB was tested 
in HOMECs. Interestingly, it was found that CathL increased NFκB activation and 
in the presence of sulfasalazine, a selective inhibitor of NFκB, both LGALS1 
mRNA expression and Gal1 secretion were significantly reduced. This agrees 
with the current literature. For instance, Toscano et al. demonstrated that the 
LGALS1 gene is a direct target of NFκB, which initiated the mRNA transcription 
upon activation in differentiated T cells and the subsequent expression and 
secretion of Gal1 (Toscano et al., 2011). Another study reported an increase in 
LGALS1 expression and Gal1 secretion in Kaposi’s sarcoma cells in response to 
hypoxia. It was shown that hypoxia-mediated activation of NFκB subsequently 
induced LGALS1 mRNA expression and Gal1 secretion (Croci et al., 2012). 
These phenomena were significantly reduced or completely halted when treated 
with NFκB inhibitors such as sulfasalazine or Bay11-7082, suggesting that NFκB 
plays a key role in inducing LGALS1 mRNA expression and subsequently Gal1 
secretion.  
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Secretory pathway for Gal1 in CathL-treated HOMECs 
Secretion of Gal1 into the extracellular space as well as on the extracellular side 
of cell membranes is well accepted. It has been suggested that Gal1 is secreted 
in a non-ER/Golgi pathway (unconventional protein secretory pathway) since it 
lacks an N-terminal signalling sequence peptide. However, the exact molecular 
mechanism of this secretory pathway remains largely unknown. Therefore, it was 
hypothesised that Gal1 secretion in HOMECs is not mediated through the 
conventional ER/Golgi pathway. This hypothesis was partially supported by the 
observation that in the presence of BFA, which destabilises the Golgi, CathL-
induced Gal1 secretion was still significantly higher, compared to control. This 
was despite the observation that BFA appeared to completely disrupt the Golgi 
integrity. This observation agrees with several studies where Gal1 was shown to 
be secreted via an unconventional secretory pathway. For example, Toyokawa 
et al. demonstrated that Gal1 secretion was not inhibited in BFA-treated ovine 
glandular epithelial cells (Toyokawa et al., 2007). There was a slight reduction in 
Gal1-secretion in the presence of CathL and BFA which is discussed later. 
Together, these data suggest that Gal1 may be secreted in a non-ER/Golgi 
pathway in HOMECs treated with CathL.  
Proteins such as FGF2, interleukin-1β and Gal1, are thought to be secreted in 
ER/Golgi-independent pathway, primarily because they lack a signal sequence 
that is used in the classical secretory pathway to target newly synthesised 
proteins to the ER. Although the exact molecular mechanism of the secretion of 
such proteins is unknown, evidence suggests that a plasma membrane resident 
transporter may play a role in directly translocating FGF2 and Gal1. An ABC 
transporter has been suggested to mediate this unconventional secretory 
pathway, although due to a lack of an experimental model with human cells, this 
has not been tested (Rees et al., 2009). Cleves et al. demonstrated release of 
Gal1 through the peri-plasmic membrane (vesicles) into the external cell wall of 
transfected yeast expressing rat Gal1 which was reduced in a strain lacking 
Ste6p, an ABC transporter (Cleves et al., 1996). More recently, the inside-out 
topology was proposed with the rationale that translocation of a given factor into 
the lumen of these vesicles would mimic its secretion, as the lumen of these 
vesicles is topologically equivalent to the extracellular space (Nickel, 2005). 
Recombinant Gal1 protein, when added, traversed the membrane of these 
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inside-out vesicles in Chinese hamster epithelial ovarian cells, with an aid of a 
plasma membrane resident transporter, possibly ABC (Schafer et al., 2004, 
Nickel, 2005). However, a role for the sodium pump (Na+/K+- ATPase) was also 
suggested in the Gal1 export pathways as ouabain, a selective inhibitor of the 
sodium pump, inhibited these export processes (Nickel, 2005). Together, these 
observations further suggest a secretory pathway for Gal1 that is independent of 
the classical ER/Golgi pathway. 
Interestingly, BFA did slightly reduce Gal1 secretion in CathL-treated HOMECs 
compared to CathL-only treatment. This may have been due to its effects on other 
organelles. BFA has been shown to affect other cellular organelles such as ER, 
lysosomes and endosomes as well as microtubules, actin and other cytoskeleton 
proteins in normal rat kidney cells (Lippincott-Schwartz et al., 1991, Alvarez and 
Sztul, 1999). The presence of BFA may have damaged the alternative secretory 
pathway of Gal1 in HOMECs, reducing its secretion slightly.  
 
Gal1 induced HOMEC proliferation 
Since Gal1 is secreted in response to CathL treatment into the cell culture media, 
it was hypothesised that Gal1 may contribute to the proangiogenic role of CathL 
in HOMECs. Indeed, it was found that Gal1 increased HOMEC proliferation in a 
dose-dependent and time-dependent manner, an observation that agrees with 
other recent findings. For instance, Thijssen et al. reported increased proliferation 
of primary HUVECs and EC-RF24 (human vascular EC line) cells when treated 
with exogenous Gal1 (Thijssen et al., 2010). Another study demonstrated an 
increase in proliferation in HUVECs and the human vascular EC line EA.hy 926 
when treated with exogenous Gal1 (D'Haene et al., 2013). Interestingly, an 
additive effect in increased cell proliferation was observed when these cells 
treated with both Gal1 and Gal3. In an earlier study, exogenous Gal1 was also 
found to induce proliferation of primary myeloma cells during tumour progression 
(Abroun et al., 2008). These combined data suggest that Gal1 plays a key pro-
proliferative role in different models. 
However, there are reports that do not agree with the current findings. For 
instance, binding of Gal1 to breast cancer cells MCF7 induced apoptosis and also 
inhibited cellular proliferation (Geiger et al., 2016). In Geiger’s study, higher 
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concentrations of Gal1 (>10 µg/ml) were used which may have induced an anti-
proliferative effect. Intriguingly, Adams et al. demonstrated a biphasic modulation 
of growth of human fibroblasts whereby higher concentrations of Gal1 (>20 µg/ml) 
inhibited cellular proliferation (Adams et al., 1996). These studies suggest that at 
higher concentrations Gal1 may be anti-proliferative, which was not reflected in 
the current study as the highest concentration of Gal1 was 125 ng/ml. 
Interestingly, Gal1 was shown to possess a growth-inhibitory site in its structure, 
which may be responsible for its anti-proliferative effect (Scott and Zhang, 2002). 
Taken together, this study and others indicate a biphasic/functional effect of Gal1 
in human cells, which should be tested in future studies using HOMECs. 
 
CathL-induced HOMEC proliferation is not mediated by secreted Gal1 
Since CathL induced secretion of Gal1 in cultured HOMEC, and both CathL and 
Gal1 were shown to induce proliferation in HOMECs, the next step was to 
investigate whether CathL-induced cell proliferation was mediated via Gal1. L-glu 
was used to examine this hypothesis. Although lactose, a disaccharide of 
galactose and (D-)glucose with a binding specificity for β-galactosidase binding 
sites (i.e. on Gal1 CRD), was used in previous studies to block Gal1 binding to 
both human and mice bone marrow cells (Vas et al., 2005) and to inhibit Gal1-
induced proliferation of human dermal fibroblasts (Adams et al 1996), it was not 
implemented in the current study. Lactose was found to increase HOMEC 
proliferation (data not shown), possibly by increasing cell metabolism. However, 
L-glucose, an isomer of (D-)glucose, is metabolically inert (Rudney, 1940) and 
hence was substituted for lactose. 
To test this, initially, HOMECs were treated with Gal1 in the presence of L-
glucose and it was found that L-glu inhibited Gal1-induced cell proliferation. 
However, no inhibition of HOMEC proliferation was observed when L-glu was 
added in CathL-supplemented media. This suggested that CathL-induced 
HOMEC proliferation is independent of Gal1-activity.  
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Gal1-induced activation of intracellular signalling pathways and their role in 
cellular proliferation 
As Gal1 induced HOMEC proliferation, it was logical to assess the intracellular 
signalling pathways activated. Previously, CathL was shown to induce 
phosphorylation in ERK and AKT which were found to be activated in the 
proangiogenic changes in HOMECs (Chapter 3, section 3.3.3). Therefore, only 
the ERK1/2 and AKT pathways were investigated. Interestingly, both of these 
kinases were found to be phosphorylated in Gal1-treated HOMECs compared to 
untreated cells. This agrees with recent evidence indicating that Gal1 induced 
phosphorylation of ERK1/2 in other human vascular ECs (EA.hy926 and EC-
RF24 cell lines) (Thijssen et al., 2010, D'Haene et al., 2013). Chung et al. also 
demonstrated an increase in the level of phosphorylated ERK1/2 in lung cancer 
cells (A549 cell line; (Chung et al., 2012)). Similar other literature is available 
regarding the activation of AKT by Gal1. For instance, Hsu et al. demonstrated 
an increase in the levels of phosphorylated AKT in human lung cancer cell lines 
(A549, CL1-0 and CL1-5; (Hsu et al., 2013)). Gal1 was also reported to induce 
AKT activation in human hepatocellular carcinoma cells, aiding tumour 
progression (Zhang et al., 2016). Together, our data suggest that Gal1 induces 
activation of pro-proliferative and pro-migratory kinases ERK1/2 and AKT in 
HOMECs. 
As previously described, activation of ERK1/2 has been extensively shown to be 
involved in cell proliferation, including in HOMECs as shown in Chapter 3 (section 
3.3.1). Therefore, it was hypothesised that ERK1/2 may play a pro-proliferative 
role in Gal1-treated HOMECs. The ERK1/2 inhibitors U0126 and PD98059 were 
used to examine this. Both inhibitors demonstrated significant inhibition of 
HOMEC proliferation compared to Gal1-treatment alone, suggesting that ERK1/2 
may mediate Gal1-induced HOMEC proliferation. This is in agreement with other 
recent studies. For example, Thijssen et al. and D’Haene et al. demonstrated that 
the ERK1/2 activation plays a key role in Gal1-induced proliferation of human 
vascular EC line (EC-RF24) (Thijssen et al., 2010) and HUVEC proliferation 
(D'Haene et al., 2013). These reports, along with the current study, suggest that 
Gal1 induces cell proliferation via activation of ERK1/2. 
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Interestingly, Fischer et al. suggested that at higher concentrations Gal1 induces 
an anti-proliferative effect in human colonic carcinoma cell lines HT-29 and Caco-
2 through an inhibitory effect on ERK1/2 phosphorylation when treated with 
200µg/ml of Gal1 (Fischer et al., 2005). As discussed previously, higher 
concentrations of Gal1 have an anti-proliferative effect in cells, and this may be 
through inhibiting the pro-proliferative ERK1/2 pathway. Further investigation 
would be required to confirm this phenomenon in HOMECs, however since levels 
of Gal1 secreted into the medium were less than 200µg/ml, this phenomenon 
may not be physiologically relevant in HOMECs. 
Based on the previously described role for PI3K/AKT in EC proliferation (Chapter 
3, section 3.4) and the fact that Gal1 induced increased levels of phosphorylated 
AKT, the activation of this pathway in HOMEC proliferation was tested. The PI3K 
inhibitor LY294002 decreased Gal1-induced HOMEC proliferation in a dose-
dependent manner. ELISA data confirmed inhibition of AKT activation in the 
presence of LY294002, and thus these data suggest that, like ERK1/2, the 
PI3K/AKT pathway may also be involved in Gal1-induced HOMEC proliferation.  
Since PI3K has been shown to induce cellular proliferation independent of AKT 
activation (discussed in chapter 3, section 3.4), the role for AKT in HOMEC 
proliferation was investigated. Selective AKT inhibitor MK2206 did not inhibit 
Gal1-induced HOMEC proliferation at non-toxic concentrations, which was 
verified by ELISA data. Thus, this data suggested that AKT activation is not 
required for Gal1-induced HOMEC proliferation.  
The role of PI3K and/or AKT in Gal1-induced cellular proliferation is not clear. 
Indeed, recently, Gal1-induced proliferation has been shown to be mediated via 
activation of the PI3K/AKT pathway. For instance, Zhang et al. demonstrated that 
inhibiting the PI3K/AKT pathway using LY294002 reduced Gal1-induced 
proliferation of human hepatocellular carcinoma cell lines (Zhang et al., 2016), 
indicating a key role for PI3K/AKT pathway in Gal1-induced cellular proliferation. 
A role for the activated PI3K/AKT pathway was also observed in Gal1-induced 
proliferation of human renal cell carcinoma cells, which was inhibited in the 
presence of PI3K inhibitor LY294002 (White et al., 2014).  Although activation of 
AKT was suggested to play a pro-proliferative role in these studies, the authors 
did not specifically target the AKT kinase (i.e. using a selective inhibitor of AKT) 
to confirm such findings. However, Lee and colleagues suggested a more direct 
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role of the AKT pathway in Gal1-induced proliferation of mouse embryonic stem 
cells (Lee et al., 2009). An unknown inhibitor of AKT was used to test this, which 
resulted in a decreased Gal1-induced cellular proliferation at S-phase, 
suggesting a role for AKT activation in this phenomenon. The current study 
suggests that activation of PI3K, but not AKT, is involved in mediating induction 
of HOMEC proliferation by Gal1 treatment. Here, selective inhibitors of both PI3K 
and AKT have been tested, unlike other studies where either PI3K or AKT was 
inhibited, and hence the results strongly suggest that Gal1-induced HOMEC 
proliferation may be mediated via an AKT-independent PI3K pathway. 
 
Gal1 induced HOMEC migration 
Cellular migration is another key element in tumour progression and 
angiogenesis. Since Gal1 has been shown to induce HOMEC proliferation, a 
proangiogenic response, its ability to induce migration was investigated. 
Interestingly, the data revealed a significant increase in cellular migration by Gal1 
compared to control (untreated cells), suggesting a possible role of Gal1 in 
omental angiogenesis. In support of these data, Gal1 has been shown to be pro-
migratory in several cell models. For example, Thijssen et al. and Hsieh et al. 
demonstrated an increased migration of HUVECs when treated with Gal1 (Hsieh 
et al., 2008, Thijssen et al., 2010). This increase in cellular migration was inhibited 
by adding lactose, suggesting activation of a cell surface receptor with an 
extracellular sugar moiety. Interestingly, the reported increase in Gal1-induced 
migration was similar to positive control VEGF-induced HUVEC migration, which 
was also observed in the current study using HOMECs. Another study revealed 
Gal1-induced migration of human oral and vulval squamous carcinoma cell lines 
in an autocrine manner (Rizqiawan et al., 2013). The authors investigated the 
molecular mechanisms of Gal1-induced cellular migration and observed that 
Gal1 increased both mRNA and cell surface expression of α2 and β5 integrins 
via activation of the JNK pathway. A collective migration, a process by which a 
group of cells move in concert, without completely disrupting their cell-cell 
contacts, was suggested for wound-healing process which was described by α2-
mediated formation of filopodia and subsequent cellular motility (Ilina and Friedl, 
2009). Soluble Gal1 has been also demonstrated to induce motility in human 
glioma cell lines via increasing expression of RhoA, a protein that modulates actin 
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polymerisation and depolymerisation (Camby et al., 2002). Together, these 
studies suggest a pro-migratory role for Gal1 which has also been revealed in the 
current report.  
Role of activated signalling pathways in Gal1-induced HOMEC migration 
Although the above studies indicated a potential proangiogenic role of Gal1 in 
angiogenesis, its exact mechanism of action remains largely unknown. Since 
activated AKT has been shown to mediate cellular migration and Gal1 was found 
to induce AKT activation in HOMECs, it was hypothesised that AKT may play a 
key role in the induction of HOMEC migration. Both inhibitors of PI3K and AKT 
were utilised to test this. Although, none of the inhibitors significantly inhibited 
Gal1-induced HOMEC migration, a small, but not statistically significant reduction 
in migration was observed when HOMECs were co-treated with Gal1 and 
MK2206. This may suggest that AKT activation and subsequent cellular migration 
is not dependent on PI3K activation (Filippa et al., 1999, Mahajan and Mahajan, 
2012). Interestingly, White et al. suggested a role for AKT/mTOR in Gal1-induced 
migration of human renal cell carcinoma cell lines (White et al., 2014). The 
authors examined this using LY294002, a selective PI3K inhibitor, and 
demonstrated that when co-treated with Gal1, the inhibitor significantly reduced 
cellular migration (White et al., 2014). This contradicts the current finding, 
whereby, PI3K inhibitor did not reduce Gal1-induced HOMEC migration, although 
significantly inhibited AKT phosphorylation as detected by the ELISA.  
This led to investigation of the role of ERK1/2 in Gal1-induced HOMEC migration. 
Interestingly, neither of the ERK1/2 inhibitors inhibited HOMEC migration when 
co-treated with Gal1, suggesting that activation of the ERK1/2 kinase may not 
solely mediate this migratory response. These data contradict the current 
literature. For instance, Thijssen et al. suggested a pro-migratory role of activated 
ERK1/2 in Gal1-induced HUVEC migration (Thijssen et al., 2010). However, the 
authors did not verify their finding by attempting to inhibit ERK1/2 activation in 
Gal1-induced migration. Interestingly, Hsieh et al. suggested that activated JNK, 
a MAP kinase, is responsible for Gal1-induced migration in HUVECs (Hsieh et 
al., 2008). Although the data revealed an activation of the ERK1/2, the authors 
did not investigate its role in Gal1-induced migration. Activation of JNK was also 
observed to be involved in the induction of migration of human vulval and oral 
squamous carcinoma cells (Rizqiawan et al., 2013), again indicating JNK to be a 
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potential pro-migratory kinase (Huang et al., 2008, Huang et al., 2003). Together, 
these data suggest that, there may be multiple intracellular kinases such as AKT, 
ERK1/2 and JNK that can be activated by Gal1, mediating the pro-migratory 
response in angiogenesis and tumour progression. This should be investigated 
further using HOMECs in future studies. For example, Gal1-induced activation of 
intracellular signalling pathways can be examined using a proteome profiler 
phosphokinase array (described in Method section 2.7.2) to identify potential 
kinases such as JNK that may be involved in Gal1-induced HOMEC migration. 
 
L-glu inhibited Gal1-induced HOMEC migration 
In these studies, L-glu was shown to inhibit Gal1-induced HOMEC proliferation. 
This was further investigated in Gal1-induced HOMEC migration. When tested, 
L-glu significantly reduced Gal-induced cellular migration, suggesting a physical 
blocking of Gal1 from binding to cell surface receptors. In the literature, Gal1-
induced HUVEC migration was significantly reduced in the presence of lactose 
(Hsieh et al., 2008). A similar observation was revealed in human glioma cell 
lines, whereby, addition of lactose inhibited Gal1-induced cellular motility (Camby 
et al., 2002). Taken together, the current report suggests that Gal1 induces 
HOMEC migration via acting upon a cell surface receptor with an extracellular 
sugar moiety.  
 
Gal1 induced angiogenic tube formation in HOMEC 
Since Gal1 has been shown to be pro-proliferative and pro-migratory in HOMECs, 
its role in angiogenesis was examined in these cells. As discussed in Chapter 3 
(section 3.3.7), initially HCMECs were utilised in a 3D angiogenesis in vitro 
model. Interestingly, Gal1 was shown to induce branching of HCMECs compared 
to control. However, when tested in HOMECs, no sprouting was observed (data 
not shown). After a number of optimisation steps, growth factor-reduced Matrigel 
was used to examine Gal1-induced tube-formation. Intriguingly, the results 
revealed a significant increase in tubule-structure formation compared to control. 
This agrees with the current literature where evidence also suggests a 
proangiogenic role for Gal1 in angiogenic tube formation. For instance, 
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exogenous Gal1 was observed to induce tube formation in HUVECs and 
EA.hy296 (human vascular EC) cells (Croci et al., 2012, D'Haene et al., 2013), 
which was inhibited by addition of lactose or specific anti-Gal1 monoclonal 
antibody (Croci et al., 2012). Additionally, Thijssen and colleagues reported an 
increase in the mean vascular density in a wild-type mice model (Gal1+/+) 
compared to knock-out (Gal1-/-) models (Thijssen et al., 2006). This phenomenon 
was also observed in vitro using HUVECs and CAM models, suggesting a 
proangiogenic role for Gal1 in tumour angiogenesis (Thijssen et al., 2006). 
 
Examining RTK activation in Gal1-treated HOMECs 
As previous data suggested that Gal1 promotes cell survival and growth via 
activation of intracellular kinases, it was hypothesised that an RTK may be 
involved. A brief investigation was carried out to identify possible RTKs in 
HOMECs that may be activated by Gal1. The data revealed no relative activation 
of RTKs by Gal1 in HOMECs. Interestingly, Gal1 has been shown to induce 
activation of neuropilin 1 (NRP1), a co-receptor for VEGFR1/2, in the 
proangiogenic responses in HUVECs (Hsieh et al., 2008, D'Haene et al., 2013). 
NRP1 is a transmembrane glycoprotein (i.e. contains sugar residues on the cell 
surface) that has been shown to be bound by VEGF-A, leading to activation of 
VEGFR2 and downstream signalling pathways (Herzog et al., 2011). Gal1 is 
believed to act in a similar manner in EC models (Hsieh et al., 2008, D'Haene et 
al., 2013), although in the current study VEGFRs was found not to be activated 
by Gal1. Previously, several binding partners of Gal1 were identified in a variety 
cell types, eliciting a number of responses. Interestingly, all of these Gal1-
targeting cell surface receptors consist of glucose moieties, which may be the 
case in HOMECs in inducing cell proliferation and migration (Table 4.2), as 
indicated in the current study. Perhaps, activation of NRP1/VEGFR2 and 
involvement of other transmembrane glycoproteins should be examined further 
in Gal1-treated HOMECs.  
 
A summary of the data from this chapter are described in figure 4.24. 
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4.5 Conclusion 
The data from the current study suggest, for the first time, that CathL induces 
expression of LGALS1 and subsequent secretion of Gal1 in HOMECs. 
Exogenous Gal1 induces proangiogenic changes in HOMECs such as 
proliferation, migration and angiogenic-tube formation. These findings shed light 
in the pathogenesis process of EOC metastasis to the omentum which fits in well 
with the clinical observations of advanced stage of the disease. Since extensive 
vascularisation is required for the tumour to survive, Gal1, with its potent 
proangiogenic response, may facilitate cellular angiogenesis in HOMECs and 
secondary tumour progression. This may, for the first time, highlight Gal1 as a 
novel anti-angiogenic therapeutic target in EOC metastasis.  
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Table 4.2: Binding partners of Gal1 (taken from (Astorgues-Xerri et al., 2014)). 
Binding partner     Biological functions Cell type Refs. 
Integrins a5b1 Inhibition of cell growth, 
Apoptosis induction 
Epithelial tumour, 
Hepatocarcinoma 
(Fischer et al., 
2005, Sanchez-
Ruderisch et al., 
2011) 
Integrins α2β5 Induce motility Human oral and 
vulval 
squamous 
carcinoma 
(Rizqiawan et al., 
2013) 
Ganglioside GM1 Inhibition of cell growth Neuroblastoma (Kopitz et al., 
2001, Kopitz et 
al., 1998) 
CD44 and CD326 Metastasis 
development 
Colon cancer (Ito and Ralph, 
2012) 
CD146 Anti-apoptotic effect Endothelial (Jouve et al., 
2013) 
Neuropilin-1 Proliferation, migration 
and adhesion induction 
Endothelial (Hsieh et al., 
2008) 
Glycoprotein 90 K Homotypic cell 
aggregation 
Melanoma (Tinari et al., 
2001) 
 
Figure 4.24: A summary of secretion of Gal1 and subsequent activation of 
the ERK1/2 and AKT pathways, and cellular functions in HOMECs. a) CathL 
induces increased expression of LGALS1 (Gal1 mRNA) possibly via NFκB 
activation, followed by protein production and secretion via a non ER/Golgi 
pathway. b) Secreted Gal1 binds to an unknown cell surface receptor in an 
autocrine manner and increases activation of EKR1/2, leading to the induction of 
cell proliferation. The MEK/ERK1/2 inhibitors U0126 and PD98059 significantly 
reduce this cellular function by inhibiting activation of ERK1/2. Both PI3K inhibitor 
LY294002 and AKT inhibitor MK2206 inhibit phosphorylation of AKT at Ser473 in 
Gal1-treated HOMECs. However, only LY294002 inhibits Gal1-induced cellular 
proliferation, suggesting activation of a pro-proliferative signalling cascade 
downstream of PI3K that is independent of AKT activation. Gal1 also acts as a 
pro-migratory factor, although the active intracellular kinases in this process 
remain unknown. 
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Chapter 5 Investigation into the proangiogenic role of cathepsin D (CathD) 
in ovarian cancer metastasis to the omentum 
 
5.1 Introduction 
The process of angiogenesis requires EC activation, proliferation, migration and 
sprouting towards the tumour which occurs via protease-mediated cleavage of 
extracellular matrix. Degradation of ECM is carried out by proteases secreted by 
ECs as well as tumour cells. Previously, a number of proteases were reported to 
be secreted by the EOC cells A2780 and SKOV3. A notable one with direct pro-
migratory effect on HOMECs is CathD. CathD, just like CathL, is a lysosomal 
protease. However, unlike CathL it is an aspartic protease with an optimum pH 
of 3.5-4.5.  
Although both CathL and CathD act in lysosomes, their optimum pH for 
proteolytic activity is slightly different. For instance, CathL is highly active 
between pH 5 and 6.5, whereas CathD has an optimum pH of 3.5-4.5. CathD has 
been found in the extracellular tumour microenvironment of several cancers 
(discussed in Chapter 1, Section 1.7.2.3) where it actively digests ECM 
components. However, reports also suggest that CathD may have a mitogenic 
role which it elicits in a non-proteolytic manner.  Interestingly, CathD was found 
to be active at neutral pH in normal physiology. In ovarian cancer there is only 
one study indicating a role for CathD where it was shown to induce migration in 
HOMECs i.e. a potential angiogenic response (Winiarski et al., 2013). However, 
the underlying mechanisms remain unknown. 
As proliferation is a key step in angiogenesis, a possible role for CathD in HOMEC 
proliferation was examined. Since CathD was found to be both proteolytically 
active and inactive in the extracellular microenvironment of several cancer 
models, and to induce a mitogenic effect, studies were carried out to explore its 
mechanism of action. Pepstatin A (pepA), a specific inhibitor of the proteolytic 
activity of CathD, was tested for its inhibitory effect on CathD-induced HOMEC 
proliferation. Subsequently, CathD activity at a range of pHs was examined to 
determine whether CathD was proteolytically active at its optimum versus at 
neutral pHs. As CathD has been reported to be proangiogenic in HOMECs, 
activated intracellular signalling pathways were also identified and tested in 
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subsequent functional studies such as cell proliferation and migration. 
Furthermore, CathD-induced EC sprouting and angiogenic tube-formation was 
tested in in vitro angiogenesis models. Finally, preliminary studies were also 
carried out to identify receptor targets of CathD. 
 
5.1.1 Aims 
The aims of this study were as follows: 
 To investigate whether CathD induced HOMEC proliferation 
 To examine the mechanism of action of CathD- whether it acts in a 
proteolytic manner or a non-proteolytic mechanism 
 To identify potential cell signalling pathways activated in HOMECs 
 To assess role of such pathways in HOMEC proliferation and migration 
induced by CathD 
 To study angiogenic-tube formation of HOMECs by CathD 
 To identify potential receptor target of CathD in HOMECs 
 
5.2 Methods 
HOMEC isolation: HOMECs were isolated according to previously published 
work (Winiarski et al., 2011) as described in the Method chapter section 2.3.1. 
Cell proliferation: HOMEC proliferation was tested using both the WST-1 assay 
and CyQuant cell proliferation kit as described in the Method chapter sections 
2.4.1 and 2.4.2. 
CathD-proteolytic activity: The WST-1 assay was used to study CathD-induced 
HOMEC proliferation in the presence or absence of pepA, a specific inhibitor of 
CathD-proteolytic activity (Method section 2.4.1). An array of pHs were used to 
investigate proteolytic activity of CathD in the presence of a CathD-specific 
fluorogenic substrate and in the presence or absence of pepA, as has been 
described in the Method chapter sections 2.6 and 2.6.1. The pH of cultured media 
was also measured. These pHs were measured down to 2 decimal places in 
100µl media/buffer using ABL800 FLEX blood gas analyser. 
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Activation of intracellular kinases: Commercially available proteome-profiler 
and cell-based ELISAs were used to detect and assess levels of phosphorylated 
intracellular kinases as described in the Method chapter sections 2.7.2 and 
2.7.4.1. 
Cell migration: A commercially available cultrex Boyden chamber kit was used 
to investigate the underlying mechanisms of CathD-induced HOMEC migration, 
as described in the Method chapter section 2.5.1. 
3D in vitro angiogenesis: A 3D angiogenesis model was used to assess 
HOMEC sprouting as described in the Method chapter section 2.8.1. 
2D Tube-formation: Angiogenic tube-formation was investigated in HOMECs 
treated with CathD using both a fibrin matrix assay and commercially available 
GFR-Matrigel, as described in the Method chapter section 2.8.2. 
Identification of potential cell surface receptors: A commercially available 
human receptor-tyrosine kinase array was used as a screening to identify 
potential receptor as described in the Method section 2.7.3. 
 
5.3 Results  
5.3.1 CathD induces HOMEC proliferation 
The first set of experiments examined the proliferative effect of CathD in 
HOMECs. As discussed in Chapter 2 (Section 2.4) and Chapter 3 (Section 3.4), 
both WST-1 and CyQUANT assays were chosen to test for cell proliferation. 
Initially, HOMECs were treated with increasing concentrations of CathD (20, 50 
and 80 ng/ml) for 72 hours. No significant increase in cell proliferation was 
observed at 20ng/ml of CathD (108.28±23.0%, n=17, vs control (100%)), 
although at 50 ng/ml CathD significantly increased HOMEC proliferation 
(147.0±25.8%, n= 20, vs control (100%); Figure 5.1a). At 80ng/ml, a significant 
reduction in cell proliferation (83.4±11.5%, n=5 vs control (100%)) was observed 
(Figure 5.1a). On the basis of these data, subsequent experiments were carried 
out using 50ng/ml of CathD. 
The initial cell proliferation data was complemented using a CyQUANT kit. 
HOMECs were treated with 50ng/ml of CathD for 72 hours. The data shows an 
increase in fluorescence intensity which correlates with an escalation of the 
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amount of DNA, and hence demonstrates proliferation of cells (109.1±10.4%, n= 
0.01 vs control (100%); Figure 5.2a). This data confirmed the WST-1 proliferation 
data, and therefore only WST-1 was carried out in further experiments. 
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Figure 5.1: Increased proliferation of HOMECs in media supplemented with 
CathD (WST-1 assay). Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without various concentrations of 
CathD and incubated for 72 hours. A commercially available WST-1 kit was used 
to assess cellular proliferation based on absorbance using a PHERAstar BMG 
plate-reader at 450nm. a) Results are mean ±SD and shown as percentage of 
the control, n.s., *p<0.05, ***p<0.001 vs control (100%), n=5-20. b) Raw data 
from representative experiment. n.s. denotes not significant. 
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Figure 5.2: Increased proliferation of HOMECs in media supplemented with 
CathD (CyQUANT). Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without 50ng/ml of CathD and 
incubated for 72 hours. A commercially available CyQUANT reagent was used to 
assess cell proliferation based on fluorescence intensity using a FLUOstar BMG 
plate-reader at Ex/Em: 485/530nm. a) Results are mean ±SD and shown as 
percentage of the control, **p<0.01, ***p<0.001 vs control (100%), n=20. b) Raw 
data from representative experiment. 
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5.3.2 CathD induces HOMECs proliferation in a non-proteolytic manner 
 
CathD is an aspartic protease that resides in the lysosomes and therefore 
functions at acidic pHs between pH 3.5 and 4.5. Since CathD was found to be 
secreted by EOC cells and has now been shown to be proangiogenic, it was 
important to investigate whether CathD is acting in a proteolytic or non-proteolytic 
mechanism in HOMECs. Initially, CathD-induced cell proliferation was tested in 
the presence of pepA, an inhibitor of CathD proteolytic activity, at increasing 
concentrations over 24, 48 and 72 hours. The data demonstrated that pepA did 
not inhibit CathD-induced HOMEC proliferation at any concentration at any time 
point (Figure 5.3a, b, c; Table 5.1). Figure 5.3 b, d and f indicated that pepA-alone 
treatment did not induce toxicity or significantly alter proliferation in HOMECs over 
24, 48 and 72 hour incubation.  
 
The above data demonstrated that pepA did not inhibit CathD-induced HOMEC 
proliferation. These data suggested that either CathD is proteolytically active in 
these conditions and pepA does not act as an inhibitor or that CathD is acting via 
non-proteolytic mechanisms. Thus, this was investigated further. Initially, the pH 
of the cell culture media was tested over 24, 48 and 72 hours to confirm that the 
pH of the media remains unchanged overtime. In the presence of CathD, the pH 
of the basal media was initially 7.34 and did not reach a lower pH than 7.12 in all 
conditions tested over time (Table 5.2). Next, CathD’s proteolytic activity at a 
range of pHs and the ability of the inhibitor to inhibit enzyme action at each pH 
was examined. Enzyme activity was tested using a CathD specific fluorogenic 
substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 (100 
nM) and in the presence or absence of pepA (1 µM, concentration which was 
previously shown to not effect cell proliferation, (Figure 5.3; Table 5.1)). The 
experiment demonstrated that CathD was highly active at its optimum pH 3.6 to 
pH 4 (Figure 5.4a), with a gradual reduction in its proteolytic activity from pH 4.6 
to 5.6. It was found that CathD was completely inactive above pH 6 to pH 7.6, 
including the pH of the culture media (Figure 5.4a). CathD was also inactive in 
the presence of pepA. PepA completely abolished enzymatic action at all pHs at 
which CathD demonstrated proteolytic activity i.e. pH 3.6 to pH 5.6 (Figure 5.4b). 
Figure 5.4c represents a summary of the proteolytic activity of CathD at pH 4 and 
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7 in the absence or presence of pepA. These combined data suggest that in cell 
culture media CathD is proteolytically inactive and induces HOMEC proliferation 
via an unknown non-proteolytic mechanism, possibly by acting as an extracellular 
ligand. Thus possible downstream signalling pathways were investigated. 
 
5.3.3 Activation of intracellular signalling kinases in CathD-treated 
HOMECs 
The induction of cell proliferation has been shown to involve activation of several 
intracellular signalling pathways including MAPK/ERK1/2 and PI3/AKT kinases 
(discussed in Chapter 3, Section 3.4). Since CathD induced proliferation, 
signalling cascades activated in CathD-treated HOMECs were examined. 
Initially, a commercially available proteome profiler was used to detect activation 
and phosphorylation of 43 kinases.  It was found that after 4 minutes treatment 
CathD increased phosphorylation of p38-α, ERK1/2 and AKT (S473) by ~5-, 2.5- 
and 3-fold respectively, compared to control (Figure 5.5). The spots for ERK1/2 
and AKT are shown in figure 2.2 (Chapter 2, Section 2.7.2). As for CathL (Chapter 
3, Section 3.3.3), the ERK1/2 and AKT pathways were selected for further 
investigation as these two kinases have been shown to be significantly involved 
in cell proliferation, survival and cell migration in tumour angiogenesis.  
The proteome profiler data was confirmed using commercially available cell-
based ELISAs. CathD significantly induced ERK1/2 phosphorylation in HOMECs 
(>2-fold compared to control), similar to positive control VEGF (>2-fold compared 
to control), after 4 minutes treatment (Figure 5.6a). However, after 10 minutes 
treatment, levels of phosphorylated ERK1/2 reduced to the basal level (Figure 
5.6b). Similar experiments were performed with AKT where AKT phosphorylation 
was induced (~1.6-fold compared to control) at 4 minutes after treatment (Figure 
5.6c) and was back down to basal level after 10 minutes (Figure 5.6d). VEGF 
was used as positive control in all cell-based ELISAs.  
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Figure 5.3: PepA, an inhibitor of CathD proteolytic activity, does not inhibit 
CathD-induced HOMEC proliferation. Cells were seeded in 2% gelatin pre-
coated 96 well plates at a density of 10,000cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
CathD (50ng/ml) in the presence or absence of various concentrations of pepA 
(as shown above- CathD + pepA a), c), e) or pepA alone b), d), f)) and incubated 
for a), b) 24, c), d) 48 and e), f) 72 hours. WST-1 assay was used to assess 
cellular proliferation based on absorbance using a PHERAstar BMG plate-reader 
at 450nm. Control wells contained 0.1% DMSO (carrier only). Results are mean 
±SD and shown as percentage of the control, n.s., *p<0.05., **p<0.01, ***p<0.001 
vs control (100%); n.s., ###p<0.001 vs CathD (expressed as % of control), n=8-
16. n.s. denotes not significant. 
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Table 5.1: Summary of effects of pepstatin A (pepA) on CathD-induced 
proliferation in HOMECs (shown in figure 5.3). HOMECs were treated with or 
without CathD (50ng/ml) and in the presence or absence of increasing 
concentrations of pepA for 24, 48 and 72 hours. Results are mean ±SD and 
shown as percentage of control (100%). n.s. vs CathD (expressed as % of 
control), n=8-16. n.s. denotes not significant. 
 
 
   CathD+ PepA (% of control) 
  
Control 
(%) 
CathD (% 
of control) 
(50ng/ml) 
0.1 µM 
(n.s.) 
1 µM  
(n.s.) 
2.5 µM 
(n.s.) 
5 µM 
 (n.s.) 
10 µM 
(n.s.) 
24h 100 115.9±6.1 126.3±8.0 117.0±17.2 117.0±20.3 125.0±14.5 115.7±13.3 
48h 100 137.1±13.4 138.0±15.7 140.3±11.9 130.2±12.6 138.5±13.0 125.3±9.5 
72h 100 144.8±18.9 145.4±22.7 144.4±18.5 134.4±21.4 132.1±20.2 140.6±26.2 
 
 
Table 5.2: pH of cell culture media and supernatant overtime. Cells were 
seeded in 6 well plates and treated with or without CathD (50ng/ml) for 24, 48 
and 72 hours. Media were collected and their pH was measured by using Blood-
gas analyser ABL800 flex. The pH of basal MV2 (starvation media) was analysed 
at 0 hour. n.d. denotes not determined. 
 
 
  pH 
  0h 24h 48h 72h 
Basal MV2 7.34 n.d. n.d. n.d. 
Control n.d. 7.19 7.13 7.12 
CathD n.d. 7.21 7.13 7.12 
 
 
229 
 
 
Figure 5.4: CathD proteolytic activity is inhibited at an array of pHs by pepA, 
an inhibitor of CathD proteolytic activity. A specific fluorogenic substrate (100 
nM) was incubated with or without CathD (50ng/ml) and in the a) absence or b) 
presence of pepA (1 µM). c) A summary of data at pH 4 and 7 with or without 
CathD and in the presence of the substrate ± pepA. Fluorescence signals were 
measured immediately using a SpectraMax plate reader at Ex/Em: 320/393.  
Control wells contained pH buffer and substrate and/or inhibitor. The data are 
represented as percentage of control. **p<0.01 vs control (substrate) (100%); 
##p<0.01 vs CathD+substrate (expressed as % of control), n=3. a) and b) 
Representative data from 1 of 3 independent experiments.  
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Figure 5.5: CathD induces phosphorylation of p38α, ERK1/2 and AKT(S473) 
in HOMECs. Phosphorylation statuses of the intracellular kinases were assessed 
in cell lysates from cells treated with or without CathD for 4 minutes. The results 
of 1 minute exposure are expressed as mean dot density (arbitrary units). The 
relative expression of specific phosphorylated proteins was determined following 
quantification of scanned images. A combination of 2 cell batches were used in 
this experiment. n= 2 (n=1). 
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Figure 5.6: CathD induces phosphorylation of ERK1/2 and AKT in HOMECs. 
Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without 50ng/ml of CathD or 20ng/ml of 
VEGF (positive control) and incubated for 4 or 10 minutes. ERK1/2 (a, b) and 
AKT (c, d) phosphorylation was examined after 4 minutes (a, c) and 10 minutes 
(b, d) treatments. Commercially available cell-based ELISAs were used for the 
determination ERK1/2 and AKT(S473) phosphorylation level.  The ELISA 
experiments were carried out on two cell batches. The data is represented by fold 
change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT (compared to 
control). Results are mean ±SD, n.s., *p<0.05, **p<0.01, ***p<0.001 vs control 
(dotted lines); n=4-6. n.s. denotes not significant. 
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5.3.4 CathD-induced HOMEC proliferation is mediated via the ERK1/2 
pathway  
Since CathD induces activation of the pro-proliferative kinase ERK1/2, it was 
hypothesised that ERK1/2 might be involved in the downstream signalling 
cascade in the induction of HOMEC proliferation and experiments were carried 
out to test this. Following initial toxicity assays using the ERK1/2 inhibitors U0126 
and PD98059 (Figure 3.7, Chapter 3), the concentrations that were selected for 
further experiments were 1, 10 and 25 µM for both inhibitors. CathD-induced 
HOMEC proliferation was reduced significantly in the presence of all inhibitor 
concentrations compared to CathD treatment alone at 72 hour after incubation. 
For instance, at 1, 10 and 25 µM of U0126, cell proliferation decreased to 
84.7±11.3% (n= 8; Figure 5.7a), 103.1±8.8% (n=8; Figure 5.7b) and 79.3±9.2% 
(n= 8; Figure 5.7c) respectively compared to CathD (140.6±17.9%, n=20), where 
both were expressed as percentage of control. In the case of PD98059, inhibition 
of proliferation was as follows: 122.2±6.1% (n= 8; Figure 5.7d), 101.4±6.2% (n= 
8; Figure 5.7e) and 74.2±4.8 (n= 8; Figure 5.7f) at concentrations 1, 10 and 25 
µM respectively, compared to CathD treatment alone (139.2±18.3%, n= 21), both 
were normalised to control. The inhibitors at all concentrations also reduced 
HOMEC proliferation at 72 hours in the absence of CathD (Figure 5.7). 
As discussed in Chapter 3 (Section 3.3.4), the concentrations that were selected 
for further investigations were: 10 µM for U0126 and 25 µM for PD98059. At these 
concentrations of ERK1/2 inhibitors, CathD-induced HOMEC proliferation was 
significantly reduced compared to CathD treatment alone. A cell-based ELISA kit 
was performed to confirm the inhibitory effects of these inhibitors on cellular levels 
of phosphorylated ERK1/2. The data showed that CathD induced 
phosphorylation of ERK1/2 was abolished or reduced to 0.8-fold and 0.3-fold in 
HOMECs in the presence of U0126 (Figure 5.8a) and PD98059 (Figure 5.8b) 
respectively, compared to CathD treatment (1.6-fold). Together, these data 
suggest that CathD may induce HOMEC proliferation via activation of the ERK1/2 
pathway. 
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Figure 5.7: Inhibition of ERK1/2 reduces CathD-induced HOMEC 
proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without CathD (50ng/ml) and in 
the absence or presence of various concentrations of a-c) U0126 and d-f) 
PD98059 as indicated above and incubated for 72 hours. WST-1 assay was used 
to assess cellular proliferation. Results are mean ±SD and shown as percentage 
of the control, n.s., **p<0.01, ***p<0.001 vs control (100%), ##p<0.01, 
###p<0.001 vs CathD (normalised to control 100%), n=7-13. n.s. denotes not 
significant.  
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Figure 5.8: CathD-induced ERK1/2 phosphorylation is inhibited in intact 
HOMECs treated with ERK1/2 inhibitors a) U0126 (10 µM) and b) PD98059 
(25 µM). Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were pre-incubated with the inhibitors for 20-30 minutes, and 
then co-treated with or without 50ng/ml of CathD or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of ERK1/2 phosphorylation level.  The 
data is represented as fold change in phosho-ERK1/2 relative to total ERK1/2 
(compared to control). Results are mean ±SD, *p<0.05, **p<0.01 vs control (1-
fold), #p<0.05 vs VEGF/CathD (normalised to control), n=4. The dotted lines 
represent basal level (control) of phosphorylation status in untreated HOMECs. 
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5.3.5 CathD-induced HOMEC proliferation is mediated via PI3K and not AKT 
activation 
The PI3K/AKT signalling pathway plays a critical role in mediating survival signals 
in a wide range of cell types. Further to the data described and discussed in 
Chapter 3, the role of AKT was assessed in CathD-induced HOMEC proliferation 
using the PI3K inhibitor LY294002 (1, 25 and 50 µM) and AKT inhibitor MK2206 
(1, 3 and 5 µM). Interestingly, although at 1 µM (157.6±12.0%, n=10; Figure 5.9a) 
there was no significant reduction in CathD-induced cell proliferation compared 
to CathD treatment alone (146.9±9.9%, n=10), LY294002 significantly reduced 
cell proliferation in a dose-dependent manner from 25 µM. For instance, cell 
proliferation at 25 µM and 50 µM of LY294002 were 108.9±7.6% (n=10; Figure 
5.9b) and 78.7±3.9% (n=10; Figure 5.9c) respectively, compared to CathD 
treatment alone (146.9±9.9%, n=10), all expressed as percentage of control. 
Intriguingly, cell proliferation significantly increased in the presence of MK2206 at 
all concentrations. For example, cell proliferation at 1, 3 and 5 µM were 
139.6±7.8% (n=6; Figure 5.9d), 144.0±7.1% (n=7; Figure 5.9e) and 140.3±8.9 
(n=10; Figure 5.9f) respectively, compared to CathD treatment (130.3±7.9%, 
n=9), all expressed as percentage of control. Data from control wells for 
LY294002 demonstrated a significant reduction in cell proliferation over a 72 hour 
period (Figure 5.9 a, b, c). Interestingly, MK2206 did not show any reduction, 
rather a significant increase in proliferation was observed across all three 
concentrations (Figure 5.9 d, e, f). These data suggest that, similarly to CathL, 
CathD induces HOMEC proliferation by activating the PI3K pathway, but in an 
AKT-independent mechanism since the AKT-specific inhibitor did not reduce cell 
growth.  
As discussed in Chapter 3 (Section 3.3.5), the concentrations that were selected 
for further investigation were: 25 µM for LY294002 and 5 µM for MK2206. The 
ELISA data with LY294002 and MK2206 confirmed that both drugs completely 
inhibit CathD-induced phosphorylation of AKT in intact HOMECs. In the presence 
of LY294002, CathD-induced levels of phosphorylated AKT reduced from ~1.7-
fold to 0.4-fold (Figure 5.10a). In the case of MK2206, levels of phosphorylated 
AKT decreased from 1.6-fold to 0.5-fold (Figure 5.10b). This suggests that both 
drugs inhibit the PI3K/AKT pathway in HOMECs. However, a lack of inhibition in 
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cell proliferation suggests that activated PI3K, but not AKT(S473) is involved in 
the induction of CathD-mediated HOMEC proliferation.  
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Figure 5.9: PI3K inhibitor, but not AKT inhibitor, reduces CathD-induced 
HOMEC proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without CathD (50ng/ml) and in 
the absence or presence of various concentrations of a-c) LY294002 (PI3K 
inhibitor) and d-f) MK2206 (AKT inhibitor) as indicated above and incubated for 
72 hours. WST-1 assay was used to assess cellular proliferation. Results are 
mean ±SD and shown as percentage of the control, ***p<0.001 vs control (100%), 
n.s., #p<0.05, ##p<0.01, ###p<0.001 vs CathD, n=10-15 (normalised to control 
100%). n.s. denotes not significant. 
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Figure 5.10: CathD-induced AKT phosphorylation is inhibited in HOMECs 
treated with PI3K and AKT inhibitors a) LY294002 (25 µM) and b) MK2206 (5 
µM), respectively. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were pre-incubated with the inhibitors for 2.5 hours, 
and then co-treated with or without 50ng/ml of CathD or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of the levels of AKT phosphorylation.  
The ELISA experiments were carried out on two cell batches. The data is 
represented by fold change in phosho-AKT relative to total AKT (compared to 
control). Results are mean ±SD, *p<0.05, **p<0.01 vs control (1–fold), #p<0.05 
vs VEGF/CathD (normalised to control), n=4. The dotted lines represent basal 
level (control) of phosphorylation status in untreated HOMECs. 
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5.3.6 CathD induces HOMEC migration via both the ERK1/2 and AKT 
pathways 
A key component of angiogenesis is EC migration. Previous data suggested that 
CathD induces migration in HOMECs. However, the intracellular signalling 
mechanisms have not been examined. Also, previously, HOMEC migration was 
tested using Oris migration assay kit and as discussed in Chapter 3 (section 3.4) 
this was replaced by a Cultrex transwell migration Boyden chamber kit, with a 
reduction in incubation time from 48 hours to 6 hours. Therefore, initially, cell 
migration was tested using this system after 6 hour treatment with CathD, and it 
was revealed that CathD (174.9±52.9%, n= 10; Figure 5.11a) significantly 
induced HOMEC migration compared to control (100%). VEGF was used as 
positive control in cell migration experiments. This led to further investigation into 
the activation of potential downstream signalling pathways. 
Since CathD was shown to activate the ERK1/2 and AKT pathways, their 
activation was examined in CathD-induced HOMEC migration. It was 
hypothesised that activated AKT may be involved in the induction of HOMEC 
migration of CathD as this role for AKT has been reported in several cell models 
(discussed in Chapter 3, Section 3.4). Therefore, the role of AKT in cell migration 
was examined in cells pre-treated with or without PI3K and AKT inhibitors and 
then co-treated with CathD in the absence or presence of the corresponding 
inhibitor for 6 hours. After 6 hour incubation, both inhibitors of PI3K and AKT 
kinase abolished HOMEC migration compared to CathD-treated cells. For 
instance, in the presence of LY294002 and MK2206, CathD-induced HOMEC 
migration was reduced to 92.9±46.3% (n=6; Figure 5.12a) and 105.6±45.8 (n=6; 
Figure 5.12b) respectively, compared to CathD treatment (180.0±65.6%, n=12), 
all expressed as percentage of control (100%). HOMECs treated with only 
LY294002 or MK2206 demonstrated a significant reduction in migration (Figure 
5.12 a), b). 
Cell migration was then examined in the presence of ERK1/2 inhibitors. HOMECs 
were pre-treated with U0126 (10 µM) or PD98059 (25 µM) and then co-treated 
with CathD. After 6 hour incubation, both inhibitors of ERK1/2 abolished HOMEC 
migration compared to CathD-treated cells. For instance, in the presence of 
U0126 and PD98059, CathD-induced HOMEC migration reduced to 91.8±7.9% 
(n=7; Figure 5.13a) and 99.2±9.9% (n=7; Figure 5.13b) respectively, compared 
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to CathD treatment alone (135.7±26.4%, n=12), all expressed as percentage of 
control (100%). U0126 treatment alone significantly reduced HOMEC migration 
(Figure 5.13a), however, although there was a slight reduction in migration by 
PD98059 alone, it was not significantly different to control (100%) (Figure 5.13b). 
These data combined with the ELISA data (Figure 3.9), suggest that CathD 
induces HOMEC migration via a pathway that requires activation of both the 
ERK1/2 and AKT(S473) pathways. 
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Figure 5.11: CathD induces HOMEC migration. HOMECs were seeded on the 
upper transwell insert and treated with or without CathD (50ng/ml) or VEGF 
(20ng/ml) supplementation of starvation media containing 0.5% FCS. The lower 
well contained correspondent treatment i.e. 0.5% FCS media, CathD (50ng/ml) 
or VEGF (20ng/ml). After 6 hours, migrated cells were stained with calcein AM 
and fluorescence was quantified using a FLUOstar plate reader at Ex/Em: 
485/520. a) Results are mean ±SD and shown as percentage of the control, 
***p<0.001 vs control (100%), n=10-15, b) Raw data from representative 
experiment. 
 
 
Figure 5.12: CathD induces HOMEC migration via activation of the AKT 
pathway. HOMECs were seeded in the upper transwell chamber and treated with 
or without CathD (50ng/ml) in the absence or presence of PI3K and AKT inhibitors 
a) LY294002 (25 µM) and b) MK2206 (5 µM) respectively in media containing 
0.5% FCS. The lower well contained correspondent treatments. After 6 hours, 
migrated cells were stained with calcein AM and fluorescence was quantified 
using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and 
shown as percentage of the control, n.s., *p<0.05 ***p<0.001 vs control (100%), 
#p<0.05 vs CathD (normalised to control (100%)), n=6-12. n.s. denotes not 
significant. 
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Figure 5.13: CathD induced HOMEC migration via activation of the ERK1/2 
pathway. HOMECs were seeded in the upper transwell chamber and treated with 
or without CathD (50ng/ml) in the absence or presence of ERK1/2 inhibitors a) 
U0126 (10 µM) and b) PD98059 (25 µM) respectively in media containing 0.5% 
FCS. The lower well contained correspondent treatments. After 6 hours, migrated 
cells were stained with calcein AM and fluorescence was quantified using a 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control, n.s., **p< 0.01, ***p<0.001 vs control (100%), 
###p<0.001 vs CathD (normalised to control (100%)), n=6-12. n.s. denotes not 
significant. 
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5.3.7 Optimisation of 3D and 2D angiogenesis with CathD 
The data described show that CathD has the potential to induce cell proliferation 
and migration in HOMECs, two critical steps of tumour-angiogenesis. To examine 
the ability of CathD to induce angiogenesis in HOMECs, a 3D in vitro model was 
established as described in Chapter 2 (Section 2.8) and Chapter 3 (section 3.3.7). 
As for CathL, initially, HCMECs were used to establish the model with different 
treatments: media supplemented with 2% FCS as basal control (Figure 5.14a), 
media supplemented with 5% FCS and manufacturer-provided growth factors as 
positive control (complete growth media) (Figure 5.14b), and 2% FCS media 
supplemented with 20ng/ml of VEGF (Figure 5.14c) or 50ng/ml of CathD (Figure 
5.14d). Cell sprouting was observed in the positive control and in CathD- and 
VEGF-treated wells, but not in control wells (media with 2% FCS). 
However, when the same conditions were applied using HOMECs, no sprouting 
was observed in any of the wells (data not shown). As described in Chapter 3 
(Section 3.3.7), several modifications of the fibrin gel were applied and a variant 
of cytodex bead was used, but no difference was observed in cell growth or 
sprouting under those conditions, and therefore, it was decided to test CathD-
induced angiogenesis tube-formation in HOMECs using a 2D in vitro model.  
This second assay was performed as described in Chapter 2 (Section 2.8.2.1). 
After overnight incubation, cells were treated with media supplemented with 2% 
FCS (control media), VEGF (20ng/ml; positive control) or CathD (50ng/ml). At 72 
hours after treatment, a complete monolayer formed in the control and VEGF-
treated wells (data not shown).  As for CathL, 2D assay based on the use of a 
fibrin matrix appeared to be a poor model to study CathD-induced angiogenesis 
in HOMECs. Therefore, commercially available growth factor-reduced (GFR) 
Matrigel was chosen to carry out further investigation on HOMECs angiogenesis.  
Initially, cells were seeded on the Matrigel and treated 2 hours later with or without 
CathD and positive control VEGF for another 6 hours. After 6 hour incubation, it 
was found that although CathD induced an increase in tube formation, it was not 
significantly different (185.7±19.1, n=3; Figure 5.15) compared to control 
(145±15). This may be because with n= 3, there is not enough power to detect a 
significant difference and this may be worth investigating further.  Positive control 
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VEGF significantly increased tube formation in HOMECs (210.3±22.4 vs control, 
n=3; Figure 5.15).   
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Figure 5.14: Formation of angiogenic sprout in human cerebral 
microvascular endothelial cells (HCMECs) in 3D fibrin gel. Cells were seeded 
on cytodex 3 microcarriers and embedded in fibrin matrix gel in media 
supplemented with 2% FCS a) Control, b) 5% FCS with added ECs growth 
factors (positive control), c) 20ng/ml of VEGF or d) 50ng/ml of CathD. 
Media/treatments were replaced every other day up to day 5. Photographs were 
taken on day 6 post-seeding using a Nikon phase-contrast microscope at 10X 
magnification. Arrow pointing to cell sprouting. Scale bar =100μM. 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
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Figure 5.15: CathD-induced tubule structure formation in HOMECs in 2D 
Matrigel. HOMECs were plated onto growth factor reduced- (GFR) Matrigel in 
medium containing 2% FCS and treated with media supplemented with VEGF 
(20ng/ml) and/or CathD (50ng/ml) for 6 hours. Control wells contained HOMECs 
grown in medium containing 2% FCS alone. Photographs were taken at 6 hours 
after treatment using a Nikon phase contrast microscope camera and tubule-
structure formation (including nascent tubule structures) was quantified as 
described in the method Section. The results are presented as an angiogenesis 
index, n.s., **p<0.01 vs control levels, n=3. n.s. denotes not significant. 
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5.3.8 Investigation of potential RTKs activated by CathD 
Since CathD has been shown to induce proangiogenic changes in HOMECs via 
activation of ERK1/2 and AKT in a non-proteolytic manner, it is possible that the 
protein acts via an extracellular receptor. The possibility that CathD acts via a 
known tyrosine kinase receptor was investigated using a commercially available 
kit. After 10 minutes treatment with or without CathD or VEGF (positive control), 
it was found that CathD induced 4-fold activation of c-Ret (RET proto-oncogene) 
RTK compared to control (Figure 5.16). VEGF induced a 5-fold activation of this 
RTK in HOMECs. The results also revealed that VEGF strongly activated 
VEGFR2 as expected and slightly activated VEGFR3. 
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Figure 5.16: CathD induces phosphorylation of RTK c-RET in HOMECs. 
Phosphorylation statuses of RTKs were assessed in cell lysates treated with or 
without CathD or VEGF for 10 minutes. The results of 1 minute exposure are 
expressed as mean dot density. The relative expression of specific 
phosphorylated proteins was determined following quantification of scanned 
images of membrane using Azure software. n=1.  
 
 
 
 
 
 
 
 
 
 
 
 
M
e
a
n
 d
o
t 
d
e
n
s
it
y
 (
n
o
rm
a
li
s
e
d
 t
o
re
fe
re
n
c
e
 s
p
o
t,
 a
rb
it
a
ry
 u
n
it
s
)
V
E
G
FR
2
V
E
G
FR
3
In
sR
 (A
LK
)
A
X
L 
(M
er
)
E
ph
 R
c-
R
et
0.00
0.05
0.10
0.15
0.5
0.6
Control
VEGF
CathD
249 
 
5.4 Discussion 
In this Chapter CathD was shown to induce HOMEC proliferation via a non-
proteolytic mechanism. Additionally, CathD was also observed to induce 
phosphorylation of ERK1/2, AKT and p38α in HOMECs. Studies investigating the 
downstream signalling involved in CathD-induced proliferation suggest that the 
activation of the pathway requires ERK1/2 and PI3K, but is independent of AKT 
phosphorylation. Interestingly, cell migration by CathD was shown to be induced 
via activation of both the ERK1/2 and AKT pathways. In a preliminary experiment, 
CathD was observed to activate c-Ret, a RTK. 
 
CathD induced HOMEC proliferation in a non-proteolytic mechanism 
Following activation by angiogenic factors secreted in the microenvironment, ECs 
undergo functional changes such as proliferation, migration and sprouting to 
make new blood vessels. Previous data suggested that CathD plays a role in 
inducing migration of HOMECs (Winiarski et al., 2013). However, its role in cell 
proliferation has not been elucidated. Therefore, in this study it was hypothesised 
that CathD induces HOMEC proliferation. Accordingly, WST-1 and CyQUANT 
assay were carried out to test for proliferation in CathD-treated cells at increasing 
concentrations. The results of the two independent techniques confirmed that 
CathD significantly induced HOMEC proliferation at 50ng/ml. The range of 
concentrations (20, 50 and 80ng/ml) was selected based on a concentration 
58ng/ml that was detected in the peritoneal fluid of women with endometriosis 
(Suzumori et al., 2001). Additionally, previously a publication from our laboratory 
suggested that the EOC cell line SKOV3 secretes 14ng/ml in to the conditioned 
media. In this study, the concentration of CathD was optimised and selected to 
be 50ng/ml as it was within the physiological range and demonstrated a 
significant increase in HOMEC proliferation. 
CathD has been reported to be proangiogenic in several EC and tumour cell 
models both in vitro and in vivo (Glondu et al., 2001, Berchem et al., 2002, Hu et 
al., 2008). However, its mechanism of action is not fully known. Since CathD was 
shown to be pro-proliferative in HOMECs, its mechanism of action was 
investigated. As CathD is a protease in normal physiology, it was possible that it 
induces HOMEC proliferation in a proteolytic manner. To investigate this further, 
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HOMECs were treated with CathD in the absence or presence of an increasing 
concentrations of pepA, an inhibitor of CathD-proteolytic activity, for 24, 48 and 
72 hours. The results demonstrated that pepA did not inhibit CathD-induced 
HOMEC proliferation. These data primarily suggested that CathD induces 
HOMEC proliferation via a non-proteolytic mechanism.  
PepA is a widely used potent inhibitor of CathD (Deiss et al., 1996, Hu et al., 
2008). The range of concentrations of pepA (0.1, 1, 2.5, 5 and 10 μM) used in 
this experiment was based around its reported effective concentration (1 μM) 
(Farias and Manca de Nadra, 2000). The highest concentration that could be 
used in this experiment was 10 μM as a higher concentration would contain more 
than 0.1% DMSO which has been found to be toxic to HOMECs (data not shown). 
Based on these data, the next set of experiments examined in vitro CathD-
proteolytic activity at an array of pHs using a CathD-specific fluorogenic 
substrate. This revealed that CathD is proteolytic at its optimum pH 3.5 to 4.5, but 
proteolytically inactive from pH 6 up to pH 7.6, a range that includes the pH of the 
culture media. When added, pepA completely abolished this proteolytic activity 
of CathD at pHs where activity was observed. This demonstrates the validity of 
the inhibitor pepA in this experiment and further supports the conclusion that 
CathD induces HOMEC proliferation via a mechanism that is independent of its 
proteolytic activity.  
This observation agrees with studies which have reported that the CathD-induced 
proangiogenic response is mediated via an as yet unknown non-proteolytic 
mechanism in other systems. For instance, in vivo, overexpression of CathD in 
xenografts in an athymic mice model correlated with increased vascular density 
(Berchem et al., 2002). The number of microvessels was significantly increased 
by 1.5-fold and 1.9-fold in the CathD and CathD-Asn 231(proteolytically inactive) 
groups respectively. This mutated version of CathD was also shown to induce 
proliferation of 3Y1-Ad12 rat cancer cells embedded in Matrigel or collagen 1 
matrices, colony formation in soft agar and tumour growth in athymic nude mice 
(Berchem et al., 2002). Furthermore, Vignon et al. demonstrated that a precursor 
of CathD, pCathD, non-proteolytically induced growth of MCF7 breast cancer 
cells in vitro (Vignon et al., 1986). A significant increase in human skin CCD45K 
fibroblast proliferation, motility and invasive capacity was also observed to be 
induced by proteolytically inactive CathD (Laurent-Matha et al., 2005). Taken 
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together these data suggest that CathD induces proangiogenic and mitogenic 
responses via an unknown mechanism other than its proteolytic activity.  
However, there are studies available which contest this observation. For 
example, Hu et al. reported that CathD-induced HUVEC proliferation via a 
proteolytic mechanism (Hu et al., 2008). CathD was also shown to be 
proteolytically active in inducing angiogenesis in the chick chorioallantoic 
membrane (CAM) model (Hu et al., 2008). These observations were completely 
inhibited by pepA, suggesting that CathD induces proangiogenic changes via its 
proteolytic mechanism. Moreover, Briozzo et al. demonstrated that proteolytically 
active CathD induced angiogenesis in MCF7 breast cancer cells by cleaving and 
releasing ECM-bound pro-angiogenic factor bFGF (Briozzo et al., 1991).  
These reports suggest that CathD can act via a non-proteolytic or proteolytic 
manner to induce cellular changes. The fact that pepA does not alter CathD-
induced proangiogenic changes in HOMECs and that CathD remains 
proteolytically inactive at cell culture media pH suggest that CathD acts via a 
novel proteolytic-independent mechanism to induce HOMEC proliferation. 
However, the exact mechanism via which CathD induces such effect should be 
investigated further in future experiments. 
 
CathD-induced activation of intracellular signalling pathways and their role in 
cellular proliferation 
As CathD induced HOMEC proliferation in a non-proteolytic manner, it was logical 
to assess the potential downstream intracellular signalling pathways. A proteome 
profiler which screens and detects levels of phosphorylated kinases revealed 
activation of the ERK1/2, AKT(S473) and p38α  pathways. These pathways, as 
discussed in Chapter 3 (Section 3.4), are activated in cell survival, proliferation 
and migration. The ERK1/2 and AKT kinases were selected for further 
investigations primarily because both kinases have been shown to be involved in 
cell proliferation and cell migration, two critical steps of angiogenesis. 
Subsequently, ELISAs were performed at two time points, 4 and 10 minutes after 
CathD treatment. These confirmed that CathD induced phosphorylation of both 
ERK1/2 and AKT 4 minutes after treatment. However, 10 minutes after treatment, 
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the level of phosphorylation reduced down to basal level (control), suggesting 
rapid and transient increase in phosphorylation in response to CathD. 
Interestingly, these data differed from those observed with VEGF (used as a 
positive control) where increases in ERK1/2 phosphorylation were sustained over 
10 minutes. 
Since CathD activates pro-proliferative kinases ERK1/2 and AKT, their role in 
CathD-induced HOMEC proliferation was examined. Firstly, two ERK1/2 
inhibitors (U0126 and PD98059) were used. Both inhibitors demonstrated 
significant inhibition in cell proliferation compared to CathD treatment alone, 
suggesting that ERK1/2 may be involved in CathD-induced HOMEC proliferation. 
This observation was later confirmed by ELISA which showed that both inhibitors 
at their selected concentrations inhibited CathD-induced ERK1/2 
phosphorylation. This agrees with a study where proteolytically inactive CathD 
was shown to induce human skin fibroblast proliferation via activation of the 
MAPK/ERK1/2 pathway (Laurent-Matha et al., 2005). This current study is the 
first report that demonstrates activation of ERK1/2 by CathD in an EC model. 
Activation of the ERK1/2 pathway in EC models and other cell models have been 
discussed in Chapter 3 (Section 3.4). 
Based on the previously described role for PI3K/AKT in EC proliferation (Chapter 
3, Section 3.4) and the fact that CathD treatment increased levels of 
phosphorylated AKT, the involvement of this pathway in HOMEC proliferation 
stimulated by CathD was tested. A PI3K (upstream of AKT) inhibitor LY294002 
and selective AKT inhibitor MK2206 was used to examine this. LY294002 
decreased HOMEC proliferation in a dose-dependent manner and ELISA data 
confirmed that LY294002 did inhibit phosphorylation of AKT in HOMECs. This 
suggested that the PI3K/AKT pathway is also involved in CathL-induced HOMEC 
proliferation.  
To further investigate the above findings, a selective allosteric inhibitor of AKT 
was used. Intriguingly, MK2206 did not inhibit CathD-induced cell proliferation. 
Instead it increased cell proliferation in the absence or presence of CathD, 
although phosphorylated levels of AKT were maintained at basal level by the 
inhibitor (ELISA data). This may indicate that activation of AKT is not required 
CathD-induced HOMEC proliferation. It is possible that inhibition of AKT by 
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MK2206 may activate other kinases in a feedback loop which enhances cell 
proliferation, although there is no available literature to support this observation. 
These data may also suggest that PI3K acts via an AKT-independent 
downstream pathway to mediate CathD-induced HOMEC proliferation. These 
results coincide with the reports discussed in Chapter 3 (Section 3.4). Previously, 
Sagulenko et al. reported an inhibition of CathD-induced AKT phosphorylation 
with LY294002 that resulted in apoptosis in the human neuroblastoma cell line 
Tet21N (Sagulenko et al., 2008). However, the authors, unlike in my study, did 
not test an AKT-selective inhibitor (e.g. MK2206) to verify whether it was PI3K or 
indeed AKT that was playing a role maintaining cell survival. To my knowledge, 
this current study is the first to report that CathD-induced activation of PI3K may 
enhance proliferation in an EC model in AKT-independent manner (discussed in 
Chapter 3, Section 3.4). 
 
CathD induced HOMEC migration 
EC migration is also a key element of angiogenesis. Previously CathD has been 
shown to be pro-migratory in HOMECs (Winiarski et al., 2013), although the 
downstream signalling pathways were not elucidated. In order to confirm the pro-
migratory role of CathD in HOMECs, firstly, as discussed in Chapter 3 (Section 
3.4), Cultrex transwell migration Boyden chamber assay kit was used to examine 
CathD-induced cell migration after 6 hour treatment. The data confirmed that 
CathD significantly induced cell migration compared to control.  
 
Role of activated signalling pathways in CathD-induced HOMEC migration 
The potential downstream signalling cascades were then examined. Based on 
the observation that CathD induces AKT phosphorylation and that AKT has a 
reported role in cell migration (discussed in Chapter 3, Section 3.4), it was 
hypothesised that AKT is involved in this process. Both the PI3K inhibitor 
LY294002 and AKT inhibitor MK2206 were used to assess CathD-induced cell 
migration. Interestingly, both inhibitors significantly inhibited CathD-induced 
HOMEC migration compared to control, suggesting that the PI3K/AKT pathway 
mediates this cellular function. The PI3K/AKT pathway has been shown to be 
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extensively linked to mammalian cell migration as discussed in Chapter 3, 
Section 3.4. 
Since the ERK1/2 pathway has also been reported to be activated in migrating 
cells (discussed in Chapter 3, Section 3.4) and it was observed that CathD 
activates ERK1/2, a role for ERK1/2 was investigated in CathD-induced HOMEC 
migration. ERK1/2 inhibitors U0126 and PD98059 were used to examine this. 
Both inhibitors significantly inhibited CathD-induced cell migration, suggesting a 
pro-migratory role for ERK1/2. This agrees with a study where ERK1/2 activation 
was observed to play a key role in migration of human skin and mammary 
fibroblasts induced by CathD (Laurent-Matha et al., 2005). 
CathD has been shown to induce migration in several cell models. Winiarski et 
al. demonstrated that CathD induced HOMEC migration in vitro (Winiarski et al., 
2013). Also migration of HUVECs was increased when cells were treated with 
pure active CathD (Hu et al., 2008).  In other studies pCathD and CathD have 
been reported to induce migration of breast cancer cells and human fibroblasts 
(Laurent-Matha et al., 2005, Ohri et al., 2008). Intriguingly, CathD has also been 
shown to selectively degrade macrophage inflammatory protein (MIP)-1α (CCL3), 
MIP-1β (CCL4), and SLC (CCL21) that, in turn, may affect the migration of human 
breast cancer cells (Wolf et al., 2003). However, no intracellular signalling 
cascade has been identified in CathD-induced EC migration in the available 
literature, although activation of the ERK1/2 pathway has been reported to be 
involved in inducing migration of human fibroblasts as discussed above (Laurent-
Matha et al., 2005). This present study reports for the first time that CathD 
induces migration in HOMECs via both the PI3K/AKT and ERK1/2 pathways. 
 
Examining angiogenesis in CathD-treated HOMECs 
Since CathD induced HOMEC proliferation and migration, both key steps in 
angiogenesis, CathD-mediated induction of angiogenic sprouting in HOMECs 
was investigated. A 3D model was initially used to investigate this phenomenon. 
As discussed in Chapter 2 (Section 2.8) and 3 (Sections 3.3.7, 3.4), initially 
human brain microvascular endothelial cells (HCMECs) were used to verify this 
technique. When treated with CathD (50ng/ml), sprouting was observed in 
HCMECs. However, with HOMECs, no sprouting was observed. A number of 
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steps and constituents were altered to optimise the 3D model for HOMECs as 
discussed in Chapter 3 (Section 3.3.7 and 3.4), however, the outcome was 
unsuccessful and therefore, a 2D angiogenesis model was adopted using 
commercially available GFR-Matrigel (Chapter 3, Section 3.3.7). 
Although there was an increase in angiogenesis index as shown in the figure, this 
was not statistically significant compared to control. As discussed in Section 
5.3.7, this may be due to low replicate numbers and should be investigated 
further.  
There are reports that CathD does induce angiogenesis in other models. For 
instance, CathD has been shown to form tubule-structures using HUVECs in 
Matrigel (Hu et al., 2008). The same study depicted blood vessel formation in 
CAM models treated with CathD. In vivo, overexpression of CathD in xenografts 
in an athymic mice model correlated with increased vascular density. The number 
of microvessels was significantly increased by 1.5-fold and 1.9-fold in the CathD 
and CathD-Asn 231(proteolytically inactive) groups respectively (Berchem et al., 
2002). These combined data suggest that CathD is capable of inducing 
angiogenesis both in vitro and in vivo.  
Although CathD did not show significant induction of tubule structure formation, 
it is possible that in the Matrigel, due to its constituents (i.e. presence of other 
growth factors), effects of CathD was not strongly elicited. This study should be 
taken further to establish a novel way to demonstrate angiogenesis- cell sprouting 
and tubule-structure formation. This should, in the future, allow in-depth research 
investigating critical and novel cell signalling pathways that aid the metastatic 
cascade in ovarian cancer. 
 
CathD induced activation of RTK c-Ret 
Since CathD activates intracellular kinases that promote cell survival and growth, 
it was hypothesised that a receptor tyrosine kinase (RTK) may be involved in 
mediating such cellular effects. A preliminary investigation was carried out to 
identify possible RTKs in HOMECs that might be activated by CathD.  It was 
found that both positive control VEGF (VEGF-A 165) and CathD induced 
activation of c-RET in HOMECs. VEGF also induced phosphorylation and 
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activation of VEGFR2 and VEGFR3 in this experiment. The RET RTK is a single-
pass transmembrane protein that is required for normal development, maturation 
and maintenance of several tissues and cell types such as the kidney and the 
nervous system (Coulpier et al., 2002, Jain et al., 2006). RET is the signalling 
receptor for the glial cell-derived neurotrophic factor (GDNF) family of ligands 
(GFLs): GDNF, Neurturin, Persephin and Artemin (Mulligan, 2014). Each of these 
ligands interacts with RET via a cell surface co-receptor of the GDNF family 
receptor-α (GFRα) family members. Once bound to the ligand–co-receptor 
complex, conformational changes facilitate RET monomer association via the 
cadherin homology domains and lead to receptor dimerization and 
autophosphorylation (Mulligan, 2014). This phosphorylation takes place on 
multiple tyrosine kinase residues which facilitate direct interactions with signalling 
molecules such as Src (proto-oncogene tyrosine-protein kinase) and 
phospholipase Cγ (PLCγ) or with any of a wide range of adaptor proteins, leading 
to the activation of multiple downstream signalling pathways. For instance, 
GDNF-stimulation induced phosphorylation of the MAPK/ERK1/2 and PI3K/AKT 
pathways in rat superior cervical ganglion cells (Creedon et al., 1997), mouse 
pro-B cell line Ba/F3 (Gu et al., 1998) and mouse fibroblast cell line MG87 (Besset 
et al., 2000) which are known to promote cell growth, proliferation, survival or 
differentiation.  
There is no evidence that CathD may induce RET phosphorylation in any cell 
model in the current literature. However, VEGF was shown to induce activation 
of RET in addition to VEGFR2 autophosphorylation in ureteric bud cells which in 
turn led to branching of these cells (Tufro et al., 2007). Also, interestingly, 
cabozantinib, an inhibitor of VEGFR2, has been shown to elicit significant activity 
against the RET receptor in medullary cancer cells (Grullich, 2014), suggesting 
that the RET receptor may display a similar homology to that of VEGFR2 and that 
VEGF may interact with RET RTK. In contrast, a recent study suggested that in 
HUVECs, VEGF-independent activation of RET is responsible for angiogenesis 
(Zhong et al., 2016). GDNF (a physiological activator of RET) secreted from 
adipose-derived stem cells induced in vitro angiogenesis, via RET activation in 
HUVECs which remained unchanged on blocking VEGF activity (Zhong et al., 
2016). The current study agrees with the former findings which demonstrate 
activation of RET RTK in VEGF-treated cells.  
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This current study suggests that CathD induced proliferation and migration in 
HOMECs via activation of the ERK1/2 and AKT pathways. Since RET RTK has 
been shown to be involved in the induction of angiogenesis in HUVECs, it is 
possible that RET may be responsible for CathD-induced proangiogenic changes 
in HOMECs. As discussed above, VEGF is able to induce phosphorylation of 
RET in ureteric bud cells and in HOMECs (in our study). Also, pro-proliferative, 
pro-migratory and pro-survival pathways ERK1/2 and AKT are downstream of 
RET activation. The fact that CathD induces these proangiogenic changes 
through activation of these pathways, it is reasonable to speculate that RET may 
be a receptor that CathD interacts with to produce such functional outcomes in 
HOMECs. At present the only receptor that CathD is known to interact with is 
M6P/IGF2 receptor, which has a well-defined function in the transport of various 
proteins via the endosomal pathway (Benes et al., 2008). It has been suggested 
that the M6P moieties of extracellular CathD may interact with the M6P receptor 
which then induces mitogenic responses in human skin fibroblasts (Laurent-
Matha et al., 2005). However, Glondu et al. contradicted this observation and 
showed that the M6P receptor was not responsible for mitogenic responses 
induced by CathD in 3Y1-Ad12 rat cancer cells (Glondu et al., 2001), rather the 
presence of an unknown receptor, other than the M6P receptor, was strongly 
suggested. Therefore, the RET RTK may be a possible candidate which is 
responsible for inducing such proangiogenic effects in HOMECs by both VEGF 
and CathD. However, as this was a brief investigation, further research needs to 
be carried out in order to verify this finding by performing immunocytochemistry 
and immunoprecipitation to investigate the presence of RET receptor in 
HOMECs, followed by functional studies using inhibitors of RET to examine 
proliferation and migration in HOMECs treated with both CathD and VEGF. 
 
A summary of CathD-induced proangiogenic responses in HOMECs are 
described in figure 5.17. 
 
5.5 Conclusion 
In this study, CathD, a factor secreted by ovarian cancer cell lines, has been 
demonstrated to induce proangiogenic changes in HOMECs via activation of the 
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ERK1/2 and AKT pathways. The fact that anti-VEGF therapies targeting VEGF-
induced angiogenesis have not shown great success indicated that factors, other 
than VEGF, may be involved in aiding the transition process of ovarian tumour 
cells becoming metastatic. CathD, despite being a lysosomal protease, is a 
potential pro-angiogenic factor which may be inducing such changes in 
HOMECs. This may indicate that CathD can be targeted as a novel anti-
tumourigenic/anti-angiogenic therapeutic target in the treatment of ovarian 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
259 
 
 
 
 
 
 
Figure 5.17: A summary of CathD -induced activation of the ERK1/2 and AKT 
pathways, and cellular functions in HOMECs.  CathD possibly activates c-RET 
receptor tyrosine kinase on the cell surface membrane of HOMECs which leads 
to an increase in phosphorylation of ERK1/2 and AKT. The MEK/ERK1/2 
inhibitors U0126 and PD98059 significantly reduce these cellular functions by 
inhibiting ERK1/2 phosphorylation. Both PI3K inhibitor LY294002 and AKT 
inhibitor MK2206 inhibit phosphorylation of AKT at Ser473 (S473) in CathD-
treated HOMECs. However, only LY294002 inhibits CathL-induced HOMEC 
proliferation, suggesting activation of a pro-proliferative signalling cascade 
downstream of PI3K that is independent of AKT activation. Interestingly, both 
PI3K and AKT kinases are activated in CathD-induced HOMEC migration, which 
was reduced in the presence of both LY294002 and MK2206. 
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Chapter 6 
Investigation into potential proangiogenic roles of IGFBP7 in human 
omental microvascular endothelial cells (HOMECs)  
 
6.1 Introduction 
In the establishment of secondary tumour foci, angiogenesis is a vital component. 
Previously, EOC cells secreted factors CathL and CathD have been shown to 
induce proangiogenic changes in HOMECs. IGFBP7, also known as 
angiomodulin, is an IGF binding protein that is also secreted from EOC cells 
(Winiarski et al., 2013). Numerous reports suggest that IGFBP7 plays an 
important role in inducing proangiogenic responses such as increased EC 
proliferation, migration and capillary like tube formation. However, IGFBP7 has 
also been shown to inhibit angiogenesis in several studies (see below- Section 
6.4). 
In HOMECs, IGFBP7 has been shown to be pro-proliferative, pro-migratory and 
induce angiogenic tube formation in vitro (Winiarski et al., 2013), although the 
activated signalling cascades involved in inducing such responses have not been 
examined. In this study, IGFBP7-induced proliferation was confirmed using two 
different methods. To identify activation of downstream phosphokinases, a 
proteome profiler and cell-based ELISAs were carried out. Subsequently, 
activation of these potential kinases were assessed in IGFBP7-induced HOMEC 
migration. In addition, tubule-structure formation was investigated using Matrigel 
in HOMECs. Finally, potential cell surface receptor targets of IGFBP7 was also 
assessed in a brief investigation. 
 
6.1.2 Aims 
The aims of this chapter are: 
 To investigate whether IGFBP7 induces HOMEC proliferation 
 To examine IGFBP7-induced migration in HOMECs 
 To study potential cell signalling pathways involved in inducing HOMEC 
migration by IGFBP7 
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 To assess HOMEC angiogenic tube-formation induced by IGFBP7 
 To identify potential cell surface receptor targets of IGFBP7 in HOMECs 
 
6.2 Methods 
HOMEC isolation: HOMECs were isolated according to (Winiarski et al., 2011) 
as described in the Method chapter section 2.3.1 
Cell proliferation: HOMEC proliferation was tested using both the WST-1 assay 
and CyQuant cell proliferation kit as described in the Method chapter sections 
2.4.1 and 2.4.2. 
Cell migration: A commercially available cultrex Boyden chamber kit was used 
to investigate the underlying mechanisms of IGFBP7-induced HOMEC migration, 
as described in the Method chapter section 2.5.1. 
Activation of intracellular kinases: A commercially available proteome-profiler 
and cell-based ELISAs were used to detect and assess levels of phosphorylated 
intracellular kinases as described in the Method chapter sections 2.7.2 and 
2.7.4.1. 
3D in vitro angiogenesis: A 3D angiogenesis model was used to assess 
HOMEC sprouting as described in the Method chapter section 2.8.1. 
2D tube-formation: Angiogenic tube-formation was investigated in HOMECs 
treated with IGFBP7 using both a fibrin matrix assay and commercially available 
GFR-Matrigel, as described in the Method chapter section 2.8.2. 
Identification of potential cell surface receptors: A commercially available 
human receptor-tyrosine kinase array was used as a screening tool to identify 
potential receptor as described in the Method chapter section 2.7.3. 
 
 
6.3 Results 
6.3.1 IGFBP7 induces HOMEC proliferation 
Previously IGFBP7 has been shown to induce HOMEC proliferation. However, 
due to the presence of conflicting data in the literature on IGFBP7-induced 
262 
 
cellular response, it was essential to confirm the pro-proliferative role of IGFBP7 
in HOMECs. In the current study, HOMEC proliferation was tested using both the 
WST-1 and CyQUANT assays. Initially, increasing concentrations (10, 20 and 50 
ng/ml) of IGFBP7 were tested which revealed a significant increase in cell 
proliferation after 72 hour treatment. At 10, 20 and 50 ng/ml of IGFBP7 cell 
proliferation was 153±32.1% (n=18), 144.3±36.1% (n=18) and 141.3±21.5% 
(n=25) respectively compared to control (100%; Figure 6.1a). The range of 
concentrations were selected based around the secreted concentration (27 
ng/ml) of IGFBP7 in SKOV3 tumour-conditioned media in our laboratory 
(unpublished data). These data confirmed the previous results published by the 
group that identified that IGFBP7 is a pro-proliferative factor for HOMECs 
(Winiarski et al., 2013). Since all three concentrations of IGFBP7 induced 
significant cell proliferation, a concentration of 50ng/ml was selected for further 
experiments.  
Cell proliferation was then tested by CyQUANT assay which also revealed a 
significant increase in cell proliferation induced by IGFBP7. For example, at 
50ng/ml IGFBP7, cell proliferation increased to 108.2±8.1% (p<0.001, n=20) 
compared to control (100%). These data confirm that IGFBP7 induces 
proliferation in HOMECs. 
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Figure 6.1: Increased proliferation of HOMECs in media supplemented with 
IGFBP7 (WST-1 assay). Cells were seeded in 2% gelatin pre-coated 96 well 
plates at a density of 10,000cells/well in starvation media containing 2% FCS. 
After overnight incubation, cells were treated with or without various 
concentrations of IGFBP7 and incubated for 72 hours. A commercially available 
WST-1 kit was used to assess cellular proliferation based on absorbance using a 
PHERAstar BMG plate-reader at 450nm. a) Results are mean ±SD and shown 
as percentage of the control, ***p<0.001 vs control (100%), n=18-25. b) Raw data 
from representative experiment. 
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Figure 6.2: Increased proliferation of HOMECs in media supplemented with 
IGFBP7 (CyQUANT). Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without 50ng/ml of IGFBP7 and 
incubated for 72 hours. A commercially available CyQUANT reagent was used to 
assess cell proliferation based on fluorescence intensity using a FLUOstar BMG 
plate-reader at Ex/Em: 485/530nm. a) Results are mean ±SD and shown as 
percentage of the control, ***p<0.001 vs control (100%), n=20. b) Raw data from 
representative experiment. 
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6.3.2 IGFBP7 induces HOMEC migration  
IGFBP7 has been shown to induce migration in HOMECs a using Oris migration 
assay kit (Winiarski et al., 2013). As discussed Chapter 3 (section 3.4), a Cultrex 
transwell Boyden chamber was used to assess IGFBP7-induced HOMEC 
migration at a reduced time point. After 6 hour incubation IGFBP7 induced 
significant cell migration (168.6±40.9%, n=11) compared to control (100%; Figure 
6.3a). Positive control VEGF also induced significant migration compared to 
control. These data confirm that IGFBP7 also has a pro-migratory role in 
HOMECs. Thus, the signalling pathways activated during IGFBP7 treatment were 
investigated. 
 
6.3.3 IGFBP7 induces activation of ERK1/2 and AKT kinases 
Based on the previous proliferation and migration data, it was hypothesised that 
IGFBP7 induces activation of pro-proliferative and pro-migratory pathways as 
identified in several cell models, including HOMECs as discussed in Chapter 3, 
4 and 5. Therefore, to investigate potential downstream signalling pathways, 
initially, IGFBP7-treated HOMECs were tested using a proteome profiler that 
simultaneously detects activation of 43 kinases. It was revealed that after 4 
minutes treatment IGFBP7 increases phosphorylation of the p38α (~3.5-fold), 
ERK1/2 (~3.4-fold), AKT (4-fold) kinases in HOMECs compared to control (Figure 
6.4). The ERK1/2 and AKT kinases were selected for further investigation as 
these two kinases have been shown to significantly induce migration in several 
cell models as previously described in Chapter 3, section 3.4.  
The proteome profiler data was confirmed using cell-based ELISAs. After 4 
minutes treatment, IGFBP7 significantly induced phosphorylation of ERK1/2 in 
HOMECs (2.33-fold vs control; Figure 6.5a). A similar increase in ERK1/2 
phosphorylation (2.6-fold vs control) was also observed in the positive control 
VEGF-treated (4 minute treatment) HOMECs (Figure 6.5a). However, after 10 
minutes treatment with IGFBP7, levels of phosphorylated ERK1/2 reduced to the 
basal level, although this remained unchanged with VEGF treatment (Figure 
6.5b). Similar experiments were performed with AKT where AKT phosphorylation 
was induced (2.1-fold compared to control) at 4 minutes after treatment (Figure 
266 
 
6.5c) and was reduced to the basal level after 10 minutes (Figure 6.5d). VEGF 
was used as positive control in all cell-based ELISA experiments.  
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Figure 6.3: IGFBP7 induces HOMEC migration. HOMECs were seeded on the 
upper transwell insert and treated with or without IGFBP7 (50ng/ml) or VEGF 
(20ng/ml) supplementation of starvation media containing 0.5% FCS. The lower 
well contained corresponding treatment i.e. 0.5% FCS media, IGFBP7 (50ng/ml) 
or VEGF (20ng/ml). After 6 hours, migrated cells were stained with calcein AM 
and fluorescence was quantified by using a FLUOstar plate reader at Ex/Em: 
485/520. a) Results are mean ±SD and shown as percentage of the control, 
***p<0.001 vs control (100%), n=11, b) Raw data from representative experiment. 
 
 
Figure 6.4: IGFBP7 induces phosphorylation of p38α, ERK1/2 and 
AKT(S473) in HOMECs. Phosphorylation status of the intracellular kinases was 
assessed in cell lysates from cells treated with or without IGFBP7 for 4 minutes. 
The results of 1 minute exposure are expressed as mean dot density (arbitrary 
units). The relative expression of specific phosphorylated proteins was 
determined following quantification of scanned images. A combination of 2 cell 
batches were used in this experiment. n= 2 (n=1). 
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Figure 6.5: IGFBP7 induces phosphorylation of ERK1/2 and AKT in 
HOMECs. Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without 50ng/ml of IGFBP7 or 20ng/ml of 
VEGF. ERK1/2 (a, b) and AKT (c, d) phosphorylation was examined after 4 
minutes (a, c) and 10 minutes (b, d) treatments. Commercially available cell-
based ELISAs were used for the determination of ERK1/2 and AKT(S473) 
phosphorylation level.  The ELISA experiments were carried out in quadruplets 
on two cell batches. The data is represented as fold change in phosho-
ERK1/2/AKT relative to total ERK1/2/AKT (compared to control). Results are 
mean ±SD, n.s., *p<0.05, **p<0.01, ***p<0.001 vs control; n=4-6. The dotted lines 
represent basal level (control) of phosphorylation status in untreated HOMECs. 
n.s. denotes not significant.  
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6.3.4 IGFBP7 induces HOMEC migration via activation of ERK1/2, but not 
AKT 
Previous data showed that IGFBP7 plays a pro-migratory role and that it induces 
activation of ERK1/2 and AKT in HOMECs. Both the activated ERK1/2 and AKT 
pathways have been shown to induce cell proliferation in several models 
(discussed in Chapter 3, section 3.4), with AKT being the most common pathway 
known in this process. Therefore, it was hypothesised that IGFBP7 induces 
HOMEC migration via activation of AKT. Thus, the role of AKT in cell migration 
was examined in cells pre-treated with or without PI3K and AKT inhibitors 
LY294002 (25 µM) and MK2206 (5 µM) (concentrations previously determined in 
Chapter 3, Section 3.3.5) respectively, and then co-treated with IGFBP7 in the 
absence or presence of the corresponding inhibitor for 6 hours. Although both 
inhibitors inhibited IGFBP7-induced migration, this was not a significant 
reduction. For instance, migration of IGFBP7-treated cells in the presence of 
LY294002 was 127.8±46.9% (n= 6) with no significant difference compared to 
IGFBP7-induced migration (165±40.1%, n= 12), both were expressed as 
percentage of control (100%; Figure 6.6a). In the case of MK2206 and IGFBP7 
treatment, cell migration was 128.8±62.0% (n= 6), which was not significantly 
different to IGFBP7-induced migration (165±40.1%, n= 12), both were normalised 
to control (100%; Figure 6.6b). HOMECs treated with only LY294002 and/or 
MK2206 demonstrated a significant reduction in migration (Figure 6.6 a),b).  
The ELISA data with LY294002 (25 µM) and MK2206 (5 µM) confirmed that both 
drugs do inhibit IGFBP7-induced phosphorylation of AKT in intact HOMECs. In 
the presence of LY294002, IGFBP7-induced levels of phosphorylated AKT 
reduced from 1.8-fold to 0.9-fold (Figure 6.7a). In the case of MK2206, levels of 
phosphorylated AKT decreased from 1.8-fold to 0.85-fold (Figure 6.7b). This 
suggests that both drugs inhibit the PI3K/AKT pathway in HOMECs. However, a 
lack of statistically significant inhibition of cell migration suggests that activation 
of AKT(S473) may not be solely involved in the induction of IGFBP7-mediated 
HOMEC migration.  
Cell migration was then tested in the presence of the ERK1/2 inhibitors U0126 
and PD98059. Cells were pre-treated with U0126 (10 µM) or PD98059 (25 µM) 
(as determined in Chapter 3, Section 3.3.4) and then were co-treated with 
IGFBP7 in the presence or absence of the inhibitors. After 6 hours incubation, 
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both inhibitors of ERK1/2 abolished HOMEC migration compared to IGFBP7-
alone treated cells. In the presence of U0126 and PD98059, IGFBP7-induced 
HOMEC migration reduced to 86.6±28.9% (n=7; Figure 6.8a) and 85.6±18.1% 
(n=6; Figure 6.8b) respectively, compared to IGFBP7-treatment alone 
(139.8±24.2%, n=9), both data were expressed as percentage of control (100%). 
U0126 treatment alone significantly reduced HOMEC migration (Figure 6.8a), 
however, although there was a slight reduction in migration by PD98059 only 
treatment, it was not significantly different compared to control (Figure 6.8b).  
Cell-based ELISAs confirmed that the levels of phosphorylated ERK1/2 abolished 
or reduced in HOMECs to 0.3-fold and 0.4-fold in the presence of U0126 (Figure 
6.9a) and PD98059 (Figure 6.9b) respectively when compared with IGFBP7-
alone (1.4-fold). These data, along with inhibition of cell migration data suggest 
that IGFBP7 induces HOMEC migration via activation of ERK1/2. 
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Figure 6.6: IGFBP7 does not induce HOMEC migration via the AKT pathway. 
HOMECs were seeded in the upper transwell chamber and treated with or without 
IGFBP7 (50ng/ml) in the absence or presence of PI3K and AKT inhibitors a) 
LY294002 (25 µM) and b) MK2206 (5 µM) respectively in media containing 0.5% 
FCS. The lower well contained corresponding treatments. After 6 hours, migrated 
cells were stained with calcein AM and fluorescence was quantified using a 
FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as 
percentage of the control (100%), *p<0.05, **p<0.01, ***p<0.001 vs control 
(100%), n=6-12. n.s. denotes not significant vs IGFBP7. 
 
Figure 6.7: IGFBP7-induced AKT phosphorylation is inhibited in HOMECs 
treated with PI3K and AKT inhibitors a) LY294002 (25 µM) and b) MK2206 (5 
µM), respectively. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were pre-incubated with the inhibitors for 2.5 hours, 
and then co-treated with or without 50ng/ml of IGFBP7 or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used to determine the level of AKT phosphorylation. The 
ELISA experiments were performed on two cell batches. The data is represented 
by fold change in phospho-AKT relative to total AKT (compared to control). 
Results are mean ±SD, n.s., *p<0.05, **p<0.01 vs control (1-fold), #p<0.05 vs 
VEGF/IGFBP7 (normalised to control), n=4. The dotted lines represent basal 
level (control) of phosphorylation status in untreated HOMECs. n.s. denotes not 
significant. 
F
lu
o
re
s
c
e
n
c
e
 o
f 
m
ig
ra
te
d
 c
e
ll
s
(%
 o
f 
c
o
n
tr
o
l)
0
10
50
100
150
200
250
*
***
n.s.
n.s.
IGFBP7
MK2206
-     - + +
- +   - +
F
lu
o
re
s
c
e
n
c
e
 o
f 
m
ig
ra
te
d
 c
e
ll
s
(%
 o
f 
c
o
n
tr
o
l)
0
10
50
100
150
200
250
***
***
**
n.s.
IGFBP7
LY294002
-     - + +
- +    - +
a) b)
F
o
ld
 c
h
a
n
g
e
 i
n
 p
h
o
s
p
h
o
-A
K
T
 r
e
la
ti
ve
 t
o
 t
o
ta
l 
A
K
T
 (
c
o
m
p
a
re
d
 t
o
 c
o
n
tr
o
l)
0.0
0.5
1.0
1.5
2.0
2.5
4
4.5
VEGF
IGFBP7
LY294002
+             + -           -
  -           -              +             +
  -             + -              +
**
*
n.s.
*
#
#
a) b)
F
o
ld
 c
h
a
n
g
e
 i
n
 p
h
o
s
p
h
o
-A
K
T
 r
e
la
ti
ve
 t
o
 t
o
ta
l 
A
K
T
 (
c
o
m
p
a
re
d
 t
o
 c
o
n
tr
o
l)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
VEGF
IGFBP7
MK2206
+            + -          -
  -          -              +            +
  -            + -            +
*
**
*
n.s.
#
#
272 
 
 
Figure 6.8: IGFBP7 induces HOMEC migration via the ERK1/2 pathway. 
HOMECs were seeded in the upper transwell chamber and treated with or without 
IGFBP7 (50ng/ml) in the absence or presence of ERK1/2 inhibitors a) U0126 (10 
µM) and b) PD98059 (25 µM) respectively in media containing 0.5% FCS. The 
lower well contained correspondent treatments. After 6 hours, migrated cells 
were stained with calcein AM and fluorescence was quantified using a FLUOstar 
plate reader at Ex/Em: 485/520. Results are mean ±SD and shown as percentage 
of the control, n.s., *p<0.05, **p<0.01, ***p<0.001 vs control (100%), ##p<0.01 vs 
IGFBP7, n=7-9. n.s. denotes not significant. 
 
 
Figure 6.9: IGFBP7-induced ERK1/2 phosphorylation is inhibited in intact 
HOMECs treated with ERK1/2 inhibitors a) U0126 (10 µM) and b) PD98059 
(25 µM). Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were pre-incubated with the inhibitors for 20-30 minutes, and 
then co-treated with or without 50ng/ml of IGFBP7 or 20ng/ml of VEGF in the 
absence or presence of the inhibitors for 4 minutes. Commercially available cell-
based ELISAs were used for determination of ERK1/2 phosphorylation levels.  
The data is represented by fold change in phosho-ERK1/2 relative to total ERK1/2 
(compared to control). Results are mean ±SD, *p<0.05, **p<0.01 vs control (1-
fold), #p<0.05 vs VEGF/IGFBP7 (normalised to control). The dotted lines 
represent basal level (control) of phosphorylation status in untreated HOMECs.  
n=4.  
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6.3.5 Optimisation of 3D and 2D in vitro angiogenesis models with IGFBP7 
The data described show that IGFBP7 has the potential to induce cell proliferation 
and migration in HOMECs, two critical steps of tumour-angiogenesis. To examine 
the ability of IGFBP7 to induce angiogenesis in HOMECs, a 3D in vitro model 
was established as described before in Chapter 2 (Section 2.8) and Chapter 3 
(Section 3.3.7). Initially, HCMECs were used to establish the model with different 
treatments: media supplemented with 2% FCS as basal control (Figure 6.10a), 
media supplemented with 5% FCS and manufacturer-provided growth factors as 
positive control (complete growth media) (Figure 6.10b), and 2% FCS media 
supplemented with 20ng/ml of VEGF (Figure 6.10c) or 50ng/ml of IGFBP7 (Figure 
6.10d). Cell sprouting was observed in the positive control, IGFBP7 and in VEGF-
treated wells, but not in cells containing media with 2% FCS (control). 
However, when the same conditions were applied using HOMECs, no sprouting 
was observed in any of the wells (data not shown). As described and discussed 
in the previous chapters, further optimisation led to the investigation of 
angiogenesis in growth factor-reduced Matrigel (GFR-Matrigel). Therefore, 
initially, cells were seeded and treated 2 hours later with or without IGFBP7 and 
positive control VEGF for another 6 hours. After 6 hour incubation, it was found 
that IGFBP7 induced a significant increase in tube formation (213±12.0, n=4; 
Figure 6.11) compared to control (145±15). Positive control VEGF significantly 
increased tube formation in HOMECs (210.3±22.4, n=4). These data, along with 
proliferation and migration data, suggest that IGFBP7 plays a role in inducing 2D 
angiogenic tube-formation in HOMECs. 
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Figure 6.10: Formation of angiogenic sprout in human cerebral 
microvascular ECs (HCMECs) in 3D fibrin gel. Cells were seeded on cytodex 
3 microcarriers and embedded in fibrin matrix gel in media supplemented with 
2% FCS a) Control, b) 5% FCS with added ECs growth factors (positive control), 
c) 20ng/ml of VEGF or d) 50ng/ml of IGFBP7. Media/treatments were replaced 
every other day up to day 5. Photographs were taken on day 6 post-seeding using 
a Nikon phase-contrast microscope at 10X magnification. Arrow pointing at cell 
sprouting. Scale bar =100 μm. 
 
 
 
 
 
 
 
a) b) 
c) d) 
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Figure 6.11: IGFBP7-induced tubule structure formation in HOMECs in 2D 
Matrigel. HOMECs were plated onto growth factor reduced- (GFR) Matrigel in 
medium containing 2% FCS and treated with media supplemented with VEGF 
(20ng/ml) and/or IGFBP7 (50ng/ml) for 8 hours. Controls contained HOMECs 
grown in medium containing 2% FCS alone. Photographs were taken at 8 hours 
after treatment using a Nikon phase contrast microscope camera and tubule-
structure formation (including nascent tubule structures) was quantified as 
described in method section. The results are presented as an angiogenesis 
index. *p<0.05, **p<0.01 vs control levels, n=4.  
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6.3.6 Investigation into the activation of receptor tyrosine kinases by 
IGFBP7 in HOMECs 
The previous data suggested that IGFBP7 plays a role in inducing proangiogenic 
changes in HOMECs via ERK1/2, and activating important intracellular kinases. 
This raised the possibility that IGFBP7 may act via a known tyrosine kinase 
receptor which was investigated using a commercially available RTK array kit. 
Cells were treated for 10 minutes with starvation media (2% FCS MV2), media 
supplemented with IGFBP7 (50ng/ml) or VEGF (20ng/ml; positive control). The 
results revealed that VEGF strongly activated VEGFR2 and slightly activated 
VEGFR3 (Figure 6.12). Intriguingly, IGFBP7 increased activation of c-RET 
receptor by ~16 fold compared to control. An increase in activation of VEGFR2 
and a slight increase in phosphorylation of InsR (ALK) and Axl (Mer) receptor 
tyrosine kinases by IGFBP7 was also observed (Figure 6.12).  
 
Since VEGFR2 is an important element of VEGF signalling and IGFBP7 induced 
activation of this receptor and the ERK1/2 and AKT kinases, its role in IGFBP7-
induced cell proliferation was examined. To test this, IGFBP7-induced HOMEC 
proliferation was assessed in the presence of SU5416 (10 µM), a potent inhibitor 
of VEGFR2 tyrosine kinase (Huss et al., 2003). Initially, cells were pre-treated 
with or without SU5416 for 1 hour at a concentration previously determined in our 
laboratory (Winiarski et al., 2013), followed by co-treatment with or without 
IGFBP7 or positive control VEGF. After 72 hour incubation it was found that 
IGFBP7-induced HOMEC proliferation (145.3±26.7%, n= 9) was partially, but 
significantly reduced in the presence of SU5416 (115.9±13.4%, n=8), both were 
expressed as percentage of control (Figure 6.13). Positive control VEGF-induced 
cell proliferation was reduced to basal level in the presence of SU5416 as shown. 
These data suggest that activation of VEGFR2 by IGFBP7 may be involved in the 
induction of HOMEC proliferation. 
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Figure 6.12: IGFBP7 induces phosphorylation and activation of receptor 
tyrosine kinase (RTK) VEGFR2 and c-RET. Phosphorylation status of RTKs 
was assessed in cell lysates treated with or without IGFBP7 or VEGF for 10 
minutes. The results of 1 minute exposure are expressed as mean dot density. 
The relative expression of specific phosphorylated proteins was determined 
following quantification of scanned images of membrane using Azure software. 
n=1. 
 
 
Figure 6.13: IGFBP7 induces HOMEC proliferation via activation of VEGFR2. 
Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were pre-treated with or without SU5416 (10 µM) in the presence 
of 0.1% BSA media for 1 hour, then co-treated with or without VEGF (20ng/ml; 
positive control) or IGFBP7 (50ng/ml) for 72 hours. WST-1 assay was used to 
assess cellular proliferation. Control wells contained 0.1% DMSO (vehicle) and 
0.1% BSA. Results are mean ±SD and shown as percentage of the control, 
*p<0.05, **p<0.01, ***p<0.001 vs control (100%); ##p<0.01, ###p<0.001 vs 
IGFBP7/VEGF, n=8-10. n.s. denotes not significant vs control. 
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6.4 Discussion 
In early angiogenic responses, tumour-secreted factors activate EC to proliferate, 
migrate and sprout out to generate new blood vessels. IGFBP7, an EOC secreted 
factor, was previously found to induce proliferation, migration and tube-formation 
in HOMECs (Winiarski et al., 2013). However, the underlying mechanisms which 
mediate these proangiogenic responses had not been elucidated. In this study, 
roles of IGFBP7 were confirmed in inducing HOMEC proliferation, migration and 
angiogenic tube-formation. Furthermore, activated downstream signalling 
cascades were also assessed and it was revealed that IGFBP7 induces HOMEC 
migration via activation of the ERK1/2 pathway. In a preliminary investigation, 
IGFBP7 was found to increase activation of c-RET, VEGFR2 and Mer (Axl) RTKs 
in HOMECs. 
 
IGFBP7 induced HOMEC proliferation 
Although IGFBP7 was previously shown to induce HOMEC proliferation, the 
contradictory data in the current literature (discussed below) meant that it was 
essential to repeat and confirm the finding in this study. Two independent 
techniques WST1 and CyQuant assay were utilised to verify the previous findings 
and both confirmed that IGFBP7 significantly induces HOMEC proliferation. This 
agrees with several studies that indicates a role for IGFBP7 in inducing cellular 
proliferation. For instance, exogenous IGFBP7 treatment significantly induced 
proliferation of LN18 and LN443 glioma cell lines in vitro (Jiang et al., 2008). 
Additionally, a recent study on haemocytes of small abalone Haliotis diversivolor 
reported a pro-proliferative role for IGFBP7 (Wang et al., 2015). When tested, 
IGFBP7 was found to increase cell density of these cells. IGFBP7 was also 
shown to induce growth of the mouse fibroblast cell line BALB/c3T3 in vitro 
(Akaogi et al., 1996b). These studies suggest that exogenous IGFBP7 can induce 
proliferation in cells. However, there are numerous studies available that contrast 
these findings. For instance, IGFBP7 was shown to inhibit VEGF-induced EC 
proliferation (Tamura et al., 2009). Also, apoptosis was induced in several cancer 
cell lines, particularly colorectal cancer and melanoma both in vitro and in vivo 
when treated with IGFBP7 (Wajapeyee et al., 2008, Wajapeyee et al., 2009). 
IGFBP7 has also been shown to strongly supress activation of the MAPK/ERK1/2 
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pathway, thereby reducing proliferation of the breast cancer cell line MDA-MB-
468 and human melanoma cell lines (mutation BRAF V600e-positive SK-MEL-28 
and SK-MEL-31) both in vitro and in vivo (Wajapeyee et al., 2008, Amemiya et 
al., 2011). When added exogenously, IGFBP7 significantly suppressed growth of 
human cervical carcinoma cells (HeLa), osteosarcoma cells (Saos-2), and murine 
embryonic carcinoma cells (Kato, 2000). These studies strongly suggest an 
inhibitory role of IGFBP7 on cell proliferation and survival. However in this current 
study, IGFBP7 was shown to induce HOMEC proliferation, and to my knowledge 
this is the only report that demonstrates such pro-proliferative response in an EC 
model.  
 
Although IGFBP7 has been shown to be pro-proliferative in HOMECs, the 
underlying signalling mechanisms involved in the proliferative response were not 
examined in this study. In the future, an in-depth investigation (using human 
phosphokinase array and ELISAs) should be carried out to identify pathways 
involved in mediating the induction of proliferation in HOMECs. 
 
IGFBP7 induced HOMEC migration 
IGFBP7 also significantly induced HOMEC migration. There is very little available 
literature on the role of IGFBP7 in migration. The data presented here confirmed 
previously published data (Winiarski et al., 2013). Also, IGFBP7 has been shown 
to interact with various ECM proteins such as collagen type IV to stimulate 
adhesion and induce migration/invasion of HUVECs in vitro (Sato et al., 1999, 
Kishibe et al., 2000).  
 
Signalling pathways involved in IGFBP7-induced HOMEC migration 
As IGFBP7 induced HOMEC migration, the activation of downstream signalling 
pathways was examined. A proteome profiler and cell-based ELISAs were used 
to detect activated signalling kinases in HOMECs treated with IGFBP7 and 
revealed activation of two pro-proliferative and pro-migratory kinases ERK1/2 and 
AKT. It was hypothesised that AKT plays a key role in inducing IGFBP7-induced 
HOMEC migration since this kinase has been shown in numerous studies to 
280 
 
mediate such cellular function (as previously described in Chapter 3, Section 3.4). 
PI3K and AKT inhibitors LY294002 and MK2206 respectively were used to 
investigate the role of these in IGFBP7-induced migration. Intriguingly, inhibition 
of the PI3K/AKT pathway reduced cellular migration in control wells, however, no 
significant difference was observed between IGFBP7-induced migration and with 
co-treatment with the inhibitors, although both inhibitors (alone) significantly 
inhibited phosphorylation of AKT by IGFBP7 in HOMECs as demonstrated by 
ELISA data. Interestingly, both ERK1/2 inhibitors U0126 and PD98059 
significantly reduced IGFBP7-induced HOMEC migration and reduced levels of 
phosphorylated ERK1/2 in IGFBP7-treated cells. This suggests that ERK1/2 may 
play a role in IGFBP7-induced HOMEC migration. 
 
This observation is supported by the literature showing IGFBP7-mediated cell 
growth and migration via ERK1/2 and AKT phosphorylation. Jiang et al. reported 
that IGFBP7 induced migration by regulating levels of phosphorylated ERK1/2 
and AKT in glioblastoma (GBM) cell lines LN 18 and LN443 (Jiang et al., 2008). 
Interestingly, it was shown that the level of phosphorylated AKT decreased in a 
time-dependent manner (0-6 hours) although the level of phosphorylated ERK1/2 
remained higher in IGFBP7-treated cells compared to untreated cells. Thus, it 
was suggested that IGFBP7 induces cell migration by increasing ERK1/2 
phosphorylation and decreasing levels of activated AKT. In the current study, 
although activation of ERK1/2 played a key role in inducing migration in 
HOMECs, level of AKT phosphorylation was also increased in IGFBP7-treated 
cells compared to control. Perhaps, in the future, levels of both ERK1/2 and AKT 
should be examined over a longer incubation to assess whether there is any 
downregulation of phosphorylated AKT as observed (up to 6 hours) previously in 
GBM cell lines (Jiang et al., 2008).  
Although IGFBP7 has been shown to induce migration in HOMECs and in GBM 
cell lines, there are reports that contest these findings. For instance, IGFBP7 was 
shown to inhibit VEGF-induced migration and angiogenesis of HUVECs in a 
dose-dependent manner by downregulating the activation of COX-2 (an enzyme 
involved in the biosynthetic pathway of prostaglandin E2) and phosphorylated 
ERK1/2 induced by VEGF treatment (Tamura et al., 2009). When treated alone, 
IGFBP7 did not induce any proangiogenic changes in HUVECs. Sun et al. also 
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reported a significant inhibition in VEGF-induced migration of the retinal EC line 
RF/6A when co-treated with an increasing concentration of IGFBP7. Although the 
authors did not test cellular migration with IGFBP7-alone, the inhibition of VEGF-
induced migration by IGFBP7 was shown to be mediated via an inhibition of the 
B-RAF/MEK/ERK1/2 pathway that subsequently induced apoptosis in these ECs 
(Sun et al., 2011), suggesting that IGFBP7 may elicit an anti-angiogenic response 
in certain ECs, although this was not the case in HOMECs. 
 
Examining angiogenesis in IGFBP7-treated HOMECs 
The observation that IGFBP7 induces HOMEC proliferation and migration 
suggested a role for this protein in angiogenesis and so angiogenic sprouting and 
tube-formation in these cells was assessed. A significant increase in tube-like 
structure formation was seen compared to control. Indeed, Winiarski et al.  also 
demonstrated that IGFBP7 induced angiogenic tube-formation in HOMECs 
(Winiarski et al., 2013). Additionally, Zhao et al. has shown that IGFBP7 plays an 
important role in inducing tube like structure in lymphatic ECs which may 
stimulate tumour progression in non-small cell lung carcinoma (Zhao et al., 
2016b). IGFBP7 was also shown to induce capillary-like tube formation in 
HCMECs in the pathogenesis of GBM (Pen et al., 2008). Together these data 
strongly suggest that IGFBP7 may play a pro-angiogenic role in tumour 
progression and metastasis.  
However, again there are studies that contradict the above findings. For instance, 
IGFBP7 was shown to inhibit VEGF-induced in vitro angiogenesis in HUVECs 
(Tamura et al., 2009) and in vascular ECs of rat corpus luteum (Tamura et al., 
2014). The authors demonstrated a dose-dependent reduction in tube-formation 
in ECs when treated with increasing concentrations of IGFBP7 in the presence 
of VEGF. Interestingly, Hooper et al. contradicted this latter finding and claimed 
that IGFBP7 interacts with VEGF by providing an extracellular scaffold to which 
VEGF can bind within the ECM milieu resulting in VEGF-induced pro-angiogenic 
responses during embryogenesis in a zebra fish model (Hooper et al., 2009). 
Although, these data suggest that IGFBP7 induces both anti- and pro-angiogenic 
responses in different EC models, the fact that this study confirms previously 
published data on the induction of tubule-structure formation in HOMECs 
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(Winiarski et al., 2013), indicates that IGFBP7 may be a potential proangiogenic 
factor in this cell model of ovarian cancer metastasis. 
 
IGFBP7 induced phosphorylation of RTKs: ALK, cRET, AXL (Mer) and VEGFR2 
Since IGFBP7 increased activation of ERK1/2 and AKT and induced 
proangiogenic changes in HOMECs, it was hypothesised that a RTK may be 
involved in mediating such cellular effects. In a brief investigation it was found 
that IGFBP7 induced activation of c-RET, and to a lesser extent activation of 
VEGFR2, anaplastic lymphoma kinase (ALK, insulin receptor superfamily) and 
Axl (Mer, member of Tyro3-Axl-MER family). This preliminary data suggests, for 
the first time in any cell model, that IGFBP7 induces activation of RET RTK. A 
role for RET has been discussed in Chapter 4 (Section 4.4). Briefly, RET has 
been reported to be activated by VEGF-VEGFR2 signalling in ureteric bud cells 
which in turn led to branching of these cells (Tufro et al., 2007). Furthermore, 
VEGF-independent activation of RET has also been suggested to induce 
angiogenesis in HUVECs (Zhong et al., 2016). Phosphorylation of signalling 
cascades such as the MAPK and PI3K/AKT pathways via RET RTK has also 
been reported in several cell models as described before (Chapter 4, Section 
4.4). The fact that IGFBP7 induces proliferation, migration and angiogenesis in 
HOMECs, raises the possibility that RET RTK plays a key role in inducing such 
functions in HOMECs. Further research is required to verify these findings, which 
may shed light on the regulation of angiogenesis in IGFBP7-treated HOMECs. 
ALK is a novel RTK that was discovered in the brain and specific neurones in the 
nervous system. It was originally identified as an oncogene activated in anaplastic 
large cell lymphomas (ALCL) (Shiota et al., 1995, Shiota et al., 1994). 
Subsequent cDNA cloning of the full-length proto-alk have shown that it encodes 
a novel, putative RTK of the insulin receptor family (Iwahara et al., 1997, Morris 
et al., 1997). This RTK was recently shown to be involved in the activation of 
several cellular functions. For instance, nucleophosmin (a nuclear protein 
involved in the biogenesis of ribosomes) was shown to interact with ALK RTKs in 
ALK-positive ALCL cell lines (SUDHL-1, Ki-JK, Karpas 299 and SR786) that 
induced significant phosphorylation of STAT3, ERK1/2 and AKT, whereby 
ERK1/2 was observed to be responsible for inducing cellular proliferation 
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(Anastasov et al., 2010). In another study, a monoclonal antibody (mAb16-39) 
targeting the extracellular domain of ALK demonstrated an increase in the level 
of endogenous ALK-phosphorylation in neuroblastoma cell line SK-N-SH (Motegi 
et al., 2004). Interestingly, ALK activation led to increased phosphorylation of 
ERK1/2 and subsequent cellular proliferation which was completely abolished by 
the ERK1/2 inhibitor PD98059 (Motegi et al., 2004). Armstrong et al. reported that 
overexpression of ALK in mouse fibroblasts (NIH3T3) induced proliferation and 
Matrigel invasion via activation of the PI3K/AKT pathway (Armstrong et al., 2004). 
Together, these data suggest that ALK may be responsible for induction of 
cellular proliferation via activation of ERK1/2. In the current study, IGFBP7 was 
demonstrated to be pro-proliferative in HOMECs. Although the activated 
signalling pathways have not yet been investigated in IGFBP7-induced HOMEC-
proliferation, ALK would be an interesting RTK candidate to be examined in future 
studies. 
ALK has also been reported to be involved in the induction of cellular migration 
via pathways that contrast with the present study. For example, Seo et al. 
demonstrated that overexpression of ALK induced activation of p55γ (a subunit 
of PI3K) that in turn resulted in migration of NIH3T3 cells (Seo et al., 2016). This 
was mediated by ALK-stimulated phosphorylation of the PI3K/AKT pathway, 
which was not observed in HOMECs when treated with IGFBP7. Interestingly, in 
another study, the phosphorylated p55γ subunit of PI3K was shown to stimulate 
angiogenesis in colorectal cancer cells by activating the NFκB pathway, via an 
AKT or ERK1/2-independent pathway (Wang et al., 2013). These data perhaps 
shed light on the role of ALK in mediating cellular migration, although in this study 
IGFBP7 has been shown to induce HOMEC migration via the ERK1/2 but not the 
AKT pathway. However, the fact that ALK has been observed to play significant 
roles in cellular proliferation and migration, suggests that these preliminary 
findings could be taken further in future experiments to investigate IGFBP7-
induced ALK activation and downstream cellular functions. It is also important to 
note that ALK activation has never been reported in an EC model, and therefore 
it would be very important to investigate expression of ALK in HOMECs further. 
Since IGFBP7 induced activation of VEGFR2 tyrosine kinase in HOMECs, the 
role of this receptor in inducing HOMEC proliferation was examined. IGFBP7-
induced HOMEC proliferation was partially but significantly reduced in the 
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presence of the VEGFR2 tyrosine kinase inhibitor SU5416. This may suggest 
that VEGFR2 activation plays an important role in IGFBP7-induced HOMEC 
proliferation. However, since SU5416 did not completely abolish IGFBP7-induced 
cell proliferation, unlike in VEGF-treated cells (positive control), it may indicate 
that other receptors might also have been activated in HOMECs, as shown in 
figure 6.13. 
Although IGFBP7 induced activation of VEGFR2 in HOMECs, there are reports 
that contradict the current finding. For instance, IGFBP7 was shown to inhibit 
VEGF-induced proliferation and tube-formation in HUVECs (Tamura et al., 2009). 
IGFBP7 was not shown to bind to VEGFR2 or VEGF itself, but it was suggested 
that this inhibition may be induced by IGFBP7-mediated blocking of the MEK-
ERK signalling pathway. In addition, Hooper et al. suggested that in 
neoangiogenesis, ECM-bound IGFBP7 plays an inhibitory role by directly binding 
to VEGF in the extracellular milieu and thereby blocking VEGF-induced vascular 
patterning in mice (Hooper et al., 2009). To my knowledge, there are no other 
reports of IGFBP7 binding to and activating VEGFR2 in any cell model. 
The data in the current study suggested that IGFBP7 induced phosphorylation of 
ERK1/2 and AKT in HOMECs. In the VEGF-VEGFR2 signalling axis, these two 
kinases are commonly activated during proliferation, migration and angiogenesis. 
The fact that IGFBP7 also induces activation of these intracellular kinases and 
also phosphorylates VEGFR2 tyrosine kinase, may indicate a role for VEGFR2 
activation in IGFBP7-induced cellular functions. Although these are only 
preliminary data, it will be very interesting to examine this further in future studies.  
 
IGFBP7 also induced activation of Mer, another RTK that was initially discovered 
in human leukaemia cells and cancer cells such as lung cancer, breast cancer, 
GBM, epidermoid carcinoma, colon cancer, and normal human fibroblasts. 
(Graham and Peng, 2006). Mer is a member of the TAM (Tyro3, Axl and Mertk) 
family of RTKs that has not been fully characterised. Interestingly, there are 
striking similarities between the tyrosine kinase domain amino acid sequences of 
family members Axl and Mer RTKs. Overall, the protein sequences of the human 
TAM receptors share 31–36% identical (52–57% similar) amino acids within the 
extracellular region. The intracellular domains share 54–59% sequence identity 
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(72–75% similarity) with higher homology in the tyrosine kinase domain (Graham 
and Peng, 2006), and hence it is believed that these RTKs, particularly Axl and 
Mer are involved in inducing similar cellular responses (Linger et al., 2008). 
 
A role for Mer RTK has been reported recently to be involved in the progression 
of GBM. This study demonstrated that Mer and Axl RTKs are highly expressed 
and often co-expressed in astrocytic and glioblastoma cell lines (Keating et al., 
2010), which may be important clinically given the correlation of TAM RTK 
coexpression and poor prognosis in gastric carcinoma. Keating et al. observed 
that downregulation of Mer or Axl RTK resulted in increased apoptosis, 
decreased short- and long-term survival, and increased chemosensitivity of GBM 
cells in vitro (Keating et al., 2010), suggesting a prosurvival role for Mer RTK, 
which has been shown to be mediated via activation of the AKT pathway (Krause 
et al., 2015). Recently, a study reported that both shRNA-knockdown of Mer RTK 
and a monoclonal antibody against Mer RTK can significantly inhibit GBM cell 
migration, which was rescued by re-introducing Mer RTK expression in these 
cells (Rogers et al., 2012). The authors observed an alteration in FAK signalling 
and suggested that an intact Mer RTK signalling is necessary for appropriate 
levels of FAK activation, and that this altered FAK signalling may be responsible 
in part for the aberrant migration of Mer-inhibited GBM cells (Rogers et al., 2012). 
Since IGFBP7 induces HOMEC migration, it is possible that Mer RTK contributes 
to this response. Interestingly, Keating and colleagues reported a reduction in the 
activation of the PI3K and ERK1/2 pathways when Mer or Axl were blocked in 
serum-treated astrocytoma cells in vitro (Keating et al., 2010). Previous reports 
have shown that the PI3K/AKT survival pathway is critical for normal CNS cell 
survival signalling (Shankar et al., 2006, Shankar et al., 2003). Several groups 
have published data implicating the PI3K and MAPK pathways in astrocytoma 
proliferation. Hlobilkova et al. have shown that aberrant activation of AKT is found 
in both low-grade and high-grade astrocytoma patient samples (Hlobilkova et al., 
2007), whereas Mizoguchi et al. showed that the PI3K/AKT and MAPK pathways 
were abnormally activated in high-grade astrocytomas (Mizoguchi et al., 2006). 
Interestingly, Keating et al. found that inhibition of either RTK (Axl or Mer) resulted 
in a similar phenotype with increased apoptosis and apoptotic biochemical 
markers as well as decreased astrocytoma cell survival in functional assays 
286 
 
(Keating et al., 2010). Together, these data suggest that upon activation, Mer 
RTK may induce phosphorylation of the PI3K/AKT and MAPK pathways, which, 
as described earlier, are involved in cell proliferation and migration. Since 
IGFBP7 induced proliferation and migration in HOMECs, it is possible that Mer 
RTK may be involved in these processes. However, these exciting preliminary 
experiments need to be repeated in the future and tested using functional studies 
to verify a role for Mer RTK in IGFBP7-treated HOMECs. 
Although a role for Mer RTK in angiogenesis has not been reported yet, Axl RTK 
(family member of Mer) has been found to be activated in the induction of 
angiogenesis. Holland et al. 2005 reported that Axl knockdown significantly 
reduced growth arrest-specific protein 6- (Gas6, a ligand for Axl RTK)-induced 
HUVEC proliferation and impaired EC-tube formation when co-cultured with 
pulmonary artery smooth muscle cells. A similar observation was also found in 
mice where severe immunodeficient mice transplanted with Axl knockdown 
human dermal microvascular ECs failed to undergo neoangiogenesis (Holland et 
al., 2005). VEGF-A-induced corneal neovascularisation in mice was significantly 
reduced in Axl-knockout mice compared to wild-type mice, suggesting a role for 
Axl in VEGFA-dependent angiogenesis (Ruan and Kazlauskas, 2012). In another 
study, glioblastoma (GBM) xenografts containing a mutant Axl exhibited reduced 
gliomagenesis (Vajkoczy et al., 2006). In vitro experiments demonstrated a 
significant reduction in proliferation and migration of glioma cells U1242, U373, 
U118, and SF126 containing a mutant form of Axl compared to wild-type Axl RTK 
(Vajkoczy et al., 2006). These results suggest that Axl kinase activity is important 
for regulating both EC and tumour cell growth, migration and angiogenesis.  
Interestingly, Axl activation has been shown to induce activation of the PI3K/AKT 
and ERK1/2 in several cell lines. Ruan and Kazlauskas reported Axl RTK to be a 
contributor to VEGF-A-dependent activation of the PI3K/AKT pathway in 
HUVECs (Ruan and Kazlauskas, 2012). The Gas6/Axl/PI3K/AKT pathway was 
shown to protect mouse embryonic fibroblast NIH3T3 cells from apoptosis by 
phosphorylating and inactivating a pro-apoptotic protein BCL2-associated 
agonist of cell death (Bad) (Goruppi et al., 1999). Gas6-Axl-mediated activation 
of AKT has been reported to inhibit pro-apoptotic caspase-3 and induce 
phosphorylation of NF-kB that increases expression of the anti-apoptotic proteins 
B-cell lymphoma 2 and B-cell lymphoma-extra-large in primary HUVECs 
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(Hasanbasic et al., 2004). Axl activation has also been shown to induce cell 
proliferation via activation of the ERK1/2 pathway. Stimulation of ERK and p38 
kinases by Axl is attributed, in part, to its ability to bind to the adapter protein Grb2 
(Fridell et al., 1996). However, there is no report of activation of RTK Axl by 
IGFBP7 in any cell model. In this study, the data indicate that IGFBP7 induces 
proliferation, migration and tube-formation in HOMECs, and migration is 
mediated via activation of the ERK1/2 pathway. This may indicate a role of active 
Axl and/or Mer RTK in IGFBP7-induced cellular functions in HOMECs. Therefore, 
this preliminary data should be investigated further using immunocytochemistry 
and immunoprecipitation to detect the presence of Axl and/or Mer RTKs and 
identify and assess their role in functional studies such as proliferation, migration 
and angiogenesis. Taken together, these preliminary data may suggest that each 
RTK may act individually or in combination with other RTKs in mediating the 
induction of proangiogenic responses in HOMECs treated with IGFBP7. 
 
A summary of the data from this chapter are described in figure 6.14. 
 
6.5 Conclusion 
As the current literature has conflicting data on the role of IGFBP7 in tumour 
progression, it was necessary to identify its role in HOMECs. In this study, 
IGFBP7, a factor secreted by ovarian cancer cell lines, has been demonstrated 
to induce proangiogenic changes in HOMECs via activation of the ERK1/2 
pathway. Interestingly, the preliminary data suggest that IGFBP7 induced 
activation of several RTKs including VEGFR2, c-RET, Mer (TAM) and ALK, which 
need to be examined further. This may shed light on novel receptors of IGFBP7 
in HOMECs that may be utilised as potential targets in anti-angiogenic therapy in 
ovarian cancer metastasis.  
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Figure 6.14: A summary of IGFBP7-induced activation of the ERK1/2 and 
AKT pathways, and their potential role in mediating cellular functions in 
HOMECs. IGFBP7 possibly activates receptor tyrosine kinases: c-RET, 
VEGFR2, Mer and ALK on the cell surface membrane of HOMECs which leads 
to phosphorylation of ERK1/2 and AKT. The ERK1/2 activation may mediate 
cellular migration in HOMECs in response to IGFBP7, since the MEK/ERK1/2 
inhibitors U0126 and PD98059 significantly reduce cell migration and activation 
of ERK1/2. Both PI3K inhibitor LY294002 and AKT inhibitor MK2206 inhibited 
phosphorylation of AKT at Ser473 (S473) in IGFBP7-treated HOMECs. However, 
the role of AKT in mediating IGFBP7-induced migration is not clear in HOMECs. 
IGFBP7 also induces proliferation, although the activating signalling cascades 
have not yet been investigated. 
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Chapter 7 General Discussion 
 
Angiogenesis is vital in tumour metastasis. A lack of oxygen in the local tumour 
microenvironment due to increased demand by tumour cells elicits a pro-
angiogenic response in the local microvasculature of the affected organ. Although 
both pro- and anti-angiogenic factors are secreted by both local cells and tumour 
cells, the ratio is in favour of the proangiogenic factors such as VEGF and bFGF. 
This cohort of proangiogenic factors triggers activation of ECs from existing local 
microvasculature, inducing secretion of proteases that aid matrix digestion, 
allowing ECs to migrate towards the secondary tumour foci. These proangiogenic 
factors also induce EC proliferation and enhance migration, forming sprouts or 
branches of neovessels, feeding the tumour cells to grow and invade further. 
 
EOC cells have been shown to secrete VEGF and hence the monoclonal anti-
VEGF antibody bevacizumab was developed to block angiogenesis at advanced 
disease stage. However, due to severe toxicity and side effects, this treatment 
has significant drawbacks. Also, recently Winiarski et al. reported that despite 
blocking the VEGF/VEGFR axis, significant angiogenesis was observed in 
HOMECs when treated with EOC conditioned media, suggesting that there are 
factors, other than VEGF, that might be involved in this process (Winiarski et al., 
2013). Subsequent studies revealed that EOC cells secrete proteases CathL and 
CathD, and IGFBP7 all of which have a potential role in angiogenesis. This 
current study hypothesised that these EOC-secreted factors play a role in tumour 
angiogenesis during metastasis of EOC to the omentum, and therefore examined 
the effects of these proteins on HOMEC proliferation, migration and the signalling 
pathways involved.  
 
CathL, a cysteine protease, has been shown to increase HOMEC proliferation. 
This is an interesting observation as CathL is a protease that works at an acidic 
pH inside cellular lysosomes. However, CathL has been reported to be present 
at a higher concentration in the plasma of ovarian cancer patients compared to 
normal patients. Published data from our lab also demonstrated increased 
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expression of CathL in the omental tissue and the microvasculature in advanced 
EOC patients, compared to EOC with benign tumour or healthy participants.  
Since CathL was detected in the tumour conditioned media and in ascites, it was 
thought that this protease may have a proangiogenic role in HOMECs. 
Intriguingly, CathL was found to induce HOMEC proliferation. This phenomenon 
was initially thought to occur via CathL-proteolytic activity. Indeed, CathL-
proteolytic activity was observed at a range of pHs including pHs 4 (optimum) 
and 7 (pH of cell culture media) and the CathL-proteolytic specific inhibitor FY-
CHO completely abolished proteolytic activity at all pHs (3-7.6). However, in the 
presence of FY-CHO, no inhibition of proliferation was observed, suggesting that 
CathL is acting in a way that is independent of its proteolytic activity. This 
suggestion was supported by the observation that CathL induced 
phosphorylation of MAP kinase ERK1/2 and p38α, and AKT (S473) at 4 minutes 
after treatment. These kinases are downstream of RTKs, which are known to be 
activated by growth factors such as EGF and VEGF. Interestingly CathL was 
shown to activate RTK Tie-1, part of the angiopoietin/Tie-1 axis, which often plays 
an important role in angiogenesis, as discussed before. This suggests for the first 
time that CathL may play a mitogenic role in a non-proteolytic manner, possibly 
via yet an unidentified allosteric site.  
Since CathL induced activation of ERK1/2, it was thought that this MAPK may 
play a role in CathL-induced HOMECs proliferation. Indeed, activation of ERK1/2 
was found to mediate CathL-induced cellular proliferation. Interestingly, PI3K, but 
not AKT, activation was also shown to play a role in CathL-induced HOMEC 
proliferation. As discussed before, activation of PI3K and, particularly, ERK1/2 
are well-known signalling events in cellular proliferation. Additionally, activated 
ERK1/2 was also shown to mediate cellular migration. Although the PI3K/AKT 
pathway is known to be activated in cellular migration in other systems, in CathL-
induced HOMEC migration, this was not the case. In recent years, activated 
ERK1/2 has been highlighted as a pro-migratory kinase in several cell models. 
The study in this thesis is the first to demonstrate a role for CathL in inducing both 
proliferation and migration of microvascular ECs in a non-proteolytic manner.  
 
The cell surface receptor target for this protein remains unconfirmed. Although 
Tie-1 was observed to be phosphorylated, it is essential to validate this 
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preliminary detection and identify other possible receptors involved in mediating 
the activation of downstream signalling pathways in HOMECs, inducing pro-
angiogenic changes. This may reveal potential novel targets for anti-angiogenic 
therapies. To test this, initially, a commercially available Human Receptor 
Tyrosine Kinase Array (R&D) could be performed, along with 
immunoprecipitation and immunocytochemistry. This could be followed by 
subsequent functional studies (e.g. proliferation and migration of HOMECs) 
whereby specific receptors will be targeted either by using a competitive blocker 
of the receptor or a receptor- kinase inhibitor. This data may then be 
complemented by knockdown studies, utilising siRNAs to knockdown expression 
of identified receptor-specific genes, followed by testing cell proliferation and 
migration with corresponding protein treatments.  
In these future studies, cellular proliferation could be examined using other 
techniques. For example, HOMECs can be stained with BrdU or fluorescently 
labelled anti-Ki-67 (cell proliferation marker) antibody and cell proliferation could 
be measured using flow cytometry. This is a more reliable method as it allows 
quantitative analysis of number of cells increased in a treatment. Cellular 
migration could also be examined using other techniques such as wound-healing 
assays, which allows visualisation of migratory cells and hence a more direct 
measurement of cell migration. 
Work investigating a role of CathL in HOMEC angiogenesis led to the 
identification of another potential proangiogenic candidate Gal1. Previously, 
unpublished data from gene sequencing experiments suggested a differential 
expression of Gal1 mRNA (LGALS1) in HOMECs when treated with CathL. This 
raised the question whether CathL induces an increase in the expression and/or 
production of Gal1 in HOMECs. A commercially available ELISA was used to test 
for secreted levels of Gal1 from HOMECs when treated with CathL. Interestingly, 
an increase in Gal1 secretion was observed in CathL-treated HOMECs 
(compared to control), which was later found to be transcriptionally-regulated. To 
our knowledge, this is the first study to report Gal1 production and secretion in 
CathL-treated cells. 
According to the literature, Gal1 has been found to be secreted from different cell 
types (discussed before) and also in mice models when oxidative stress or 
hypoxia is applied. However, in this study, exogenous CathL increased this 
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secretion, which could mean that CathL activates yet an unknown signalling 
pathway that induces upregulation of Gal1 mRNA, followed by its secretion. One 
possible signalling pathway that may be involved upstream of LGALS1 
expression is p38α. p38α has been shown to be activated by both intracellular 
(mitochondrial reactive oxygen species) and extracellular (e.g. hypoxia) stress, 
and Gal1 has been shown to be secreted by induced-stress in mice and in vitro 
cell models. Also, NFκB activation has been detected in the upstream of LGALS1 
expression, both in the current studies and other published works, as discussed 
above. Since CathL activates p38α, it could be possible that this kinase is 
responsible for the activation of NFκB and hence an increase in LGALS1 
expression and subsequent Gal1 secretion. However, this needs to be further 
verified by ELISA or western blotting technique with inclusion of inhibitors of p38α.  
 
The secretion process of Gal1 also remains a mystery. It had been shown that 
Gal1 is not secreted via the conventional ER/Golgi secretory pathway. In this 
current study, a significant level of Gal1 was secreted despite breakdown of the 
Golgi body, suggesting that in HOMECs, Gal1 secretory pathway is independent 
of the classical route, agreeing with the previous reports. However, this should 
be investigated further. Firstly, the intracellular localisation of Gal1 should be 
examined by immunocytochemistry. If it reveals an area concentrated with Gal1 
proteins, it may indicate that Gal1 is produced/stored within that particular 
compartment. For example, it has been shown that glycoproteins (integrins) are 
internalised and recycled in the perinuclear recycling endosomal compartments 
(Caswell et al., 2009). Since Gal1 is a glycoprotein that interacts with integrins 
and also is expressed at cell surface membrane, it could be possible that 
trafficking and subsequent secretion of Gal1 is regulated in a similar manner as 
cellular integrins. This requires further research such as immunochemical 
detection of Gal1 within HOMECs. Following visualisation of Gal1, co-localisation 
studies can be performed combining specific antibodies targeting particular 
organelles or compartments and Gal1. Once identified, the pathway can be 
inhibited or the organelle can be destabilised using a pharmacological inhibitor, 
followed by measurement of the secreted levels of Gal1 in the cell supernatant. 
This may unveil a new area of focus in the future. 
293 
 
As Gal1 was found to be secreted from HOMECs by CathL treatment, it was 
thought that Gal1 may induce a proangiogenic response in these cells. Firstly, 
proliferation assays were carried out, which revealed that Gal1 induced HOMEC 
proliferation via both ERK1/2 and PI3K, but not AKT, pathways. Additionally, Gal1 
was also found to induce HOMEC migration. These functional studies suggested 
an autocrine mechanism which Gal1 utilises to induce such proangiogenic 
responses. This begged a question whether CathL-induced proangiogenic 
responses are dependent on Gal1. To test this, HOMEC proliferation was 
examined in the presence of L-glucose (binds to Gal1) and CathL or Gal1. 
Intriguingly, Gal1-induced HOMEC proliferation was inhibited in the presence of 
L-glucose, however, no inhibition was observed in CathL-treated cells. This 
suggested, for the first time, that CathL may induce HOMEC proliferation in a 
manner that is independent of Gal1 activity. However, both proteins (exogenously 
added) may produce an additive effect in inducing cell proliferation which has not 
been tested yet. Also, CathL-induced cell migration in HOMECs was not tested 
in the presence of L-glu, which should be examined in the future to determine 
whether CathL-induced HOMEC migration is dependent on Gal1. 
 
Since L-glu inhibited both Gal1-induced HOMEC proliferation and migration, it 
may be suggested that Gal1 interacts with a cell surface receptor displaying a 
sugar residue in its N-terminal domain. Indeed there are a number of studies 
(cited in Chapter 4) that demonstrated interaction of Gal1 with integrins and 
neuropilin-1 (a co-receptor of VEGFR2), activating proangiogenic pathways. This 
could be further investigated in HOMECs by repeating the RTK array kit (as 
discussed above), followed by immunoprecipitation and immunocytochemistry. 
Additionally, enzymes that break down glucose residues on the cell surface 
membrane, such as hyaluronidase and neuraminidase, could be used to examine 
Gal1-induced proangiogenic events in HOMECs. This may reveal whether Gal1 
acts on a cell surface receptor containing a sugar residue in HOMECs. 
Although Gal1 induced HOMEC migration, neither ERK1/2 nor AKT activation 
was observed to play a role in this, suggesting that other signalling pathways may 
be involved in this process and/or a combination of activated kinases may play a 
role. This could be further investigated using a commercially available 
phosphokinase array kit, which will allow identification of activated kinases in 
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Gal1-treated HOMECs, followed by ELISAs to validate the array data. 
Subsequent migration experiments may be carried out in the presence of 
pharmacological inhibitors to test for the role of activated signalling kinases. 
 
The unique relationship between CathL and Gal1 could be researched further as 
both of these proteins have been shown, for the first time, to be involved in 
proangiogenic responses in HOMECs and therefore may be involved in EOC 
metastasis. Gal1 has already been reported to induce tumour angiogenesis in 
several cancer models. However, a non-proteolytic proangiogenic role for CathL 
along with it eliciting Gal1 production and secretion, is exclusive in this study. 
Therefore, both CathL and Gal1 could be further examined as discussed above 
and explored with regards to identifying novel anti-angiogenic therapies in EOC 
metastasis in near future.  
 
Another potential proangiogenic factor that was investigated in this study was 
CathD, an aspartic protease that resides in the acidic milieu of lysosomes. This 
thesis investigated its role in inducing proangiogenic responses in HOMECs. 
Interestingly, CathD was found to induce both proliferation and migration in 
HOMECs, possibly via a mechanism that is independent of its proteolytic activity. 
Whether CathD acts via its native proteolytic mechanisms or not was tested at a 
range of pHs in the presence of an inhibitor, pepA. Interestingly, CathD was found 
to be inactive at pHs similar to that of the cell culture conditions, suggesting that 
CathD is also acting in a non-proteolytic manner, an important observation that 
agrees with the current literature. However, further work is needed to examine 
and identify an as yet unknown non-proteolytic, mitogenic mechanism. 
Additionally, CathD was found to activate both ERK1/2 and AKT pathways in 
HOMECs. To my knowledge, this is the first study to demonstrate such as 
observation in a vascular EC model. Further investigation demonstrated that 
these pathways are activated in CathD-induced HOMEC proliferation and 
migration. Additionally, investigation of the activated RTK by CathD revealed an 
increased level of phosphorylated RET RTK in HOMECs. As discussed 
previously, this RTK is upstream of ERK1/2 and PI3K/AKT kinases which are 
known to be involved in mediating cell proliferation and migration, and hence it 
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may be suggested, for the first time, that CathD mitogenically induces a 
proangiogenic response in HOMECs via activation of RET RTK. However, the 
receptor target for CathD should be further investigated in future studies to 
confirm and validate this observation. 
In the current study, ovarian tumour-secreted factor IGFBP7 was also examined 
for its potential role in proangiogenic changes in HOMECs. IGFBP7 has been 
found to increase HOMEC proliferation and migration. Due to time constraints, 
the signalling pathways involved in IGFBP7-induced cellular proliferation have 
not been elucidated in this study, however, cellular migration was observed to 
occur via activation of the ERK1/2 pathway. As discussed above, the activated 
ERK1/2 kinase plays a key role in cellular migration. However, IGFBP7-activated 
signalling pathways could be investigated further in both HOMEC proliferation 
and migration as the current literature has conflicting data on its role in 
angiogenesis.  
Interestingly, when tested, IGFBP7 was found to activate VEGFR2 in HOMECs. 
This was further tested using WST1 proliferation assay in the presence of 
SU5416, a potent inhibitor of VEGFR2 tyrosine kinase. Intriguingly, SU5416 
significantly reduced IGFBP7-induced HOMEC proliferation, suggesting, for the 
first time, that IGFBP7 may act on VEGFR2 to induce proangiogenic changes in 
HOMECs. However, the receptor target should be examined further as discussed 
above.  
 
Development of an appropriate in vitro angiogenesis model 
 
Since angiogenesis plays a significant role in aiding tumour metastasis, an 
attempt was made to investigate sprouting (3D model) or tube-forming (2D 
model) capabilities of HOMECs when treated with the selected tumour secreted 
factors. Unfortunately, it was not possible to optimise the right model to study 
HOMEC angiogenesis in this report. However, when tested with human brain 
microvascular ECs, sprouting was observed in the 3D model using a fibrin matrix, 
which was completely absent in HOMECs. This could be explained by the 
heterogeneity that exists between ECs from different vascular beds and organs, 
which suggests that an EC type requires a particular niche that suits their normal 
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functions. A commercially available growth factor reduced-matrigel was also used 
to test tube-formation. However, it was shown to be an ineffective method to test 
for proangiogenesis as the gel contains, albeit in very low concentrations, potent 
growth factors which enhanced tube-like structures in basal media in HOMECs 
in the 2D assay.  
The 3D in vitro model used to study angiogenesis in this report was mainly 
constituted of fibrin matrix. This is a well-known matrix used in the angiogenic 
studies of different EC models. Since this model failed to establish angiogenesis 
in HOMECs, a different model will need to be proposed in the future. Alterations 
that could be made are addition of laminin and/or fibronectin in the matrix mix.  
 
Laminins are multifunctional matrix molecules that are widely expressed, forming 
the major scaffold of the basement membrane. There are different types of 
laminins which display organ, site and developmental specificity (Simon-
Assmann et al., 2011). For example, in most tissues, only laminin-411 (α4 chain) 
and -511 (α5 chain) are found in the endothelial basement membrane. However, 
formation of new blood vessels during angiogenesis requires degradation of the 
BM, a process in which ECs are exposed to other laminin isoforms such as 
laminin-111 (α1 chain), reviewed in (Simon-Assmann et al., 2011). Laminin-411 
is a specific high affinity ligand for αvB3 and α3β1 integrins, which enhance EC-
ECM interactions aiding cell adhesion and migration. Using dermal microvascular 
EC, Li et al. reported that laminin-411 promoted cell spreading and migration in 
a scratch wound assay and accelerated angiogenic tube formation in collagen 
gel overlay assays (Li et al., 2006). Therefore, a mixture of laminin-411, -511 and 
a low concentrations of -111 isoforms could be used to constitute a fibrin-based 
gel to test for both 2D (tube formation) and 3D in vitro sprouting angiogenesis 
assay using HOMECs. 
 
As developing microvessels enter different stages of maturation, the ECM around 
them undergoes complex structural and compositional changes that may 
influence the ability of ECs to respond to growth factors and organise into 
capillary tubes. One of the major components of the provisional ECM of 
developing microvessels is fibronectin (Nicosia et al., 1993). As a result of its 
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multiple binding sites for ECs and other ECM proteins, fibronectin functions as an 
adhesive scaffold for the migration of ECs. Fibronectin has been shown to bind 
VEGF-A and support directed migration of EC tip cells (Mettouchi, 2012). In the 
presence of both fibrin and fibronectin, cells with actin filament stress fibres were 
more spreading than those in fibrin (Fournier and Doillon, 1992). In an ex vivo 
study using rat aorta, fibronectin incorporated in the collagen gel promoted a 
selective dose-dependent elongation of the newly formed microvessels without 
stimulating vascular proliferation. The fibronectin-treated microvessels were 
longer due to a proportional increase in the number of microvascular cells 
(Nicosia et al., 1993). However, fibronectin had no effect on microvascular DNA 
synthesis and mitotic activity. Therefore, a 2D or 3D in vitro angiogenesis model 
could be developed by incorporating fibrin matrix and fibronectin to examine 
angiogenic tube formation or sprouting of microvessels in HOMECs. Currently 
there is no method available to test for angiogenic tube-formation or sprouting in 
HOMECs, and hence it is a potential project for future studies. 
 
Further work and potential projects 
 
As discussed before, metastasis of EOC cells to the omentum requires a 
microenvironment that aids their attachment to the mesothelium of the omentum 
and enhances invasion and metastasis. Cancer cells secrete factors that activate 
surrounding cells within the stroma which actively support tumour progression 
such as fibroblasts, pericytes, ECs, diverse immune cells and adipocytes. 
Although the focus of this thesis was to investigate roles of tumour-secreted 
factors on omental angiogenesis, it should be noted that proangiogenic effects of 
local fibroblasts or, in this case, cancer activated fibroblasts (CAFs) may 
significantly contribute to the pathogenesis process. For example, it has been 
shown that CAFs possess high contractile ability, promote angiogenesis, and 
stimulate epithelial cell growth via production of ECM and secretion of growth 
factors and cytokines such insulin-like growth factor 1, VEGF and hepatocyte 
growth factor 1 (Mueller and Fusenig, 2004). CAFs have also been shown to 
increase proliferation and migration of tumour cells. These functions of CAFs are 
observed in breast, colon, oral, pancreatic, bile duct, prostate, skin cancers and 
ovarian (primary) tumour (Yeung et al., 2015). However, there is a lack of 
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understanding of how CAFs may interact with migrant ovarian tumour cells and 
microvascular ECs at the metastatic site- omentum. Since angiogenesis in the 
metastatic site is key to metastasis, CAF-induced tumour angiogenesis could 
also be examined, possibly by combining tumour conditioned media and CAFs in 
co-cultured HOMECs. This may reveal a more physiological scenario of the 
omental microenvironment that aids advanced ovarian cancer progression. 
 
Another key cell type within the omentum is adipocytes. EOC cells preferably 
metastasise to the omentum, a pad of fat cells, in 80% of serous ovarian 
carcinoma patients, suggesting that this is not a random event. The adipocytes 
which are in close proximity to cancer cells are called cancer-associated 
adipocytes (CAAs). A number of studies have investigated potential cross-talks 
between CAAs and ovarian tumour cells. For example, Nieman and colleagues 
reported that CAAs promote homing, migration, and invasion of ovarian cancer 
cells, possibly by secreting soluble factors such as tumour necrosis factor-α, IL6, 
IL8 and monocyte chemoattractant factor-1 (Nieman et al., 2011). Also, CAAs 
were shown to provide energy for the tumour cells to grow via stimulating 
mitochondrial metabolism in these cells (Yeung et al., 2015).  
 
Although research has been carried out on investigating the interaction between 
ovarian cancer cells and omental adipocytes, very little is known about the cross-
talk events between HOMECs and the host adipocytes. As adipocytes provide 
energy to cells and promote tumour cell proliferation and migration, it is 
reasonable to speculate that the omental fat cell-secreted factors could also 
induce angiogenesis. Therefore, it would be very interesting to investigate the 
role of adipocytes (or their secreted adipokines and free fatty acids) on HOMEC 
survival, migration, proliferation, and hence angiogenesis, in future studies. This 
could be followed by further studies whereby EC function in angiogenesis could 
be tested in a combination of tumour conditioned media as well CAFs conditioned 
media along with CAAs, which should produce a more physiological in vitro model 
of metastatic EOC microenvironment within the omentum. 
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Another potential study that could be carried out using HOMECs is to examine 
the effects of pericytes. Tumour microvessels tend to be leaky due to an unstable 
basement membrane and lack of organised pericytes surrounding the 
endothelium (Cooke et al., 2012). These “leaky” vessels allow tumour cells to 
enter the circulation and hence aid tumour invasion and metastasis. Therefore, 
transendothelial electrical resistance could be used to measure the integrity of 
tight junction dynamics in HOMEC monolayers treated with tumour secreted 
factors such VEGF, CathL, CathD and IGFBP7, or HOMEC-secreted 
proangiogenic factor Gal1. This experiment could also be carried out in a 
transwell co-culture system with pericytes (from omentum) growing on the 
underside and HOMECs on the top chamber of the transwell, which will create a 
more physiological milieu of the microvessels. This could be combined with 
ovarian tumour cell conditioned media or individual secreted factors to test for 
induced permeability in EC monolayer under different conditions. As not much is 
known about the secreted factors in the angiogenic process of ovarian cancer 
metastasis involving the microenvironment at the secondary site, a combination 
of the aforementioned studies could shed light in the gap of information that 
currently exists. 
Despite ongoing efforts to develop effective surgery and treatment regimens for 
advanced EOC, the overall survival rate (5 year) remains a dismal 45%, which in 
large part results from diagnosis at a late stage. When ovarian cancer is detected 
at an early stage (tumour tissue is confined to one or both ovaries), the cure rate 
with conventional therapies such as cytoreductive surgery and chemotherapy, is 
as high as 90%. However, after the disease has spread to peritoneal organs, 
particularly the omentum, the cure rate decreases substantially owing to the 
limited efficacy of optimal debulking and tumour management. Also, 
chemoresistance poses a greater challenge, limiting the overall treatment 
efficacy. Therefore, understanding the molecular mechanisms that enhance 
tumour progression and metastasis at the secondary site is crucial, so that 
therapeutic interventions may be developed against the components of the 
tumour microenvironment. Although anti-VEGF therapy bevacizumab was 
developed to block angiogenesis in advanced disease, it was shown that VEGF 
is not solely responsible for the proangiogenic response in omental metastasis. 
Therefore, this thesis investigated potential proangiogenic factors (CathL, Gal1, 
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CathD and IGFBP7) and their roles in tumour-angiogenesis. This work may 
explain the lack of success in treating advanced ovarian cancer, as these novel 
factors have been clearly shown to induce proangiogenic responses in HOMECs 
in vitro. However, a greater understanding of the processes involved in omental 
angiogenesis and metastatic tumour growth could lead to improvements in the 
treatment and prognosis of ovarian cancer patients. 
 
A summary diagram depicting the overall data are described in figure 7.1: 
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Figure 7.1: A summary of ovarian cancer secreted factors (CathL, CathD and 
IGFBP7) and CathL-induced HOMEC-secreted factor Gal1, and their 
potential role in mediating cellular functions in HOMECs. Ovarian tumour-
secreted factors CathL, CathD and IGFBP7 induce HOMEC proliferation and 
migration, possibly via activation of the ERK1/2 and/or AKT pathways. This thesis 
suggest that both proteases (e.g. CathL and CathD) act via an unknown 
mechanism that is independent of their proteolytic activity. Preliminary 
investigation suggested an activation of receptor tyrosine kinases (e.g. c-RET, 
Tie-1, VEGFR2, Mer and ALK; as shown) by these tumour-secreted factors in the 
upstream of the aforementioned cellular responses. Interestingly, CathL was 
found to induce secretion of Gal1 over 30 mins and 8 hours. After 30 mins, CathL 
was thought to induce a rapid secretion of Gal1 from HOMECs via an unknown 
mechanism (yellow arrow). However, Gal1 secretion at the latter time-point (8 
hours) was thought to be transcriptionally regulated. Indeed, CathL was found to 
induce an increase in the expression of Gal1 mRNA (LGALS1) via activation of 
NFκB, which led to the secretion of Gal1 via a non-ER-Golgi pathway from 
HOMECs (olive arrow). Interestingly, secreted Gal1 was found to be pro-
proliferative and pro-migratory in HOMECs via an autocrine mechanism, probably 
by acting through a receptor with extracellular sugar moieties. Gal1-induced 
phosphorylation of ERK1/2 and AKT kinases was shown to mediate these cellular 
responses in HOMECs. Overall, this thesis suggests an increased proangiogenic 
responses in HOMECs, induced by CathL, Gal1, CathD and IGFBP7. ER; 
endoplasmic reticulum, ALK; anaplastic lymphoma kinase. 
302 
 
Appendix 1 
 
Figure A1.1: Increased proliferation of HOMECs in media supplemented with 
VEGF (positive control) (WST-1 assay). Cells were seeded in 2% gelatin pre-
coated 96 well plates at a density of 10,000cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
VEGF (20ng/ml) and incubated for 72 hours. A commercially available WST-1 kit 
was used to assess cellular proliferation based on absorbance using PHERAstar 
BMG plate-reader at 450nm. Results are mean ±SD and shown as percentage 
of the control, ***p<0.001 vs control (100%), n=18. 
 
Figure A1.2: Increased proliferation of HOMECs in media supplemented with 
VEGF (positive control) (CyQUANT). Cells were seeded in 2% gelatin pre-
coated 96 well plates at a density of 10,000cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
20ng/ml of VEGF and incubated for 72 hours. A commercially available 
CyQUANT reagent was used to assess cell proliferation based on fluorescence 
intensity using FLUOstar BMG plate-reader at Ex/Em: 485/530nm. Results are 
mean ±SD and shown as percentage of the control, ***p<0.001 vs control (100%), 
n=20. 
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Figure A1.3: Inhibition of ERK1/2 reduces positive control VEGF-induced 
HOMEC proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates 
at a density of 10,000cells/well in starvation media containing 2% FCS. After 
overnight incubation, cells were treated with or without VEGF (20ng/ml) and in 
the absence or presence of various concentrations of ERK1/2 inhibitors a) U0126 
and b) PD98059 as indicated above and incubated for 72 hours. WST-1 assay 
was used to assess cellular proliferation. Results are mean ±SD and shown as 
percentage of the control, n.s., **p<0.01, ***p<0.001 vs control (100%), 
###p<0.001 vs VEGF (normalised to control 100%), n=7-13. n.s. denotes not 
significant. 
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Figure A1.4: PI3K inhibitor, but not AKT inhibitor, reduces positive control 
VEGF-induced HOMEC proliferation. Cells were seeded in 2% gelatin pre-
coated 96 well plates at a density of 10,000cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
VEGF (20ng/ml) and in the absence or presence of various concentrations of a) 
LY294002 (PI3K inhibitor) and b) MK2206 (AKT inhibitor) as indicated above and 
incubated for 72 hours. WST-1 assay was used to assess cellular proliferation. 
Results are mean ±SD and shown as percentage of the control, *p<0.05, 
***p<0.001 vs control (100%), n.s., ##p<0.01, ###p<0.001 vs VEGF, n=10-15 
(normalised to control 100%). n.s. denotes not significant. 
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Figure A1.5: Positive control VEGF does not induce HOMEC migration via 
the AKT pathway. HOMECs were seeded in the upper transwell chamber and 
treated with or without VEGF (20ng/ml) in the absence or presence of PI3K and 
AKT inhibitors LY294002 (25 µM) and MK2206 (5 µM) respectively in media 
containing 0.5% FCS. The lower well contained correspondent treatments. After 
6 hours, migrated cells were stained with calcein AM and fluorescence was 
quantified using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean 
±SD and shown as percentage of the control, n.s., **p<0.05, ***p<0.001 vs control 
(100%), n.s. vs VEGF (normalised to control), n=6-12. n.s. denotes not 
significant. 
 
 
Figure A1.6: Positive control VEGF induces HOMEC migration via the 
ERK1/2 pathway. HOMECs were seeded in the upper transwell chamber and 
treated with or without VEGF (20ng/ml) in the absence or presence of ERK1/2 
inhibitors U0126 (10 µM) and PD98059 (25 µM) respectively in media containing 
0.5% FCS. The lower well contained correspondent treatments. After 6 hours, 
migrated cells were stained with calcein AM and fluorescence was quantified 
using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean ±SD and 
shown as percentage of the control, n.s., **p< 0.01, ***p<0.001 vs control (100%), 
##p<0.001 vs VEGF, n=7-9. n.s. denotes not significant. 
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Figure A1.7: CathL induces secretion of Gal1 in HOMECs. Cells were seeded 
in 2% gelatin pre-coated 24-well plates at a density of 35,000 cells/well in 
starvation media containing 2% FCS. After overnight incubation, cells were 
treated with or without CathL (50ng/ml) and supernatants were collected after 4 
minutes, 30 minutes and 8 hours treatment. A commercially available ELISA kit 
was used to assess the levels of secreted Gal1 using a SpectraMax plate reader. 
Results are represented as secreted Gal1 (ng/ml) (raw data from representative 
experiment). Gal1 was also measure in media only (without cells) (MV2) and in 
supernatant from serum-free media treatment.  
 
 
 
 
Figure A1.8: Activation of RTK VEGFR2 and VEGFR3 in VEGF-treated 
HOMECs. Representation of developed membrane using AzureSpot.  
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Figure A1.9: Increased proliferation of HOMECs in media supplemented with 
treatments (BrdU assay). Cells were seeded in 2% gelatin pre-coated 96 well 
plates at a density of 10,000cells/well in starvation media containing 2% FCS. 
After overnight incubation, cells were treated with or without growth media 
(positive control), IGFBP7 (50 ng/ml), CathD (50 ng/ml), CathL (50 ng/ml) and 
Gal1 (50ng/ml) and incubated for 48 hours. A commercially available BrdU 
reagent was added to the wells for the last 24 hour incubation and cellular 
proliferation was assessed (according to the manufacturer’s instructions) based 
on fluorescence intensity using a SpectraMax plate-reader at Ex/Em of 450/550 
nm. Results are mean ±SD and shown as percentage of the control, *p<0.05, 
**p<0.01, ***p<0.001 vs control (100%), n= 4-7. 
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Appendix 2 
 
A2.1 Publication  
Journal article 
Pranjol, M. Z., Gutowski, N., Hannemann, M. & Whatmore, J. 2015. The Potential 
Role of the Proteases Cathepsin D and Cathepsin L in the Progression and 
Metastasis of Epithelial Ovarian Cancer. Biomolecules, 5, 3260-79. 
Conference papers 
Pranjol, M.Z.I., Gutowski, N. J., Hannemann, M. and Whatmore, J.L. 2017. 
Cathepsins D and L Induce Proangiogenic Changes in Human Omental 
Microvascular Endothelial Cells. The British Microcirculation Society Abstracts of 
the 66th annual meeting in University of Newcastle. Microcirculation, 24, 4. 
Pranjol, Z., Gutowski, N., Hannemann, M. & Whatmore, J. 2015. Tumour 
secreted factors cathepsins D and L induce pro-angiogenic changes in human 
omental microvascular endothelial cells (HOMECs) in ovarian cancer metastasis. 
T26. European Journal of Cancer Supplements, 13(1), 44.  
 
A2.2 Key presentations and achievements during PhD studies 
Oral presentations 
 “Cathepsins D and L induce pro-angiogenic changes in human omental 
microvascular endothelial cells in epithelial ovarian cancer metastasis”- 
66th Annual British Microcirculation Society Meeting- Microvessels of 
the Heart, Newcastle, UK, 2016. 
 
 “Tumour secreted factors cathepsins D and L induce pro-angiogenic 
changes in human omental microvascular endothelial cells (HOMECs) in 
ovarian cancer metastasis”- Conference on “Cellular and molecular 
mechanism of tumour–microenvironment crosstalk”, European 
Molecular Biology Organization (EMBO), Tomsk, Russia, 2015. 
 
Poster presentations 
 “Cathepsin D induces migration in human omental microvascular 
endothelial cells (HOMECs)”- 67th Annual British Microcirculation Society 
meeting, Birmingham, UK, 2017. 
 
 “Cathepsins D and L induce proangiogenic changes in human omental 
microvascular endothelial cells (HOMECs)”- 65th Annual British 
Microcirculation Society meeting, Manchester, UK, 2015. 
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Travel awards 
 Student Assisted Scheme Travel Award at 65th, 66th and 67th Annual 
British Microcirculation Society Meetings, UK. 
 EMBO Travel Grant award, Tomsk, Russia. 
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